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Over the past several years, our group has been interested in designing and synthesizing different 
novel octahedral chiral-at-metal complexes and their application in asymmetric catalysis, including 
visible-light-induced asymmetric catalysis.  
This thesis mainly includes two parts: one is the versatile asymmetric catalysis by octahedral 
chiral-at-metal iridium complexes, and the other one is the visible-light-promoted asymmetric 
α-amination by octahedral chiral-at-metal rhodium complex. 
In the first part of this thesis, octahedral chiral-at-metal iridium complexes IrS and IrO are used as 
highly effective chiral Lewis acid catalysts for a variety of asymmetric reactions, including 
Friedel-Crafts alkylations, Michael additions with CH-acidic compounds, 1,3-dipolar cycloadditions, 
Diels Alder cycloadditions, hetero Diels Alder cycloadditions and Henry reactions. 
In the second part of the thesis, a very efficient photoactivated enantioselective radical amination of 
2-acyl imidazoles catalyzed by an octahedral chiral-at-metal rhodium complex RhO is introduced. 
Rhodium complex here serves a dual function, namely as a chiral Lewis acid to catalyze asymmetric 
enolate chemistry and furthermore as a light-activated smart initiator of a radical chain process. 
vi 
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Abstract (Deutsch) 
 
 
 
 
In den letzten Jahren war unsere Arbeitsgruppe daran interessiert, verschiedene neue oktaedrische 
Komplexe mit metallzentrierter Chiralität zu entwickeln und sie in der asymmetrischen Katalyse 
einzusetzen. Der Fokus lag dabei vor allem auf der durch sichtbares Licht induzierten asymmetrischen 
Katalyse. 
Diese Arbeit beinhaltet hauptsächlich zwei Teile: der erste Teil handelt von der vielseitigen 
asymmetrischen Katalyse durch oktaedrische Iridium-Komplexe mit metallzentrierter Chiralität, der 
zweite Teil handelt von der durch sichtbares Licht geförderten asymmetrischen α-Aminierung durch 
oktaedrische Rhodium-Komplexe mit metallzentrierter Chiralität. 
Im ersten Teil der Arbeit werden die oktaedrischen Iridium-Komplexe IrS and IrO mit 
metallzentrierter Chiralität als hocheffektive chirale Lewis-Säure-Katalysatoren für eine Vielzahl von 
asymmetrischen Reaktionen, wie Friedel-Crafts-Alkylierungen, Michael-Additionen mit CH-aciden 
Verbindungen, 1,3-dipolare Cycloadditionen, Diels-Alder Cycloadditionen, hetero-Diels-Alder 
Cycloadditionen und Henry-Reaktionen, eingesetzt. 
Im zweiten Teil der Arbeit wird eine sehr effiziente photoaktivierte enantioselektive radikalische 
Aminierung von 2-Acylimidazolen vorgestellt, die durch einen oktaedrischen Rhodium-Komplex 
RhO mit metallzentrierter Chiralität katalysiert wird. Der Katalysator besitzt die Doppelfunktion als 
chirale Lewis-Säure die asymmetrische Enolat-Chemie zu katalysieren und darüber hinaus als 
lichtaktivierter smarter Initiator eines Radikalketten-Prozesses. 
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Chapter 1. Theoretical Part 
 
 
 
1.1 Introduction 
The field of asymmetric catalysis has grown rapidly and plays an important role in drug discovery and 
for the synthesis of pharmaceuticals.1 One of the most interesting and important research areas of 
current asymmetric catalytic chemistry is asymmetric catalysis by transition-metal complexes.2 The 
outermost d orbitals of the transition metal ions are incompletely filled with electrons so they can both 
lend electrons to or take electrons from other molecules. By taking advantage of their outmost d 
orbitals, transition metal complexes can activate substrates and accelerate reactions by means of 
coordination, ligand exchange insertion, elimination, and so on.3 The selectivity, activity and stability 
of chiral transition metal complexes can be tuned by modification of their ligands. 
Visible-light-induced photoredox catalysis has sparked much excitement in recent years because 
visible light which is considered an inexpensive, abundant, and environmentally benign form of 
energy offers a sustainable, convenient and very mild method to initiate the transfer of single electron.4 
However, the cooperation of such photoredox chemistry with asymmetric catalysis poses significant 
challenges due to the high reactivities and limited life times of radical ion and radical intermediates 
which is indicated by the still limited number of catalytic asymmetric photoredox systems.5 
This chapter will focus on introduction of chiral transition metal complexes and their application for 
asymmetric catalysis and visible-light-promoted asymmetric catalysis. 
 
1.2 Asymmetric Catalysis by Chiral Only-at-Metal Complexes 
Chiral metal complexes are one of the important research objects in current organometallic chemistry.6 
This research interest is mainly driven by the potential application of chiral metal complexes in the 
field of catalysis2, matericals science7, and life science8. Traditionally, chirality is established in metal 
complexes with chiral ligands,9 the chiral information is then located in the coordination sphere of the 
metal ion. A less well studied of chirality in chiral metal complexes is where the metal center itself is 
chiral, relying on achiral ligands in the coordination sphere (chiral only-at-metal complex). In this 
perspective, chiral only-at-metal complexes, including tetrahedaral chiral only-at-metal complexes,10 
half-sandwich chiral only-at-metal complexes,11 and octahedral chiral only-at-metal complexes,12 and 
their application in asymmetric catalysis would be introduced.  
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1.2.1 Tetrahedral chiral only–at–metal complexes 
Similar with chiral carbon, tetrahedral metal complexes bearing four different ligands are also chiral 
(tetrahedral chiral-at-metal complexes) (Figure 1). However, most of tetrahedral chiral-at-metal 
complexes are not configurationally stable,13 and their application in asymmetric catalysis is rarely 
investigated. There are only few reports about using tetrahedaron chiral-at-metal for catalysis. 
 
Figure 1 Chiral carbon center and organometallic analog. 
In 2008, the Hoveyda group reported a class of novel tetrahedral chiral-at-metal compplexes that 
initiate alkene metalthesis with very high efficiency and enantioselectivity (Scheme 1).14 These new 
catalysts have a stereogenic metal center with four different monodentate ligands. In the presence of 1 
mol% molybdenum complex Mo(1), generated in situ, triene is transformed to a relatively natural 
product (+)-quebrachamine in 84% yield with 96% ee. In 2012, they reported the first examples of 
catalytic enantioselective ring opening/cross-metathesis (EROCM) reactions by tetrahedral 
chiral-at-metal Mo complexes (Scheme 2).15 In the presence of 0.07−1.0 mol% chiral-at-metal 
molybdenum complex Mo(2), the desired products are formed in up to 90% yield and >99:1 
enantiomeric ratio (er) with the disubstituted enol ether generated in >90% Z selectivity. These 
findings outline a promosing direction for the development of tetrahedral chiral-at-metal complexes. 
 
Scheme 1 Efficient and Highly Enantioselective Synthesis of (+)-Quebrachamine 
 
Scheme 2 Highly Efficient, Z- and Enantioselective ROCM Reactions with Chiral-at-Mo Complex 
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1.2.2 Half-sandwich chiral only–at–metal complexes 
Compare to tetrahedral chiral-at-metal complexes, half-sandwich chiral-at-metal complexes are 
somewhat more stable. 6 This class of complexes is common and many examples are known (some 
representative half-sandwich chiral-at-metal complexes, see Figure 2).11  
Mn
OC PPh3
NO
+
PF6-
Re
Ph3P ON
CH3
+
PF6-
MnON
I
(S)-Re
(S)-Mn(1) (S)-Mn(2)
Mn
NO
PPh3
(R)-Mn(3)
Ph
O
MoON
I
(R)-Mo
Fe
COPh
CO
H3C
(R)-Fe   
Figure 2 Some representative half-sandwich chiral-at-metal complexes. 
However, the report of asymmetric catalysis by these half-sandwich chiral-at-metal complexes is also 
rare because most of these chiral complexes are not confugurationally stable in solution.16 The 
metal-ligand bond is so week that could break easily, leading to isomerizaiton progress. In 2006, the 
Gladysz group reported one example of half-sandwich chiral-at-metal complex (S)-Re(2) for 
enantioselective cycloadditions involving allenes and imines (Scheme 3).17 In the presence of 20 
mol% (S)-Re(2), the [3+2] cycloaddition products were obtained in 90–93% yield with moderate 
enantioselectivity (51–60% ee). By using the same catalyst (S)-Re(2) (10 mol% catalyst loading), the 
products of intramolecular Morita-Baylis-Hillman reaction were isolated in 88–99% yield with 38–74% ee 
(Scheme 4).18 Although the enantioselectivity was not high, these findings indeed encouraged us to explore 
more numerous and stable chiral-at-metal complexes. 
 
Scheme 3 Asymmetric [3+2] Cycloadditions by (S)-Re(2) 
 
Scheme 4 Asymmetric intramolecular Morita-Baylis-Hillman Reaction by (S)-Re(2) 
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1.2.3 Octahedral chiral only–at–metal complexes 
In 1893, Werner’s coordination theory that octahedral coordination complexes are capable of 
possessing metal-centered optical activity was proposed. In 1911, Alfred Werner reported the 
resolution of enantiomers of the octahedral chiral-at-metal cobalt complexs [Co(en)2X(NH3)]2+ (X = 
Cl or Br, en = ethylenediamine) into their individual mirror-imaged Λ- and Δ-enanotiomers (Figure 
3).19 These studies represented a powerful evidence to validate Werner’s coordinary theory. However, 
the coordination chemistry of the octahedral chiral-at-metal complexes is more complicate than those 
of the tetrahedral chiral-at-metal complexes or half-sandwich chiral-at-metal complexes mentioned 
before. In the next 100 years, there are a few reports about synthesizing enantiopure octahedral 
chiral-at-metal complexes because the synthesis of enantiopure octahedral chiral-at-metal complexes 
is full of challenge, and their application for asymmetric catalysis is even fewer.20 
 
Figure 3 The resolution of enantiomers of the octahedral chiral-at-metal cobalt complexs. 
In 2001, the Soai group reported the highly enantioselective asymmetric autocatalysis induced by 
chiral octahedral cobalt complexes (Scheme 5). 21  In the presence of 2.4 mol% Δ-Co(2), the 
enantiomer excess of the corresponding product pyrimidyl alkanol can reached 94%. It is postulated 
that enantioselective addition occurs at the interface between the crystal of Δ-Co(2) and the solvent 
(the solubility of Δ-Co(2) is poor in toluene). The potassium ion within the cobalt salt might as a 
Lewis acid affords the product with low enantioselectivity. And then, chirality amplification occurs in 
the subsequent asymmetric autocatalysis progeress.22 So, strictly speaking, Δ-Co(2) here is not a true 
catalyst but acts as an initiator in this progress.23 
N
N
tBu
CHO
iPr2Zn, toluene, 0 oC
N
N
tBu
OH2.4 mol% -Co(2)
99% yield, 94% ee
O
O
O
N
N
Co
O
O
O
O
O
K+
2H2O
one example
 
Scheme 5 Enantioselective Addition of Diisopropylzinc to Aldehyde in the Presence of Chiral Octahedral Cobalt 
Complex Co(2) 
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Some other examples of asymmetric catalysis by octahedral chiral only-at-metal complexes are shown 
in Scheme 6. By using these chiral-at-metal complexes as catalyts, the products include sulfoxides (up 
to 18% ee),24 alcohols (up to 26% ee)25, and Michael addition products (up to 33% ee)26 were 
obtained with good yield but poor enantioselectivity.  
 
Scheme 6 Asymmetric Catalysis by Different Chiral-at-Metal Complexes 
From 2013, the Meggers group made a great contribution in this area and reported a series of novel 
work about asymmetric catalysis by octahedral chiral only-at-metal complexes. His work can be 
divided by two parts: one is inert octahedral chiral only-at-metal complexs as chiral templates for 
asymmetric catalysis, in which the transition metal serves as a structural center, whereas catalysis is 
mediated through the organic ligand sphere;2e another is octahedral chiral only–at–metal reactive 
transition metal catalysis, in which the metal center activates a substrate by metal coordination and at 
the same time comprises the configurationally stable sole element of chirality, thus entirely relying on 
achiral ligands in the coordination sphere. 
 
1) Octahedral metal-templated organocatalysis 
In 2013, the Meggers group reported the asymmetric conjugate reduction of nitroalkenes with a 
Hantzsch ester as the reducing agent by octahedral chiral only-at-metal hydrogen bonding catalysts 
(Scheme 7).27 The disired products were obtained in excellent yields (89−96% yield) with excellent 
enantioselectivities (93−99% ee) in the presence of just 0.1 mol% Λ-IrO(1). The amidopyrazole 
moiety of Λ-IrO(1) searves as a hydrogen-bond donor to nitro group and the OH group is in a proper 
position to accept a hydrogen bond from NH group of the Hantzsch ester. Afterwards, the Meggers 
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group extended the research on chiral-at-metal hydrogen bonding catalysts to the enantioselective 
Friedel Craft alkylation of indoles (Scheme 7). 28  The products with a quaternary 
all-carbon-substituted stereocenter were also obtained in impressive yields (72−97% yield) with 
excellent enantioselectivities (92−98% ee) by using 0.5 mol% Λ-IrO(2) as a hydrogen bonding 
catalyst. These researches revealed the potential of octahedral metal complexes as chiral scaffolds for 
the design of high-performance asymmetric catalysts. 
 
Scheme 7 Asymmetric Catalysis by Chiral only-at-Metal Hydrogen Bonding Catalysts 
On the basis of chiral only-at-metal hydrogen bonding catalysts, the Meggers group developed a new 
kind of catalyst—chiral only-at-metal brønsted base catalyst in 2014 (Scheme 8). This kind of catalyst 
can be synthesized easily from hydrogen bonding catalyst by adding base and shaking vigorously for 
several times. Highly effective asymmetric sulfa-Michael addition (by Λ-IrO(3))29 and aza-Henry 
addition (by Λ-IrO(4))29,30 catalyzed by octahedral chiral-at-metal brønsted base catalysts (catalyst 
loadings down to 0.02 and 0.25 mol%, respectively) afford the desired products in excellent yields (86
−96% and 90−97% yield, respectively) with excellent enantioselectivities (91−97% and 90−98% ee, 
respectively). 
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Scheme 8 Asymmetric Catalysis by Chiral-at-Metal Brønsted Base/H-Bonding Dual Activation Catalysts 
The Meggers group also presented an asymmetric enamine catalyst build from an octahedral 
chiral-at-metal complex (Scheme 9). This iridium complex Λ-IrO(5) can convert the aldehyde into a 
nucleophilic enamine, and activate the azodicarboxylate electrophile through hydrogen bonding with 
one OH-group at the same time. The desired product N-(benzyloxycarbonylamino) oxazolidinones 
were obtained in very high yields (73−96% yield) with excellent enantioselectivities (87−97% ee). 
With respect to catalyst loading in asymmetric organocatalysis, Λ-IrO(5) is one of the most efficient 
catalyst for the enantioselective α-amination of aldehydes to date.31 
 
Scheme 9 Asymmetric Catalysis by Chiral-at-Metal Enamine/H-Bonding Dual Activation Catalysts 
2) Octahedral chiral only–at–metal reactive transition metal catalysis 
In addition, the Meggers group developed a novel concept about the catalysis of octahedral chiral 
only-at-metal iridium(III) complex, in which the metal center activate one of substrates by coordinaion 
and at the same time serving as the sole source of chirality (Scheme 10).32 This complex Λ-IrO turns 
out to be a highly effective asymmetric Lewis catalyst for the enantioselective Friedel−Crafts addition 
of indoles to α,β-unsaturated 2-acyl imidazoles in high yields (75%−99%) with excellent 
enantioselectivities (90−98% ee) at low catalyst loadings (0.25−2 mol%) (Scheme 10). And, the 
octahedral chiral only-at-metal rhodium complex Λ or Δ-RhO was also reported to be a catalyst for 
asymmetric Michael additions (electrophile activation) and asymmetric α-aminations (nucleophile 
activation) in very high yields (83%−99% and 64−95% yield, respectively) with excellent 
enantioselectivities (85−99% and 90−97% ee, respectively) in 2015 (Scheme 10).33 
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Scheme 10 Asymmetric Catalysis by Octahedral Chiral-at-Metal Lewis Acid Catalysts 
The octahedral chiral-at-metal complexes here serve as versatile catalysts for some asymmetric 
reactions strongly encourage us to explore more application for the asymmetric organic 
transformations. Shortly after, the Meggers group demonstrated that these octahedral chiral-at-metal 
complexes could be used for photo-induced asymmetric catalysis (see Section 1.3.2).  
 
1.3 Visible-Light-Induced Asymmetric Catalysis by Metal Complexes 
Visible-light-induced organic transformation has been received increasing attention in the recent years, 
more and more reports appeared in last five years (Figure 4). The organic molecules normally only 
absorb energy photons which are in the UV region. However, the UV is not a good applicable light 
source, specialized and expensive equipment for UV needs to be involved; the high energy of UV 
photons might cause considerable unproductive decomposition reactions. Visible light has its 
advantages compared to the UV: it is abundant in the solar radiation (44%, see Figure 5), standard 
LED or household lamb could be used as light source. In a typical visible-light-induced reaction, the 
visible light is absorbed by photosensitizer which then triggers an energy or electron transfer process. 
Photoactivated sensitizer are metal complexes or organic dyes, in the following, we only focus on 
metal complexes used as photosensitizers.4 
Chapter 1. Theoretical Part 
-9- 
0 0 4 1 7 14
49
121
175
336
418
2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015
0
50
100
150
200
250
300
350
400
450
the
 nu
mb
er 
of 
pu
bli
sh
ed
 pa
pe
rs
Year
 the number of published papers
 
Figure 4 The growing numbers of published papers about “photoredox catalysis” in recent 10 years. 
(The results are searched from the Web of Science, and the key word is “photoredox catalysis”) 
 
Figure 5 Solar spectrum. 
The common classic transition metal photosensitizers are ruthenium or iridium complexes, such as 
Ru(bpy)32+, Ir(ppy)3, Ir(ppy)2(dtbbpy)+, and Ir[dF(CF3)ppy]2(dtbbpy)+ (Figure 6).4 The excited state of 
photosensitizer has the remarkable property of being both more oxidizing and more reducing than 
ground state of photocatalyst. 
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Figure 6 Popular classic transition metal photocatalysts. 
This property could be explained by their molecular orbital diagram, as depicted in Figure 7. The Ru(II) 
and Ir(III) cations are d6 center (for Ru2+: 4d6; for Ir3+: 5d6). Under the irradiation of visible light and 
upon absorption of one photon, an electron in one of the photosensitizer’s metal-centered t2g orbitals is 
excited to a ligand-centered π* obital, the higher energy electron which is in π* obital maybe expelled 
from π* obital when the photosensitizer serves as a reductant. If the lower energy vacant in the t2g 
orbital accepts an electron, then the photosensitizer acts as an oxidant.  
 
Figure 7 Simplified molecular orbital diagram. 
As a result of this unique property of the photoexcited Ru(II)* or Ir(III)*, redox transformation of 
Ru(II)* or Ir(III)* could proceed either by oxidative or by reductive quenching cycle (Figure 8a). In 
the oxidative quenching cycle, the PS* serves as a reductant, gives an electron to the electron acceptor. 
PS+ is a strong oxidant and may accept an electron from the electron donor, and return to the groud 
state PS; alternatively, in the reductive quenching cycle, the PS* acts as an oxidant, accepts an 
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elelctron from the electron donor to form a good reductant PS-. PS- may donate an electron to the 
electron acceptor and returned to the groud state PS. In addition, PS* can transfer energy to a suitable 
substrate directly (Figure 8b). The resulting excited substrate with high energy performs quite 
differently with its groud state.  
 
Figure 8 Induction of chemical processes by visible light activated photosensitizers. 
 
1.3.1 Visible-light-induced asymmetric catalysis by a dual-catalysis system 
As mentioned before, organic catalysis activated by visible light has experienced a renaissance in the 
last several years. The asymmetric organic transformations that are activated by visible light are still in 
its infancy.5 The combination of organocatalysis or transition-metal catalysis and photosensitizer as 
dual-catalysis system is the main strategy. We will firstly summarize and discuss some recently 
progress in visible-light-induced asymmetric catalysis by a dual-catalysis system. 
1) Chiral amine/photosensitizer dual-catalysis system 
In 2008, the MacMillan group reported the first asymmetric alkylation of aldehydes by visible light 
(Scheme 11).34 His strategy is to combine the photosensitizer and an imidazodinone organocatalyst to 
form a dual-catalysis system. By using this strategy, the enantioenriched α-alkylated aldehydes 
(63−93% yields and 88−99% ee)34, α-trifluoromethylation of aldehydes (61−89% yield and 90−99% 
ee)35 and α-benzylation of aldehydes (72−91% yield and 87−93% ee)36 can be generated (Scheme 11). 
The mechanisms of these reactions are quite similar. The proposed mechanism is shown in Figure 9 
(the imidazolone 3 is taken for example). The imidazolidinone catalyst reacts with aldehyde to 
generate π-rich enamine I. Then, the electrophilic alkyl radical rapidly undergoes coupling with this 
π-rich enamine to form intermediate II. Intermediate II was oxidized to intermediate III by the excited 
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photosensitizers via single-electron transfer (SET) progress. Hydrolysis of intermediate III gives the 
α-alkyl aldehyde product and reconstitutes the imidazolidinone catalyst. 
 
Scheme 11 Enantioselective α-Alkylation of Aldehydes via Asymmetric Photoredox Catalysis 
 
Figure 9 Putative mechanism for visible-light-induced enantioselective α-alkylation of aldehydes. 
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In 2014, the Luo group merged chiral primary amine catalysis and photoredox catalysis for the 
asymmetric α-photoalkylation of β-ketocarbonyls by merging (Scheme 12).37 The catalyst system enables 
the creation of all-carbon stereocenters with excellent enantioselectivities (up to 99% ee) and encompass a 
broad range of substrates including the elusive 1,3-diketones and β-keto amides for the first time in an 
asymmetric alkylation reaction. This reaction was suggested to proceed with photoredox catalysis (an EDA 
reaction pathway may also coexist but should be minor in this case) involving phenacyl radical addition as 
the key C-C forming step and a hydrogen bond in the transition state contributes to the high asymmetric 
induction.  
 
Scheme 12 α-Photoalkylation of β-Ketocarbonyls 
2) Chiral N-heterocyclic carbene/photosensitizer dual-catalysis system 
In 2012, the Rovis group reported the catalytic asymmetric α-acylation of tertiary amines with 
aldehydes facilitated by the combination of chiral N-heterocyclic carbine and photoredox catalyst 
(Scheme 13).38 The nuclephile intermediate I is formed by interaction of an NHC and an aldhyde, it 
reacts with iminium II which is generated from single-electron oxidation of a tertiary amine followed 
by hydrogen atom abstraction to give intermediate III. Elimination of NHC from III would give the 
product amino ketone (up to 94% yield and 92% ee).  
 
Scheme 13 Asymmetric α-Acylation of Tertiary Amines with Aldehydes 
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3) Chiral brønsted acid/photosensitizer dual-catalysis system 
In 2013, the Knowles group reported the first enantioselective catalytic protocol for the reductive 
coupling of ketones and hydrazones (45−96% yields and 77−94% ee) (Scheme 14).39 The aza-pinacol 
cyclizations proceed through ketyl radical intermediates formed by a concerted proton-coupled 
electron transfer (PCET) event jointly mediated by a chiral BINOL phosphoric acid and the 
photoredox catalyst Ir(ppy)2(dtbpy)PF6. The concept of PCET is interesting because it allows reducing 
functional groups at significant lower oxidation potentials and provides new opportunities for the 
further development of catalytic asymmetric radical chemistry by using chial brønsted acid. 
 
Scheme 14 Asymmetric Aza-Pinacol Cyclization by Merged Photoredox Catalysis and Chiral Brønsted Acid 
Catalysis 
4) Chiral Lewis acid/photosensitizer dual-catalysis system 
In 2014, the Yoon group reported a dual-catalysis approach to enantioselective [2+2] photo- 
cycloadditions by visible light (Scheme 15).40 
   
Scheme 15 A Dual-Catalysis Approach to Enantioselective [2+2] Photocycloadditions Using Visible Light 
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This dual-catalysis system consists of a visible light activated photoredox catalyst Ru(bpy)3Cl2 and a 
chiral Lewis acid co-catalyst. The Lewis acid co-catalyst composed of 10 mol% Eu(OTf)3 and 20 
mol% chiral Shiff base afforded 1,2-trans cycloadduct in 34−72% yields and 86−93% ee with 
moderate diastereoselectivities (dr = 4/1 to 9/1). Interestingly, the chiral ligand can control both the 
relative and absolute stereochemistry of the [2+2] photocycloaddition products. Modified the chiral 
Shiff base to the corresponding reduced secondary amine led to a switch in diastereoselectivity from 
1,2-trans to 1,2-cis cyclobutanes in 49−80% yields and 84−97% ee with moderate 
diastereoselectivities (dr = 1.5/1 to 4.5/1). 
The proposed mechanism is shown in Figure 10. The crucial step in this cycloaddition is that 
[Ru(bpy)3]+ transfers a single electron to a Lewis acid- activated aryl enones. The hereby generated 
intermediate radical anions can subsequently react with other Michael acceptors to form cyclobutane 
containing ketyl radical. The formed cyclobutane containing ketyl radicals loose an electron to give 
the intermediate that Lewis acid coordinated product. After ligand exchange, the product cyclebutane 
is formed and a new catalytic cycle is regenerated. 
 
Figure 10 Plausible mechanism for enantioselective [2+2] photocycloadditions. 
5) Chiral Nickel catalyst/photosensitizer dual-catalysis system 
MacMillan and Fu recently reported enantioselective decarboxylative Csp3-Csp2 cross-coupling reaction 
of α-amino acids with aryl halides via the merger of photoredox and nickel catalysis (Scheme 16).41 
Decarboxylation of an α-amino acid by photocatalyst-mediated oxidation would give a prochiral 
α-amino radical I. Meanwhile, oxidative addition of an aryl halide to Ni complex would generate a 
Ni(II)-aryl complex II, which would react with α-amino radical I to give intermedidate III. The 
resulting intermediate III would then undergo reductive elimination to afford the enantioenriched 
benzylic aminbe product (up to 84% yield and 92% ee).  
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Scheme 16 Photoinduced Enatioselective Decarboxylative Arylation 
 
1.3.2 Visible-light-induced asymmetric catalysis by a “2-in-1” chiral metal complex 
1.3.2.1 Visible-light-induced asymmetric catalysis by a “2-in-1” chiral iridium complex 
In contrast to asymmetric photoredox reactions catalyzed by a dual-catalysis system, the Meggers 
group has demonstrated visible-light-induced asymmetric catalysis could be realized by single chiral 
iridium complex since 2014. “2-in-1” chiral iridium complex combines photoredox sensitization and 
asymmetric induction in a single chiral iridium complex to offer new opportunities for the ‘green’ 
synthesis of non-racemic chiral molecules. I would like to introduce this part of works by two parts: 
one is visible-light-induced asymmetric catalysis by oxidative quenching cycle; another is 
visible-light-induced asymmetric catalysis by reductive quenching cycle. 
1) Photoinduced asymmetric catalysis by oxidative quenching cycle 
Meggers group reported iridium-catalyzed photoinduced enantioselective alkylation of acyl imidazole 
with benzyl bromide, affording the α-alkylation products in quantitative yield with a superior 
enantioselectivity of 99% ee (Scheme 17) in 2014.42  
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Scheme 17 Photoinduced Enantioselective Alkylation of Acyl Imidazole with Benzyl Bromide 
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Figure 11 Plausible mechanism for a combined photoredox and asymmetric catalysis. 
A proposed mechanism is shown in Figure 11. The catalysis is initiated by the coordination of 2-acyl 
imidazoles to the iridium catalyst in a bidentate fashion (intermediate I), followed by the formation of 
iridium enolate complex upon deprotonation (intermediate II). The photo-reductively generated benzyl 
radical then reacted with intermediate II to form an iridium-coordinated ketyl radical (intermediate 
III). Intermediate III is oxidated to a ketone via single electron transfer. After ligand exchange, 
intermediate I is formed again, followed by a new catalytic cycle. IrS and IrS-enolate complex 
(intermediate II) here not only serve as a chiral Lewis acids but also serve as photoredox catalysts. 
Compared to IrS, IrS-enolate complex (intermediate II) has a significantly decreased oxidation 
potential (Figure 12). In other word, IrS-enolate complex is a much strong reducing agent in the groud 
state (the estimated excited state redox potential of IrS-enolate complex is –1.74 V versus Ag/AgCl 
and it is comparable to that of fac-Ir(ppy)3). 
 
Figure 12 The properties of IrS and IrS-enolate. 
In 2015, the Meggers group reported firstly an enantioselective, catalytic trichloromethylation through 
visible light activated photoredox catalysis with a chiral iridium complex IrS (Scheme 18).43 Some 
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products are formed with 99% ee and even higher. The report of the asymmetric introduction of the 
trichloromethyl group are limited, although trichloromethyl groups are present in natural products and 
very useful in the pharmacological research,44 therefore the method they presented were extremely 
useful. The proposed mechanism is shown in Figure 13. The key step is the addition of a reductively 
gernerated electrophilic trichloromethyl radical to the nucleophilic double bond of iridium-enolate 
complex provides an iridium coordinated ketyl radical (intermediate III). A determined quantum yield 
of 5 (more than 1) indicates that the trichloromethyl radical is also formed by direct single electron 
transfer from intermediate III to BrCCl3 (chain mechanism). 
 
Scheme 18 The Catalytic Enantioselective α-Trichloromethylation Activated by Visible Light 
 
Figure 13 Putative mechanism for the visible-light-activated enantioselective trichloromethylation. 
Meggers group continued to develop the related enantioselective perfluroalkylations. In 2016, the dual 
function chiral Lewis acid/photoredox catalyst concept (a chiral iridium catalyst) for developping a 
photoactivated enantioselective perfluoroalkylation of 2-acyl imidazoles was further advanced 
(Scheme 19).45 The products with high enantioselectivities (up to >99.5% ee) are observed. The 
proposed mechnism of perfluoroalkylation is very similar with trichloromethylation’s. The key step is 
the addition of a reductively gernerated electron-deficient perfluoroalkyl radical to the nucleophilic 
double bond of iridium-enolate complex. 
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Scheme 19 The Visible-Light-Induced Enantioselective Perfluoroalkylation 
2) Photoinduced asymmetric catalysis by reductive quenching cycle 
In 2015, the Meggers and coworkers reported the simple chiral iridium complex catalyzes the visible 
light acitivated asymmetric aerobic α-aminoakylation of 2-acyl imidazoles to provide aminoalkylated 
products in 61−93% yields with high enantiomeric excess (90−98% ee) (Scheme 20).46 The iridium 
complex here has also a dual function of being photosensitized oxidation and asymmetric alkylation. 
The plausible mechanism is displayed in Figure 14. The catalytic cycle is initiated by the coordination 
of substrate (2-acyl imidazole) to the iridium complex IrO (intermediate A), followed by 
deprotonation to form IrO-enolate imtermediate B. Intermediate B reacts with iminiun ion which is 
generated by an iridium-photosensitized oxidation of α-silylamine to provide the iridium-coordinated 
product C. After ligand exchange, intermediate A is formed again, followed by a new catalytic cycle. 
Compared with previous work, the photoexcited iridium complex IrO(III)* here functions as oxidant, 
accepting an electron from α-silylamine to form a reductant IrO(II). IrO(II) can be oxidized to ground 
state IrO(III) by oxgen easily.  
 
Scheme 20 The Asymmetric Aerobic α-Aminoakylation of 2-Acyl Imidazoles by Visible Light 
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Figure 14 Putative mechanism for asymmetric aerobic α-aminoakylation. 
At the same time, the Meggers group reported a unique catalytic asymmetric process in which a 
visible light driven single electron transfer reaction between a donor substrate and a catalyst-activated 
acceptor substrate is followed by a stereocontroled radical-radical recombination (Scheme 21).47 With 
the iridium complex as a dual function catalyst, 1,2-amino alcohols were obtained from 
trifluoromrthyl ketones and tertiary amines in high enantioselectivities (up to 99% ee). The plausible 
mechanism is shown in Figure 15. The catalytic cycle is initiated by the coordination of substrate 
(2-acyl imidazole) to the iridium complex IrS to form intermediate I. The intermediate I is activated 
by visible light to form photoactivated intermediate II. And then a single electron transfer from tertiary 
amine to intermediate II to generate an iridium-coordinated ketyl radical III and an amino radical 
cation. After a proton transfer and a radical-radical cross-coupling between the electron-deficient 
intermediate IV and the electron-rich α-aminoalkyl radical, the intermediate V (product coordinates 
the iridium complex) is generated. Finally, the product is replaced by new substate. A quantum yield of 
0.09 (<< 1) is in agreement with the expected closed catalytic cycle and no chain progress is possible 
(At least one photon is needed for each asymmetric C-C bond formation.).  
 
Scheme 21 Visible-Light-Induced Asymmetric C-C Bond Formation 
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Figure 15 Putative mechanism for the visible-light-activated asymmetric radical–radical cross-coupling process. 
1.3.2.2 Visible-light-induced asymmetric catalysis by other “2-in-1” chiral metal complexes 
The Meggers group explored “2-in-1” chiral rhodium catalyst in addition to the “2-in-1” chiral iridium 
complexes. In 2015, they reported the chiral-at-rhodium complex catalyzes the visible light activitated 
asymmetric cross-coupling with oxygen as the oxidant to afford the products in 35−81% yield with 79
−97% ee (Scheme 22).48 This work is the first example for an asymmetric photoredox reaction 
catalyzed by a chiral rhodium complex. Rhodium complex here does not only serve as a catalyst for 
the enatioselective enolate chemistry, but also acts as a photosensitizer. The proposed mechanism 
involves a rhodium coordination of the substrate followed by deprotonation (Figure 16). The 
intermediate rhodium enolate complex then reacts with iminiun ion which is formed by 
photosensitized oxidation of the corresponding N,N-diakylaniline. 
 
Scheme 22 Aerobic Asymmetric Dehydrogenative Cross-Coupling 
 
Figure 16 Putative mechanism for the catalytic asymmetric cross-dehydrogenative couplings. 
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Shortly thereafter, the Fu group reported asymmetric copper-catalyzed C-N cross-couplings induced 
by visible light (Scheme 23).49 The copper catalyst here is formed in situ by CuCl, chiral ligand and 
nuclophiles, acting as both the photocatalyst and the source of asymmetric induction. Irradiation of the 
cross-coupling partners by a blue light-emitting diode at −40 oC for 16 h in the presence of CuCl, 
chiral ligand, and a base provides the amines in good yields (73−98%) with excellent 
enantioselectivities (87−99% ee). An outline of a possible mechanism for this reaction is illustrated in 
Figure 17. The catalytic cycle is initiated by the formation of the copper-nucleophile complex (A). 
Under the irradiation of visible light, the copper-nucleophile complex (A) is activated to an 
excited-state complex (B) which would then enage in SET with alkyl halide (R-X) to form 
intermediate (C) and an alkyl radical. Then, the product amine is formed by the bonding formation 
between nuleophile and the alkyl radical through an innersphere pathway involving intermediate (C). 
 
Scheme 23 Asymmetric Copper-Catalyzed C-N Cross-Couplings Induced by Visible Light 
 
Figure 17 Outline of a possible pathway for photoimduced copper-catalyzed C-N cross-couplings of alkyl 
halides. 
To sum up, this section elaborated visible-light-induced asymmetric catalysis by a dual-catalysis 
system or a “2-in-1” chiral metal complex. The report of visible-light-induced asymmetric catalysis 
catalyzes by a “2-in-1” metal complex is not much, especially catalyzed by a “2-in-1” chiral rhodium 
complex or other chiral transition metal complexes. This field is growing rapidly and it will play a 
pivotal role in the ‘green’ synthesis of non-racemic chiral molecules. 
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Chapter 2. Aim of the Work 
 
 
 
My research work can be divided into the following two main parts: 
1) Explore the generality of chiral Lewis acid catalysts with respect to reaction types and 
substrates by octahedral chiral-at-metal complexes 
Asymmetric catalysts which draw their chirality exclusively from a chiral metal center are much less 
investigated although such catalysts might display some attractive features such as structural 
simplicity (only achiral ligands required) and an effective chirality transfer in the course of the 
reaction due to direct proximity of the metal-based stereocenter to the metal-coordinating substrate.  
Recently, our group introduced octahedral chiral-at-metal iridium(III) and rhodium(III) complexes as a 
novel class of chiral Lewis acid catalysts. One highly appealing goal in this area of research is the 
development of chiral Lewis acid catalysts that exhibit a broad generality with respect to reaction 
types and substrates. In this work, we would like to first design and synthesize different octahedral 
chiral-at-metal complexes by modifying the ligands in order to find the higher activity and better 
selectivity transition metal chiral catalysts. And, explore their catalytic behavior in some different 
kinds of reactions such as Friedel-Crafts alkylations, Michael additions with CH-acidic compounds, a 
variety of cycloadditions and Henry reactions. In addition, we want to expand the scope of substituted 
alkenes, in order to make them more general. The mechanism of reactions will be also investigated. 
 
2) Explore the visible-light-induced enantioselective C-N formation by octahedral chiral-at- 
metal complex 
Reactions involving single electron transfer (SET) steps have sparked much attention over the last 
several years. Visible light photosensitization offers a sustainable, convenient and very mild method to 
initiate the transfer of single electron. However, the cooperation of such photoredox chemistry with 
asymmetric catalysis poses significant challenges due to the high reactivities and limited lifetimes of 
radical ion and radical intermediates which is indicated by the still limited number of catalytic 
asymmetric photoredox systems.  
Nitrogen-centered radicals (NCRs) hold much promise as useful synthetic intermediates and they can 
be generated via single electron transfer (SET) progress by photoredox catalysis under mild 
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conditions. 
Therefore, we would like to explore the possibility of visible-light-induced enantioselective C-N 
formation via nitrogen-centered radicals by the octahedral chiral-at-metal complexes. If possible, the 
octahedral chiral-at-metal complexes here would serve a dual function, namely as a chiral Lewis acid 
to catalyze asymmetric enolate chemistry and furthermore as a photoredox sensitizer. In addition, we 
will focus on the mechanism study for this reaction, in order to comprehend the progress of 
visible-light-induced asymmetric catalytic reaction and provide some useful information for exploring 
other asymmetric photoredox reactions.  
Chapter 3. Results and Discussion 
-28- 
 
 
 
Chapter 3. Results and Discussion 
 
 
 
Metal-based asymmetric catalysts are typically constructed from a central metal ion in combination 
with one or multiple chiral ligands.1 In contrast, asymmetric catalysts which draw their chirality 
exclusively from a chiral metal center2 are much less investigated although such catalysts might 
display some attractive features such as structural simplicity (only achiral ligands required) and an 
effective chirality transfer in the course of the reaction due to the direct proximity of the metal-based 
stereocenter to the metal-coordinating substrate.3 In this section, a number of octahedral metal 
complexes were designed and synthesized, and their catalytic activities were carefully studied. 
3.1 Design of New Catalysts 
 
Figure 18 Design plans of catalysts. 
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Our group developed an octahedral chiral-at-metal iridium(III) complex IrO, in which the metal 
center served as Lewis acid to activate one of substrates and at the same time serving as the sole 
source of chirality.4 We wondered whether it is possible to develop the higher activity and better 
selectivity transition metal catalysts by modifying the ligands. 
Based on IrO, the modifications of iridium catalyst are shown in Figure 18:  
a) Two iridium complexes with larger steric hinderance around the central metal were designed. One 
is replacing cyclometalated 2-phenylbenzoxazole by 2-phenylbenzothiazole because the long C-S 
bonds which might position the two tert-butyl groups closer to the two vacant coordination sites 
(IrS); another is replacing tert-butyl group of 2-phenylbenzoxazole by adamantyl group which has 
larger size than tert-butyl group (IrO(ada)). 
b) Five iridium complexes with electron withdrawing group or electron donating group were 
designed (IrO(F), IrO(CF3), IrO(NO2), IrO(OMe), IrO(nap)). The Lewis acidity of iridium 
complexes would be different by introducing the different groups to cyclometalated ligand. 
c) Two cyclometalated pyrenyl iridium complexes were designed (IrO(pyrene) and IrN(pyrene)) 
because they might have longer triplet excited state lifetimes (τT) so that they might be more 
efficient catalysts in photoinduced reactions.  
3.1.1 Synthesis of chloro-bridged Ir or Rh dimers 
The chloro-bridged Ir or Rh dimers with N,N-trans-configuration rac-11-13 were synthesized 
according to a published route with some modifications (Method A), which involves refluxing 
IrCl3•nH2O or RhCl3•nH2O with 2–2.2 equivalents of cyclometalating ligand in a 3:1 mixture of 
2-ethoxyethanol and water at 120–130 oC for 24 hours (Scheme 24).5  
 
Scheme 24 The Synthesis of Chloro-Bridged Ir or Rh Dimers with N,N-trans-Configuration 
However, when there are electron withdrawing groups on the cyclometalating ligands, the 
N,N-cis-Ir-dimers rac-14, 16, 18 instead of N,N-trans-Ir-dimers were obtained via method A (Scheme 
25). The formation of N,N-cis-dimer was proved by 1HNMR and the crystal structure, and the 
structure of N,N-cis-Ir-dimers rac-18 is shown in Figure 19. 
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Scheme 25 The Synthesis of Chloro-Bridged Ir Dimers with N,N-cis-Configuration 
 
Figure 19 Crystal structure of rac-18 (N,N-cis-configuration). ORTEP drawing with 50% probability thermal 
ellipsoids. Selected bond lengths (Å) and angles (deg): Ir1−N1 = 2.131(3), Ir1−N20 = 2.040(3), Ir1−C11 = 
2.003(4), Ir1−C30 = 2.023(4), Ir1−Cl1 = 2.4811(10), Ir1−Cl2 = 2.3744(10), Ir2−N39 = 2.028(3), Ir2−N58 = 
2.161(3), Ir2−C49 = 2.007(4), Ir2−C68 = 2.003(4), Ir2−Cl1 = 2.3718(10), Ir2−Cl2 = 2.4824(3); N20−Ir1−Cl1 = 
95.33(10), Cl1−Ir1−Cl2 = 83.80(3), Cl2−Ir1−C11 = 87.49(12), C11−Ir1−N20 = 94.29(15), C30−Ir1−N1 = 
171.66(16). 
Chapter 3. Results and Discussion 
-31- 
The corresponding N,N-trans-Ir-dimers rac-15, 17, 19 can be synthesized with Method B by avoiding 
water and increasing the temperature to 140–150 oC, and other related N,N-trans-Ir-dimers rac-20-24 
could also be synthesized by this method as shown in Scheme 26. 
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Scheme 26 The Synthesis of Chloro-Bridged Ir Dimers with N,N-trans-Configuration 
3.1.2 Synthesis of racemic Ir or Rh catalysts 
Racemic Ir or Rh catalysts were synthesized according to the literature procedure6 with some 
modifications. Heating the corresponding N,N-trans-dimer with 2.2–2.5 equivalents of AgPF6 in 
acetonitrile at 50−70 °C over night afforded desired racemic Ir or Rh catalysts in 80−99% yield 
(Scheme 27). The crystal structures of catalysts rac-IrO(NO2), rac-IrO(ada), rac-IrO(nap), 
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rac-IrO(pyrene) and rac-IrN(pyrene) were obtained, which are shown in Figure 20-Figure 24, 
respectively. 
 
Scheme 27 The Synthesis of Racemic Ir or Rh Catalysts 
 
Figure 20 Crystal structure of rac-IrO(NO2). Only Δ-IrO(NO2) is shown and the hexafluorophosphate 
counteranion is omitted for clarity. ORTEP drawing with 50% probability thermal ellipsoids. Selected bond 
lengths (Å) and angles (deg): Ir1−N1 = 2.0459(16), Ir1−N23 = 2.1095(15), Ir1−C11 = 2.0282(18); 
N23i−Ir1−N23 = 94.23(10), N23−Ir1−C11 = 90.30(6), C11−Ir1−C11i= 90.86(9), C11i−Ir1−N23i = 91.30(6), 
N1−Ir1−N1i = 171.22(8). Symmetry transformations used to generate equivalent atoms: #1 -x+1, y, -z+1/2. 
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Figure 21 Crystal structure of rac-IrO(ada). Only -IrO(ada) is shown and the hexafluorophosphate 
counteranion is omitted for clarity. ORTEP drawing with 50% probability thermal ellipsoids. Selected bond 
lengths (Å) and angles (deg): Ir1−N1 = 2.033(2), Ir1−N26 = 2.035(2), Ir1−N100 = 2.113(2), Ir1−N103 = 
2.107(2), Ir1−C11 = 2.028(3), Ir1−C26 = 2.023(3); N100−Ir1−C11 = 94.23(10), C11−Ir1−C36 = 87.12(10), 
C36−Ir1−N103 = 90.98(10), N103−Ir1−N100 = 87.76(9), N1−Ir1−N26 = 171.64(9). 
 
Figure 22 Crystal structure of rac-IrO(nap). Only Δ-IrO(nap) is shown and the hexafluorophosphate 
counteranion is omitted for clarity. ORTEP drawing with 50% probability thermal ellipsoids. Selected bond 
lengths (Å) and angles (deg): Ir1−N1 = 2.0385(15), Ir1−N24 = 2.0372(15), Ir1−N47 = 2.1172(16), Ir1−N50 = 
2.1067(16), Ir1−C11 = 2.0223(18), Ir1−C35 = 2.0209(18); N50−Ir1−N47 = 90.12(6), N47−Ir1−C11 = 93.09(6), 
C11−Ir1−C34 = 86.56(7), C34−Ir1−C50 = 90.43(6), N1−Ir1−N24 = 172.23(6). 
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Figure 23 Crystal structure of rac-IrO(pyrene). Only Δ-IrO(pyrene) is shown and the hexafluorophosphate 
counteranion is omitted for clarity. ORTEP drawing with 50% probability thermal ellipsoids. Selected bond 
lengths (Å) and angles (deg): Ir1−N1 = 2.0470(17), Ir1−N30 = 2.1163(17), Ir1−C11 = 2.0321(19); 
N30−Ir1−N30i = 91.47(9), N30i−Ir1−C11 = 88.86(7), C11−Ir1−C11i = 90.85(10), C11i−Ir1−N30 = 88.86(7), 
N1−Ir1−N1i = 170.77(8). Symmetry transformations used to generate equivalent atoms: #1 –x, y, -z+1/2. 
 
Figure 24 Crystal structure of rac-IrN(pyrene). Only Δ-IrN(pyrene) is shown and the hexafluorophosphate 
counteranion is omitted for clarity. Selected bond lengths (Å) and angles (deg): Ir01−N11 = 2.036(8), Ir01−N005 
= 2.136(6), Ir1−C3 = 2.028(5); N005−Ir01−C3 = 90.58(9), C3−Ir01−C3’ = 93.79(4), C3’−Ir01−N005’ = 
90.60(5), N005’−Ir01−N005 = 85.17(1), N11−Ir01−N11’ = 178.70(6). Symmetry transformations used to 
generate equivalent atoms: 1–x, y, -z+3/2. (The quality of this crystal is not good enough.) 
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3.1.3 Synthesis of non-racemic Ir or Rh Lewis acid catalysts 
The chiral-at-metal complexes can be synthesized with high enantiomeric purity through a convenient 
auxiliary-mediated strategy developed in our laborator.7 The synthesis of -IrS and -IrS is shown in 
Scheme 28. 
 
Scheme 28 Auxiliary-Mediated Synthesis of the Enantiomerically Pure Chiral-at-Metal Iridium(III) Complexes 
-IrS and -IrS 
Accordingly, the iridium dimer complex rac-13 is reacted with the chiral auxiliary ligand 
(S)-4-isopropyl-2-(2'-hydroxyphenyl)-2-thiazoline ((S)-25) to afford the iridium(III) complexes 
-(S)-26 and -(S)-26 as a mixture of diastereomers, which can be resolved easily by standard silica 
gel chromatography on a gram scale (Figure 25).12 Upon reaction in acetonitrile in the presence of the 
weak acid such as NH4PF6, at slightly elevated temperature (50 °C), these complexes are converted to 
virtually enantiopure complexes -IrS and -IrS (each 99% ee) by a stereospecific substitution of 
the (protonated) chiral auxiliary with two acetonitrile ligands under retention of configuration. The 
confirguration of this new catalyst was proved by X-ray crystal structure, which is shown in Figure 26. 
The enantiomeric purity of -IrS or -IrS was verified by HPLC on a chiral stationary phase (Figure 
27).  
-IrO(ada) and -IrO(ada) can be synthesized by the same method with some modifications (see 
Experimental Part for more details). The synthesis of non-racemic IrO11 or chiral RhO8 is followed 
published procedures. 
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Figure 25 Two diastereomers could be resolved by standard silica gel chromatography on a gram scale. 
 
 
Figure 26 Crystal structure of -IrS. The hexafluorophosphate counteranion is omitted for clarity. ORTEP 
drawing with 50% probability thermal ellipsoids. Selected bond lengths (Å) and angles (deg): Ir1−N1 = 2.065(6), 
Ir1–N20 = 2.072(7), Ir1−N39 = 2.119(6), Ir1−N42 = 2.123(7), Ir1−C11 = 2.011(9), Ir1−C30 = 2.012(8); 
N39−Ir1−N42 = 88.7(3), N42−Ir1−C30 = 92.0(3), C30−Ir1−C11 = 89.5(3), C11−Ir1−N39 = 89.9(3), 
N1−Ir1−N20 = 169.6(3). 
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Figure 27 Enantiomeric purities of the catalysts -IrS and -IrS. 
HPLC conditions: Daicel Chiralpak IB (250 × 4.6 mm); mobile phase: A = 0.1% TFA, B = MeCN; gradient: 
38% to 46% B in 60 min; flow rate: 1.0 mL/min; 254 nm; 20 oC. 
-IrS 
>100:1 e.r.
-IrS 
>100:1 e.r.
rac-IrS 
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The chiral auxiliary (S)-25 9 can be synthesized in three steps starting from acid chloride 27 in an 
overall yield of 57%. Reaction with the chiral amino alcohol (S)-28 affords amide 29 (91%), which is 
cyclized to the thiazoline 30 with P2S5 (93%), followed by ether cleavage with BBr3 (67%) (Scheme 
29). It is noteworthy that the chiral auxiliary can be recovered after this reaction in high yield (96%) 
and without any loss of enantiomeric purity (99.9% ee) (Figure 28). 
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Scheme 29 The Synthesis of the Chiral Auxiliary (S)-25 
 
 
Figure 28 HPLC traces of recovery of auxiliary. 
HPLC conditions: OD-H (250 × 4.6 mm); mobile phase: hexane/isopropanol = 99: 1; flow rate: 1.0 mL/min; 
254 nm; 25 oC. 
All these chiral catalysts are configurationally stable, as they did not show any significant sign of 
configurational lability or decomposition from 1H NMR and HPLC upon storage under N2 in a 
refrigerator (5 °C) for 3 months. 
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X-ray diffraction analyses showed that -IrS and -configuration of rac-IrO(NO2), rac-IrO(ada), 
rac-IrO(nap), rac-IrO(pyrene) are isostructural and all are six-coordinate monomers. The central 
metal in -IrS, rac-IrO(NO2), rac-IrO(ada), rac-IrO(nap) and rac-IrO(pyrene) is ligated by two 
cyclometalating ligands and two MeCN molecules. The six-coordinate metal can be described as an 
octahedron with two nitrogen atoms from two cyclometalating ligands repectively occupying the axial 
sites in an distorted fashion. The average Ir1-N(MeCN) bond lengths (2.121(7) Å for -IrS, 
2.1095(15) Å for rac-IrO(NO2), 2.110(2) Å for rac-IrO(ada), 2.1120(16) Å for rac-IrO(nap), 2.1163 
(17) Å for rac-IrO(pyrene)) are comparable to the corresponding values found in IrO (2.106(9) Å)11, 
but shorter than the cooresponding values found in rac-IrN(pyrene) (2.136(6) Å) or RhO (2.148(2) Å 
for Rh1-N(MeCN)8. 
 
3.2 Investigation for Asymmetric Lewis Acids Catalysis 
Many functional groups in organic chemistry are amenable to Lewis acid activation in a 
straightforward and predictable fashion and chiral Lewis acids are therefore attractive tools for 
effective asymmetric catalysis.10 One highly appealing goal in this area of research is the development 
of chiral Lewis acid catalysts which exhibit a broad generality with respect to reaction types and 
substrates. IrO11,12 and RhO8 complexes were found to be able to act as efficient chiral Lewis acid 
catalysts by our group. The octahedral metal center of these complexes is coordinated irreversibly by 
two cyclometalating bidentate ligands in a propeller-type fashion. Two additional exchange-labile 
coordinated acetonitriles allow substrates to become activated by two-point binding. These complexes 
are structurally quite simple and only contain achiral ligands, with metal-centered chirality being the 
exclusive source of chirality.2 Importantly, despite the two labile acetonitrile ligands, the catalysts are 
configurationally inert and retain their relative and absolute configurations throughout the catalysis. In 
this work, we demonstrate the high versatility of the iridium(III) complexes -IrO and -IrS as chiral 
Lewis acid catalysts for a variety of asymmetric reactions with acceptor-substituted alkenes, including 
Friedel–Crafts alkylations, Michael additions with CH-acidic compounds, and cycloadditions. 
 
3.2.1 Asymmetric conjugate additions by chiral-at-metal Lewis acids 
As shown in Scheme 30, the catalytic activity of the following six different octahedral Lewis acids 
complexes on the Michael addition of malonodinitrile was firstly tested. It is found that the 
performance of these new synthesized catalysts were worse than IrO, modifying the ligand by 
introduction electron withdrawing or electron donating group on the cyclometalated 
2-phenylbenzoxazole could not improve the activity of catalyst.  
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Scheme 30 Comparison of Different Octahedral Lewis Acid Catalysts for Michael Addition of Malonodinitrile 
We then were speculating that the derivative - and -IrS,12 in which the cyclometalated 
2-phenylbenzoxazole is replaced by a 2-phenylbenzothiazole, might provide a higher asymmetric 
induction due to the long C-S bonds which position the two tert-butyl groups closer to the two vacant 
coordination sites. Beside, we thought that the derivative - and -IrO(ada), in which the tert-butyl 
group at the cyclometalated 2-phenylbenzoxazole is replaced by an adamantyl group, would have a 
bigger steric hinderance due to the bigger size of adamantane. Thus - and -IrO(ada) might also 
provide the better asymmetric induction (see Figure 21). Based on the result and speculation, we 
focused on catalysts -IrO, -IrS, and -IrO(ada) for further study. 
 
3.2.1.1 Asymmetric Friedel-Crafts alkylations 
- and -IrO could efficiently catalyze the enantioselective Friedel-Crafts addition of indoles to 
,-unsaturated 2-acyl imidazoles.11 We compared our new catalysts to this reaction at the same 
conditions. 
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Figure 29 Chiral octahedral iridium (III) Lewis acid catalysis applied to Friedel-Crafts alkylations with 
,-unsaturated 2-acyl imidazole 31. Haohua Huo (PhD student in Meggers Group) did a preliminary 
exploration by using -IrO as catalyst. 
By using -IrS (1.0 mol%) as catalyst, the Friedel-Crafts alkylation of indole with 2-acyl imidazole 
31 afforded expected alkylation product (S)-36 with 99% ee at room temperature compared to 96% ee 
for -IrO (as shown in  Figure 29).13,14 However, -IrO(ada) failed to give the alkylation product 
(S)-36 with higher ee (only 93% ee). Then, we focused on comparison of -IrO and -IrS. The trend 
holds also for the Friedel-Crafts reaction with 3-dimethylaminoanisole, for which -IrS (2.0 mol%) 
affords (S)-37 in 97% yield and with higher 99% ee, compared to 94% ee when using -IrO (2 mol%) 
instead. In contrast, for 2-methoxyfuran14a,14b and pyrrole14a,14b,15 the respective Friedel-Crafts products 
(S)-38 and (S)-39 were obtained with almost equal enantioselectivities (as shown in Figure 29). 
Overall, compared to -IrO, -IrS generally requires somewhat elongated reaction time which can be 
attributed to the larger steric hinderance around the coordination sites.16 The larger steric hinderance 
of IrS was confirmed by a crystal structure. As shown in Figure 30, a plane through the iridium and 
two MeCN ligands was drawn. The distance between the quaternary carbon atoms of the tert-butyl 
groups and plane in IrS (4.82 Å) is shorter than that in IrO (5.10 Å).  
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Figure 30 Distances between the quaternary carbon atoms of the tert-butyl groups and the plane which through 
Iridium and MeCN ligands in IrS and IrO. 
Meantime, the reactions can be accelerated by raising the temperature without affecting much the 
enantioselectivity (Table 1). For example, increasing the temperature for the reaction 31(S)-37 from 
room temperature to 60 °C leads to full conversion in just 5 hours with only a slightly diminished 
enantioselectivity of 98% ee (Table 1, entry 5).  
Table 1 Friedel-Crafts Alkylation with ,-Unsaturated 2-Acyl Imidazoles: Effects of Temperaturea 
 
entry substrate product cat. loading temp (°C) time (h) yield (%)b ee (%)c 
1 R = Me (31) (S)-37 2.0 mol% r.t. 66 97 99 
2 R = Me (31) (S)-37 2.0 mol% 30 48 94 99 
3 R = Me (31) (S)-37 2.0 mol% 40 25 95 99 
4 R = Me (31) (S)-37 2.0 mol% 50 <20 99 98 
5 R = Me (31) (S)-37 2.0 mol% 60 5 96 98 
a Reaction conditions: 2-acyl imidazole 31 (0.20 mmol), 3-dimethylaminoanisole (0.60 mmol), in 
THF (0.1 mL). b Isolated yields. c Enantiomeric excess was determined by HPLC on chiral stationary 
phase. 
Interestingly, this reaction is insensitive to air, and the product (S)-37 was formed in a slight reduced 
yield (83% yield) with excellent enantioselectivity (99% ee) under the air (Table 2, entry 1). It is also 
noteworthy that the catalyst loading can be decreased for this reaction to 0.5 mol%, and the (S)-37 was 
still obtained in excellent yield (96% yield) with excellent enantioselectivity (98% ee) by just prolong 
the reaction time (Table 2, entry 2). The different acyl imidazole substrates 32-34 also provide the 
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respective Friedel-Crafts alkylation products (R)-40, (S)-41 and (S)-42 in high yields (81−99% yield) 
with excellent enantioselectivities (96−99% ee) (Table 2, entries 3-5). 
Table 2 Friedel-Crafts Alkylation with ,-Unsaturated 2-Acyl Imidazoles: Effects of Catalyst Loading
andSubstituents a 
 entry substrate product cat. loading temp (°C) time (h) yield (%)b ee (%)c 
1 d R = Me (31) (S)-37 2.0 mol% 40 25 83 99 
2 R = Me (31) (S)-37 0.5 mol% 60 32 96 98 
3 R = Ph (32) (R)-40 2.0 mol% 40 18 99 99 
4 R = CO2Et (33) (S)-41 2.0 mol% 40 24 95 99 
5 R = nBu (34) (S)-42 2.0 mol% 40 48 81 96 
a Reaction conditions: 2-acyl imidazoles 31-34 (0.20 mmol), 3-dimethylaminoanisole (0.60 mmol), in 
THF (0.1 mL). b Isolated yields. c Enantiomeric excess was determined by HPLC on chiral stationary 
phase. d Yield and enantioselectivity for the analogous reaction performed under air. 
 
3.2.1.2 Asymmetric Michael additions 
Next, we studied our catalysts on the asymmetric Michael additions, the addition of CH-acidic 
malonodinitrile and 1,3-dicarbonyl compounds to the Michael acceptor 31. 
1) Asymmetric addition of malononitrile 
By using -IrO at a loading of 1.0 mol%, the malonodinitrile addition product (S)-4317 was formed in 
a full conversion with 70% ee (Table 3, entry 1). Compared to -IrO, -IrS afforded the product with 
much higher enantioselectivity at the same conditions (84% ee, see entry 2). After conditions 
screening (entries 3-10), by using 1.2 equiv of malononitrile and 1.0 mol% of -IrS, the (S)-43 was 
generated in a yield of 95% with 90% ee at room temperature after 24 hours (entry 5). At the 
optimized conditions, -IrO afforded the product in a yield of 96% with a slightly lower ee (88% ee, 
see entry 11). -IrO(ada) was also tried for this reaction and gave the similar result with -IrS (96% 
yield and 90% ee, see entry 12). 
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Table 3 Asymmetric Addition of Malononitrilea 
 
entry catalystb solvent equiv of malononitrile concn.
c t (h) conv. (%)d ee (%)e 
1 -IrO (1.0) THF 3 1.0 M 18 >99 70 
2 -IrS (1.0) THF 3 1.0 M 14 >99  84 
3f -IrS (1.0) THF 3 1.0 M 40 >99 84 
4 -IrS (1.0) THF 3 0.5 M 40 >99 85 
5 -IrS (1.0) THF 1.2 0.5 M 24 >99 (95)g 90 
6 -IrS (2.0) THF 1.2 0.5 M 14 >99 90 
7 -IrS (1.0) THF 1.2 0.1 M 30 n.d. 80 
8 -IrS (1.0) Et2O 1.2 0.5 M 16 >99 88 
9 -IrS (1.0) cyclohexane 1.2 0.5 M 16 n.d. 54 
10 -IrS (1.0) iPrOH 1.2 0.5 M 16 n.d. 64 
11 -IrO (1.0) THF 1.2 0.5 M 16 >99 (96)g 88 
12 -IrO(ada) 
(1.0) 
THF 1.2 0.5 M 14 >99 (96)g 90 
a Reaction conditions: 2-acyl imidazoles 31 (0.20 mmol), malononitrile (0.24 mmol or 0.60 mmol), 
in THF, at room temperature. b Catalyst loading given in brackets. c Concentration of 2-acyl 
imidazoles 31. d Conversion is determined by 1H NMR. e Enantiomeric excess was determined by 
HPLC on chiral stationary phase. f The reaction is operated at 5 oC. g Isolated yield. The experiment 
in entry 1 was investigated by Haohua Huo (PhD student in Meggers group). 
 
2) Asymmetric addition of Meldrum's acid 
Then, the asymmetric addition of Meldrum’s acid was investigated (Table 4). By using -IrS (2.0 
mol%) as catalyst, the Micheal addition of Meldrum’s acid with 2-acyl imidazole 31 afforded expected 
product (S)-44 in a yield of 94% with 91% ee (entry 3) at room temperature compared to 81% ee for 
-IrO (entry 5). 
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Table 4 Asymmetric Addition of Meldrum's Acida 
 
entry catalystb  concn.c T (oC) t (h) conv. (%)d ee (%)e 
1 -IrO (1.0) 0.5 M r.t. 18 >99 64 
2 -IrS (1.0) 0.5 M r.t. 16 >99  80 
3 -IrS (2.0) 1.0 M r.t. 6 >99 (94)f 91 
4 -IrS (2.0) 1.0 M 5 20 >99 92 
5 -IrO (2.0) 1.0 M r.t. 6 >99 (93)f 81 
a Reaction conditions: 2-acyl imidazoles 31 (0.20 mmol), Meldrum's Acid (0.60 
mmol), in THF, at room temperature. b Catalyst loading given in brackets. c 
Concentration of 2-acyl imidazole 31. d Conversion is determined by 1H NMR. e 
Enantiomeric excess was determined by HPLC on chiral stationary phase. f Isolated 
yield. The experiment in entry 1 was investigated by Haohua Huo (PhD student in 
Meggers group). 
 
3) Generation of asymmetric quaternary stereocenters with Michael additions 
-IrO and -IrS are also suitable to catalyze the formation of an all-carbon quaternary stereocenter18. 
In the presence of -IrS (2.0 mol%), the reaction of tert-butyl 2-oxocyclopentane-1-carboxylate with 
2-acyl imidazole 31 afforded (S,S)-46 in 85% yield with 96% ee, and 1.5:1 dr compared to 53% yield 
with 90% ee for -IrO (dr = 1.8:1). The related Michael addition of 2,3-dihydro-1-oxo-1H- 
indene-2-carboxylic acid tert-butyl ester to 2-acyl imidazole 31 provided (S,S)-47 in 93% yield with 
97% ee and 22:1 dr by using -IrS (1.0 mol%). Compared to -IrS, -IrO afforded (S,S)-47 with the 
identical enantioselectivity (97% ee) albeit with lower diastereomeric ratio (dr = 10:1). (Figure 31) 
Next, a brief substrate scope was investigated by using -IrS as catalyst. tert-Butyl 5-oxo-6,7- 
dihydro-5H-indeno[5,6-d][1,3]dioxole-6-carboxylate reacted with 2-acyl imidazole 31 to afford 
(S,S)-48 in 72% yield with 97% ee and 11:1 dr. The related reaction of tert-butyl 
2-oxocyclopentane-1-carboxylate with different 2-acyl imidazoles 33, 34, 45 afforded the product 
(S,S)-49 (81% yield with 96% ee, and 15:1 dr), (S,S)-50 (20% yield with 85% ee, and 9:1 dr) and 
(S,S)-51 (87% yield with 96% ee, and 49:1 dr) respectively (Figure 31). The relative configuration of 
the main diastereomer of (S,S)-51 was assigned from a crystal structure (Figure 32). 
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Figure 31 Generation of asymmetric quaternary stereocenters with Michael additions.  
aReaction conditions: 2-acyl imidazoles (0.20 mmol), 1,3-dicarbonyl compounds (0.40 mmol), in THF, at 40 °C. 
bReaction conditions: 2-acyl imidazoles (0.20 mmol), 1,3-dicarbonyl compounds (0.40 mmol), in THF, at room 
temperature. Chuanyong Wang (PhD student in Meggers group) did the conditions screening for 46 and 47. 
 
Figure 32 The crystal structure of (S,S)-51. ORTEP drawing with 50% probability thermal ellipsoids. 
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3.2.1.3 Asymmetric cycloadditions 
Asymmetric cycloadditions with ,-unsaturated 2-acyl imidazoles by using -IrO and -IrS as 
catalysts were next investigated (Figure 33). Accordingly, the reaction of 31 with the nitrone catalyzed 
by 2.0 mol% of -IrS provided the 1,3-dipolar cycloaddition product 52 in a yield of 86% with 
excellent 98% ee, while virtually forming just one diastereomer (endo:exo >100:1). 19 , 20  The 
enantioselectivity was significantly lower by using -IrO (92% ee). In contrast, for the 
hetero-Diels-Alder reaction between 31 or 35 with 2,3-dihydrofuran under formation of the 
dihydropyrans 53 and 54, respectively, -IrO (2 mol%) turned out to be the catalyst of choice, 
providing higher yield with higher diastereo- and enantioselectivities (99% yield, 98% ee and 
endo/exo > 50:1 for 53; 81 yield, 99% ee and endo/exo > 50:1 for 54) than those of -IrS (80% yield, 
95% ee and endo/exo > 30:1 for 53; 40% yield, 99% ee and endo/exo > 20:1 for 54).21,22 At last, the 
Diels-Alder reaction of 31 with isoprene provided the desired product 55 with excellent enantio- and 
diastereoselectivities with -IrO and -IrS (76% yield, 98% ee and dr > 99:1 for -IrO; 56% yield, 
99% ee and dr > 99:1 for -IrS).23 
 
Figure 33 Chiral octahedral iridium(III) Lewis acid catalysis applied to cycloadditions with ,-unsaturated 
2-acyl imidazoles.  
Haohua Huo (PhD student in Meggers Group) did a preliminary exploration for 1,3-dipolar addition by using 
-IrO as catalyst and Bo Zhang (Master student in Meggers Group) did a preliminary exploration for 
Diels-Alder addition by using -IrO as catalyst. 
In order to determine the absolute and relative configuration of the Diels-Alder product, 2-acyl 
imidazole 55 was transformed into 56 by treatment with MeOTf (methylation of 55) and a base (DBU) 
(Scheme 31). The observed optical rotation of 56 is opposite to that of (1S, 6S)-56 in literature,24,25 
and absolute and relative configuration of 55 is 1R, 6R. 
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 Optical rotation of (1R, 6R)-56: 
[]D20 = 131.6° (c 0.7, CH2Cl2, 98% ee). 
Lit.24 : []D20 = +54 (c 0.055, CH2Cl2), (1S,6S)-56. 
Lit.25 : []D = +171 (c 1.0, CH2Cl2, 99% ee), (1S,6S)-56. 
 
Scheme 31 Assignment of the Absolute and Relative Configuration of the Diels-Alder Product 56 
3.2.1.4 Scope of acceptor-substituted alkenes 
After revealing that IrO and IrS catalyse the asymmetric conjugate addition of a wide variety of 
nucleophiles to ,-unsaturated 2-acyl imidazoles, the scope with respect to acceptor substituted 
alkenes was next investigated and the enantioselective Friedel-Crafts alkylation with 
3-dimethylaminoanisole was used as model reaction (Figure 34). 
 
Figure 34 Substrate scope with respect to electron acceptor substituted alkenes. aThe yield and ee were 
determined with the ester derivative. 
We were pleased to find that a significant number of the tested acceptor-substituted alkenes 
57-6714a,14b,26-34 proved to be suitable substrates, providing the expected products in high yields with 
high enantioselectivities, such as the benzimidazole 57 (86% yield, 96% ee),26 2-thiazole 58 (99% 
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yield, 98% ee),27 pyridine 59 (87% yield, 97% ee),28 pyrazoles 62 (86% yield, 98% ee), 63 (99% yield, 
95% ee),31 and α-ketoester 65 (99% yield, 95% ee).33 Apparently, only substrates that can efficiently 
coordinate to the iridium catalyst in a bidentate fashion give satisfactory results, whereas the simple 
,-unsaturated carboxylic ester 67 does not afford any product even at higher catalyst loadings of 5 
mol% and an elevated temperature of 60 °C. On the other hand, we do not have an explanation for the 
failing or sluggish conversion of some of the other substrates such as the 2-oxazolidinone 59 (no 
reaction),29 2-thiazolidinethione 61 (47% yield, 68% ee),30 phosphonate 64 (49% yield, 82% ee),31 and 
Weinreb amide 66 (no reaction).34 However, it is believed that the addition to ,-unsaturated 
ketoesters,33 ,-unsaturated N-acyl pyrazoles,31 ,-unsaturated 2-acyl thiazoles27, 35  and 
,-unsaturated 2-acyl imidazoles36 are particularly useful substrates since they are easily converted 
to a variety of different carbonyl compounds. 
 
3.2.1.5 Mechanistic considerations 
It is plausible that the catalytic cycle starts with the bidentate coordination of the ,-unsaturated 
carbonyl compound to the catalyst through the carbonyl and one additional moiety (e.g. imidazole, 
benzimidazole, pyrazole, pyridine or carboxylic ester) under release of the two labile acetonitrile 
ligands, thereby leading to the intermediate A (79, Figure 35). This two-point binding of the substrate 
increases the electrophilicity of the double bond and promotes a nucleophilic addition to the -position 
of the alkene. Figure 36 displays a crystal structure of such an intermediate A, namely the substrate 35 
coordinated to -IrO (Scheme 32). The space filling model of this structure also convincingly 
illustrates that the prochiral Si-face is shielded by one tert-butyl group and therefore guides the 
nucleophilic addition to the Re-face. This is consistent with the obtained absolute configuration of the 
addition products and leads to the intermediate enolate complex B, which after protonation, provides 
the bidentate coordinated substrate (intermediate C). The replacement of the coordinated product by a 
new substrate, followed by a new catalytic cycle, presumably occurs through an intermediate in which 
the product is monocoordinated and the sixth coordinate site either filled by acetonitrile or the new 
substrate (intermediate D, 80). Such formed iridium coordinated product was trapped for the 
conversion 3554. Figure 37 shows that the cycloaddition product 54 is coordinated to the catalyst 
through the imidazole moiety and an acetonitrile ligand is filling the remaining coordination sphere 
(also see Scheme 33). 
Chapter 3. Results and Discussion 
-50- 
 
Figure 35 Plausible mechanistic cycle for the reported asymmetric Lewis acid catalysis.
 
Scheme 32 Iridium-Coordinated Substrate (Intermediate A, 79) 
Nuc
=
 
Figure 36 Crystal structure obtained upon reaction of /-IrO with the substrate 35. See Experimental Part for 
more details. Only the -enantiomer is shown and the hexafluorophosphate counteranion is omitted for clarity. 
ORTEP drawing with 50% probability thermal ellipsoids and space filling representation with an adjusted 
orientation.  
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Scheme 33 Iridium-Coordinated Product (Intermediate D, 80) 
 
Figure 37 Crystal structure obtained upon the reaction of racemic /-IrO with substrate 35 over night, 
followed by the addition of 2,3-dihydrofuran. See Experimental Part for more details. Only the -enantiomer is 
shown and the hexafluorophosphate counteranion is omitted for clarity. ORTEP drawing with 50% probability 
thermal ellipsoids. 
Finally, kinetic experiments (Figure 38, see Experimental Part for more details) performed with the 
reaction 3137 revealed that the rate of the overall catalysis does not depend on the concentration of 
the nucleophile 3-dimethylaminoanisole but is directly proportional to the concentration of the 
,-unsaturated 2-acyl imidazole 31, thus demonstrating that rate determining step cannot be the 
nucleophilic addition to the iridium-coordinated substrate (conversion AB in Figure 35) but instead 
must be the replacement of iridium-coordinated product with a new substrate molecule (conversion 
DA in Figure 35). This is not unexpected because of the well known kinetic stability of coordinative 
bonds to iridium(III) in octahedral complexes. 
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Figure 38 Kinetic experiments to get insight into the rate determining step. Dependence of the conversion 
3137 as a function of substrate concentrations. 
In summary, the reactions discussed here reveal the versatility of the chiral-at-metal iridium(III) 
catalysts. It is quite remarkable that a single class of chiral Lewis acid catalysts is capable of 
effectively catalyzing different reaction types, as demonstrated for Friedel-Crafts alkylations 
(including indole (up to 99% ee), 3-dimethyl-aminoanisole (up to 99% ee), 2-methoxyfuran (up to 
94% ee), and pyrrole (up to 95% ee)), Michael additions of CH-acidic compounds (including 
malonodinitrile (up to 90% ee), and 1,3-dicarbonyl compounds (up to 97% ee)), and a variety of 
cycloadditions (including 1,3-dipolar cycloaddition (up to 98% ee, endo: exo > 100:1), 
hetero-Diels-Alder reactions (up to 99% ee, endo: exo > 50:1), and Diels-Alder reaction (up to 99% ee, 
d.r. >99:1)). A significant variability also exists with respect to the ,-unsaturated carbonyl substrates 
as long as they allow a two-point binding to the iridium catalyst. It is convincing that this novel class 
of chiral-only-at-metal catalysts are of significant practical value as they are accessible in a 
straightforward fashion, are unproblematic for long term storage, provide excellent yields and 
asymmetric inductions at low catalyst loadings, can be used at room temperature or slightly elevated 
temperatures, and do not require a stringent exclusion of air and moisture. 
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3.2.2 Generation of asymmetric quaternary stereocenters with the Henry reaction 
The asymmetric Henry reaction, namely the addition of nitroalkane with α-hydrogen to an aldehyde or 
ketone (form a β-nitro alcohol), is a highly useful C–C bond forming reaction and provides 
straightforward access to a variety of nitrogen-containing chiral building blocks and scaffolds. To our 
best of knowledge, there is no report about asymmetric Henry reaction with 2-acyl pyridine due to 
strong background reaction, and only one report that was dealt with the direct asymmetric Henry 
reaction with 2-acyl-pyridine N-oxides, leading to pyridine-derived tertiary nitroaldols as far. In 2014, 
Pedro reported the asymmetric addition of nitromethane to 2-acylpyridine N-oxides catalyzed by 
Cu(II)-BOX complexes to give the corresponding tertiary nitroaldols in variable yield (17–96% yield) 
with moderate to good enatiomeric excesses (48–96% ee).37 For their study, the high catalyst loading 
(20 mol%), low temperature (–30 oC) and long time (24–96 h) were necessary. These products can be 
easily transformed into pyridyl amino alcohols bearing a quaternary stereocenter which are very useful 
in the pharmaceutical industry, agrochemical industry and asymmetric catalysis.37 Some representative 
applications based on pyridyl amino alcohols38-41 are shown in Figure 39.  
 
Figure 39 Representative applications based on pyridyl aminoalcohols. 
We present that our -IrO and -IrS could act as effective asymmetric catalysts (4 mol% catalyst 
loading) for Henry reaction (up to 98% ee) at room temperature. Based on the reported literature37, 
nitromethane was chosen as solvent, in the presence of diisopropylamine (20 mol%) and -IrS (4 
mol%), the target product tertiary nitroaldol was obtained with modest enantiomeric excess of 76% ee 
within 50 min at room temperature (Table 5, entry 1). A solvent screening reveals that DCM, THF, 
toluene and Et2O provides the product with much better enantioselectivity (entry 4–7). Although 
reaction offered the best result by using Et2O as the solvent, by changing base from diisopropylamine 
to diisopropylethylamine led to a high ee of 91% at room temperature within 17 hours (entry 8), it was 
found that the product easilier racemize in this solvent at the same time. We therefore decided to use 
toluene as our solvent for the following study. Control experiment in the absence of base fails to 
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provide any product (entry 14). By comparison of catalysts -IrO, -IrS, and -RhO in this reaction, 
it was found that -IrO was the best option which afforded the product with the highest 
enantioselectivity (96% ee) (entry 15–17). 
Table 5 Screening of Solvents, Bases and Catalystsa 
 entry catalyst base solvent 50 min (“conv.”b; eec) 2 h (“conv. ” b; eec) 
1 -IrS iPr2NH MeNO2 75%; 76% ee n.d. 
2 -IrS iPr2NH MeOH 95%; 42% ee n.d. 
3 -IrS iPr2NH MeCN 7%; 11% ee n.d. 
4 -IrS iPr2NH CH2Cl2 56%; 87% ee 74%; 83% ee 
5 -IrS iPr2NH THF 59%; 86% ee 76%; 85% ee 
6 -IrS iPr2NH toluene 62%; 87% ee 78%; 86% ee 
7 -IrS iPr2NH Et2O 80%; 86% 90%; 83% 
8 -IrS iPr2NEt Et2O 26%; 94% ee 86% ; 91% ee (17 h) 
9 -IrS NEt3 Et2O 40%; 93% ee 71% ; 90% ee 
10 -IrS Et2NH Et2O 33%; 81% ee n.d. 
11 -IrS DBU Et2O 97%; 0% ee n.d. 
12 -IrS NaHCO3 Et2O No product n.d. 
13 -IrS Na2HPO4 Et2O No product n.d. 
14 -IrS No base Et2O No product n.d. 
15 -IrS iPr2NEt Et2O 26%; 94% ee 86% ; 91% ee (17 h) 
16 -RhO iPr2NEt Et2O 77% ; 96% ee 91% ; 93% ee 
17 -IrO iPr2NEt Et2O 52% ; 97% ee 81% ; 96% ee 
18 -IrO iPr2NEt toluene 54%; 98% ee (2 h) 76%; 97% ee (6 h) 
aConditions: 81 (0.05 mmol), base (20 mol%) with catalyst (4.0 mol%) in MeNO2/solvent 
(v/v= 1:4, 0.4 M for 81) under nitrogen. b“Conv.” is determined by HPLC, not real 
conversion. cEe determined by Chiral HPLC analysis. d n.d. = not determined. 
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Next, the substrate scope of catalyst -IrO in Henry reaction was tested (Scheme 34). The effect of 
substituents on the pyridine ring was first studied. The methyl group at 4, 5, 6 positions of the pyridine 
ring led to the corresponding products 95–97 in moderate yields (59–74% yield) with excellent 
enantioselectivities (91–98% ee), while the methyl group at 3 position of pyridine ring failed to give 
any product (94) which showed that this reaction was sensitive to the steric hinderance. The methoxyl, 
ethyl, n-propyl or phenyl group at 4 position of pyridine ring also gave the corresponding products 
98–101 in good yields (72–83% yield) with good enantioselectivities (85–93% ee). However, when 
the group in 4-position is tert-butyl group, the corresponding product 102 has only 52% ee. A substrate 
scope was also performed under optimized conditions with studied different aliphatic ketones. The 
high enantiomeric excesses (92–95% ee) of products 103 and 104 were obtained with ethyl or n-butyl 
ketones. Although the yield of these tertiary nitroaldols obtained under these conditions was not high, 
no other byproducts were formed and all of the unreacted starting material could be recovered. 
 
Scheme 34 Scope of Substrates 
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It is plausible that the catalytic cycle starts with the bidentate coordination of the 2-acylpyridine 
N-oxides to the catalyst. This two point binding of the substrate increases the electrophilicity of the 
carbonyl group and promotes a nucleophilic addition to the carbonyl group to form a tertiary nitroaldol. 
After ligand exchange, the product and regenerated intermediate I was formed. (Figure 40) 
 
Figure 40 Proposed mechanism of Henry reaction catalyzed by iridium catalysts. 
In summary, a direct asymmetric Henry reaction catalyzed by chiral-at-metal asymmetric catalysts was 
first reported. Λ-IrO could efficient catalyze this reaction to give the corresponding tertiary nitroaldols 
bearing a quaternary stereocenter that bonded to a pyridine ring in decent yields (up to 86% yield) 
with excellent enantioselectivities (up to 98% ee). This reaction showed that our chiral-at-metal 
catalysts are versatile. 
 
3.3 Investigation for Asymmetric Photoredox Catalysis 
In this section, a surprising finding that a bis-cyclometalated rhodium(III) complex RhO serves as a 
highly effective visible light activated chiral photoredox sensitizer for the enantioselective radical 
amination of 2-acyl imidazoles would be introduced. After this work, visible-light-induced aerobic 
dehydrogenative cross-coupling and alkylation of acyl imidazole by cyclometalated pyrene iridium 
complexes were explored preliminarily. 
3.3.1 Visible-light-induced enantioselective C-N bond formation 
3.3.1.1 Initial experiments of the Visible-Light-Induced C-N Bond Formation 
Our group recentnly developed the asymmetric photoredox alkylation of 2-acyl pyridines and 2-acyl 
imidazoles using iridium complexes which serve a dual function as catalytically active chiral Lewis 
acids and as visible light triggered photoredox catalysts. 42-44 Consequently, our study was initiated by 
investigating the reaction of 2-acyl imidazole 105 with the ODN-carbamate 117 in the presence of the 
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previously disclosed photoredox catalysts -IrO (2.0 mol%) or -IrS (2.0 mol%) under irradiation 
with blue LEDs, but failed to provide any C-N bond formation product (Table 6, entries 1 and 2). Even 
with the optimal substrate 107 (oTol group at imidazole) and longer reaction time (16 h), iridium 
catalyst rac-IrO cannot provide acceptable yields as shown for a number of standard solvents (Table 6, 
entries 3-8). 
Table 6 Initial Experiments of the Visible-Light-Induced C-N Bond Formation by IrO or IrSa 
 
entry catalyst R solvent t (h) yield (%)b 
1 -IrO (2.0) iPr DMSO/MeCN = 1/3 12 0 
2 -IrS (2.0) iPr DMSO/MeCN = 1/3 12 0 
3 rac-IrO (2.0) oTol DMSO/MeCN = 1/3 16 <2  
4 rac-IrO (2.0) oTol DCM 16 26  
5 rac-IrO (2.0) oTol THF 16 5  
6 rac-IrO (2.0) oTol Toluene 16 2  
7 rac-IrO (2.0) oTol CHCl3 16 9  
8 rac-IrO (2.0) oTol EtOAc 16 23  
a Conditions: 105 or 107 (0.40 mmol), 117 (0.20 mmol) and 2,6-lutidine (0.34 mmol) with 
catalyst (2.0 mol%) in solvent (1.0 mL) under nitrogen; 24 W blue LEDs as light source; at 
room temperature. b Yields are determined by 1H NMR and based on trimethyl(phenyl)silane as 
an internal standard. 
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Table 7 Preliminary Conditions Screeninga 
 
entry catalystb solvents base R t (h) yield (%)c ee (%)d 
1 -RhO (2.0) DMSO/MeCN=1/3 2, 6-lutidine iPr 12 44  80 
2 -RhO (2.0) DMSO/MeCN=1/3 2, 6-lutidine Ph 2 92 89 
3 -RhO (2.0) MeCN 2, 6-lutidine Ph 2 40 87 
4 -RhO (2.0) DMSO 2, 6-lutidine Ph 2 70 84 
5 -RhO (2.0) DMSO/MeCN=1/1 2, 6-lutidine Ph 2 80 89 
6 -RhO (2.0) NMP/MeCN=1/3 2, 6-lutidine Ph 2 50 86 
7 -RhO (2.0) DMF/MeCN=1/3 2, 6-lutidine Ph 2 63 88 
8 -RhO (2.0) THF 2, 6-lutidine Ph 2 trace n.d. 
9 -RhO (2.0) DMSO/MeCN=1/3 NaHCO3 Ph 3 75 87 
10 -RhO (2.0) DMSO/MeCN=1/3 DTBP Ph 16 trace n.d. 
11e -RhO (2.0) DMSO/MeCN=1/3 2, 6-lutidine Ph 3 47 89 
12f -RhO (2.0) DMSO/MeCN=1/3 2, 6-lutidine Ph 2 69 89 
13g -RhO (2.0) DMSO/MeCN=1/3 2, 6-lutidine Ph 2 81 89 
14h -RhO (2.0) DMSO/MeCN=1/3 2, 6-lutidine Ph 2 59 86 
15i -RhO (2.0) DMSO/MeCN=1/3 2, 6-lutidine Ph 2 93 89 
16 -RhPP (2.0) DMSO/MeCN=1/3 2, 6-lutidine Ph 2 <20 n.d. 
a Conditions: 105-106 (0.20 mmol, 2.0 equiv), 117 (0.10 mmol, 1.0 equiv) and base (0.17 mmol, 1.7 
equiv) with catalyst (2.0 mol%) in solvents (0.1 M for 117) under nitrogen, 24 W blue LEDs. b 
Catalyst loading given in brackets. c Isolated yields. d Chiral HPLC analysis. n.d. = not determined. e 
The reaction was conducted in the 0 – 10 oC. f 1.0 equiv of 2, 6-lutidine was used. g 1.0 equiv of 106
was used. h 1.0 equiv of 106 (0.10 mmol) and 2.0 equiv of 117 (0.2 mmol) were used in 
MeCN/DMSO (v/v = 3:1, 1.0 mL). i The concentration is 0.2 M for 117. 
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However, to our surprise and delight, when we tried the rhodium complex -RhO8,46 (2.0 mol%), the 
α-aminated 2-acyl imidazole 122 was obtained with 44% yield and with respectable 80% ee (Table 7, 
entry 1). Replacing the isopropyl substituent of the imidazole moiety with a phenyl (106) group 
improved the yield to 92% with 89% ee (entry 2). A brief solvent screening revealed that mixed 
solvents (DMSO/MeCN = 1/3) afforded the best result (entries 3-8). The different kinds of bases, 
ratios of starting materials, and temperatures were also tested but failed to give the better results 
(entries 9-14). Compared to entry 2, the higher concentration (0.2 M for 117) afforded a slightly better 
result (entry 15, 93% yield and 89% ee). -RhPP catalyst (it is synthesized by Yu Zheng–PhD student 
in Meggers group) canld not provide the product with an acceptable yield (entry 16). 
Table 8 Initial Experiments of the Visible-Light-Induced Enantioselective C-N Bond Formation by 
Rhodium Catalystsa 
O
N
N
oTol 2,6-lutidineMeCN/DMSO
visible light, r.t.
Ph
O
N
N
oTol
N
Ph
CO2Me
MeMeN CO2MeNDO
107
117
124
PF6
N
OtBu
Rh
N
OtBu
N
N
Me
Me
-RhO
PF6
N
S tBu
Rh
N
S tBu
N
N
Me
Me
-RhS  
entry catalystb hc t (h) product yield (%)d ee (%)e
1 -RhO (2.0) blue LEDs 2 (S)-124 96 97 
2 -RhO (2.0) CFL 4 (S)-124 94 97 
3 -RhO (1.0) blue LEDs 6 (S)-124 71 97 
4 -RhO (0.5) blue LEDs 10 (S)-124 65 95 
5 -RhO (2.0) none 16 -- 0 n.d. 
6 none blue LEDs 16 -- 0 n.d. 
7f -RhO (2.0) blue LEDs 6 (S)-124 38 97 
8 Sc(OTf)3 (2.0) blue LEDs 6 124 8 n.d. 
9 Mg(OTf)2 (2.0) blue LEDs 6 124 3 n.d. 
10 Λ-RhS (2.0) blue LEDs 2 (R)-124 96 >99.5 
a Conditions: 107 (0.40 mmol), 117 (0.20 mmol) and 2,6-lutidine (0.34 mmol) with 
catalyst (0.5–2.0 mol%) in MeCN/DMSO (v/v = 3:1, 1.0 mL) under nitrogen. b Catalyst 
loading given in brackets. c 24 W blue LEDs or 20 W CFL. d Isolated yields. e Chiral 
HPLC analysis. n.d. = not determined. f the analogous reaction was run under air. 
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Replacing the phenyl substituent of the imidazole moiety with an ortho-tolyl substituent (107) even 
provided excellent 96% yield with 97% ee (Table 8, entry 1). Intriguingly, a short photolysis time with 
blue LEDs of just 2 hours is sufficient to achieve full conversion. The reaction can also be activated 
with a regular compact fluorescent light bulb (CFL), although the reaction time doubles to 4 hours 
(94% yield and 97% ee, see entry 2). Lower catalyst loadings afford the C-N formation product in 
somewhat reduced yield but still with high enantioselectivity (95−97% ee, see entries 3 and 4). 
Importantly, control experiments in the absence of either light (entry 5) or rhodium catalyst (entry 6) 
fail to provide any product, thereby demonstrating that this catalytic, enantioselective C-N bond 
formation crucially depends on both the chiral rhodium complex and visible light. In the presence of 
oxygen, the product 124 can be isolated in a reduced yield (6 h, 38% yield) with excellent selectivity 
(97% ee) (entry 7). As further control experiments, simple Lewis acids such as Sc(OTf)3 or Mg(OTf)2 
are not capable of catalyzing this reaction to a significant degree (entries 8 and 9). At last, the new 
rhodium catalyst Λ-RhS, which was synthesized by Jiajia Ma (PhD student in Meggers group) 
recently, was also tried in this reaction. It is found that the determined enantioselectivitiy is 
appreciably higher for the benzothiazole catalyst (RhS, > 99.5% ee) over the benzoxazole catalyst 
(RhO, 97% ee) (entry 10). It is consistent and analogous with a comparison of the related benzoxazole 
and benzothiazole iridium complexes. 
 
3.3.1.2 Scope of substates 
Scheme 35 displays a substrate scope, revealing that substituents are well tolerated in the aromatic 
moiety in α-position to the carbonyl group (125−130; 81−99% yield and 92−98% ee) although a 
para-methoxy group reduces the yield and requires higher catalyst loadings (131; 52% yield and 97% 
ee). Furthermore, a naphthyl moiety affords the C-N formation product in 81% yield with 97% ee (132) 
and more bulky ODN-carbamates 118–121 provide excellent results (133−136; 62−99% yield and 97−
98% ee) (for example, the bulky ODN-carbamate with an isobutyl group at the nitrogen (120) 
affording the α-amination product 135 in 99% yield with 98% ee). However, it has to be noted that this 
reaction only works with aromatic substituents in α-position to the carbonyl group (137 is failed to be 
obtained), presumably to lower the pKa value of the methylene group.  
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Scheme 35 Scope of Substrates 
 
3.3.1.3 Assignment of the absolute and relative configuration of α-aminated 2-acyl imidazole 
In order to figure out the absolute configuration of α-aminated 2-acyl imidazole, the complexation 
with Δ-RhO was used as a handle to determine the absolute configuration of the product 124 (124 in 
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Scheme 36 is obtained by using Λ-RhO as a catalyst). X-ray analysis of 138, obtained by successive 
crystallizations from CH2Cl2 and n-hexane, indicates that α-aminated 2-acyl imidazole is an R 
configuration (Figure 41). In other words, the absolute configuration of α-aminated 2-acyl imidazole 
124 is an S configuration when Δ-RhO is used as a catalyst. The observed absolute configuration is in 
agreement with the model outlined in Figure 42. 
 
Scheme 36 Assignment of the Absolute Configuration of α-Aminated 2-Acyl Imidazole 124 
 
Figure 41 Crystal structure of 138. The hexafluorophosphate counteranion is omitted for clarity. ORTEP 
drawing with 50% probability thermal ellipsoids.  
 
Figure 42 Stereochemical model of reaction 
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3.3.1.4 Photo reaction in flow 
Conducting the photo reaction in flow has many advantages compared to that in batch: a higher 
surface area to volume to make more efficient to absorb the photons; a more predictable reaction 
scale-up; more safety, and improved reproducibility.47,48 Tthe photo reaction 107 with 117 was applied 
in flow reactor.  
A close up photograph of the assembled photo flow reactor is shown in Figure 43. The left picture is 
Vapourtec’s R-Series systems (flow system) and the right picture is a simple photo reactor (photo 
system. 6W blue LEDs; a total of 600 cm the PFA tube is wrapped in figureeights around the glass 
column). The photo reaction was first conducted on a 0.4 mmol scale (for 107) in flow. The product 
was obtained with 96% yield and 98% ee within 30 min. Performing this reaction in flow indeed 
afforded a much higher reaction rate than that in batch. This photo reaction was then tried on a 4 mmol 
scale (for 107), and we obtained a yield of 90% with 97% ee for a reaction time of 3 hours, which 
demonstrated that this reaction was scalable (on a gram scale) in flow system (Scheme 37).   
 
a) flow system                              b) photo system 
Figure 43 Photo flow reactor. 
 Scheme 37 Photo Reaction in Flow 
Reaction conditions: 2-acyl imidazole 107 (4.0 mmol), the amine reagent 117 (2.0 mmol), 2, 6-lutidine (3.4 mmol) 
with catalyst Δ-RhO (2.0 mol%) in MeCN/DMSO (v/v = 3:1, 20 mL) were irradiated with blue LEDs (6 W) 
under nitrogen (see Experimental Part for more details). 
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3.3.1.5 Mechanism of enantioselective C-N bond formation 
MacMillan recently reported a photoinduced enantioselective α-amination of aldehydes using 
2,4-dinitrophenylsulfonyloxy (ODN)-N- functionalized carbamates catalyzed via chiral secondary 
amines which was proposed to proceed through the intermediate formation of electron deficient 
aminyl radicals and their stereocontrolled reactions with chiral enamine intermediates.49 Combined 
MacMillan’s research with my work, a possible mechanism (Mechanism A) is shown in Figure 44.  
In MacMillan’s system, presumably, photonic excitation of amine yields excited amine*, which 
readily undergoes single-electron reduction and mesolysis of the weak N−O bond to yield the desired 
amine-centered radical and ODNs anion. In my system, the control experiments by using simple Lewis 
acid such as Sc(OTf)3 or Mg(OTf)2 instead of RhO are not capable of catalyzing this reaction to 
significant degrees, which did not support this mechansim (Mechanism A) (Table 8, entries 8-9).  
 
Figure 44 A possible mechanism for the visible light activated enantioselective rhodium catalysis (initiation via 
photolabile amine). 
Melchiorre recently reported a direct and effective method to install perfluoroalkyl and trifluoromethyl 
groups within the aromatic ring of a-cyano arylacetates. 50  This reaction is driven by the 
photochemical activity of in situ generated EDA complexes, formed by the aggregation of enolates 
and perfluoroalkyl iodides. For my system, is it possible that the reaction is driven by EDA complex 
(enolate as an electron donor and amine as an electron acceptor)? A possible mechanism involved 
EDA complex is shown in Figure 45 (Mechanism B).  
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Figure 45 A possible mechanism for the visible light activated enantioselective rhodium catalysis (initiation via 
EDA complex). 
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Figure 46 Optical absorption spectra recorded in MeCN/DMSO (v/v = 3/1) in quartz cuvettes (1 cm path). 
Mixed 106 (2.0 equiv), 117 (1.0 equiv) and base (2,6-lutidine, 1.7 equiv) in MeCN/DMSO (v/v = 3/1). 
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The color of solution changed soon, while its optical absorption spectrum showed a new peak near 520 
nm, diagnostic of an EDA complex (enolate as an electron donor and amine as an electron acceptor) 
(Figure 46). However, this new peak near 520 nm disappeared when rac-RhO (2 mol%) was added, 
which indicated that the formation of the EDA complex could be inhibited by rhodium complex. 
Accordingly, C-N bond formation in my system is not initiated by EDA complex. 
We then proposed another mechanism (Mechanism C, see Figure 47): The acyl imidazole substrate 
coordinates to the rhodium catalyst in a bidentate fashion (intermediate I) followed by a deprotonation 
of the α-methylene group which affords a neutral rhodium enolate complex (intermediate II). It is 
believed that this enolate II (139) has a crucial dual function. Firstly, it serves as an initiator and 
reinitiator, dubbed “smart initiator” by Studer and Curren,51 upon photoactivation (II + h  II*) by 
transfering a single electron (II* II+ + e-) to the ODN-carbamate which then fragments into a 
sulfonate anion and an aminyl radical. Secondly, enolate II contains a very electron rich double bond 
that reacts with the electrophilic nitrogen-centered radical in a stereocontrolled fashion. This provides 
a rhodium-coordinated ketyl (intermediate III) which is highly reducing and either donates an electron 
to the photosensitizer redox cycle to regenerate the oxidized photosensitizer (II+ + e-  II) or directly 
transfers a single electron to the ODN-carbamate, thereby propagating a chain process. 
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Figure 47 Putative mechanism for the visible light activated enantioselective rhodium catalysis. 
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A number of experiments strongly support this mechanism, such as isolation of the intermediate II, 
trapping experiments by TEMPO and N-methylindole, “light-dark” experiments, the determination of 
quantum yield, and kinetic study by NMR (ligand change experiments). 
(1) Crystal structure of the proposed enolate intermediate II 
The crystal structure of the proposed enolate intermediate II was obtained (Figure 48) and its catalytic 
competence was also confirmed (for the reaction 106 + 117 123 catalyzed by intermediate II, the 
product 123 is isolated in a yield of 91% after 2 hours, see Scheme 38). 
 
Figure 48 Crystal structure of the proposed key rhodium enolate intermediate II with the deprotonated substrate 
107. ORTEP drawing with 50% probability thermal ellipsoids. 
 
Scheme 38 Visible-Light-Induced C-N Bond Formation by Intermediate II 
 
(2) Trapping experiments 
The model reaction 107 + 117 124 is run by adding 5 equiv of TEMPO, a suppression of product 
formation below 10% in the presence of TEMPO (as well as a reduced yield in the presence of 
Chapter 3. Results and Discussion 
-68- 
oxygen , see Table 8, entry 9) support a radical mechanism (Scheme 39) (see Experimental Part for 
details).  
 
Scheme 39 Trapping Experiment by TEMPO 
Table 9 Verification of the Formation of Intermediate Nitrogen-Centered Radicals via Trapping 
Experiments[a] 
 entry catalyst imidazole substrate 106 yield (%)[b] 
1 RhO (2 mol%)  20 mol% 61 
2 RhO (2 mol%) -- 6 
3 no transition metal catalyst -- 4 
4 IrO (2 mol%) 20 mol% 77 
5 IrS (2 mol%) 20 mol% 78 
[a] Reaction conditions: N-methylindole (0.20 mmol), 117 (0.10 mmol), 106 (0.02 mmol or not) and 
2,6-lutidine (0.17 mmol) with catalyst (2.0 mol% or not) in MeCN/DMSO (v/v = 3:1, 0.5 mL) were 
irradiated with blue LEDs (24 W) under nitrogen. [b] Yields are determined by 1H NMR and based 
on trimethyl(phenyl)silane as an internal standard. 
Trapping reactions with N-methylindole as shown in Table 9 provide further very important insights 
into the mechanism: a) The observed amination of the 2-position (141) is indicative for a radical 
reaction through intermediate nitrogen-centered radicals. b) RhO is an effective catalyst only in the 
presence of catalytic amounts of 2-acyl imidazole (Table 9, entries 1 and 2), thereby being consistent 
with our proposal that the intermediate rhodium enolate complex II is responsible for the 
light-activated reductive formation of the nitrogen radical (the role of rhodium enolate II as the in situ 
generated photosensitizer is further corroborated by a 30 nm bathochromic wavelength shift of the 
long wavelength absorbance band compared to rac-RhO, see Experimental Part). c) In the complete 
absence of any transition metal catalyst only small amounts of product are formed, thus revealing that 
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MacMillan’s proposed mechanism 49 of a direct activation of the ODN-carbamate could be ignored in 
our system. d) For IrO and IrS in the presence of some 2-acyl imidazole, the indole amination product 
was obtained in high yields upon visible light activation (Table 9, entries 4 and 5). These mean that the 
incompetence of the established dual function chiral Lewis acid / photoredox catalysts IrO43 and 
IrS42,44 to catalyze the enantioselective C-N bond formation 107 + 117  124 is not related to the 
photoredox-induced formation of the nitrogen-centered radical intermediate.  
(3)“Light-dark”experiments 
One topic of debate has concerned the extent to which photoredox reactions involve chain process. 
Studying the reaction progress with alternating periods of irradiation and darkness (“light-dark” 
experiment) has commonly been used to resolve these processes.52  
Alternate irradiation (5 min) and dark intervals (60 min) reveal that after a photochemical initiation, 
the reaction proceeds to some degree in the dark (Figure 49), thereby lending support to a chain 
mechanism in which the electron transfer from the ketyl intermediate III to the ODN-carbamate 
dominates (apparently, light activation generates small amounts of intermediates or side products 
which can serve as inefficient initiators of new chain processes during the dark phase). 
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Figure 49 Light-dark interval reaction 106 + 117 123 under standard conditions. 
(4) Measurement of quantam yield 
Melchiorre and Yoon estimated the extent of chain processes in photoredox catalysis through the 
quantum yield measurements.53,54 In the quantum yield measurements, the closed catalytic cycle (no 
chain processes) exhibits a maximum theoretical quantum yield of 1. If the quantum yield is far more 
than 1 would suggest that the major mechanism for photoredox catalysis is chain mechanism.52 
The photon flux of light source was measured by standard ferrioxalate actinometry.55 A 150 W Xenon 
Chapter 3. Results and Discussion 
-70- 
lamp (50% of light intensity, 420±5 nm bandpass filter high transmittance) was used as the light 
source. The moles of products formed were determined by GC measurement (FID detector) using 
tetradecane as reference standard. A quantum yield (Φ) of 14 (λ = 420 nm) was determined for the 
model reaction (106 + 117 123), corroborating a radical chain mechanism as the main pathway (the 
determination of quantum yield is shown in Experimental Part, see Section 5.5.2.6.). Considering 
non-productive quenching and energy decay processes of the photoexcited rhodium enolate complex 
II, an even higher chain length can be assumed for this reaction.53 
(5) Kinetic study by NMR 
It is intriguing that the here introduced asymmetric photoredox amination works highly efficient with 
the rhodium catalyst RhO but fails to provide significant amounts of the desired C-N bond formation 
product with the established dual function chiral Lewis acid / photoredox catalysts IrO and IrS, which 
have been employed successfully for related enantioselective C-C bond formation reactions42-44. 
From single-crystal structural analysis of the catalysts, we can get some useful information. The 
average Metal−N(MeCN) bond distances of IrO, IrS, and RhO after subtracting the metal ionic radii 
(taking into account the differences in metal ionic radii56) are 1.426(9), 1.441(7), and 1.483(2) Å, 
respectively. Compared to Ir−N(MeCN) bond distances, Rh−N(MeCN) bond distance is longer. It 
indicates that the bond strength of the RhO−N(MeCN) is probably weaker than that of Ir−N(MeCN), 
and MeCN which coordinated to Rh might be easier replaced by other substrates. In other word, 
RhO-enolate may be formed faster than IrO/IrS-enolate. 
Therefore, the superiority of RhO over its iridium congeners in this reaction can rather be pinpointed 
to kinetic effects, namely the requirement of a high turnover frequency of the catalysis cycle. Amidyl 
radicals are known to be highly reactive electrophilic -type radicals57 which add to electron rich 
alkenes much faster than carbon-centered radicals.58,59 Such electrophilic nitrogen-centered radicals 
are also highly prone towards reduction.18 A concomitant short lifetime and fast reaction of the 
nitrogen-centered radical intermediate with the rhodium enolate II require a fast turnover frequency of 
the catalytic cycle in order to regenerate new rhodium enolate II rapidly enough as a reaction partner 
for the aminyl radical. 
In order to confirm our speculation, a series of ligand exchange experiments were conducted 
(exchange of the acetonitrile ligands against substrate 106) by proton NMR (Figure 50-52). As shown 
in Figure 50, mix the RhO and substrate 106 in CD3CN/DMSO-6d (v/v = 3/1) without 2,6-lutidine 
does not afford the rhodium enolate II, even does not afford intermediate I. However, the rhodium 
enolate II was generated very fast when 2,6-lutidine was added to the solution of rac-RhO and 106 in 
CD3CN/DMSO-6d (this ligand exchange reaction reached the dynamic equilibrium within 1 min, 77% 
conv., see Figure 51). The interesting thing is that the formation of iridium enolate (60 min, 2.8% 
conv.; 960 min, 35% yield, see Figure 52) in the same condition is much slower than the formation of 
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rhodium enolate II. Comparison of initial rates for an exchange of the acetonitrile ligands against 
substrate in RhO versus IrO demonstrates an increased rate constant for ligand exchange of the 
rhodium complex by 1650-fold (Scheme 40). 
On the other hand, the inferior photophysical properties of bis-cyclometalated rhodium over iridium 
complexes,60 resulting in a less efficient rhodium photoredox sensitizer, is not relevant for this 
reaction due to a highly efficient chain propagation as demonstrated by the observed high quantum 
yield. Thus, the rhodium enolate intermediate II serves as a smart initiator12 which is needed to initiate 
and from time to time to reinitiate the chain reaction after chain termination. 
 
Scheme 40 Ligand Exchange Kinetics 
 
Figure 50 The background of ligand exchange experiments with rac-RhO. 
a) To a mixture of rac-RhO (8.3 mg) and 106 (26.2 mg) in NMR tube was added CD3CN/DMSO-6d (v/v = 3/1); 
b) To a solution of rac-RhO (8.3 mg) in CD3CN/DMSO-6d (v/v = 3/1) was added 2, 6-lutidine (12 μL). 
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Figure 51 The ligand exchange experiments with rac-RhO. 
To a solution of rac-RhO (8.3 mg) and 106 (26.2 mg) in 0.6 mL of CD3CN/DMSO-6d (v/v = 3/1) was added the 
solution of 2, 6-lutidine (12μL) in 0.2 mL of CD3CN/DMSO-6d (v/v = 3/1); Note: when it was tested in 1 minute, 
don’t lock and shim the magnetic field in order to save time. 
  
Figure 52 The ligand exchange experiments with rac-IrO. 
To a solution of rac-IrO (9.2 mg) and 106 (26.2 mg) in 0.6 mL of CD3CN/DMSO-6d (v/v = 3/1) was added the 
solution of 2, 6-lutidine (12 μL) in 0.2 mL of CD3CN/DMSO-6d (v/v = 3/1). 
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In conclusions, a very efficient photoactivated enantioselective radical amination of 2-acyl imidazoles 
catalyzed by a chiral-at-metal rhodium complex, which serves a dual function, namely as a chiral 
Lewis acid to catalyze asymmetric enolate chemistry and furthermore as a light-activated smart 
initiator of a radical chain process was introduced. Intriguingly, under related conditions, previously 
developed iridium complexes fail to work in this context. This is attributed to much faster ligand 
exchange kinetics in the rhodium system which is required to match the high reactivity and short 
lifetime of the intermediate nitrogen-centered radicals. The inferior photosensitization properties of the 
rhodium system do not play a role here due to an efficient chain mechanism. Thus, this work 
demonstrates the importance of fine tuned kinetics for radical formation, propagation, and 
regeneration of key catalytic intermediates in photoredox catalysis. 
 
3.3.2 Investigation for other photoredox reactions by rac-IrO(pyrene) and 
rac-IrN(pyrene) 
Next, other photoreox reactions such as aerobic dehydrogenative cross-coupling, and photoinduced 
alkylation of acyl imidazole catalyzed by cyclometalated pyrene complexes (rac-IrO(pyrene) and 
rac-IrN(pyrene)) were also explored.  
3.3.2.1 Aerobic dehydrogenative cross-coupling by visible light 
The Pope group found that the cyclometalated pyrene complex of iridium(III) [Ir(L)2(bpy)](PF6) (L = 
1-butyl-2-(pyren-1-yl)-1H-benzo[d]imidazole) has much longer triplet excited state lifetimes (τT) and 
shows much larger rate constants compared to [Ir(ppy)2(bpy)](PF6).61 Inspired by Pope’s work, the 
new iridium complexes rac-IrO(pyrene) and rac-IrN(pyrene) with the pyrene group were 
investigated in our system. The visible-light induced aerobic dehydrogenative cross-coupling by 
cyclometalated pyrene complex of iridium was first tested.  
 
Scheme 41 Aerobic Dehydrogenative Cross-Coupling by Visible Light 
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As shown in Scheme 41, by using rac-IrO or rac-IrO(pyrene) (2.0 mol%) as catalyst, only 9% yield 
of the C-C coupling product was isolated. Disappointingly, rac-IrN(pyrene) afforded only trace 
product.  
3.3.2.2 Photoinduced alkylation of acyl imidazole 
Photoinduced alkylation of acyl imidazole catalyzed by cyclometalated pyrene complex of iridium 
was also investigated. As found for the aerobic dehydrogenative cross-coupling, the performance of 
rac-IrO(pyrene) was not better than that of rac-IrO. Meantime, rac-IrN(pyrene) failed to afford any 
product in this reaction. The bad performance of rac-IrN(pyrene) can be explained by the parameters 
of crystal structure. 
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Scheme 42 Photoinduced Alkylation of Acyl Imidazole 
As shown in Figure 53, a plane through the iridium and two MeCN ligands was drawn. The distance 
between the quaternary carbon atoms of the tert-butyl groups and plane in rac-IrN(pyrene) (4.43 Å) 
is 0.67 Å shorter than that in rac-IrO (5.10 Å). It indicates that the steric hinderance around the 
central iridium ion in rac-IrN(pyrene) is so larger that it decreased the activity of reactions 
dramatically.  
Although the performance of cyclometalated pyrentyl iridium complexes is not good for aerobic 
dehydrogenative cross-coupling and photoinduced alkylation of acyl imidazole, it still deserves us to 
have a further exploration in the future. 
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4.43 Å
 
Figure 53 Distances between the quaternary carbon atoms of the tert-butyl groups and the plane which through 
Iridium and MeCN ligands in rac-IrN(pyrene). 
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In this thesis, a number of octahedral metal complexes containing two bidentate cyclometalating 
ligands in addition to two labile acetonitrile ligands are designed and synthesized. Among these 
complexes, the octahedral chiral-at-metal iridium(III) complexes IrO and IrS are demonstrated to be 
effective chiral Lewis acid catalysts in a variety of asymmetric catalytic reactions; the octahedral 
chiral-at-metal rhodium(III) complex RhO is proved to be an efficient “2-in-1” catalyst for 
visible-light-activated enantioselective radical amination of 2-acyl imidazoles. 
1) The synthesis of octahedral metal complexes 
A number of racemic octahedral metal complexes which are tuned by modification of their ligands 
were synthesized (Scheme 43), in which chiral IrS and IrO(ada) were synthesized through a 
convenient auxiliary-mediated strategy developed in our laboratory (Scheme 43), chiral IrO or RhO 
were synthesized by published procedures. 
 
Scheme 43The Synthesis of Octahedral Metal Complexes 
2) Asymmetric catalysis by octahedral chiral-at-metal complexes 
We then demonstrated the high versatility of the iridium(III) complexes -IrO and -IrS as effective 
chiral Lewis acid catalysts (0.5−5.0 mol% catalyst loading) for a variety of asymmetric reactions with 
α,β-unsaturated carbonyl compounds, including Friedel-Crafts alkylations (up to 99% ee), Michael 
additions with CH-acidic compounds (up to 97% ee), cycloadditions (up to 99% ee with high d.r.), 
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and Henry reactions (up to 98% ee). (Scheme 44) 
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Scheme 44 Asymmetric Reactions Catalyzed by -IrO and -IrS
We studied the scope of acceptor-substituted alkene in addition to 2-acyl imidazoles for the 
Friedel-Crafts alkylation and found that a significant number of the tested acceptor-substituted alkenes 
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could be suitable substrates, providing the expected products in high yields with high 
enantioselectivities, such as the benzimidazole (86% yield, 96% ee), 2-thiazole (99% yield, 98% ee), 
pyridine (87% yield, 97% ee), pyrazoles (86% yield, 98% ee), (99% yield, 95% ee), and α-ketoester 
(99% yield, 95% ee).   
The mechanism of this Lewis acid catalysis was also studied, some important intermediates were trapped, 
together with kinetic experiments revealed that the rate of the overall catalysis does not depend on the 
concentration of the nucleophile but is directly proportional to the concentration of substrate that will 
coordinate to the iridium catalyst, thus demonstrating that rate determining step must be the 
replacement of iridium-coordinated product with a new substrate molecule. 
3) Visible-light-induced enantioselective C-N formation by octahedral chiral-at-metal complex 
Finally, it is found the chiral-at-metal rhodium complex RhO could catalyze a very efficient 
photoactivated enantioselective radical amination of 2-acyl imidazoles. Notably, related 
bis-cyclometalated iridium(III) complexes, which were previously demonstrated to serve as dual 
function photoredox/chiral Lewis acid catalysts for enantioselective C-C bond formation reactions, are 
not suitable for the here described enantioselective C-N bond formation chemistry. (Scheme 45) 
 
 
Scheme 45 Previous Work and This Study Regarding Catalytic Enantioselective Photoredox Chemistry with 
SingleTransition Metal Complexes  
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In this reaction, RhO serves a dual function, namely as a chiral Lewis acid to catalyze asymmetric 
enolate chemistry and furthermore as a light-activated smart initiator of a radical chain process.  
Scheme 46 displays a substrate scope, revealing that substituents are well tolerated in the aromatic 
moiety in α-position to the carbonyl group (up to 99% yield and 98% ee). However, it has to be noted 
that this reaction only works with aromatic substituents in α-position to the carbonyl group. 
 
Scheme 46 Scope of Substrates for Visible-Light-Induced Enantioselective C-N Formation
A mechanism was carefully proposed: the acyl imidazole substrate coordinates to the rhodium 
complex in a bidentate fashion (intermediate I) followed by a deprotonation of the α-methylene group 
which affords a neutral rhodium enolate complex (intermediate II, the crystal structure of II is 
obtained). It is believed that this enolate II has a crucial dual function. Firstly, it serves as an initiator 
and reinitiator upon photoactivation (II + h  II*) by transfering a single electron (II* II+ + e-) to 
the ODN-carbamate which then fragments into a sulfonate anion and an aminyl radical (the aminyl 
radical can be trapped by N-methylindole). Secondly, enolate II contains a very electron rich double 
bond that reacts with the electrophilic nitrogen-centered radical in a stereocontrolled fashion. This 
provides a rhodium-coordinated ketyl (intermediate III) which is highly reducing and either donates 
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an electron to the photosensitizer redox cycle to regenerate the oxidized photosensitizer (II+ + e-  II) 
or directly transfers a single electron to the ODN-carbamate, thereby propagating a chain process 
which is further confirmed by a determined quantum yield of 14 for this photochemical reaction. 
 
Figure 54 Proposed mechanism for the visible-light-activated enantioselective C-N formation. 
Notably, related previously reported iridium-based photoredox catalysts fail for the here described 
enantioselective radical C-N bond formation. This surprising preference for rhodium over iridium is 
pinpointed to much faster ligand exchange kinetics of the rhodium complexes involved in the catalytic 
cycle, which is crucial to keep pace with the highly reactive and therefore short-lived 
nitrogen-centered radical intermediate. 
 
4) Outlook 
Future work will be focused on designing and synthesizing more types of octahedral chiral-at-metal 
complexes, and exploring more reactions (such as C-H activiations, cascade reactions). In addition, the 
novel asymmetric photoinduced catalytic reactions by using boryl radicals/  alkoxyl radicals/ 
phosphonyl radicals/ sulfur radicals will also be explored. 
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5.1 Materials and Methods 
All reactions were carried out under an atmosphere of nitrogen with magnetic stirring. Catalytic 
reactions were performed using standard Schlenk glassware or simple glass vials.  
 
Solvents and Reagents 
Solvents were distilled under nitrogen from calcium hydride (CH3CN, CH2Cl2, DMF), 
sodium/benzophenone (THF), or magnesium turnings/iodine (MeOH). Dry dimethylsulfoxide (DMSO) 
is purchased from Sigma-Aldrich without further purification. 2,3-Dihydrofuran and isoprene were 
used after freshly distilled from calcium hydride. All other reagents were purchased from Sigma 
Aldrich, Alfa aesar, TCI, Acros, Fluorochem, and ChemPUR and used without further purification.  
 
Chromatographic Methods 
Flash column chromatography was performed with silica gel 60 M from Macherey-Nagel (irregular 
shaped, 230–400 mesh, pH 6.8, pore volume: 0.81 mL × g–1, mean pore size: 66 Å, specific surface: 
492 m2 × g–1, particle size distribution: 0.5% < 25 m and 1.7% > 71 m, water content: 1.6%). For 
thin layer chromatography (TLC) analysis throughout this work, Merck precoated TLC plates (silica 
gel 60 F254, 0.25 mm) were employed. 
 
Nuclear Magnetic Resonance Spectroscopy (NMR) 
1H NMR, proton coupled 19F NMR and proton decoupled 13C NMR spectra were measured at room 
temperature on a Bruker Avance 300 system (1H-NMR resonance: 300 MHz, 19F-NMR resonance: 282 
MHz, 13C-NMR resonance: 75 MHz) or Bruker Avance 500 system (1H-NMR resonance: 500 MHz, 
13C-NMR resonance: 125 MHz), equipped with an autosampler BACS-60 and analyzed using 
MESTRENOVA software.  
Chemical shifts are given in ppm on the δ scale, and were determined after calibration to the residual 
signals of the solvents, which were used as an internal standard. NMR standards were used as follows: 
1H NMR spectroscopy:  = 7.26 ppm (residual CHCl3 in CDCl3),  = 5.32 ppm (residual CHDCl2 in 
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CD2Cl2),  = 1.94 ppm (residual CHD2CN in CD3CN). Data are reported as: br = broad, s = singlet, d 
= doublet, t = triplet, q = quartet, m = multiplet; coupling constant(s) J is given in Hert (Hz) and was 
calculated by the program. Multiplicities of the signals are assigned as observed in the spectra, not 
according to theoretical expectations. 13C{1H} NMR spectroscopy:  = 77.0 ppm (CDCl3),  = 53.8 
ppm (CD2Cl2),  = 1.3 ppm and 118.3 ppm (CD3CN).  
 
Infrared Spectroscopy (IR)  
IR spectra were recorded on a Bruker Alpha FT-IR spectrophotometer. The absorption bands were 
indicated a wave numbers v (cm-1). All substances were measured as films or solids. 
 
Mass Spectrometry 
High-resolution mass spectra were recorded on a Bruker En Apex Ultra 7.0 TFT-MS instrument using 
ESI technique. Ionic masses are given in units of m/z for the isotopes with the highest natural 
abundance. 
 
High Performance Liquid Chromatography (HPLC) 
Chiral HPLC chromatography was performed with an Agilent 1200 HPLC system equipped with a 
quaternary pump, autosampler, column oven and variable wavelength detector and analyzed using 
CHEMSTATION B03.01 software. All the compounds in the thesis were detected by UV at λ = 254 
nm or 220 nm. The corresponding mobile phase, the type of the columns and the flow rate were 
specified in the individual procedures. 
 
Circular Dichroism Spectroscopy (CD) 
CD spectra were recorded on a JASCO J-810 CD spectropolarimeter in a 1 mm path length quartz 
cuvette. The parameters we used as follows: from 600 nm to 200 nm; data pitch (0.5 nm); bandwdith 
(1 nm); response (1 second); sensitivity (standard); scanning speed (50 nm/min); accumulation (3 
times). The concentration of the compounds for the measurements was 0.1 mM. 
 
Crystal Structure Analysis 
X-ray data were collected with a Bruker 3 circuit D8 Quest diffractometer with MoKa radiation 
(microfocus tube with multilayer optics) and Photon 100 CMOS detector at 115 K. Scaling and 
absorption correction was performed by using the SADABS1 software package of Bruker. Structures 
were solved using direct methods in SHELXS or SHELXT2, refined using the full matrix least squares 
procedure in SHELXL-20153, and drawn using DIAMOND4. The Flack parameter is a factor used to 
estimate the absolute configuration of the compounds.5 The hydrogen atoms were placed in calculated 
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positions and refined as riding on their respective C atom, and Uiso(H) was set at 1.2 Ueq(Csp2) and 
1.5 Ueq(Csp3). Disorder of PF6 ions, solvent molecules or phenyl and t-butyl groups was refined using 
restraints for both the geometry and the anisotropic displacement factors. 
 
Other Analysis 
Optical rotations were measured with a Perkin-Elmer 241 polarimeter or Krüss P8000-T polarimeter at 
20 oC or 25 oC in DCM. UV/Vis measurements were taken on a Spectra Max M5 microplate reader in 
a 10.0 mm quartz cuvette. Cut off and band-pass photochemical experiments have been performed 
using a 150W Xenon short arc lamp (USHIO INC. JAPAN) to irradiate the reaction mixture. 
 
5.2 Synthesis of Catalysts 
5.2.1 Synthesis of ligands 
5-tert-Butyl-2-phenylbenzo[d]oxazole (1) 
 
The compound was synthesized following a published procedure with slight modifications6. A 
solution of 2-amino-4-tert-butylphenol (0.825 g, 5.0 mmol) and benzaldehyde (0.530g, 0.5 mL, 5.0 
mmol) in m-xylene (16 mL) was stirred at 120 °C for 30 minutes. 4-Methoxy-TEMPO (46.5 mg, 5 
mol%) was added to the mixture and the reaction mixture was stirred at this temperature for a further 8 
h under an oxygen atmosphere. The reaction mixture was cooled to room temperature and 
concentrated under reduced pressure. The residue was purified by flash chromatography on silica gel 
(EtOAc/n-hexane = 1: 20) to obtain the product 1 (1.152 g, 4.6 mmol, 92% yield) as a white solid.  
1H NMR (300 MHz, CDCl3) δ 8.29 – 8.22 (m, 2H), 7.81 (d, J = 1.8 Hz, 1H), 7.56 – 7.48 (m, 4H), 7.42 
(dd, J = 8.6, 1.9 Hz, 1H), 1.40 (s, 9H). All spectroscopic data were in agreement with the literature.7 
 
5-(tert-Butyl)-2-phenylbenzo[d]thiazole (2) 
 
5-(tert-Butyl)-2-phenylbenzo[d]thiazole 2 could be synthesized according to the literature with slight 
modifications,8 a mixture of 1-bromo-4-(tert-butyl)-2-nitrobenzene9 (2.29 g, 8.9 mmol), sulfur (430 
mg, 13.4 mmol), and phenylmethanamine (2.38 g, 22.3 mmol) in pyridine (1.8 mL) was stirred under 
an atmosphere of nitrogen in a Schlenk tube at 100 oC for 16 h. After being cooled to room 
temperature, the volatiles were removed in vacuo. The crude reaction mixture was triturated with 
CH2Cl2 (3 mL × 5). The combined CH2Cl2 layers were concentrated and purified by silica gel column 
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chromatography (EtOAc/n-hexane = 1: 100) to afford the desired product 2 (1.92 g, 7.2 mmol, 81% 
yield) as a pale yellow solid. 1H NMR (300 MHz, CDCl3) δ 8.02 (dd, J = 1.9, 0.4 Hz, 1H), 7.95 – 7.99 
(m, 2H), 7.67 (dd, J = 8.5, 0.4 Hz, 1H), 7.32 – 7.38 (m, 4H), 1.30 (s, 9H). 13C NMR (75 MHz, CDCl3) 
δ 168.3, 154.7, 150.2, 133.9, 132.1, 131.0, 129.1, 127.6, 123.6, 121.1, 119.9, 35.1, 31.7. IR (film): ν 
(cm1) 2960, 2903, 2863, 1542, 1508, 1474, 1453, 1442, 1412, 1361 1316, 1282, 1260, 1243, 1210, 
1098, 1064, 1023, 963, 921, 880, 812, 770, 762, 736, 704, 687, 660, 606, 480, 411. HRMS (ESI, m/z) 
calcd for C17H18N1S1 [M+H]+: 268.1154, found: 268.1152. 
 
5-(tert-Butyl)-2-(4-fluorophenyl)benzo[d]oxazole (3) 
 
Starting from 4-fluorobenzaldehyde (0.737 g, 5.94 mmol), 2-amino-4-tert-butylphenol (1.000 g, 6.06 
mmol) and 4-methoxy-TEMPO (56 mg, 5 mol%) according to the general procedure for 1 to give 3 as 
a white solid (EtOAc/n-hexane = 1: 10; 1.520 g, 5.65 mmol, 95% yield). 1H NMR (300 MHz, CDCl3) 
δ 8.26 – 8.12 (m, 2H), 7.78 (dd, J = 1.8, 0.7 Hz, 1H), 7.42 (dd, J = 8.6, 0.7 Hz, 1H), 7.37 (dd, J = 8.6, 
1.8 Hz, 1H), 7.19 – 7.06 (m, 2H), 1.39 (s, 9H). 13C NMR (75 MHz, CDCl3) δ 166.3, 163.0, 162.2, 
148.8, 148.1, 142.0, 129.7, 129.5, 123.7, 123.6, 122.8, 116.5, 116.2, 115.9, 109.6, 34.9, 31.7. 19F NMR 
(282 MHz, CDCl3) δ – 107.6 (s, 1F). IR (film): ν (cm1) 2955, 2904, 2872, 1597, 1559, 1492, 1475, 
1460, 1426, 1411, 1389, 1362, 1330, 1286, 1266, 1219, 1199, 1152, 1127, 1095, 1078, 1053, 1008, 
926, 872, 840, 822, 803, 734, 710, 693, 650, 638, 630, 588, 540, 512, 459, 427, 413. HRMS (ESI, m/z) 
calcd for C17H17F1N1O1 [M+H]+: 270.1289, found: 270.1291. 
 
5-(tert-Butyl)-2-(4-(trifluoromethyl)phenyl)benzo[d]oxazole (4) 
 
Starting from 4-(trifluoromethyl)benzaldehyde (1.033 g, 5.94 mmol), 2-amino-4-tert-butylphenol 
(1.000 g, 6.06 mmol) and 4-methoxy-TEMPO (56 mg, 5 mol%) according to the general procedure 
for 1 to give 4 as a white solid (EtOAc/n-hexane = 1: 20; 1.850 g, 5.80 mmol, 98% yield). 1H NMR 
(300 MHz, CDCl3) δ 8.41 – 8.31 (m, 2H), 7.83 (d, J = 1.7 Hz, 1H), 7.81 – 7.73 (m, 2H), 7.52 (d, J = 
8.6 Hz, 1H), 7.46 (dd, J = 8.7, 1.8 Hz, 1H), 1.41 (s, 9H). 13C NMR (75 MHz, CDCl3) δ 161.6, 148.9, 
148.6, 141.8, 133.0, 132.6, 130.6, 127.7, 126.0, 125.91, 125.86, 125.8, 125.6, 123.6, 122.0, 116.8, 
109.9, 35.0, 31.7. 19F NMR (282 MHz, CDCl3) δ – 63.9 (s, 1F). IR (film): ν (cm1) 2972, 2956, 2869, 
1622, 1557, 1478, 1465, 1413, 1367, 1319, 1266, 1202, 1185, 1162, 1118, 1079, 1067, 1053, 1013, 
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926, 882, 846, 812, 749, 703, 650, 591, 553, 503, 461, 431, 407. HRMS (ESI, m/z) calcd for 
C18H17F3N1O1 [M+H]+: 320.1257, found: 320.1261.  
 
5-(tert-Butyl)-2-(4-nitrophenyl)benzo[d]oxazole (5) 
 
Starting from 4-nitrobenzaldehyde (0.896 g, 5.94 mmol), 2-amino-4-tert-butylphenol (1.000 g, 6.06 
mmol) and 4-methoxy-TEMPO (56 mg, 5 mol%) according to the general procedure for 1 to give 5 as 
a pale yellow solid (put it in the fridge (4 oC) over night to give pale yellow crystal which was washed 
by n-hexane; 1.278 g, 4.32 mmol, 73% yield). 1H NMR (300 MHz, CDCl3) δ 8.45 – 8.37 (m, 4H), 
8.37 – 8.32 (m, 2H), 7.83 (dd, J = 1.8, 0.8 Hz, 1H), 7.53 (dd, J = 8.7, 0.8 Hz, 2H), 7.49 (dd, J = 8.7, 
1.7 Hz, 1H), 1.40 (s, 9H). 13C NMR (75 MHz, CDCl3) δ 160.7, 149.2, 149.0, 148.9, 141.8, 132.9, 
128.2, 124.2, 124.1, 117.0, 110.0, 77.4, 77.0, 76.6, 35.0, 31.7. IR (film): ν (cm1) 2964, 2907, 2869, 
1617, 1604, 1552, 1521, 1477, 1422, 1409, 1396, 1366, 1342, 1321, 1303, 1291, 1270, 1221, 1196, 
1135, 1107, 1081, 1054, 1007, 937, 928, 877, 853, 814, 759, 718, 703, 648, 532, 484, 469, 457, 420. 
HRMS (ESI, m/z) calcd for C17H17N2O3 [M+H]+: 297.1234, found: 297.1237. 
 
5-(tert-Butyl)-2-(4-methoxyphenyl)benzo[d]oxazole (6) 
 
Starting from 4-fluorobenzaldehyde (0.809 g, 5.94 mmol), 2-amino-4-tert-butylphenol (1.000 g, 6.06 
mmol) and 4-methoxy-TEMPO (56 mg, 5 mol%) according to the general procedure for 1 to give 6 as 
a white solid (EtOAc/n-hexane = 1: 15; 1.650 g, 5.87 mmol, 99% yield). 1H NMR (300 MHz, CDCl3) 
δ 8.22 – 8.14 (m, 1H), 7.77 (dd, J = 1.9, 0.6 Hz, 1H), 7.46 (d, J = 8.6 Hz, 1H), 7.38 (dd, J = 8.6, 1.9 
Hz, 1H), 7.06 – 6.99 (m, 2H), 3.88 (s, 3H), 1.39 (s, 9H). 13C NMR (75 MHz, CDCl3) δ 163.3, 162.2, 
148.7, 147.9, 142.1, 129.3, 122.3, 119.9, 116.2, 114.3, 109.5, 55.4, 34.9, 31.8. IR (film): ν (cm1) 3071, 
2973, 2952, 2905, 1606, 1582, 1559, 1498, 1474, 1463, 1440, 1417, 1390, 1361, 1338, 1318, 1302, 
1253, 1224, 1202, 1184, 1169, 1118, 1108, 1056, 1025, 1006, 933, 922, 868, 835, 811, 787, 737, 699, 
652, 643, 629, 588, 553, 516. HRMS (ESI, m/z) calcd for C18H20N1O2 [M+H]+: 282.1489, found: 
282.1489.  
 
Chapter 5. Experimental Part 
-92- 
 
4-((3r,5r,7r)-Adamantan-1-yl)-2-nitrophenol 144 
 
Compound 144 was synthesized following a published procedure.10 To a solution of 175 μL 94% 
HNO3 in 1.5 mL of glacial acetic acid was added to a suspension of 1.00 g (4.38 mmol) of 
4-(1-adamantyl)phenol in 15 mL of glacial acetic acid dropwise under vigorous stirring at room 
temperature. The reaction mixture was stirred for 30 min and poured into crushed ice, and the 
precipitate was separated by filtration and washed with water until the washings were neutral. The 
precipitale was dried under reduced pressure to give the crude product 144 (1.15 g, 4.21 mmol, 96% 
yield) which was used without further purification. 1H NMR (300 MHz, CDCl3) δ 10.47 (s, 1H), 8.02 
(d, J = 2.4 Hz, 1H), 7.63 (dd, J = 8.8, 2.4 Hz, 1H), 7.10 (d, J = 8.8 Hz, 1H), 2.12 (p, J = 3.0 Hz, 3H), 
2.00 – 1.84 (m, 6H), 1.84 – 1.70 (m, 6H). All spectroscopic data were in agreement with the 
literature.10   
 
5-((3r,5r,7r)-Adamantan-1-yl)-2-phenylbenzo[d]oxazole (7) 
 
5-((3r,5r,7r)-Adamantan-1-yl)-2-phenylbenzo[d]oxazole 7 was synthesized according to a published 
procedure with some modifications.11 4-((3r,5r,7r)-Adamantan-1-yl)-2-nitrophenol 144 (500 mg, 1.83 
mmol) was added to a mixture of indium powder (420 mg, 3.66 mmol) and acetic acid (1.0 mL, 18.3 
mmol) in toluene (6 mL), and then trimethyl orthoester (689 mg, 3.66 mmol) was added. The reaction 
mixture was stirred at 100 oC under a nitrogen atmosphere. After the reaction was complete, the 
reaction mixture was diluted with CH2Cl2 (20 mL), filtered through Celite, poured into sat. aq. NH4Cl 
solution (20 mL), and then extracted with CH2Cl2 (20 mL×3). The combined organic extracts were 
dried over Na2SO4, filtered, and concentrated. The residue was eluted with ethyl acetate/hexane 
(EtOAc/n-hexane = 1: 15) through a silica gel column to give the corresponding the desired product 7 
(431 mg, 1.31 mmol, 72% yield) as a white solid. 1H NMR (300 MHz, CDCl3) δ 8.33 – 8.19 (m, 2H), 
7.78 (d, J = 1.8 Hz, 1H), 7.52 (dd, J = 7.5, 3.8 Hz, 4H), 7.41 (dd, J = 8.6, 1.9 Hz, 1H), 2.14 (s, 3H), 
2.03 – 1.89 (m, 6H), 1.88 – 1.72 (m, 6H). 13C NMR (75 MHz, CDCl3) δ 163.1, 148.8, 148.5, 142.1, 
131.3, 128.9, 127.5, 127.4, 122.4, 116.2, 109.7, 43.7, 36.8, 36.4, 29.0. IR (film): ν (cm1) 2908, 2846, 
1550, 1474, 1448, 1425, 1332, 1321, 1283, 1263, 1246, 1203, 1186, 1127, 1102, 1052, 1023, 977, 933, 
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925, 870, 851, 813, 798, 778, 706, 687, 649, 637, 489, 455, 435, 422. HRMS (ESI, m/z) calcd for 
C23H24N1O1 [M+H]+: 330.1852, found: 330.1855. 
 
5-(tert-Butyl)-2-(naphthalen-1-yl)benzo[d]oxazole (8) 
 
Starting from 1-naphthaldehyde (0.928 g, 5.94 mmol), 2-amino-4-tert-butylphenol (1.000 g, 6.06 
mmol) and 4-methoxy-TEMPO (56 mg, 5 mol%) according to the general procedure for 1 to give 8 as 
a brown oil (EtOAc/n-hexane = 1: 10; 1.780 g, 5.91 mmol, 99% yield). 1H NMR (300 MHz, CDCl3) δ 
9.49 (d, J = 8.6 Hz, 1H), 8.43 (dd, J = 7.4, 1.3 Hz, 1H), 8.03 (d, J = 8.2 Hz, 1H), 7.98 – 7.84 (m, 2H), 
7.78 – 7.66 (m, 1H), 7.66 – 7.53 (m, 3H), 7.48 (dd, J = 8.6, 1.9 Hz, 1H), 1.44 (s, 9H). 13C NMR (75 
MHz, CDCl3) δ 162.7, 148.0, 147.7, 142.2, 133.8, 131.9, 130.5, 128.9, 128.4, 127.6, 126.3, 126.1, 
124.7, 123.5, 122.8, 116.6, 109.4, 34.8, 31.7. IR (film): ν (cm1) 3050, 2958, 2902, 2864, 1541, 1509, 
1479, 1459, 1424, 1396, 1362, 1327, 1284, 1269, 1257, 1218, 1202, 1180, 1134, 1110, 1072, 973, 918, 
875, 852, 803, 771, 741, 719, 662, 651, 578, 538, 432. HRMS (ESI, m/z) calcd for C21H20N1O1 
[M+H]+: 302.1539, found: 302.1543.  
 
5-(tert-Butyl)-2-(pyren-1-yl)benzo[d]oxazole (9) 
 
Starting from pyrene-1-carbaldehyde (1.380 g, 6.00 mmol), 2-amino-4-tert-butylphenol (1.000 g, 6.06 
mmol) and 4-methoxy-TEMPO (56 mg, 5 mol%) according to the general procedure for 1 to give 9 as 
a yellow solid (EtOAc/n-hexane = 1: 10; 2.050 g, 5.47 mmol, 91% yield). 1H NMR (300 MHz, CDCl3) 
δ 9.76 (d, J = 9.4 Hz, 1H), 8.88 (d, J = 8.1 Hz, 1H), 8.36 – 8.22 (m, 4H), 8.17 (d, J = 9.0 Hz, 1H), 8.08 
(dd, J = 15.1, 7.6 Hz, 2H), 7.99 (d, J = 1.7 Hz, 1H), 7.62 (d, J = 8.6 Hz, 1H), 7.50 (dd, J = 8.6, 1.9 Hz, 
1H), 1.47 (s, 9H). 13C NMR (75 MHz, CDCl3) δ 1163.5, 148.3, 148.0, 142.5, 133.2, 131.0, 130.5, 
129.7, 129.2, 129.0, 127.3, 127.0, 126.1, 126.0, 125.8, 125.3, 124.8, 124.4, 124.2, 122.8, 120.2, 116.7, 
109.6, 35.0, 31.8. IR (film): ν (cm1) 3040, 2949, 2899, 2863, 1596, 1584, 1548, 1533, 1504, 1478, 
1433, 1423, 1386, 1330, 1259, 1214, 1189, 1135, 1118, 1073, 1016, 969, 937, 922, 879, 879, 870, 855, 
843, 817, 798, 764, 753, 730, 706, 680, 648, 596, 504, 456, 410, 400. HRMS (ESI, m/z) calcd for 
C27H22N1O1 [M+H]+: 376.1696, found: 376.1698.  
 
5-(tert-Butyl)-1-butyl-2-(pyren-1-yl)-1H-benzo[d]imidazole (10) 
Chapter 5. Experimental Part 
-94- 
 
Pyrene-1-carbaldehyde (920 mg, 4.00 mmol) and 4-(tert-butyl)benzene-1,2-diamine (656 mg, 4.00 
mmol) were heated at 120oC in nitrobenzene (14 mL) for 18 h. After cooling to room temperature, the 
mixture was concentrated in vacuo. The residue was purified by flash chromatography on silica gel 
(n-hexane to EtOAc/n-hexane = 1: 3) to afford the 5-(tert-butyl)-2-(pyren-1-yl)-1H-benzo[d]imidazole 
(1.20 g, 3.21 mmol, 80% yield) as a yellow solid. To a mixture of 
5-(tert-butyl)-2-(pyren-1-yl)-1H-benzo[d]imidazole (374 mg, 1.00 mmol), 1-bromobutane (158 mg, 
1.15 mmol) and tetrabutylammonium iodide (152 mg, 0.41 mmol) was added sodium hydroxide 
solution (in 12.5 mL of pentan-3-one). The mixture was stirred at 100 oC for 12 h. The solution was 
then removed in vacuo. The crude product was dissolved in DCM (15 mL), and washed with water. 
The organic phase was concentrated and purified by flash chromatography on silica gel 
(EtOAc/n-hexane = 1: 4) to afford the target product 10 (184 mg, 0.43 mmol, 43% yield) as a yellow 
oil. 1H NMR (300 MHz, CDCl3) δ 8.35 – 8.13 (m, 6H), 8.12 – 8.01 (m, 3H), 7.93 (d, J = 9.2 Hz, 1H), 
7.53 (dd, J = 8.6, 1.7 Hz, 1H), 7.48 (d, J = 8.5 Hz, 1H), 4.07 (t, J = 7.3 Hz, 2H), 1.68 – 1.55 (m, 2H), 
1.48 (s, 9H), 1.11 – 0.95 (m, 2H), 0.60 (t, J = 7.3 Hz, 3H). 13C NMR (75 MHz, CDCl3) δ153.0, 145.8, 
143.4, 133.0, 132.2, 131.2, 130.8, 130.4, 128.7, 128.5, 127.9, 127.2, 126.3, 125.8, 125.6, 125.1, 124.7, 
124.6, 124.43, 124.37, 120.8, 116.3, 109.5, 44.4, 34.9, 31.9, 31.7, 19.7, 13.3. IR (film): ν (cm1) 3041, 
2956, 2865, 1618, 1604, 1583, 1477, 1455, 1431, 1393, 1363, 1330, 1282, 1260, 1243, 1198, 1179, 
1081, 1032, 925, 925, 906, 845, 817, 760, 726, 717, 682, 655, 638, 613, 505, 458, 399. HRMS (ESI, 
m/z) calcd for C31H31N2 [M+H]+: 431.2482, found: 431.2484. 
 
5.2.2 Synthesis of chloro-bridged Ir or Rh dimers 
N,N-trans-Iridium Complex rac-11 
 
The N,N-trans-iridium complex rac-11 was synthesized according to a route developed by Nonoyama 
for iridium(III) μ-chloro-bridged dimers with related cyclometalated ligands, which involves refluxing 
IrCl3•nH2O with 2–2.5 equivalents of cyclometalating ligand in a 3:1 mixture of 2-methoxyethanol 
and water.12 Accordingly, 5-tert-butyl-2-phenylbenzo[d]oxazole 1 (979 mg, 3.90 mmol) was added to 
iridium chloride hydrate (671 mg, 1.90 mmol) in a mixture of 2-ethoxyethanol/water (3:1, 80 mL). 
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The reaction mixture was heated at 130 °C for 24 h under nitrogen. The resulting precipitate was 
collected by centrifugation, washed with diethyl ether and dried to yield the product rac-11 (1.16 g, 
0.80 mmol, 84% yield) as a yellow solid. 1H NMR (300 MHz, CD2Cl2) δ 8.40 – 8.27 (m, 4H), 7.58 (dd, 
J = 7.6, 1.3 Hz, 4H), 7.36 – 7.16 (m, 8H), 6.88 (dd, J = 11.0, 3.9 Hz, 4H), 6.64 (td, J = 7.5, 1.3 Hz, 
4H), 6.09 (d, J = 7.8 Hz, 4H), 1.25 (s, 36H). All spectroscopic data were in agreement with the 
literature.12   
 
N,N-trans-Rhodium Complex rac-12 
 
The N,N-trans-rhodium complex rac-12 was synthesized according to a route reported by Mesmaeker 
for rhodium(III) μ-chloro-bridged dimers with related cyclometalated ligands. Accordingly, 
5-tert-butyl-2-phenyl-benzo[d]oxazole 1 (1.014 g, 4.04 mmol) was added to RhCl3•3H2O (524 mg, 
2.00 mmol) in a mixture of 2-ethoxyethanol and water (3:1, 88 mL). The reaction mixture was heated 
at 120°C for 21 h under an atmosphere of nitrogen. The resulting precipitate was collected by 
centrifugation, washed with methanol and dried to obtain the product rac-12 (940 mg, 0.74 mmol, 
74% yield) as a pale yellow solid. 1H NMR (300 MHz, CD2Cl2) δ 8.38 (t, J = 1.3 Hz, 4H), 7.65 (dd, J 
= 7.6, 1.2 Hz, 4H), 7.22 (d, J = 1.2 Hz, 8H), 6.97 (td, J = 7.4, 1.1 Hz, 4H), 6.76 (td, J = 7.6, 1.6 Hz, 
4H), 6.12 (d, J = 7.8 Hz, 4H), 1.22 (s, 36H). All spectroscopic data were in agreement with the 
literature.15 
 
N,N-trans-Iridium Complex rac-13 
 
The N,N-trans-iridium complex rac-13 was synthesized by the same method for synthesizing rac-11. 
5-(tert-butyl)-2-phenylbenzo[d]thiazole 2 (1040 mg, 3.90 mmol) was added to iridium chloride 
hydrate (686 mg, 1.95 mmol) in a mixture of 2-ethoxyethanol/water (3:1, 88 mL). The reaction 
mixture was heated at 130 °C for 18 h under nitrogen. The resulting precipitate was collected by 
centrifugation, washed with n-hexane and dried to yield the product rac-13 (1.07 g, 0.70 mmol, 72% 
yield) as a yellow solid. 1H NMR (300 MHz, CDCl3) δ 8.86 (d, J = 1.5 Hz, 4H), 7.44 (dd, J = 7.6, 0.9 
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Hz, 4H), 7.38 (d, J = 8.5 Hz, 4H), 7.26 (dd, J = 8.5, 1.8 Hz, 4H), 6.73 (t, J = 7.4 Hz, 4H), 6.44 – 6.28 
(m, 4H), 6.01 (d, J = 7.7 Hz, 4H), 1.24 (s, 36H). 13C NMR (75 MHz, CDCl3) δ 179.0, 151.5, 149.9, 
146.3, 141.9, 134.0, 128.9, 127.5, 125.1, 122.1, 121.4, 121.2, 120.3, 35.5, 31.8. IR (film): ν (cm1) 
2961, 1580, 1460, 1438, 1411, 1292, 1280, 1262, 1247, 1104, 1079, 1025, 993, 808, 797, 781, 753, 
731, 720, 697, 689, 668, 459, 381. 
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N,N-cis-Iridium Complex rac-14 
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The N,N-cis-iridium complex rac-14 was synthesized by the same method for synthesizing rac-11. 
5-(tert-Butyl)-2-(4-fluorophenyl)benzo[d]oxazole 3 (928 mg, 3.45 mmol) was added to iridium 
chloride hydrate (608 mg, 1.73 mmol) in a mixture of 2-ethoxyethanol/water (3:1, 76 mL). The 
reaction mixture was heated at 130 °C for 18 h under nitrogen. The resulting precipitate was collected 
by centrifugation, washed with MeOH and dried to yield cis-iridium product rac-14 (1.04 g, 0.68 
mmol, 79% yield, contained 33% trans rac-14) as a yellow solid. 1H NMR (300 MHz, CDCl3) δ 8.15 
– 8.10 (m, 2H), 7.80 (dd, J = 8.5, 5.7 Hz, 2H), 7.61 – 7.52 (m, 2H), 7.39 (dd, J = 11.2, 2.4 Hz, 2H), 
7.30 – 7.27 (m, 4H), 7.25 (d, J = 3.4 Hz, 2H), 7.08 (dd, J = 8.7, 1.9 Hz, 2H), 6.99 (td, J = 8.7, 2.5 Hz, 
2H), 6.50 (td, J = 8.6, 2.5 Hz, 2H), 6.01 (dd, J = 10.3, 2.5 Hz, 2H), 5.82 (d, J = 1.5 Hz, 2H), 1.24 (s, 
18H), 0.60 (s, 18H). IR (film): ν (cm1) 2960, 2908, 2868, 1596, 1562, 1520, 1480, 1450, 1428, 1391, 
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1367, 1325, 1297, 1272, 1244, 1197, 1128, 1116, 1082, 1055, 1029, 931, 886, 865, 833, 804, 754, 745, 
701, 647, 592, 572, 452. 
 
N,N-trans-Iridium Complex rac-15 
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OtBu
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The N,N-trans-iridium rac-15 was synthesized by the silimar method for synthesizing rac-11 with 
some modifications. 5-(tert-Butyl)-2-(4-fluorophenyl)benzo[d]oxazole 3 (307 mg, 1.14 mmol) was 
added to iridium chloride hydrate (168 mg, 0.48 mmol) in 2-ethoxyethanol (16 mL). The reaction 
mixture was heated at 145 °C for 18 h under nitrogen. After cooling to room temperature, the mixture 
was added 1 N HCl. The colored precipitate was filtered off, washed with 1 N HCl and MeOH, and 
then dried to yield the product rac-15 (308 mg, 0.20 mmol, 84% yield) as a yellow solid. 1H NMR 
(300 MHz, CDCl3) δ 8.23 (d, J = 1.8 Hz, 4H), 7.55 (dd, J = 8.4, 5.7 Hz, 4H), 7.23 (dd, J = 8.9, 1.9 Hz, 
4H), 7.16 (d, J = 8.8 Hz, 4H), 6.58 (td, J = 8.7, 2.4 Hz, 4H), 5.74 (dd, J = 10.0, 2.4 Hz, 4H), 1.25 (s, 
36H). 19F NMR (282 MHz, CDCl3) δ – 106.4 (s, 4F). IR (film): ν (cm1) 2961, 2908, 2871, 1618, 
1597,1561, 1519, 1481, 1457, 1428, 1385, 1364, 1296, 1273, 1243, 1196, 1127, 1114, 1080, 978, 932, 
888, 859, 834, 812, 803, 754, 744, 702, 673, 646, 598, 582, 572, 452. 
 
N,N-cis-Iridium Complex rac-16 
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The N,N-cis-iridium complex rac-16 was synthesized by the same method for synthesizing rac-11. 
5-(tert-Butyl)-2-(4-(trifluoromethyl)phenyl)benzo[d]oxazole 4 (1140 mg, 3.57 mmol) was added to 
iridium chloride hydrate (615 mg, 1.74 mmol) in a mixture of 2-ethoxyethanol/water (3:1, 76 mL). 
The reaction mixture was heated at 130 °C over night under nitrogen. The resulting precipitate was 
collected by centrifugation, washed with MeOH and dried to yield the cis-iridium product rac-16 (1.16 
g, 0.67 mmol, 77% yield) as an orange solid. 1H NMR (300 MHz, CDCl3) δ 8.23 (t, J = 1.3 Hz, 2H), 
8.07 (d, J = 1.6 Hz, 2H), 7.88 (d, J = 8.0 Hz, 2H), 7.67 (dd, J = 8.0, 0.9 Hz, 2H), 7.42 (dd, J = 8.0, 1.7 
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Hz, 2H), 7.37 – 7.30 (m, 6H), 7.16 (dd, J = 8.8, 1.9 Hz, 2H), 7.01 (ddd, J = 8.0, 1.8, 0.8 Hz, 2H), 6.37 
– 6.31 (m, 2H), 5.93 (d, J = 1.6 Hz, 2H), 1.26 (s, 18H), 0.61 (s, 18H). 19F NMR (282 MHz, CDCl3) δ – 
62.5 (s, 2F), – 63.4 (s, 2F). IR (film): ν (cm1) 2963, 2905, 2869, 1598, 1574, 1480, 1461, 1428, 1388, 
1366, 1312, 1273, 1250, 1195, 1161, 1117, 1094, 1069, 1040, 932, 898, 885, 829, 812, 794, 764, 702, 
671, 639, 453, 383. 
 
N,N-trans-Iridium Complex rac-17 
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The N,N-trans-iridium complex rac-17 was synthesized by the same method for synthesizing rac-15. 
5-(tert-Butyl)-2-(4-(trifluoromethyl)phenyl)benzo[d]oxazole 4 (268 mg, 0.84 mmol) was added to 
iridium chloride hydrate (123 mg, 0.35 mmol) in 2-ethoxyethanol (12 mL). The reaction mixture was 
heated at 145 °C for 20 h under nitrogen. After cooling to room temperature, the mixture was added 1 
N HCl. The colored precipitate was filtered off, washed with 1 N HCl and MeOH, and then dried to 
yield the product rac-17 (270 mg, 0.16 mmol, 91% yield) as an orange solid. 1H NMR (300 MHz, 
CDCl3) δ 8.12 (dd, J = 2.0, 0.6 Hz, 4H), 7.64 (d, J = 7.9 Hz, 4H), 7.31 (dd, J = 8.9, 1.9 Hz, 4H), 7.22 
(dd, J = 8.8, 0.6 Hz, 4H), 7.10 (ddd, J = 7.9, 1.6, 0.7 Hz, 4H), 6.43 – 6.34 (m, 4H), 1.28 (s, 36H). 19F 
NMR (282 MHz, CDCl3) δ – 64.2 (s, 12F). IR (film): ν (cm1) 2965, 2909, 2870, 1599, 1574, 1479, 
1459, 1388, 1366, 1310, 1271, 1252, 1157, 1118, 1093, 1081, 1068, 1040, 1015, 978, 932, 883, 847, 
821, 806, 793, 762, 702, 674, 639, 454. 
 
N,N-cis-Iridium Complex rac-18 
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The N,N-cis-iridium complex rac-18 was synthesized by the same method for synthesizing rac-9. 
5-(tert-Butyl)-2-(4-nitrophenyl)benzo[d]oxazole 5 (1037 mg, 3.50 mmol) was added to iridium 
chloride hydrate (618 mg, 1.75 mmol) in a mixture of 2-ethoxyethanol/water (3:1, 76 mL). The 
reaction mixture was heated at 130 °C for 24 h under nitrogen. The resulting precipitate was collected 
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by centrifugation, washed with MeOH and dried to yield the product rac-18 (1.05 g, 0.64 mmol, 73% 
yield) as a red solid. 1H NMR (300 MHz, CD2Cl2) δ 8.53 (d, J = 1.5 Hz, 2H), 8.26 – 8.18 (m, 2H), 
8.00 – 7.97 (m, 2H), 7.87 – 7.75 (m, 4H), 7.63 (dd, J = 8.4, 2.1 Hz, 2H), 7.49 – 7.44 (m, 4H), 7.40 (d, 
J = 8.7 Hz, 2H), 7.26 (dd, J = 8.8, 1.7 Hz, 2H), 6.84 (d, J = 2.0 Hz, 2H), 5.90 (d, J = 1.4 Hz, 2H), 1.28 
(s, 18H), 0.63 (s, 18H). IR (film): ν (cm1) 2960, 2905, 2870, 1599, 1538, 1504, 1479, 1448, 1428, 
1393, 1365, 1334, 1298, 1272, 1244, 1190, 1163, 1119, 1107, 1069, 1036, 932, 886, 867, 828, 814, 
739, 728, 706, 699, 668, 646, 452. 
 
N,N-trans-Iridium Complex rac-19 
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The N,N-trans-iridium complex rac-19 was synthesized by the same method for synthesizing rac-15. 
5-(tert-Butyl)-2-(4-nitrophenyl)benzo[d]oxazole 5 (200 mg, 0.68 mmol) was added to iridium chloride 
hydrate (108 mg, 0.31 mmol) in 2-ethoxyethanol (10 mL). The reaction mixture was heated at 150 °C 
for 20 h under nitrogen. After cooling to room temperature, the mixture was added 1 N HCl. The 
colored precipitate was filtered off, washed with 1 N HCl and MeOH, and then dried to yield the 
product rac-19 (217 mg, 0.13 mmol, 84% yield) as a red solid. IR (film): ν (cm1) 2967, 2907, 2869, 
1601, 1554, 1537, 1523, 1505, 1479, 1447, 1427, 1389, 1364, 1337, 1301, 1272, 1246, 1135, 1107, 
1082, 1056, 1036, 932, 886, 869, 855, 833806, 740, 727, 706, 645, 452, 402. 
 
N,N-trans-Iridium Complex rac-20 
 
The N,N-trans-iridium complex rac-20 was synthesized by the same method for synthesizing rac-15. 
5-(tert-Butyl)-2-(4-methoxyphenyl)benzo[d]oxazole 6 (375 mg, 1.33 mmol) was added to iridium 
chloride hydrate (196 mg, 0.56 mmol) in 2-ethoxyethanol (18 mL). The reaction mixture was heated at 
150 °C for 20 h under nitrogen. After cooling to room temperature, the mixture was added 1 N HCl. 
The colored precipitate was filtered off, washed with 1 N HCl and MeOH, and then dried to yield the 
product rac-20 (380 g, 0.24 mmol, 86% yield) as a yellow solid. 1H NMR (300 MHz, CDCl3) δ 8.41 
(dd, J = 1.6, 0.9 Hz, 4H), 7.59 (d, J = 8.5 Hz, 4H), 7.40 (s, 4H), 7.26 (s, 5H), 6.54 (dd, J = 8.5, 2.4 Hz, 
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4H), 5.82 (d, J = 2.4 Hz, 4H), 3.28 (s, 12H), 1.37 (s, 36H). IR (film): ν (cm1) 2965, 2936, 2905, 2872, 
2833, 1616, 1587, 1564, 1506, 1480, 1460, 1429, 1379, 1362, 1309, 1262, 1230, 1214, 1166, 1141, 
1130, 1116, 1082, 1039, 1020, 975, 930, 890, 861, 851, 843, 804, 794, 754, 744, 704, 676, 646, 610, 
585, 569, 449, 405. 
 
N,N-trans-Iridium Complex rac-21 
 
The N,N-trans-iridium complex rac-21 was synthesized by the same method for synthesizing rac-15. 
Accordingly, 5-((3r,5r,7r)-adamantan-1-yl)-2-phenylbenzo[d]oxazole 7 (384.0 mg, 1.17 mmol) was 
added to iridium chloride hydrate (200 mg, 0.57 mmol) in 2-ethoxyethanol (18 mL). The reaction 
mixture was heated at 150 °C for 18 h under nitrogen. After cooling to room temperature, the mixture 
was added 1 N HCl. The colored precipitate was filtered off, washed with 1 N HCl and MeOH, and 
then dried to yield the product rac-21 (440.0 mg, 0.25 mmol, 88% yield) as a yellow solid. 1H NMR 
(300 MHz, CDCl3) δ 8.27 (s, 4H), 7.58 – 7.48 (m, 4H), 7.21 (d, J = 1.2 Hz, 8H), 6.80 (td, J = 7.4, 1.1 
Hz, 4H), 6.58 (td, J = 7.5, 1.5 Hz, 4H), 6.09 (d, J = 7.8 Hz, 4H), 2.07 (s, 12H), 1.90 – 1.67 (m, 48H). 
IR (film): ν (cm1) 2901, 2847, 1590, 1554, 1519, 1476, 1447, 1425, 1385, 1345, 1316, 1298, 1263, 
1244, 1155, 1132, 1102, 1075, 1052, 1038, 1016, 975, 929, 886, 823, 792, 767, 736, 726, 705, 651, 
634, 583, 451, 441, 384. 
 
N,N-trans-Iridium Complex rac-22 
 
The N,N-trans-iridium complex rac-22 was synthesized by the same method for synthesizing rac-15. 
5-(tert-Butyl)-2-(naphthalen-1-yl)benzo[d]oxazole 8 (316 mg, 1.05 mmol) was added to iridium 
chloride hydrate (154 mg, 0.44 mmol) in 2-ethoxyethanol (15 mL). The reaction mixture was heated at 
145 °C for 20 h under nitrogen. After cooling to room temperature, the mixture was added 1 N HCl. 
The colored precipitate was filtered off, washed with 1 N HCl and MeOH, and then dried to yield the 
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product rac-22 (340 mg, 0.21 mmol, 95% yield) as a red solid. 1H NMR (300 MHz, CDCl3) δ 8.87 (d, 
J = 8.9 Hz, 4H), 8.42 (d, J = 1.6 Hz, 4H), 7.57 – 7.50 (m, 8H), 7.35 (dd, J = 8.8, 0.6 Hz, 4H), 7.33 – 
7.26 (m, 8H), 6.95 (d, J = 8.6 Hz, 4H), 6.29 (d, J = 8.6 Hz, 4H), 1.27 (s, 36H). IR (film): ν (cm1) 3055, 
2960, 2906, 2868, 1616, 1575, 1551, 1511, 1479, 1461, 1435, 1425, 1399, 1360, 1304, 1270, 1255, 
1210, 1191, 1136, 1096, 1030, 1022, 926, 888, 862, 829, 815, 802, 785, 744, 727, 663, 643, 630, 606, 
522, 455, 427. 
 
5.2.3 Synthesis of racemic iridium and rhodium catalysts 
Racemic Iridium Catalyst rac-IrO 
 
rac-IrO was synthesized according to the literature procedure13 with some modifications. rac-11 (434 
mg, 0.298 mmol) in 50 mL of acetonitrile was added AgPF6 (266 mg, 0.895 mmol). Heat this mixture 
in the dark at 70 °C over night. The solvent was removed in vacuum, and the residue was purified by 
flash chromatography on silica gel (DCM/MeCN = 20: 1 to 10: 1) to afford the rac-IrO (540 mg, 99% 
yield) as a yellow solid. 1H NMR (300 MHz, CD2Cl2) δ 7.85 (d, J = 1.3 Hz, 2H), 7.82 – 7.64 (m, 6H), 
7.02 (td, J = 7.5, 1.0 Hz, 2H), 6.85 (td, J = 7.5, 1.5 Hz, 2H), 6.37 (d, J = 7.4 Hz, 2H), 2.44 (s, 6H), 
1.46 (s, 18H). All spectroscopic data were in agreement with the literature.13  
 
Racemic Rhodium Catalyst rac-RhO 
 
rac-RhO was synthesized according to the literature procedure13 with some modifications. rac-12 
(344 mg, 0.27 mmol) in 15 mL of acetonitrile was added AgPF6 (149 mg, 0.59 mmol). Heat this 
mixture in the dark at 50 °C for 16 h. The solvent was removed in vacuum, and the residue was 
purified by flash chromatography on silica gel (DCM/MeCN = 20: 1) to afford the rac-RhO (443 mg, 
0.52 mmol, 99% yield) as a pale yellow solid. 1H NMR (300 MHz, CD2Cl2) δ 7.88 (d, J = 1.6 Hz, 2H), 
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7.80 – 7.74 (m, 6H), 7.09 (td, J = 7.5, 0.9 Hz, 2H), 6.94 (td, J = 7.6, 1.5 Hz, 2H), 6.40 (d, J = 7.8 Hz, 
2H), 2.31 (s, 6H), 1.46 (s, 18H). All spectroscopic data were in agreement with the literature.15 
 
Racemic Iridium Catalyst rac-IrS 
 
rac-IrS was synthesized by the same procedure of synthesizing rac-IrO. rac-13 (453 mg, 0.298 mmol) 
in 50 mL of acetonitrile was added AgPF6 (266 mg, 0.895 mmol). Heat this mixture in the dark at 
70 °C over night. The solvent was removed in vacuum, and the residue was purified by flash 
chromatography on silica gel (DCM/ MeCN = 20: 1 to 10: 1) to afford the rac-IrS (562 mg, 99% yield) 
as a yellow solid. 1H NMR (300 MHz, CD2Cl2) δ 8.42 (d, J = 1.5 Hz, 2H), 8.02 (d, J = 8.6 Hz, 2H), 
7.73 (dd, J = 8.6, 1.8 Hz, 2H), 7.67 (dd, J = 7.7, 0.9 Hz, 2H), 6.96 (td, J = 7.5, 1.1 Hz, 2H), 6.74 (td, J 
= 7.6, 1.4 Hz, 2H), 6.18 (d, J = 7.3 Hz, 2H), 2.35 (s, 6H), 1.47 (s, 18H). 13C NMR (75 MHz, CD2Cl2) δ 
181.3, 153.0, 150.3, 142.7, 141.0, 132.9, 131.5, 128.7, 126.1, 125.4, 123.6, 123.1, 121.6, 116.7, 35.6, 
31.6, 4.0. IR (film): ν (cm1) 3060, 2961, 2289, 1583, 1555, 1461, 1444, 1413, 1363, 1321, 1295, 1270, 
1253, 1169, 1156, 1126, 1103, 1053, 1020, 998, 936, 874, 835, 787, 757, 732, 700, 669, 616, 589, 458, 
403. HRMS (ESI, m/z) calcd for C38H38IrN4S2 [MPF6]+: 807.2162, found: 807.2163. 
 
Racemic Iridium Catalyst rac-IrO(F) 
 
rac-IrO(F) was synthesized by the same procedure of synthesizing rac-IrO. rac-15 (40 mg, 0.026 
mmol) in 13 mL of acetonitrile was added AgPF6 (15 mg, 0.059 mmol). Heat this mixture in the dark 
at 70 °C for 24 h. The solvent was removed in vacuum, and the residue was purified by flash 
chromatography on silica gel (DCM/MeCN = 20: 1 to 10: 1) to afford the rac-IrO(F) (43 mg, 0.045 
mmol, 86% yield) as a yellow solid. 1H NMR (300 MHz, CD2Cl2) δ 7.83 (dd, J = 1.8, 0.7 Hz, 2H), 
7.79 – 7.69 (m, 6H), 6.77 (ddd, J = 9.0, 8.5, 2.4 Hz, 2H), 6.05 (dd, J = 9.5, 2.4 Hz, 2H), 2.46 (s, 6H), 
1.47 (s, 18H). 13C NMR (75 MHz, CD2Cl2) δ 176.3, 166.5, 163.1, 151.2, 148.6, 144.9, 144.8, 137.9, 
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128.4, 128.3, 126.3, 125.1, 121.2, 119.8, 112.7, 112.0, 111.4, 111.0, 35.6, 31.7, 3.8. IR (film): ν (cm1) 
2969, 2957, 2867, 1600, 1562, 1522, 1482, 1467, 1397, 1365, 1284, 1200, 1127, 1117, 937, 849, 825, 
807, 757, 649, 574, 557, 453. 
 
Racemic Iridium Catalyst rac-IrO(CF3) 
 
rac-IrO(CF3) was synthesized by the same procedure of synthesizing rac-IrO. rac-17 (40 mg, 0.022 
mmol) in 22 mL of acetonitrile was added AgPF6 (12 mg, 0.049 mmol). Heat this mixture in the dark 
at 70 °C over night. The solvent was removed in vacuum, and the residue was purified by flash 
chromatography on silica gel (DCM/MeCN = 20: 1 to 10: 1) to afford the rac-IrO(CF3) (37 mg, 0.035 
mmol, 80% yield) as a yellow solid. 1H NMR (300 MHz, CD2Cl2) δ 7.89 (dd, J = 1.8, 0.7 Hz, 2H), 
7.87 – 7.83 (m, 2H), 7.81 (d, J = 0.8 Hz, 2H), 7.78 (dd, J = 8.9, 1.7 Hz, 2H), 7.29 (ddd, J = 8.0, 1.7, 
0.8 Hz, 2H), 6.55 (s, 2H), 2.47 (s, 6H), 1.47 (s, 18H). IR (film): ν (cm1) 2937, 1621, 1594, 1518, 1441, 
1390, 1345, 1323, 1271, 1242, 1167, 1120, 1083, 1051, 1041, 1017, 926, 837, 777, 734, 711, 680, 656, 
600, 556, 451, 426, 388.  
 
Racemic Iridium Catalyst rac-IrO(NO2) 
 
rac-IrO(NO2) was synthesized by the same procedure of synthesizing rac-IrO. rac-19 (48 mg, 0.029 
mmol) in 15 mL of acetonitrile was added AgPF6 (16 mg, 0.065 mmol). Heat this mixture in the dark 
at 70 °C for 17 h. The solvent was removed in vacuum, and the residue was purified by flash 
chromatography on silica gel (DCM/MeCN = 20: 1 to 10: 1) to afford the rac-IrO(NO2) (47 mg, 
0.047 mmol, 81% yield) as a brown solid. 1H NMR (300 MHz, CD2Cl2) δ 7.93 – 7.91 (m, 2H), 7.89 (d, 
J = 0.6 Hz, 2H), 7.88 – 7.83 (m, 6H), 7.05 (dd, J = 2.0, 0.6 Hz, 2H), 2.48 (s, 6H), 1.48 (s, 18H). IR 
(film): ν (cm1) 2959, 2939, 2868, 1602, 1544, 1513, 1481, 1449, 1393, 1340, 1300, 1273, 1244, 1107, 
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1094, 1036, 933, 870, 842, 813, 740, 728, 705, 647, 556, 454. 
 
Racemic Iridium Catalyst rac-IrO(OMe) 
 
rac-IrO(OMe) was synthesized by the same procedure of synthesizing rac-IrO. rac-20 (62 mg, 0.039 
mmol) in 20 mL of acetonitrile was added AgPF6 (22 mg, 0.086 mmol). Heat this mixture in the dark 
at 70 °C over night. The solvent was removed in vacuum, and the residue was purified by flash 
chromatography on silica gel (DCM/MeCN = 20: 1 to 10: 1) to afford the rac-IrO(OMe) (72 mg, 
0.073 mol, 94% yield) as a yellow solid. 1H NMR (300 MHz, CD2Cl2) δ 7.78 (d, J = 1.8 Hz, 2H), 7.75 
– 7.68 (m, 4H), 7.65 (dd, J = 8.8, 1.8 Hz, 2H), 6.62 (dd, J = 8.6, 2.4 Hz, 2H), 5.86 (d, J = 2.3 Hz, 2H), 
3.50 (s, 6H), 2.44 (s, 6H), 1.45 (s, 18H). 13C NMR (75 MHz, CD2Cl2) δ 177.1, 162.9, 150.8, 148.5, 
144.2, 138.4, 128.0, 124.2, 122.5, 120.7, 118.4, 112.5, 111.7, 109.0, 55.2, 35.5, 31.8, 3.8. IR (film): ν 
(cm1) 2968, 2954, 2941, 1621, 1595, 1566, 1508, 1460, 1434, 1400, 1388, 1313, 1269, 1216, 1175, 
1144, 1048, 1037, 1022, 935, 847, 828, 806, 756, 746, 706, 650, 572, 557, 538, 450. 
 
Racemic Iridium Catalyst rac-IrO(ada) 
 
rac-IrO(ada) was synthesized by the same procedure of synthesizing rac-IrO. rac-21 (206 mg, 0.117 
mmol) in 58 mL of acetonitrile was added AgPF6 (88 mg, 0.350 mmol). Heat this mixture in the dark 
at 70 °C for 2 days. The solvent was removed in vacuum, and the residue was purified by flash 
chromatography on silica gel (DCM/MeCN = 100: 1 to 20: 1) to afford the rac- IrO(ada) (220 mg, 
0.204 mmol, 87% yield) as a yellow solid. 1H NMR (300 MHz, CD2Cl2) δ 7.82 (d, J = 1.5 Hz, 2H), 
7.78 (d, J = 8.8 Hz, 2H), 7.71 (dt, J = 7.0, 1.6 Hz, 4H), 7.02 (td, J = 7.5, 1.1 Hz, 2H), 6.85 (td, J = 7.5, 
1.5 Hz, 2H), 6.37 (d, J = 7.6 Hz, 2H), 2.47 (s, 6H), 2.15 (s, 6H), 2.12 – 1.98 (m, 12H), 1.90 – 1.74 (m, 
12H). 13C NMR (75 MHz, CD2Cl2) δ 177.2, 151.3, 148.7, 141.9, 138.4, 132.8, 132.5, 130.0, 126.2, 
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124.3, 123.5, 120.8, 112.8, 111.9, 43.9, 37.1, 36.9, 29.4, 3.9. IR (film): ν (cm1) 2901, 2847, 1593, 
1523, 1476, 1449, 1432, 1388, 1265, 1041, 933, 874, 838, 796, 774, 740, 729, 705, 651, 637, 556, 454, 
446. 
 
Racemic Iridium Catalyst rac-IrO(nap) 
 
rac-IrO(nap) was synthesized by the same procedure of synthesizing rac-IrO. rac-22 (78 mg, 0.047 
mmol) in 24 mL of acetonitrile was added AgPF6 (26 mg, 0.10 mmol). Heat this mixture in the dark at 
70 °C over night. The solvent was removed in vacuum, and the residue was purified by flash 
chromatography on silica gel (DCM/MeCN = 20: 1 to 10: 1) to afford the rac-IrO(nap) (96 mg, 0.094 
mmol, 99% yield) as a yellow solid. 1H NMR (300 MHz, CD2Cl2) δ 9.00 – 8.90 (m, 2H), 7.96 – 7.88 
(m, 4H), 7.77 (dd, J = 8.8, 1.9 Hz, 2H), 7.72 – 7.60 (m, 4H), 7.40 (ddd, J = 8.2, 7.0, 1.1 Hz, 2H), 7.27 
(d, J = 8.4 Hz, 2H), 6.61 (d, J = 8.5 Hz, 2H), 2.42 (s, 6H), 1.49 (s, 18H). IR (film): ν (cm1) 2964, 
2935, 1618, 1576, 1555, 1516, 1481, 1432, 1404, 1361, 1269, 1192, 1035, 1023, 930, 869, 835, 813, 
787, 746, 731, 698, 658, 645, 556, 523, 425. 
 
Racemic Iridium Catalyst rac-IrO(pyrene) 
 
5-(tert-Butyl)-2-(pyren-1-yl)benzo[d]oxazole 9 (769 mg, 2.05 mmol) was added to iridium chloride 
hydrate (353 mg, 1.00 mmol) in 2-ethoxyethanol (33 mL). The reaction mixture was heated at 145 °C 
for 80 h under nitrogen. After cooling to room temperature, the mixture was added 1 N HCl. The 
colored precipitate was filtered off, washed with 1 N HCl and MeOH, and then dried to yield the 
iridium dimer 23 (950 mg, 0.49 mmol, 98% yield) as a red powder which was used without further 
purification. The iridium dimer 23 (195 mg, 0.10 mmol) in 50 mL of acetonitrile was added AgPF6 (56 
mg, 0.22 mmol). Heat this mixture in the dark at 70 °C for 39 h. The solvent was removed in vacuum, 
and the residue was purified by flash chromatography on silica gel (DCM/MeCN = 10: 1) to afford the 
rac-IrO(pyrene) (102 mg, 0.087 mmol, 87% yield) as a yellow solid. 1H NMR (300 MHz, CD2Cl2) δ 
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9.34 (d, J = 9.3 Hz, 2H), 8.29 (d, J = 9.4 Hz, 2H), 8.23 – 8.17 (m, 2H), 8.12 – 8.05 (m, 4H), 8.04 (d, J 
= 3.1 Hz, 2H), 7.93 (d, J = 7.6 Hz, 2H), 7.90 – 7.83 (m, 4H), 7.52 (d, J = 9.0 Hz, 2H), 7.23 (s, 2H), 
2.40 (s, 6H), 1.53 (s, 18H). IR (film): ν (cm1) 2953, 2937, 1624, 1583, 1543, 1498, 1478, 1459, 1427, 
1400, 1382, 1366, 1341, 1310, 1270, 1236, 1187, 1144, 1085, 1048, 984, 938, 877, 838, 780, 757, 733, 
708, 653, 636, 626, 581, 556, 459, 405. HRMS (ESI, m/z) calcd for C58H46IrN4O2 [MPF6]+: 
1023.3249, found: 1023.3255.  
 
Racemic Iridium Catalyst rac-IrN(pyrene) 
   
5-(tert-Butyl)-1-butyl-2-(pyren-1-yl)-1H-benzo[d]imidazole 10 (68.8 mg, 0.16 mmol) was added to 
iridium chloride hydrate (28.2 mg, 0.08 mmol) in 2-ethoxyethanol (3 mL). The reaction mixture was 
heated at 145 °C over night under nitrogen. After cooling to room temperature, the mixture was added 
1 N HCl. The colored precipitate was filtered off, washed with 1 N HCl and MeOH, and then dried to 
yield iridium dimer 24 (65 mg, 0.03 mmol, 75% yield) as a red powder which was used without 
further purification. Iridium dimer 24 (62 mg, 0.029 mmol) in 14 mL of acetonitrile was added AgPF6 
(22 mg, 0.086 mmol). Heat this mixture in the dark at 65 °C over night. The solvent was removed in 
vacuum, and the residue was purified by flash chromatography on silica gel (DCM/MeCN = 20: 1) to 
afford the rac-IrN(pyrene) (59 mg, 0.046 mmol, 80% yield) as a dark red solid (not pure, contained 
14% isomer). 1H NMR (300 MHz, CD2Cl2) δ 8.56 (d, J = 8.1 Hz, 2H), 8.42 (d, J = 8.1 Hz, 2H), 8.22 (s, 
4H), 8.00 (d, J = 7.4 Hz, 2H), 7.62 (t, J = 7.6 Hz, 2H), 7.37 (d, J = 8.6 Hz, 2H), 7.20 (d, J = 5.9 Hz, 
4H), 7.08 (dd, J = 8.6, 1.8 Hz, 2H), 5.99 (d, J = 1.8 Hz, 2H), 4.53 (t, J = 8.0 Hz, 4H), 2.14 – 1.99 (m, 
4H), 1.94 (s, 6H), 1.45 (dt, J = 14.7, 7.3 Hz, 4H), 1.00 (t, J = 7.4 Hz, 6H), 0.20 (s, 18H). IR (film): ν 
(cm1) 2957, 2929, 2864, 1556, 1505, 1471, 1438, 1415, 1402, 1333, 1174, 871, 836, 758, 711, 677, 
651, 627, 576, 556, 424, 404, 393. HRMS (ESI, m/z) calcd for C66H64IrN6 [MPF6]+: 1133.4822, 
found: 1133.4821.  
 
5.2.4 Synthesis of non-racemic iridium catalysts 
The synthesis of non-racemic IrO14 or chiral RhO15 is followed published procedures. 
5.2.4.1 Synthesis of the Chiral Auxiliary (S)-25 
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(S)-N-(1-hydroxy-3-methylbutan-2-yl)-2-methoxybenzamide (29) 
 
(S)-28 (3.43 g, 33.3 mmol) and triethylamine (4.63 mL, 33.3 mmol) were dissolved in 175 mL of 
MeOH. 2-Methoxybenzoyl chloride 27 (6.23 g, 36.6 mmol) was added at 0 °C. The reaction mixture 
was stirred at 0 °C for one hour. The solvent was evaporated and the white residue was dissolved in 
200 mL of ethyl acetate / H2O (v/v = 1: 1). The aqueous layer was separated and extracted twice with 
ethyl acetate. The combined organic layers were dried over MgSO4, filtered and the solvent was 
removed in vacuo. The residue was purified by flash chromatography on silica gel (short column, 
EtOAc/n-hexane = 1: 2 to 2: 1) to give the compound 29 (7.20 g, 30.4 mmol, 91% yield) as a white 
solid. 1H NMR (300 MHz, CDCl3) δ 8.17 (dd, J = 7.8, 1.9 Hz, 1H), 8.13 (s, 1H), 7.45 (ddd, J = 8.3, 
7.3, 1.9 Hz, 1H), 7.13 – 7.02 (m, 1H), 6.97 (dd, J = 8.3, 1.1 Hz, 1H), 4.08 – 3.90 (m, 1H), 3.97 (s, 3H), 
3.86 – 3.65 (m, 2H), 3.50 (s, 1H), 2.12 – 1.92 (m, 1H), 1.02 (d, J = 7.1 Hz, 3H), 1.00 (d, J = 7.1 Hz, 
3H). 13C NMR (75 MHz, CDCl3) δ 166.8, 157.6, 133.1, 132.5, 121.6, 121.5, 111.5, 65.4, 58.3, 56.2, 
29.3, 19.9, 18.5. IR (film): ν (cm1) 3374, 2958, 2942, 2878, 2839, 1642, 1627, 1598, 1552, 1484, 
1464, 1436, 1420, 1385, 1365, 1354, 1313, 1295, 1239, 1179, 1165, 1156, 1138, 1123, 1103, 1075, 
1054, 1034, 1021, 969, 864, 824, 786, 755, 695, 638, 608, 567, 535, 519, 448. HRMS (ESI, m/z) calcd 
for C13H20N1O3 [M+H]+: 238.1438, found: 238.1443. 
 
(S)-4-Isopropyl-2-(2-methoxyphenyl)-4,5-dihydrothiazole (30) 
 
A mixture of compound 29 (4.50g, 19.0 mmol) and phosphorus pentasulfide (7.00 g, 31.6 mmol) in 
CH2Cl2 (100mL) was heated under reflux with vigorous stirring for 40 h. The resulting suspension was 
filtered and the filtrate was washed with 2 N sodium hydroxide (3 × 40 mL) and water (2 × 40 mL), 
dried and the solvent was evaporated. The crude product was purified by flash chromatography on 
silica gel (EtOAc/n-hexane = 1: 4) to give the compound 30 (4.16 g, 17.7 mmol, 93% yield) as a 
colorless oil. 1H NMR (300 MHz, CDCl3) δ 7.86 (dd, J = 7.7, 1.8 Hz, 1H), 7.38 (ddd, J = 8.3, 7.4, 1.8 
Hz, 1H), 7.04 – 6.89 (m, 2H), 4.35 (ddd, J = 9.8, 8.8, 6.2 Hz, 1H), 3.89 (s, 3H), 3.32 (dd, J = 10.9, 8.8 
Hz, 1H), 3.05 (dd, J = 10.8, 9.7 Hz, 1H), 2.21 – 2.03 (m, 1H), 1.11 (d, J = 6.8 Hz, 3H), 1.02 (d, J = 6.8 
Hz, 3H). 13C NMR (75 MHz, CDCl3) δ 163.6, 157.7, 131.8, 130.4, 123.1, 120.8, 112.0, 82.1, 56.0, 
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35.2, 33.2, 19.9, 19.0. IR (film): ν (cm1) 2957, 2870, 2836, 1590, 1486, 1460, 1434, 1383, 1365, 1283, 
1249, 1222, 1178, 1160, 1114, 1049, 1021, 986, 955, 937, 887, 788, 752, 674, 616, 602, 572, 529, 495. 
HRMS (ESI, m/z) calcd for C13H18N1O1S1 [M+H]+: 236.1104, found: 236.1105. 
 
(S)-2-(4-Isopropyl-4,5-dihydrothiazol-2-yl)phenol (25) 
 
A flame-dried flask (500 mL) was equipped with the compound 30 (8.97 g, 38.1 mmol, 1.0 eq) and 
dried for 30 min in vacuo. Subsequently, the compound 30 was dissolved with dry DCM (180 mL) and 
the resulting solution was cooled to 78 °C. Neat BBr3 (7.30 mL, 75.8 mmol, 2.0 eq) was added 
dropwise via syringe over a perdiod of 10 min. The resulting mixture was stirred at 78 °C for 20 min 
and then stirred at 0 °C for 3 h. Then, the mixture was quenched at 0 °C by addition of MeOH (80 mL) 
and N(EtOH)3 (33 mL, 248 mmol, 6.5 equiv). Subsequently, DCM was selectively removed in vacuo 
and additional MeOH (170 mL) was added. The resulting yellow suspension was stirred at 70 °C 
(reflux) for 12 h. After cooling to room temperature, the white precipitate was filtered off and washed 
thoroughly with MeOH. All volatiles were removed from the filtrate in vacuo and the residue was 
dissolved in DCM and adsorbed on silica gel. The adsorbed crude product was purified by flash 
chromatography on silica gel (short column, EtOAc/n-hexane = 1: 20). After solvent removal and 
drying in vacuo, the desired product (S)-25 was obtained as a yellow viscous oil (5.65 g, 25.5 mmol, 
67%). 1H NMR (300 MHz, CDCl3) δ 12.85 (s, 1H), 7.43 – 7.32 (m, 2H), 7.05 (dd, J = 8.3, 1.2 Hz, 1H), 
6.88 (td, J = 7.8, 1.2 Hz, 1H), 4.48 (ddd, J = 9.5, 8.7, 6.6 Hz, 1H), 3.41 (dd, J = 11.0, 8.7 Hz, 1H), 3.11 
(dd, J = 11.0, 9.5 Hz, 1H), 2.14 – 1.97 (m, J = 6.8 Hz, 1H), 1.08 (dd, J = 17.4, 6.7 Hz, 6H). All 
spectroscopic data were in agreement with the literature.16  
 
5.2.4.2 Synthesis of  and Δ-IrS 
Catalysts  and Δ-IrS were synthesized following a recently published procedure.17  
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Iridium Auxiliary Complexes  and -(S)-26 
 
A mixture of iridium (III) dimer complex rac-13 (500 mg, 0.329 mmol), the chiral auxiliary 
(S)-4-isopropyl-2-(2'-hydroxyphenyl)-2-thiazoline {(S)-25} (160 mg, 0.724 mmol), AgOTf (186 mg, 
0.724 mmol) and triethylamine (460 L, 3.29 mmol) in ethanol (33 mL) was purged with nitrogen for 
5 min and then heated at reflux overnight. The reaction mixture was cooled to room temperature and 
concentrated to dryness. The residue was subjected to a flash silica gel chromatography (EtOAc / 
n-hexane = 1: 25 to 1: 10) to separate the two diastereomers. The first eluting diastereomer was 
assigned as Λ-(S)-26 (orange solid, 305 mg, 0.323 mmol, 49%) and the second eluting diastereomer 
was assigned as -(S)-26 (orange solid, 305 mg, 0.324 mmol, 49%).  
-(S)-26: 1H NMR (300 MHz, CD2Cl2) δ 9.00 (d, J = 1.7 Hz, 1H), 7.87 (d, J = 8.5 Hz, 1H), 7.77 (d, J 
= 1.6 Hz, 1H), 7.75 (dd, J = 7.7, 0.9 Hz, 1H), 7.73 (d, J = 8.5 Hz, 1H), 7.62 (dd, J = 7.6, 1.0 Hz, 1H), 
7.51 (ddd, J = 8.5, 4.1, 1.8 Hz, 2H), 7.19 (dd, J = 8.1, 1.7 Hz, 1H), 6.98 – 6.80 (m, 4H), 6.72 (td, J = 
7.5, 1.4 Hz, 1H), 6.69 – 6.62 (m, 1H), 6.58 (dd, J = 8.6, 1.1 Hz, 1H), 6.21 – 6.00 (m, 2H), 4.45 (dt, J = 
9.7, 2.1 Hz, 1H), 3.38 (dd, J = 11.6, 9.8 Hz, 1H), 2.97 (dd, J = 11.7, 1.9 Hz, 1H), 1.48 (s, 9H), 1.17 (s, 
9H), 0.72 – 0.58 (m, 1H), 0.34 (d, J = 7.0 Hz, 3H), 0.06 (d, J = 6.9 Hz, 3H). 13C NMR (75 MHz, 
CD2Cl2) δ 181.3, 180.4, 170.1, 169.3, 152.2, 152.1, 152.0, 151.5, 151.3, 150.4, 142.9, 142.6, 136.4, 
133.3, 133.1, 132.2, 130.6, 129.7, 128.7, 128.2, 126.4, 126.0, 124.3, 124.1, 123.5, 122.4, 122.1, 121.7, 
120.8, 119.9, 119.8, 116.3 113.4, 83.8, 35.4, 35.3, 32.0 (3 C), 31.4 (3 C), 31.2, 28.4, 19.8, 14.7. CD 
(MeOH): λ, nm (Δε, M-1cm-1) 458 (14), 369 (+27), 340 (+38), 304 (11), 268 (+13), 252 (+2). 
-(S)-26: 1H NMR (300 MHz, CD2Cl2) δ 8.79 (d, J = 1.8 Hz, 1H), 7.88 (s, 1H), 7.82 (dd, J = 28.4, 9.6 
Hz, 2H), 7.64 (ddd, J = 15.8, 7.6, 0.9 Hz, 2H), 7.50 (ddd, J = 21.2, 8.6, 1.8 Hz, 2H), 7.31 (dd, J = 8.0, 
1.7 Hz, 1H), 6.95 (ddd, J = 8.6, 6.9, 1.8 Hz, 1H), 6.91 – 6.79 (m, 2H), 6.69 (td, J = 7.5, 1.4 Hz, 1H), 
6.63 (td, J = 7.5, 1.3 Hz, 1H), 6.57 – 6.47 (m, 2H), 6.31 – 6.19 (m, 2H), 3.49 (ddd, J = 9.0, 5.0, 3.8 Hz, 
1H), 2.90 (dd, J = 11.3, 5.1 Hz, 1H), 2.45 (dd, J = 11.2, 9.2 Hz, 1H), 1.92 (m, 1H), 1.25 (s, 9H), 1.11 
(s, 9H), 0.81 (d, J = 6.8 Hz, 3H), 0.14 (d, J = 7.0 Hz, 3H). 13C NMR (75 MHz, CD2Cl2) δ 181.62, 
180.87, 169.81, 168.16, 153.17, 152.49, 151.87, 151.53, 151.06, 150.08, 142.42, 142.07, 135.73, 
133.31, 132.62, 132.17, 130.53, 130.43, 128.65, 128.42, 126.46, 125.75, 124.26, 124.15, 124.06, 
122.12, 121.91, 121.89, 121.32, 120.80, 118.80, 117.62, 113.04, 83.20, 35.45, 35.28, 31.69 (3 C), 
31.30 (3 C), 30.72, 30.26, 20.75, 17.93. CD (MeOH): λ, nm (Δε, M-1cm-1) 488 (+15), 443 (+5), 425 
(+10), 344 (52), 319 (+43), 293 (+22), 285 (+26), 268 (10), 253 (+9). 
IR (film): ν (cm1) 3055, 2953, 2906, 2866, 1601, 1580, 1556, 1522, 1459, 1436, 1407, 1361, 1331, 
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1314, 1290, 1278, 1244, 1194, 1151, 1123, 1101, 1045, 1030, 1006, 992, 928, 844, 808, 780, 755, 736, 
725, 697, 670, 658, 587, 555, 523, 466. HRMS (ESI, m/z) calcd for C46H47IrN3OS3Na [M+Na]+: 
968.2324, found: 968.2323. 
 
Enantiopure Iridium Catalysts  and -IrS 
 
A suspension of the auxiliary complex -(S)-26 (220 mg, 0.233 mmol) or -(S)-26 (113.0 mg, 0.120 
mmol) and NH4PF6 (for -(S)-26: 1.14 g, 6.99 mmol; for -(S)-26: 0.59 g, 3.60 mmol,) in acetonitrile 
(5 mM, 47.0 mL for -(S)-26; 24.0 mL for -(S)-26) was heated at 50 C for 16 h under argon in the 
dark. The reaction mixture was concentrated to dryness and subjected to a flash silica gel 
chromatography (CH2Cl2/CH3CN = 100:1 to 30:1) to give the enantiopure catalyst -IrS (221 mg, 
0.232 mmol, >99% yield) or -IrS (113 mg, 0.119 mmol, >99% yield) as yellow solids. The chiral 
auxiliary (S)-25 can be recovered (-(S)-26-IrS + (S)-25, 25.5 mg, 96% yield, > 99.9% ee). The 
absolute configurations of the obtained - and -configured iridium (III) complexes were verified by 
CD spectroscopy and confirmed by an X-ray crystal structure of -IrS. The enantiomeric purity was 
verified by chiral HPLC analysis. 1H NMR (300 MHz, CD2Cl2) δ 8.42 (d, J = 1.5 Hz, 2H), 8.02 (d, J = 
8.6 Hz, 2H), 7.73 (dd, J = 8.6, 1.8 Hz, 2H), 7.67 (dd, J = 7.7, 0.9 Hz, 2H), 6.96 (td, J = 7.5, 1.1 Hz, 
2H), 6.74 (td, J = 7.6, 1.4 Hz, 2H), 6.18 (d, J = 7.3 Hz, 2H), 2.35 (s, 6H), 1.47 (s, 18H). All 
spectroscopic data were in agreement with rac-IrS. 
-IrS: CD (MeOH, 0.2 mM): λ, nm (Δε, M-1cm-1) 460 (7), 358 (+29), 287 (17), 256 (+11), 242 
(9). 
-IrS: CD (MeOH, 0.2 mM): λ, nm (Δε, M-1cm-1) 461 (+14), 359 (34), 289 (+27), 255 (9), 243 
(+17). 
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5.2.4.3 Synthesis of  and Δ-IrO(ada) 
  
Iridium Auxiliary Complexes  and -(S)-145 
 
Iridium auxiliary complexes  and -(S)-145 were synthesized according to the procedure of  and 
-(S)-26 with some modifications. A mixture of iridium (III) dimer complex rac-21 (520 mg, 0.29 
mmol), the chiral auxiliary (S)-4-isopropyl-2-(2'-hydroxyphenyl)-2-thiazoline {(S)-25} (143 mg, 0.65 
mmol), and triethylamine (409 L, 2.94 mmol) in ethanol (30 mL) was purged with argon for 5 min 
and then heated at 95 oC for 38 h. The reaction mixture was cooled to room temperature and separated 
by centrifugation. The main comound in filtrate is Λ-(S)-145 and the main compound in solid is 
-(S)-145 and iridium (III) dimer. They are subjected to a flash silica gel chromatography 
(n-hexane/CH2Cl2 = 4: 1 to 1: 2) to afford Λ-(S)-145 (orange solid, 127 mg, 0.12 mmol, 21%) and 
-(S)-145 (orange solid, 116 mg, 0.11 mmol, 19%).   
Λ-(S)-145: 1H NMR (300 MHz, CD2Cl2) δ 7.93 (d, J = 1.9 Hz, 1H), 7.71 (d, J = 7.6 Hz, 1H), 7.68 – 
7.40 (m, 7H), 7.23 – 7.14 (m, 1H), 7.02 – 6.68 (m, 6H), 6.38 (d, J = 7.6 Hz, 1H), 6.31 (t, J = 7.5 Hz, 
1H), 4.88 – 4.74 (m, 1H), 3.48 (t, J = 10.6 Hz, 1H), 3.05 (d, J = 11.6 Hz, 1H), 2.24 – 1.95 (m, 12H), 
1.92 – 1.62 (m, 18H), 0.85 – 0.72 (m, 1H), 0.23 (d, J = 6.9 Hz, 3H), 0.14 (d, J = 6.9 Hz, 3H). 13C 
NMR (75 MHz, CD2Cl2) δ 178.3, 178.0, 167.7, 167.1, 150.8, 150.7, 150.5, 149.9, 148.8, 148.5, 139.4, 
138.9, 135.2, 133.6, 133.5, 131.9, 131.8, 131.5, 131.3, 126.2, 125.9, 124.7, 122.6, 122.5, 122.0, 120.9, 
118.3, 115.0, 113.3, 112.9, 111.1, 110.6, 85.5, 43.9, 43.6, 37.2, 37.0, 36.9, 36.9, 31.8, 30.1, 29.5, 29.5, 
28.1, 19.1, 14.1. CD (DCM/MeOH = 1/4, 0.2 mM): λ, nm (Δε, M-1cm-1) 454 (10), 361 (+32), 338 
(+26), 326 (+42), 304 (34), 300 (30), 293 (38), 262 (+10), 251 (+12). 
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-(S)-145: 1H NMR (300 MHz, CD2Cl2) δ 7.92 (d, J = 1.9 Hz, 1H), 7.75 – 7.65 (m, 2H), 7.61 (d, J = 
8.7 Hz, 1H), 7.55 (d, J = 8.6 Hz, 1H), 7.49 – 7.34 (m, 4H), 7.05 (ddd, J = 8.6, 6.8, 1.8 Hz, 1H), 6.96 – 
6.83 (m, 3H), 6.81 – 6.73 (m, 2H), 6.62 (dd, J = 8.6, 1.2 Hz, 1H), 6.44 (d, J = 7.4 Hz, 1H), 6.30 (ddd, 
J = 8.1, 6.8, 1.3 Hz, 1H), 3.64 – 3.59 (m, 1H), 2.88 (dd, J = 11.2, 2.0 Hz, 1H), 2.73 – 2.60 (m, 1H), 
2.25 – 2.12 (m, 1H), 2.08 (s, 3H), 1.95 (s, 3H), 1.87 – 1.57 (m, 24H), 1.07 (d, J = 6.8 Hz, 3H), 0.03 (d, 
J = 7.0 Hz, 3H). 13C NMR (75 MHz, CD2Cl2) δ 178.9, 178.7, 167.4, 167.3, 151.97, 151.50, 150.5, 
149.8, 149.0, 148.5, 139.9, 138.7, 135.9, 133.2, 132.6, 132.4, 131.5, 131.4, 131.2, 130.5, 126.3, 126.0, 
124.3, 122.5, 122.4, 121.7, 120.9, 119.6, 114.9, 114.0, 113.1, 110.9, 110.7, 82.4, 43.7, 43.5, 37.1, 37.0, 
36.9, 36.9, 32.2, 29.9, 29.5, 29.5, 20.4, 17.3. CD (DCM/MeOH = 1/4, 0.2 mM): λ, nm (Δε, M-1cm-1) 
458 (+18), 407 (+10), 329 (52), 306 (+45), 300 (+34), 289 (+36), 284 (+37), 261 (9), 250 (15).  
IR (film): ν (cm1) 2899, 2846, 1590, 1559, 1520, 1475, 1462, 1441, 1379, 1356, 1345, 1291, 1263, 
1253, 1244, 1194, 1153, 1132, 1115, 1102, 1070, 1035, 1010, 973, 960, 943, 929, 845, 823, 796, 770, 
739, 729, 705, 693, 650, 635, 600, 581, 554, 522, 455, 444, 400, 385. HRMS (ESI, m/z) calcd for 
C58H59IrN3OS1 [M+H]+: 1070.3904, found: 1070.3908. 
 
Enantiopure Iridium Catalyst -IrO(ada) 
 
The suspension of -(S)-145 (38 mg, 0.036 mmol) in MeCN (6 mL) was added TFA (13.6 μL, 0.18 
mmol) at room temperature and the mixture was stirred for 6 hour. After the solvent was removed, 
ethanol was added to dissolve the product. Then the product was transferred to the centrifugal tube, 
NH4PF6 and H2O were added. The mixture was under ultra sonic for 10 min. After centrifugation, 
reserve the solid. Purified the solid by flash silica gel chromatography (CH2Cl2/CH3CN = 100:1 to 
20:1) to give the enantiopure catalyst -IrO(ada) (33 mg, 0.031 mmol, 86%) as a yellow solid. 
-IrO(ada) can be obtained by the same method as -IrO(ada). The absolute configurations of the 
obtained - and -configured iridium (III) complexes were verified by CD spectroscopy. 1H NMR 
(300 MHz, CD2Cl2) δ 7.82 (d, J = 1.5 Hz, 2H), 7.78 (d, J = 8.8 Hz, 2H), 7.71 (dt, J = 7.0, 1.6 Hz, 4H), 
7.02 (td, J = 7.5, 1.1 Hz, 2H), 6.85 (td, J = 7.5, 1.5 Hz, 2H), 6.37 (d, J = 7.6 Hz, 2H), 2.47 (s, 6H), 
2.15 (s, 6H), 2.12 – 1.98 (m, 12H), 1.90 – 1.74 (m, 12H). All spectroscopic data were in agreement 
with rac-IrO(ada). 
-IrO(ada): CD (MeOH, 0.2 mM): λ, nm (Δε, M-1cm-1) 436 (14), 368 (+38), 360 (+36), 344 (+52), 
288 (38), 269 (48), 251 (+3). 
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Δ-IrO(ada): CD (MeOH, 0.2 mM): λ, nm (Δε, M-1cm-1) 436 (+15), 367 (37), 361 (35), 344 (53), 
289 (+40), 269 (+52), 251 (2). 
 
5.3 Synthesis of Substrates 
5.3.1 Synthesis of the ,-unsaturated substrates 
Substrate 67 is purchased from Sigma-Aldrich. All other substrates were synthesized according to 
reported procedures with some modifications.  
   
31 32 33 34 
    
35 45 57 58 
    
59 60 61 62 
    
63 64 65 66 
 
(E)-1-(1-Methyl-1H-imidazol-2-yl)but-2-en-1-one (31) 
 
To a solution of N-methyl-imidazole (5.2 mL, 66.0 mmol) in THF (100 mL) at 78 C was added 
dropwise n-BuLi (26.4 mL, 2.5 M in hexane, 66.0 mmol). The reaction mixture was stirred at 78 C 
for 10 min, and then stirred at room temperature for additional 30 min. (E)-but-2-enoic acid (2.580 g, 
30.0 mmol) was added to the flask after the reaction mixture was cooled back down to 78 C. The 
reaction mixture was allowed to warm to room temperature slowly (over a period of 3-4 h) and stirred 
over night. The reaction mixture was quenched with a saturated aqueous solution of Na2CO3 (30 mL, 
about 1 mL/ mmol of carboxylic acid) and extracted with EtOAc (4  100 mL). The combined organic 
layers were dried over anhydrous Na2SO4, filtered, and concentrated under reduced pressure. The 
residue was purified by flash chromatography on silica gel (EtOAc/n-hexane = 1:1) to give 3 (1.67 g, 
11.1 mmol, 37% yield, E / Z > 100: 1) as a white solid. 1H NMR (300 MHz, CDCl3) δ 7.42 (dq, J = 
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15.5, 1.6 Hz, 1H), 7.23 – 7.06 (m, 2H), 7.03 (s, 1H), 4.03 (s, 3H), 1.98 (dd, J = 6.9, 1.6 Hz, 3H). All 
spectroscopic data were in agreement with the literature.18 
 
 
N-Methoxy-N-methylcinnamamide (146) 
 
To a solution of N, O-dimethylhydroxylamine hydrochloride (2.93 g, 30.0 mmol) in CH2Cl2 (60 mL) 
at 0 C were added trans- cinnamoyl chloride (5.00 g, 33.0 mmol) and pyridine (5.3 mL, 66.0 mmol) 
successively. The reaction mixture was stirred at 0 C for 30 min, then stirred at room temperature for 
additional 30 min. The reaction mixture was diluted with EtOAc (100 mL). The organic layer was 
washed with 1 N HCl (3  25 mL), aqueous saturated NaHCO3 (3  40 mL), and brine (40 mL). The 
combined organic layers were dried over anhydrous Na2SO4, filtered, and concentrated under reduced 
pressure. The residue was purified by flash chromatography on silica gel (EtOAc/n-hexane = 1:10 to 
1:5) to give 146 (5.67 g, 29.7 mmol, 99% yield) as a white solid. 1H NMR (300 MHz, CDCl3) δ 7.73 
(d, J = 15.8 Hz, 1H), 7.62 – 7.52 (m, 2H), 7.45 – 7.32 (m, 3H), 7.03 (d, J = 15.8 Hz, 1H), 3.75 (s, 3H), 
3.30 (s, 3H). All spectroscopic data were in agreement with the literature.18  
 
(E)-1-(1-Methyl-1H-imidazol-2-yl)-3-phenylprop-2-en-1-one (32) 
 
To a solution of N-methyl-imidazole (0.96 mL, 12.0 mmol) in THF (25 mL) at 78 C was added 
n-BuLi (4.8 mL, 2.5 M in hexane, 12.0 mmol) dropwise. The reaction mixture was stirred at 78 C 
for 10 min, and then stirred at room temperature for 30 min. The Weinreb amide 146 (1.91 g, 10.0 
mmol) was added to the flask after the reaction mixture was cooled back down to 78 C. The reaction 
mixture was allowed to warm to room temperature slowly (over a period of 34 h) and stirred 
overnight. The reaction mixture was quenched with acetic acid (6 equiv) at 0 oC and then the reaction 
mixture was allowed to warm to room temperature before being diluted with EtOAc (100 mL). The 
organic layer was washed with a saturated aqueous solution of Na2CO3 and extracted with EtOAc (4  
30 mL), and dried with anhydrous Na2SO4, filtered, and concentrated under reduced pressure. The 
residue was purified by flash chromatography on silica gel (EtOAc/n-hexane = 1: 3 to 1: 2) to produce 
32 (1.78 g, 8.4 mmol, 84% yield, E/Z > 100: 1) as a white solid. 1H NMR (300 MHz, CDCl3) δ 8.08 (d, 
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J = 16.0 Hz, 1H), 7.82 (d, J = 16.1 Hz, 1H), 7.74 – 7.60 (m, 2H), 7.49 – 7.30 (m, 3H), 7.21 (s, 1H), 
7.07 (s, 1H), 4.08 (s, 3H). All spectroscopic data were in agreement with the literature.18 
 
(E)-1-(1-Isopropyl-1H-imidazol-2-yl)-3-phenylprop-2-en-1-one (35) 
 
Following the procedure for the preparation of 32, N-isopropylimidazole (1.36 mL, 12.0 mmol) was 
converted to ,-unsaturated 2-acylimidazole 35 (2.20 g, 9.2 mmol, 92% yield, E/Z > 100: 1) as a 
white solid. 1H NMR (300 MHz, CDCl3) δ 8.12 (d, J = 16.0 Hz, 1H), 7.80 (d, J = 16.0 Hz, 1H), 7.73 – 
7.64 (m, 2H), 7.45 – 7.35 (m, 3H), 7.31 (d, J = 0.7 Hz, 1H), 7.25 (s, 1H), 5.72 (hept, J = 6.7 Hz, 1H), 
1.48 (d, J = 6.7 Hz, 6H). All spectroscopic data were in agreement with the literature.18 
 
 
2-Chloro-1-(1-methyl-1H-imidazol-2-yl) ethanone (147) 
 
To a solution of N-methylimidazole (1.6 mL, 20.0 mmol) in THF (50 mL) at 78 C was added 
dropwise n-BuLi (8.0 mL, 2.5 M in hexane, 20.0 mmol). The reaction mixture was stirred at 78 C 
for 10 min, and then stirred at room temperature for additional 30 min. Next, tert-butyl 2-chloroacetate 
(30.0 mmol) was added to the flask at 78 C. After being stirred at 78 C for 2.5 h, the reaction 
mixture was quenched with H2O and extracted with EtOAc (4  50 mL). The combined organic layers 
were dried over anhydrous Na2SO4, filtered, and concentrated under reduced pressure. The residue was 
purified by flash chromatography on silica gel (EtOAc/n-hexane = 1: 1) to afford 147 (2.16 g, 13.7 
mmol, 68%) as a white solid. 1H NMR (300 MHz, CDCl3) δ 7.16 (d, J = 0.8 Hz, 1H), 7.11 (s, 1H), 
4.93 (s, 2H), 4.03 (s, 3H). All spectroscopic data were in agreement with the literature.18 
 
1-(1-Methyl-1H-imidazol-2-yl)-2-(triphenyl-phosphoranylidene) ethanone (148) 
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To a solution of 147 (2.12 g, 13.4 mmol) in toluene (28 mL) at room temperature was added PPh3 
(3.87 g, 14.8 mmol). After being stirred at 95 C for overnight, the reaction mixture was diluted with 1 
N HCl (90 mL) and Et2O (80 mL). The aqueous layer was separated and organic layer was extracted 
with 1 N HCl (2  20 mL). The combined aqueous layers were washed with Et2O (2  60 mL) and 
neutralized with aqueous saturated Na2CO3. Then the aqueous layer was extracted with EtOAc (3  60 
mL). The combined organic layers were dried over anhydrous Na2SO4, filtered, and concentrated 
under reduced pressure to produce Wittig reagent 148 (4.70 g, 12.2 mmol, 91%) as a pale yellow solid 
which was used for the next reaction without further purification. 1H NMR (300 MHz, CDCl3) δ 7.81 
– 7.66 (m, 6H), 7.62 – 7.51 (m, 3H), 7.50 – 7.40 (m, J = 8.3, 2.9, 1.3 Hz, 6H), 6.99 (d, J = 1.0 Hz, 1H), 
6.82 (s, 1H), 4.97 (d, J = 24.0 Hz, 1H), 4.00 (s, 3H). All spectroscopic data were in agreement with the 
literature.18 
 
(E)-Ethyl 4-(1-methyl-1H-imidazol-2-yl)-4-oxobut-2-enoate (33) 
 
To a solution of Wittig reagent 148 (1.29 g, 3.3 mmol) in toluene (14 mL) at room temperature was 
added ethyl 2-oxoacetate (~50% in toluene, 1.3 mL, 6.5 mmol). The reaction mixture was stirred at 
room temperature over night. After the solvent was removed in vacuum, the material was dissolved in 
10 mL of CH2Cl2 and 67 mg of DMAP was added to the flask. The flask was sealed with a septum and 
purged with dried N2. The reaction mixture was stirred until homogeneous and stored in a freezer (20 
C) for several days. The reaction mixture was directed loaded on a SiO2 and purified by flash silica 
chromatography (EtOAc/n-hexane = 1: 1) to afford 33 (438 mg, 2.1 mmol, 65% yield, E/Z > 100: 1). 
1H NMR (300 MHz, CDCl3) δ 8.26 (d, J = 15.9 Hz, 1H), 7.20 (d, J = 0.8 Hz, 1H), 7.10 (s, 1H), 6.88 (d, 
J = 15.9 Hz, 1H), 4.24 (q, J = 7.1 Hz, 2H), 4.03 (s, 3H), 1.30 (t, J = 7.1 Hz, 3H). All spectroscopic 
data were in agreement with the literature.18 
 
(E)-1-(1-Methyl-1H-imidazol-2-yl)hept-2-en-1-one (34) 
 
To a solution of Wittig reagent 148 (1.99 g, 5.0 mmol) in toluene (25 mL) at room temperature was 
added pentanal (8.0 mL, 75 mmol). The reaction mixture was stirred at room temperature for 24 h 
(monitored by TLC). After the solvent was removed in vacuo, the material was dissolved in 20 mL of 
CH2Cl2 and 95 mg of DMAP (0.17 equiv) was added to the flask. The flask was sealed with a septum 
and purged with dried N2. The reaction mixture was stirred until homogeneous and stored in a freezer 
(20 C) for several days. The reaction mixture was directed loaded on a SiO2 and the disired 
compound was purified by flash silica chromatography (EtOAc/n-hexane = 1: 3 to 1: 2) to afford 34 
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(920 mg, 4.8 mmol, 96% yield, E/Z > 100: 1). 1H NMR (300 MHz, CDCl3) δ 7.38 (dt, J = 15.6, 1.4 Hz, 
1H), 7.20 – 6.95 (m, 3H), 4.02 (s, 3H), 2.50 – 2.02 (m, 2H), 1.58 – 1.42 (m, 2H), 1.42 – 1.28 (m, 2H), 
0.89 (t, J = 7.2 Hz, 3H). All spectroscopic data were in agreement with the literature.18 
 
(E)-1-(1-Isopropyl-1H-imidazol-2-yl) but-2-en-1-one (45) 
N
N
O
iPr  
Following the procedure of 31, N-isopropyl-imidazole (7.50 mL, 66.0 mmol) was converted to 
,-unsaturated 2-acylimidazole 45 (1.76 g, 9.9 mmol, 33% yield) as a white solid. 1H NMR (300 
MHz, CDCl3) δ 7.46 (dq, J = 15.5, 1.6 Hz, 1H), 7.28 (d, J = 0.9 Hz, 1H), 7.20 (d, J = 0.8 Hz, 1H), 
7.18-7.03 (m, 1H), 5.74 – 5.56 (m, 1H), 1.99 (dd, J = 6.9, 1.6 Hz, 3H), 1.46 (d, J = 6.7 Hz, 6H). All 
spectroscopic data were in agreement with the literature.14 
 
 
(E)-N-Methoxy-N-methylbut-2-enamide (66) 
 
According to the procedure for the preparation of 146, (E)-but-2-enoyl chloride (4.2 mL, 44.0 mmol) 
was converted to 66 (3.20 g, 9.2 mmol, 62% yield, E/Z > 100: 1) as a colorless oil. 1H NMR (300 
MHz, CDCl3) δ 6.97 (dq, J = 15.4, 6.9 Hz, 1H), 6.41 (dq, J = 15.3, 1.7 Hz, 1H), 3.69 (s, 3H), 3.22 (s, 
3H), 1.90 (dd, J = 6.9, 1.7 Hz, 3H). All spectroscopic data were in agreement with the literature.18 
 
(E)-1-(1-Methyl-1H-benzo[d]imidazol-2-yl)but-2-en-1-one (57) 
 
To a solution of 1-methyl-1H-benzo[d]imidazoles (0.41 g, 3.1 mmol) in THF (5 mL) at 78 C was 
added dropwise n-BuLi (1.24 mL, 2.5 M in hexane, 3.1 mmol). The reaction mixture was stirred at 
78 C for 10 min, and then stirred at 40 C for 1.5 h. To a solution of 66 in THF (10 mL) at 78 C 
was added the anionic benzimidazole solution via cannula. The mixture was stirred at 40 C over 
night. The reaction mixture was quenched by 0.70 mL of AcOH, diluted with 50 mL of EtOAc, and 
Chapter 5. Experimental Part 
-118- 
washed with NaHCO3 (50 mL) and brine (50 mL). The organic layer was dried over anhydrous 
Na2SO4, filtered, and concentrated under reduced pressure. The residue was purified by flash 
chromatography on silica gel (EtOAc/n-hexane = 1: 2) to afford 57 (0.21 g, 1.1 mmol, 35% yield, E / 
Z > 100: 1) as a white solid. 1H NMR (300 MHz, CDCl3) δ 7.90 (dt, J = 8.0, 1.0 Hz, 1H), 7.60 (dq, J = 
15.5, 1.6 Hz, 1H), 7.48 – 7.42 (m, 2H), 7.42 – 7.33 (m, 1H), 7.31 – 7.18 (m, 1H), 4.18 (s, 3H), 2.05 
(dd, J = 6.9, 1.6 Hz, 3H). All spectroscopic data were in agreement with the literature.19 
 
(E)-1-(Thiazol-2-yl)but-2-en-1-one (58) 
 
To a solution of thiazole in 15 mL of THF at –15 oC was added iPrMgCl (1.8 mL, 2.0 M, 3.6 mmol) 
slowly. After stirring for 40 min at –15 oC, a solution of 66 (0.39 g, 3.0 mmol) in 5 mL of THF was 
added slowly. The reaction mixture was allowed to warm to room temperature and stirred over night. 
It was quenched by aqueous NH4Cl and extracted once with EtOAc (15 mL). The organic layer was 
dried over anhydrous Na2SO4, filtered, and concentrated under reduced pressure. The residue was 
purified by flash chromatography on silica gel (EtOAc/n-hexane = 1: 10) to afford 58 (78 mg, 0.51 
mmol, 17% yield, E/Z > 100: 1) as a colorless oil. 1H NMR (300 MHz, CDCl3) δ 8.01 (d, J = 3.0 Hz, 
1H), 7.66 (d, J = 3.0 Hz, 1H), 7.45 – 7.28 (m, 2H), 2.03 (d, J = 5.4 Hz, 3H). All spectroscopic data 
were in agreement with the literature.19 
 
 
3-Hydroxy-1-pyridin-2-ylbutan-1-one (149) 
 
2-Acetylpyridine (1.5 mL, 13.4 mmol) was added dropwise to a solution of LDA (20 mmol in 20 mL 
of THF) at 20 oC. The resulting solution was stirred at 20 oC for 2 h. Acetaldehyde (1.50 mL, 26.8 
mmol) was added dropwise. After the reaction mixture was stirred for 0.5 h, a saturated solution of 
NH4Cl (15 mL) was added. The organic phase was collected, and the aqueous was extracted with 10 
mL of Et2O. The combined organic layers were dried over anhydrous Na2SO4, filtered, and 
concentrated under reduced pressure. The residue was purified by flash chromatography on silica gel 
(EtOAc/n-hexane = 1: 2) to afford 149 (1.30 g, 7.9 mmol, 59% yield) as a colorless oil. 1H NMR (300 
MHz, CDCl3) δ 8.66 (ddd, J = 4.8, 1.7, 0.9 Hz, 1H), 8.03 (dt, J = 7.8, 1.1 Hz, 1H), 7.84 (td, J = 7.7, 
1.7 Hz, 1H), 7.48 (ddd, J = 7.6, 4.8, 1.3 Hz, 1H), 4.33 (tq, J = 9.0, 2.7 Hz, 1H), 3.82 (s, 1H), 3.41 (dd, 
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J = 17.0, 2.8 Hz, 1H), 3.22 (dd, J = 17.1, 8.8 Hz, 1H), 1.29 (d, J = 6.3 Hz, 3H). All spectroscopic data 
were in agreement with the literature.20 
 
(E)-1-(Pyridin-2-yl)but-2-en-1-one (59) 
 
To a solution of 149 (1.25 g, 7.6 mmol) in 32 mL of dry DCM was added TEA (3.2 mL, 22.7 mmol) at 
30 oC, and then sulfonyl chloride (0.70 mL, 9.1 mmol) was added dropwise. The reaction mixture 
was allowed to reach room temperature over night. The solution was quenched by water, and extract 
by DCM. The combined organic layers were dried over anhydrous Na2SO4, filtered, and concentrated 
under reduced pressure. The residue was purified by flash chromatography on silica gel 
(EtOAc/n-hexane = 1: 5) to afford 59 (0.87 g, 5.9 mmol, 78% yield, E/Z = 40: 1) as a pale yellow oil. 
1H NMR (300 MHz, CDCl3) δ 8.74 – 8.67 (m, 1H), 8.18 – 8.07 (m, 1H), 7.90 – 7.80 (m, 1H), 7.61 (dq, 
J = 15.6, 1.6 Hz, 1H), 7.46 (ddd, J = 7.3, 4.5, 1.3 Hz, 1H), 7.35 – 7.16 (m, 1H), 2.08 – 1.99 (m, 3H). 
All spectroscopic data were in agreement with the literature.20 
 
(E)-3-(But-2-enoyl)oxazolidin-2-one (60) 
 
To the solution of 2-oxazolinone (0.87 g, 10 mmol) in THF (20 mL), n-BuLi (4.0 mL, 2.5 M in hexane, 
10 mmol) was added dropwise at 78 oC. After stirring for 3 h, crotonoyl chloride (1.04 mL, 11 mmol) 
was added slowly. The mixture was stirred for 30 min at 78 °C and other 15 min at 0 °C. Then the 
reaction mixture was quenched by a saturated solution of NH4Cl and extracted with EtOAc. The 
combined organic layers were dried over anhydrous Na2SO4, filtered, and concentrated under reduced 
pressure. The residue was purified by flash chromatography on silica gel (EtOAc/n-hexane = 1: 2) to 
afford 60 (1.01 g, 6.5 mmol, 65%) as a colorless oil. 1H NMR (300 MHz, CDCl3) δ 7.26 (dq, J = 15.0, 
1.2 Hz, 1H), 7.18 (dq, J = 15.0, 6.4 Hz, 1H), 4.41 (t, J = 8.0 Hz, 2H), 4.07 (t, J = 8.0 Hz, 2H), 1.96 (dd, 
J = 6.4, 1.2 Hz, 3H). All spectroscopic data were in agreement with the literature.21 
 
(E)-1-(2-Thioxothiazolidin-3-yl)but-2-en-1-one (61) 
 
Triethylamine (4.6 mL, 33.0 mmol) was added dropwise to stirred solution of 1,3-thiazolidine- 
2-thione (3.58 g, 30.0 mmol) and crotonoyl chloride (2.9 mL, 30.0 mmol) in CH2Cl2 (46 mL) at 78 
oC. The mixture was stirred at 78 oC for 30 min and 0 oC for another 30 min. Then, it was diluted 
with Et2O, and washed with saturated NaHCO3 and water. The combined organic layers were dried 
Chapter 5. Experimental Part 
-120- 
over anhydrous Na2SO4, filtered, and concentrated under reduced pressure. The residue was purified 
by flash chromatography on silica gel (EtOAc/n-hexane = 1: 3) to afford 61 (2.09 g, 11.2 mmol, 37%, 
E / Z = 30: 1) as a yellow oil (stored at 20 oC). 1H NMR (300 MHz, CDCl3) δ 7.21 (dq, J = 15.1, 1.5 
Hz, 1H), 7.02 (dq, J = 14.9, 6.8 Hz, 1H), 4.51 (t, J = 7.4 Hz, 2H), 3.32 (t, J = 7.4 Hz, 2H), 1.94 (dd, J 
= 6.9, 1.5 Hz, 3H). All spectroscopic data were in agreement with the literature.22 
 
(E)-1-(1H-Pyrazol-1-yl)but-2-en-1-one (62) 
 
To a solution of pyrazole (2.75 g, 40.4 mmol) in 60 mL of CH2Cl2 was added SOCl2 (0.88 mL, 12.2 
mol) and stirred at room temperature for 1 h. Then, (E)-but-2-enoic acid (0.87 g, 9.9 mmol) was added 
in one portion. The mixture was stirred for additional 3 h. The resulting solution was diluted with 
CH2Cl2 (60 mL), washed with aqueous NaOH solution (0.50 M, 3  20 mL) and water (3  20 mL). 
The organic layer was dried over anhydrous Na2SO4, filtered, and concentrated under reduced pressure. 
The residue was purified by flash chromatography on silica gel (EtOAc/n-hexane = 1: 20) to afford 62 
(1.13 g, 8.3 mmol, 84% yield, E/Z > 100: 1) as a colorless oil. 1H NMR (300 MHz, CDCl3) δ 8.33 (d, J 
= 2.8 Hz, 1H), 7.80 – 7.68 (m, 1H), 7.44 – 7.24 (m, 2H), 6.46 (dd, J = 2.9, 1.5 Hz, 1H), 2.05 (d, J = 
5.5 Hz, 3H). All spectroscopic data were in agreement with the literature.23  
 
(E)-1-(3,5-Dimethyl-1H-pyrazol-1-yl)but-2-en-1-one (63) 
 
A toluene (5 mL) solution of SOCl2 (1.55g, 13 mmol) was added dropwise to a mixture of pyrazole 
(0.96g, 10 mmol), (E)-but-2-enoic acid (1.12g, 13 mmol) and TEA (5.56 mL, 40 mmol) in toluene (25 
mL) at 5 oC. After being continuously stirred for 2 hours, it is quenched by water, and washed with 1 N 
HCl, aqueous NaOH and aqueous NaCl. Then it was extracted with DCM. The combined organic 
layers were dried over anhydrous Na2SO4, filtered, and concentrated under reduced pressure. The 
residue was purified by flash chromatography on silica gel (EtOAc/n-hexane = 1: 10) to afford 63 
(1.45 g, 8.8 mmol, 88% yield, E/Z > 100: 1) as a colorless oil. 1H NMR (300 MHz, CDCl3) δ 7.36 – 
7.28 (m, 1H), 7.28 – 7.14 (m, 1H), 5.98 (s, 1H), 2.57 (d, J = 1.0 Hz, 3H), 2.26 (s, 3H), 2.01 (dd, J = 
6.4, 1.2 Hz, 3H). All spectroscopic data were in agreement with the literature.24 
 
(E)-Dimethyl but-2-enoylphosphonate (64) 
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4.25 mL (4.47 g, 36.0 mmol) of trimethyphosphite was added to 3.83 mL (4.18 g, 40.0 mmol) of 
crotonoyl chloride very slowly (3-4 drops per minute) at 0 oC. The reaction mixture was stirred at 0 oC 
for 1 h and at room temperature for 5 h. The reaction mixture was directed loaded on a SiO2 and the 
disired compound was purified by flash silica chromatography (EtOAc/n-hexane = 2: 3) to afford 64 
(2.31 g, 13.0 mmol, 36% yield, E/Z = 15:1) as a yellow oil. 1H NMR (300 MHz, CDCl3) δ 7.53 (dq, J 
= 16.0, 6.9 Hz, 1H), 6.41 (ddq, J = 16.6, 15.9, 1.6 Hz, 1H), 3.87 (s, 3H), 3.84 (s, 3H), 2.02 (dd, J = 6.9, 
1.6 Hz, 3H). All spectroscopic data were in agreement with the literature.25 
 
(E)-Ethyl 2-oxo-4-phenylbut-3-enoate (65) 
 
To a solution of alkyl pyruvate (3.460 g, 30 mmol) and aldehyde (2.120 g, 20 mmol) in 50 mL of dry 
dichloromethane was added Cu(OTf)2 (720 mg, 0.2 mmol). After reflux over a period of 46 h, the 
cooled reaction mixture was deposited on a short pad of basic alumina and filtered with additional 
dichloromethane (200 mL). The homogeneous organic solution was evaporated and the residue was 
purified by column chromatography on silica gel (EtOAc/n-hexane = 1: 50) and recrystallisation (in 
EtOH at 20 oC) to afford 65 (1.72 g, 8.4 mmol, 42%) as a yellow oil (r.t.). 1H NMR (300 MHz, 
CDCl3) δ 7.87 (d, J = 16.1 Hz, 1H), 7.68 – 7.59 (m, 2H), 7.52 – 7.37 (m, 3H), 7.36 (d, J = 16.1 Hz, 
1H), 4.40 (q, J = 7.1 Hz, 2H), 1.42 (t, J = 7.2 Hz, 3H). All spectroscopic data were in agreement with 
the literature.26 
 
5.3.2 Synthesis of the 2-acylpyridine N-oxides 
5.3.2.1 Synthesis of 2-acylpyridine 
2-Acylpyridines 150 and 152 are commercial. All other substrates were synthesized according to 
reported procedures with some modifications.  
    
150 151 152 153 
    
154 155 156 157 
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158 159 160 161 
 
 
1-(3-Methylpyridin-2-yl)ethanone (151) 
 
To a solution of 2-bromo-3-methylpyridine (1.720 g, 10.0 mmol, 1.0 equiv) in dry toluene (100 mL, 
0.1 M), cooled to –40 oC (dry ice/MeCN bath), was added n-butyllithium (4.0 mL, 2.5 M solution in 
hexanes, 1.0 equiv) dropwise. The reaction mixture was stirred at this temperature for 60 min, then 
N,N-dimethylacetamide (1.568 g, 18 mmol, 1.8 equiv) was added dropwise and the mixture was 
allowed to warm to –15 oC for 1 h. Saturated aqueous ammonium chloride was added and the organic 
layer was separated. The aqueous layer was extracted with EtOAc and the combined organic layers 
were dried over anhydrous sodium sulfate, filtered, and concentrated in vacuo to give 151 as a yellow 
oil (EtOAc/n-hexane = 1: 20; 774 mg, 5.73 mmol, 57% yield). 1H NMR (300 MHz, CDCl3) δ 8.51 (d, 
J = 4.5 Hz, 1H), 7.59 (d, J = 7.8 Hz, 1H), 7.33 (dd, J = 7.8, 4.6 Hz, 1H), 2.71 (d, J = 1.0 Hz, 3H), 2.58 
(s, 3H). All spectroscopic data were in agreement with the literature.27 
 
1-(5-Methylpyridin-2-yl)ethanone (153) 
 
To a solution of 2-bromo-5-methylpyridine (1.720 g, 10.0 mmol, 1.0 equiv) in dry ether (20 mL, 0.5 
M), cooled to –78 °C, was added n-butyllithium (4.0 mL, 2.5 M solution in hexanes, 1.0 equiv) 
dropwise. The reaction mixture was allowed to warm to –40° C for 15 min, and then cooled back to 
–78 °C again. N,N-dimethylacetamide (1.568 g, 18 mmol, 1.8 equiv) was added dropwise and the 
mixture was stirred at –78 °C for 2 h. Saturated aqueous ammonium chloride was added and the 
organic layer was separated. The aqueous layer was extracted with EtOAc and the combined organic 
layers were dried over anhydrous sodium sulfate, filtered, and concentrated in vacuo to give 153 as a 
yellow oil (EtOAc/n-hexane = 1: 10; 1.03 g, 7.63 mmol, 76% yield). 1H NMR (300 MHz, CDCl3) δ 
8.50 – 8.48 (m, 1H), 7.94 (d, J = 7.8 Hz, 1H), 7.63 – 7.60 (m, 1H), 2.70 (s, 3H), 2.41 (s, 3H). All 
spectroscopic data were in agreement with the literature.28 
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1-(6-Methylpyridin-2-yl)ethanone (154) 
 
Starting from 2-bromo-6-methylpyridine (302 mg, 1.76 mmol) and N,N-dimethylacetamide (230 mg, 
2.64 mmol) according to the general procedure for 153 to give 154 as a yellow oil (EtOAc/n-hexane = 
1: 30 to 1/20; 110 mg, 0.81 mmol, 46% yield). 1H NMR (300 MHz, CDCl3) δ 7.83 (d, J = 7.7 Hz, 1H), 
7.69 (t, J = 7.7 Hz, 1H), 7.31 (d, J = 7.6 Hz, 1H), 2.71 (s, 3H), 2.61 (s, 3H). All spectroscopic data 
were in agreement with the literature.29 
 
 
4-Methoxypyridine 1-oxide (162) 
 
4-Methoxylpyridine (1.6 mL, 15.0 mmol, 1.0 equiv) was dissolved in glacial acetic acid (10.0 mL), 
30% hydrogen peroxide (1.87 mL, 16.5 mmol, 1.1 equiv) was added, and the reaction mixture was 
refluxed for 24 h. The reaction mixture was concentrated in vacuo and washed with aqueous sat. 
NaHCO3. Remove the water from the reaction mixture under the reducing pressure, and then DCM 
was added to the mixture. After centrifugation, the solution was concentrated in vacuo and the 
resulting crude product was purified by flash chromatography on silica gel (very short colomn, 
EtOAc/MeOH = 10: 1) to provide the target compound 162 (1.730 g, 13.84 mmol, 92% yield). 1H 
NMR (300 MHz, CDCl3) δ 8.35 – 8.22 (m, 1H), 6.98 – 6.74 (m, 2H), 3.88 (s, 3H). All spectroscopic 
data were in agreement with the literature.30  
 
4-Methoxypicolinonitrile (163) 
 
To a solution of pyridine N-oxide 162 (make sure no water in 162) (500 mg, 4.0 mmol) in dry DCM (4 
mL, 1.0 M), was added trimethylsilyl cyanide (498 mg, 5.0 mmol, 1.25 equiv) at the room temperature. 
Dimethylcarbamyl chloride (538 mg, 5.0 mmol, 1.25 equiv) in dry DCM was added to the reaction 
mixture dropwise (over a 30 min period). After the reaction mixture was stirred at the room 
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temperature for 24 hours, a solution of 10% K2CO3 (4 mL) was added dropwise, and stirring was 
continued for another 15 min. The organic layer was separated, and the aqueous layer was extracted 
two times with DCM. The combined organic layers was concentrated in vacuo to give the disired 
compound 163 (475 mg, 3.54 mmol, 89% yield) as a white solid without further purification. 1H NMR 
(300 MHz, CDCl3) δ 8.51 (d, J = 5.8 Hz, 1H), 7.22 (d, J = 2.5 Hz, 1H), 7.00 (dd, J = 5.8, 2.6 Hz, 1H), 
3.91 (s, 3H). All spectroscopic data were in agreement with the literature.30 
 
1-(4-Methoxypyridin-2-yl)ethanone (155) 
  
To a stirred solution of 4-methoxypicolinonitrile 163 (402 mg, 3.00 mmol, 1.0 equiv) in dry THF (5 
mL, 0.64 M; the solubility of B1 is not good in Et2O) was added a 1.2 equivalents of a solution of the 
methylmagnesium bromide (3.0 M, 1.2 mL, 3.6 mmol, 1.2 equiv) dropwise at –15 °C (NaCl/ice bath) 
under N2 atmosphere. After the addition, the reaction mixture was further stirred at this temperature for 
1 h and the cooling bath was removed. After warming to room temperature (3 h), the reaction mixture 
was quenched by the addition of 1 N HCl and stirring continued for another 30 min. After separation 
of the two phases, the water phase was neutralized to pH 8 with 2 N NaOH solution and extracted with 
CH2Cl2. The combined organic layers were washed with water, saturated brine, dried over anhydrous 
Na2SO4, and filtered. The resulting crude oil was purified by flash chromatography on silica gel 
(EtOAc/n-hexane = 1: 4) to provide the target compound 155 as a white solid (280 mg, 1.85 mmol, 
62% yield). 1H NMR (300 MHz, CDCl3) δ 8.46 (d, J = 5.6 Hz, 1H), 7.54 (d, J = 2.6 Hz, 1H), 6.96 (dd, 
J = 5.6, 2.7 Hz, 1H), 3.88 (s, 3H), 2.69 (s, 3H). All spectroscopic data were in agreement with the 
literature.31 
 
4-Ethylpyridine 1-oxide (164) 
 
Starting from 4-ethylpyridine (2.143 g, 20.0 mmol) and 30% hydrogen peroxide (2.493 g, 2.5 mL, 
22.0 mmol, 1.1 equiv) according to the general procedure for 162 to give 164 as a white solid (without 
further purification; 2.250 g, 18.3 mmol, 92% yield). 1H NMR (300 MHz, CDCl3) δ 8.14 (d, J = 7.0 
Hz, 2H), 7.11 (d, J = 6.9 Hz, 2H), 2.65 (q, J = 7.6 Hz, 2H), 1.24 (t, J = 7.6 Hz, 3H). All spectroscopic 
data were in agreement with the literature.32 
 
4-Ethylpicolinonitrile (165) 
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Starting from pyridine N-oxide 164 (984 mg, 8.0 mmol), trimethylsilyl cyanide (992 mg, 10.0 mmol, 
1.25 equiv) and dimethylcarbamyl chloride (1075 mg, 10.0 mmol, 1.25 equiv) according to the 
general procedure for 163 to give 165 as a colorless oil (EtOAc/n-hexane = 1: 4; 1.050 g, 7.95 mmol, 
99% yield). 1H NMR (300 MHz, CDCl3) δ 8.58 (d, J = 5.1 Hz, 1H), 7.54 (dt, J = 1.5, 0.8 Hz, 1H), 7.34 
(ddt, J = 5.1, 1.6, 0.7 Hz, 1H), 2.72 (q, J = 7.6 Hz, 3H), 1.28 (t, J = 7.6 Hz, 3H). 13C NMR (75 MHz, 
CDCl3) δ 154.5, 150.8, 133.9, 128.2, 126.5, 117.4, 27.9, 13.9. IR (film): ν (cm1) 3052, 2973, 2937, 
2878, 2235, 1736, 1595, 1555, 1463, 1431, 1403, 1376, 1328, 1292, 1250, 1153, 1096, 1061, 992, 895, 
881, 852, 791, 741, 673, 638, 565, 531, 475, 420, 401, 386. HRMS (ESI, m/z) calcd for C8H8N2Na1 
[M+Na]+: 155.0580, found: 155.0579. 
 
1-(4-Ethylpyridin-2-yl)ethanone (156) 
 
Starting from 4-ethylpicolinonitrile 165 (400 mg, 3.0 mmol) and methylmagnesium bromide (3.0 M, 
1.2 mL, 3.6 mmol, 1.2 equiv) according to the general procedure for 155 to give 156 as a colorless oil 
(EtOAc/n-hexane = 1: 10; 320 mg, 2.15 mmol, 72% yield). 1H NMR (300 MHz, CDCl3) δ 8.54 (d, J = 
4.9 Hz, 1H), 7.87 (s, 1H), 7.30 – 7.26 (m, 1H), 2.77 – 2.60 (m, 5H), 1.25 (t, J = 7.6 Hz, 3H). 13C NMR 
(75 MHz, CDCl3) δ 200.3, 154.0, 153.6, 148.9, 126.7, 121.2, 28.2, 25.8, 14.2. IR (film): ν (cm1) 3052, 
2970, 2935, 2877, 1697, 1599, 1555, 1461, 1416, 1378, 1352, 1282, 1185, 1115, 1087, 1060, 1019, 
995, 958, 908, 843, 744, 728, 591, 555, 483, 394. HRMS (ESI, m/z) calcd for C9H11N1O1Na1 [M+Na]+: 
172.0733, found: 172.0735. 
 
4-Propylpyridine 1-oxide (166) 
 
Starting from 4-propylpyridine (2.424 g, 20.0 mmol) and 30% hydrogen peroxide (2.493 g, 2.5 mL, 
22.0 mmol, 1.1 equiv) according to the general procedure for 162 to give 166 as a white solid (without 
further purification; 2.470 g, 18.0 mmol, 90% yield). 1H NMR (300 MHz, CDCl3) δ 8.07 (d, J = 6.9 
Hz, 2H), 7.03 (d, J = 6.6 Hz, 2H), 2.53 (t, J = 7.6 Hz, 2H), 1.60 (h, J = 7.4 Hz, 2H), 0.90 (t, J = 7.3 Hz, 
3H). 13C NMR (75 MHz, CDCl3) δ 141.94, 138.62, 125.88, 36.21, 23.21, 13.35. IR (film): ν (cm1) 
3119, 3093, 3055, 3023, 2958, 2926, 2867, 1481, 1462, 1426, 1372, 1238, 1195, 1176, 1090, 1044, 
1030, 915, 888, 864, 838, 786, 770, 714, 660, 615, 563, 547, 525, 511, 481, 416, 380. HRMS (ESI, 
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m/z) calcd for C8H12N1O1 [M+H]+: 138.0913, found: 138.0912. 
 
4-Propylpicolinonitrile (167) 
 
Starting from pyridine N-oxide 166 (1.370 g, 10.0 mmol), trimethylsilyl cyanide (1.240 g, 12.5 mmol, 
1.25 equiv) and Dimethylcarbamyl chloride (1.340 g, 12.5 mmol, 1.25 equiv) according to the general 
procedure for 163 to give 167 as a colorless oil (EtOAc/n-hexane = 1: 8; 1.450 g, 9.9 mmol, 99% 
yield). 1H NMR (300 MHz, CDCl3) δ 8.57 (dd, J = 5.0, 0.8 Hz, 1H), 7.51 (dd, J = 1.7, 0.8 Hz, 1H), 
7.32 (ddd, J = 5.0, 1.6, 0.8 Hz, 1H), 2.64 (d, J = 7.8 Hz, 2H), 1.68 (h, J = 7.4 Hz, 2H), 0.96 (t, J = 7.3 
Hz, 3H). All spectroscopic data were in agreement with the literature.33 
 
1-(4-Propylpyridin-2-yl)ethanone (157) 
 
Starting from 4-propylpicolinonitrile 167 (400 mg, 3.0 mmol) and methylmagnesium bromide (3.0 M, 
1.2 mL, 3.6 mmol, 1.2 equiv) according to the general procedure for 155 to give 157 as a colorless oil 
(EtOAc/n-hexane = 1: 10; 320 mg, 2.15 mmol, 72% yield). 1H NMR (300 MHz, CDCl3) δ 8.55 (d, J = 
4.9 Hz, 1H), 7.87 (dd, J = 1.7, 0.8 Hz, 1H), 7.28 (dd, J = 5.0, 1.7 Hz, 1H), 2.72 (s, 3H), 2.65 (t, J = 7.8 
Hz, 2H), 1.68 (dq, J = 14.8, 7.4 Hz, 2H), 0.94 (t, J = 7.4 Hz, 3H). 13C NMR (75 MHz, CDCl3) δ 200.4, 
153.6, 152.7, 148.8, 127.3, 121.8, 37.3, 25.9, 23.4, 13.6. IR (film): ν (cm1) 2961, 2932, 2872, 1696, 
1599, 1554, 1465, 1415, 1352, 1282, 1254, 1186, 1087, 995, 968, 912, 868, 831, 781, 732, 724, 592, 
580, 562, 489, 396. HRMS (ESI, m/z) calcd for C10H14N1O1 [M+H]+: 164.1070, found: 164.1069. 
 
4-(tert-Butyl)pyridine 1-oxide (168) 
 
Starting from 4-(tert-butyl)pyridine (2.030 g, 15.0 mmol) and 30% hydrogen peroxide (1870 mg, 1.87 
mL, 16.5 mmol, 1.1 equiv) according to the general procedure for 162 to give 168 as a pale yellow 
solid (without further purification; 1.909 g, 12.6 mmol, 84% yield). 1H NMR (300 MHz, CDCl3) δ 
8.17 – 8.05 (m, 2H), 7.25 – 7.17 (m, 2H), 1.28 (s, 9H). All spectroscopic data were in agreement with 
the literature.34 
 
4-(tert-Butyl)picolinonitrile (169) 
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Starting from 4-(tert-butyl)pyridine N-oxide 168 (1.510 g, 10.0 mmol), trimethylsilyl cyanide (1.240 g, 
12.5 mmol, 1.25 equiv) and dimethylcarbamyl chloride (1.340 g, 12.5 mmol, 1.25 equiv) according to 
the general procedure for 163 to give 169 as a colorless oil (EtOAc/n-hexane = 1: 10; 1.571 g, 9.8 
mmol, 98% yield). 1H NMR (300 MHz, CDCl3) δ 8.60 (dd, J = 5.2, 0.8 Hz, 1H), 7.68 (dd, J = 2.0, 0.8 
Hz, 1H), 7.48 (dd, J = 5.3, 1.9 Hz, 1H), 1.33 (s, 9H). All spectroscopic data were in agreement with 
the literature.35 
1-(4-(tert-Butyl)pyridin-2-yl)ethanone (159) 
 
Starting from 4-(tert-butyl)picolinonitrile 169 (480 mg, 3.0 mmol) and methylmagnesium bromide 
(3.0 M, 1.2 mL, 3.6 mmol, 1.2 equiv) according to the general procedure for 155 to give 159 as a 
colorless oil (EtOAc/n-hexane = 1: 10; 388 mg, 2.19 mmol, 73% yield). 1H NMR (300 MHz, CDCl3) δ 
8.57 (d, J = 5.2 Hz, 1H), 8.05 (d, J = 2.0 Hz, 1H), 7.44 (dd, J = 5.2, 2.0 Hz, 1H), 2.71 (s, 3H), 1.32 (s, 
9H). All spectroscopic data were in agreement with the literature.35 
 
 
1-(4-Phenylpyridin-2-yl)ethanone (158) 
 
To a stirred solution of 4-phenylpicolinonitrile (901 mg, 5.0 mmol, 1.0 equiv) in dry diethyl ether (7.8 
mL, 0.64 M) was added a solution of methylmagnesium bromide (3.0 M, 2.0 mL, 6.0 mmol 1.2 equiv) 
dropwise at –15 °C (NaCl/ice bath) under N2 atmosphere. After the addition, the reaction mixture was 
further stirred at this temperature for 1 h and the cooling bath was removed. After warming to room 
temperature (3 h) the reaction mixture was quenched by the addition of 2 N HCl and stirring continued 
for another 15 min. After separation of the two phases, the water phase was neutralized to pH = 8 with 
2 N NaOH solution and extracted with CH2Cl2. The combined organic layers were washed with water, 
saturated brine, dried over anhydrous Na2SO4, and filtered. The resulting crude oil was purified by 
flash chromatography on silica gel (EtOAc/n-hexane = 1: 4) to provide 158 as a colorless oil 
(EtOAc/n-hexane = 1: 10; 895 mg, 4.54 mmol, 91% yield). 1H NMR (300 MHz, CDCl3) δ 8.70 (d, J = 
5.1 Hz, 1H), 8.30 – 8.24 (m, 1H), 7.73 – 7.59 (m, 3H), 7.57 – 7.37 (m, 3H), 2.76 (s, 3H). 13C NMR (75 
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MHz, CDCl3) δ 200.0, 154.2, 149.4, 149.3, 137.4, 129.4, 129.2, 127.0, 124.6, 119.4, 25.8. IR (film): ν 
(cm1) 3059, 1695, 1593, 1540, 1469, 1404, 1347, 1300, 1222, 1114, 1081, 1047, 995, 961, 901, 851, 
810, 767, 700, 644, 615, 585, 546, 517, 476, 397. HRMS (ESI, m/z) calcd for C13H11N1O1Na [M+Na]+: 
220.0733, found: 220.0732. 
 
1-(Pyridin-2-yl)propan-1-one (160) 
 
Starting from 2-cyanopydine (1.04 g, 10.0 mmol) and ethylmagnesium bromide (1.0 M in Et2O, 12 
mL, 12.0 mmol 1.2 equiv) according to the general procedure for 158 to give 160 as a pale yellow oil 
(EtOAc/n-hexane = 1: 4; 578 mg, 4.28 mmol, 43% yield) (The yield is low due to the bad quality of 
Grignard reagents). 1H NMR (300 MHz, CDCl3) δ 8.68 (ddd, J = 4.8, 1.7, 0.9 Hz, 1H), 8.05 (dt, J = 
7.8, 1.1 Hz, 1H), 7.84 (td, J = 7.7, 1.7 Hz, 1H), 7.47 (ddd, J = 7.6, 4.8, 1.3 Hz, 1H), 3.25 (q, J = 7.3 Hz, 
2H), 1.22 (t, J = 7.3 Hz, 3H). All spectroscopic data were in agreement with the literature.36 
 
1-(Pyridin-2-yl)pentan-1-one (161) 
 
Starting from 2-cyanopydine (1.04 g, 10.0 mmol) and n-butylmagnesium chloride (2.0 M in Et2O, 6.0 
mL, 12.0 mmol 1.2 equiv) according to the general procedure for 158 to give 161 as a colorless oil 
(EtOAc/n-hexane = 1: 8; 1.160 g, 7.12 mmol, 71% yield). 1H NMR (300 MHz, CDCl3) δ 8.65 (ddd, J 
= 4.8, 1.8, 0.9 Hz, 1H), 8.01 (dt, J = 7.9, 1.1 Hz, 1H), 7.81 (tt, J = 7.7, 1.6 Hz, 1H), 7.43 (ddd, J = 7.5, 
4.8, 1.3 Hz, 1H), 3.19 (t, J = 7.4 Hz, 2H), 1.69 (p, J = 7.6 Hz, 2H), 1.40 (dq, J = 14.6, 7.3 Hz, 2H), 
0.92 (t, J = 7.3 Hz, 3H). All spectroscopic data were in agreement with the literature.37 
 
5.3.2.2 Synthesis of 2-acylpyridine N-oxides 
All substrates were synthesized according to reported procedures with some modifications.  
    
81 82 83 84 
    
85 86 87 88 
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Gernaral Procedure: m-chloroperbenzoic acid (MCPBA, 70% purity, 3.2 equiv) was added to a 
solution of 2-acylpyridines 150-161 (1.0 equiv) in CH2Cl2 (0.11 M for 2-acylpyridines) at 0 °C. The 
mixture was stirred at the room temperature over night. After that, the solvent was removed under 
reduced pressure and the residue chromatographed on silica gel eluting with EtOAc and EtOAc-EtOH 
mixtures to give compounds 81-92. 
 
2-Acetylpyridine 1-oxide (81) 
 
Starting from 2-acyl pyridine 150 (1.210 g, 10.0 mmol) and m-chloroperbenzoic acid (6.040 g, 35.0 
mmol) according to the general procedure to give 81 as a grey solid (28 h, 0.860 g, 6.28 mmol, 63% 
yield). 1H NMR (300 MHz, CDCl3) δ 8.20 (d, J = 6.2 Hz, 1H), 7.68 (dd, J = 7.6, 2.8 Hz, 1H), 7.43 – 
7.24 (m, 2H), 2.80 (s, 3H). All spectroscopic data were in agreement with the literature.38 
 
2-Acetyl-3-methylpyridine 1-oxide (82) 
 
Starting from 1-(3-methylpyridin-2-yl)ethanone 151 (405 mg, 3.00 mmol) and m-chloroperbenzoic 
acid (1810 mg, 10.50 mmol) according to the general procedure to give 82 as a white solid (28 h, 441 
mg, 2.92 mmol, 97% yield). 1H NMR (300 MHz, CDCl3) δ 8.17 – 8.07 (m, 1H), 7.29 – 7.18 (m, 2H), 
2.64 (s, 3H), 2.27 (s, 3H). All spectroscopic data were in agreement with the literature.38 
 
2-Acetyl-4-methylpyridine 1-oxide (83) 
 
Starting from 1-(4-methylpyridin-2-yl)ethanone 152 (554 mg, 4.10 mmol) and m-chloroperbenzoic 
acid (2480 mg, 14.40 mmol) according to the general procedure to give 83 as a grey solid (19 h, 441 
mg, 3.51 mmol, 86% yield). 1H NMR (300 MHz, CDCl3) δ 8.09 (d, J = 6.6 Hz, 1H), 7.48 (d, J = 2.6 
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Hz, 1H), 7.16 (dd, J = 6.2, 2.6 Hz, 1H), 2.80 (s, 3H), 2.36 (s, 3H). All spectroscopic data were in 
agreement with the literature.38 
 
2-Acetyl-5-methylpyridine 1-oxide (84) 
 
Starting from 1-(5-methylpyridin-2-yl)ethanone 153 (554 mg, 4.10 mmol) and m-chloroperbenzoic 
acid (2480 mg, 14.40 mmol) according to the general procedure to give 84 as a pale yellow solid (19 h, 
520 mg, 3.44 mmol, 84% yield). 1H NMR (300 MHz, CDCl3) δ 8.05 (dt, J = 1.5, 0.8 Hz, 1H), 7.63 (d, 
J = 8.2 Hz, 1H), 7.11 (ddd, J = 8.2, 1.5, 0.7 Hz, 1H), 2.80 (s, 3H), 2.34 (s, 3H). All spectroscopic data 
were in agreement with the literature.38 
 
2-Acetyl-6-methylpyridine 1-oxide (85) 
 
Starting from 1-(6-methylpyridin-2-yl)ethanone 154 (540 mg, 4.00 mmol) and m-chloroperbenzoic 
acid (2416 mg, 14.00 mmol) according to the general procedure to give 85 as a pale yellow solid (20 h, 
490 mg, 3.25 mmol, 81% yield). 1H NMR (300 MHz, CDCl3) δ 7.55 (dd, J = 7.7, 2.1 Hz, 1H), 7.40 
(dd, J = 7.7, 2.1 Hz, 1H), 7.26 (t, J = 7.8 Hz, 1H), 2.81 (s, 3H), 2.57 (s, 3H). All spectroscopic data 
were in agreement with the literature.38 
 
2-Acetyl-4-methoxypyridine 1-oxide (86) 
 
Starting from 1-(4-methoxypyridin-2-yl)ethanone 155 (227 mg, 1.50 mmol) and m-chloroperbenzoic 
acid (906 mg, 5.25 mmol) according to the general procedure to give 86 as a pale yellow solid (3 days, 
180 mg, 1.08 mmol, 72% yield). 1H NMR (300 MHz, CDCl3) δ 8.21 (d, J = 7.2 Hz, 1H), 7.22 (d, J = 
3.6 Hz, 1H), 6.97 (dd, J = 7.3, 3.6 Hz, 1H), 3.92 (s, 3H), 2.85 (s, 3H). All spectroscopic data were in 
agreement with the literature.38 
 
2-Acetyl-4-ethylpyridine 1-oxide (87) 
 
Starting from 1-(4-ethylpyridin-2-yl)ethanone 156 (290 mg, 2.00 mmol) and m-chloroperbenzoic acid 
Chapter 5. Experimental Part 
-131- 
(1.201 g, 7.00 mmol) according to the general procedure to give 87 as a pale yellow solid (21 h, 284 
mg, 1.72 mmol, 86% yield). 1H NMR (300 MHz, CDCl3) δ 8.08 (d, J = 6.6 Hz, 1H), 7.51 – 7.43 (m, 
1H), 7.16 (dd, J = 6.6, 2.8 Hz, 1H), 2.78 (s, 3H), 2.63 (q, J = 7.6 Hz, 2H), 1.23 (t, J = 7.6 Hz, 3H). 13C 
NMR (75 MHz, CDCl3) δ 195.2, 146.1, 142.9, 140.0, 127.5, 125.7, 30.6, 27.3, 14.0. IR (film): ν (cm1) 
2970, 2932, 2874, 1687, 1614, 1537, 1463, 1431, 1353, 1289, 1236, 1191, 1133, 1070, 1017, 903, 878, 
836, 781, 705, 581, 535, 488, 453. HRMS (ESI, m/z) calcd for C9H12N1O2 [M+H]+: 166.0863, found: 
166.0861. 
 
2-Acetyl-4-propylpyridine 1-oxide (88) 
 
Starting from 1-(4-propylpyridin-2-yl)ethanone 157 (326 mg, 2.00 mmol) and m-chloroperbenzoic 
acid (1.201 g, 7.00 mmol) according to the general procedure to give 88 as a colorless oil (21 h, 290 
mg, 1.62 mmol, 81% yield). 1H NMR (300 MHz, CDCl3) δ 8.08 (d, J = 6.6 Hz, 1H), 7.46 (d, J = 2.7 
Hz, 1H), 7.14 (dd, J = 6.6, 2.7 Hz, 1H), 2.78 (s, 3H), 2.57 (t, J = 7.8 Hz, 2H), 1.63 (h, J = 7.4 Hz, 2H), 
0.93 (t, J = 7.3 Hz, 3H). 13C NMR (75 MHz, CDCl3) δ 195.2, 146.0, 141.6, 134.0, 128.0, 126.3, 36.3, 
30.7, 23.2, 13.4. IR (film): ν (cm1) 2960, 2930, 2868, 1686, 1614, 1536, 1462, 1431, 1352, 1288, 
1242, 1189, 1131, 1072, 1018, 978, 908, 834, 803, 761, 705, 583, 548, 452. HRMS (ESI, m/z) calcd 
for C10H13N1O2Na1 [M+Na]+: 202.0838, found: 202.0839. 
 
2-Acetyl-4-phenylpyridine 1-oxide (89) 
 
Starting from 1-(4-phenylpyridin-2-yl)ethanone 158 (865 mg, 4.39 mmol) and m-chloroperbenzoic 
acid (2.650 g, 15.27 mmol) according to the general procedure to give 89 as a white solid (19 h, 792 
mg, 3.72 mmol, 85% yield). 1H NMR (300 MHz, CDCl3) δ 8.22 (d, J = 6.8 Hz, 1H), 7.92 (d, J = 2.8 
Hz, 1H), 7.64 – 7.54 (m, 3H), 7.53 – 7.35 (m, 3H), 2.84 (s, 3H). All spectroscopic data were in 
agreement with the literature.38 
 
2-Acetyl-4-(tert-butyl)pyridine 1-oxide (90) 
 
Starting from 1-(4-(tert-butyl)pyridin-2-yl)ethanone 159 (368 mg, 2.08 mmol) and 
m-chloroperbenzoic acid (1.260 g, 7.28 mmol) according to the general procedure to give 90 as a 
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white solid (38 h, 334 mg, 1.73 mmol, 83% yield). 1H NMR (300 MHz, CDCl3) δ 8.11 (d, J = 6.9 Hz, 
1H), 7.64 (d, J = 2.9 Hz, 1H), 7.33 (dd, J = 6.9, 2.9 Hz, 1H), 2.81 (s, 3H), 1.31 (s, 9H). 13C NMR (75 
MHz, CDCl3) δ 195.4, 150.2, 145.9, 139.9, 125.2, 123.5, 34.7, 30.7, 30.4. IR (film): ν (cm1) 2960, 
2917, 2869, 1672, 1605, 1477, 1453, 1418, 1394, 1358, 1293, 1263, 1241, 1181, 1137, 969, 918, 829, 
747, 677, 580, 554, 511, 465. HRMS (ESI, m/z) calcd for C11H16N1O2 [M+H]+: 194.1176, found: 
194.1175. 
 
2-Propionylpyridine 1-oxide (91) 
 
Starting from 1-(pyridin-2-yl)propan-1-one 160 (270 mg, 2.00 mmol) and m-chloroperbenzoic acid 
(1.208 g, 7.0 mmol) according to the general procedure to give 91 as a pale yellow oil (23 h, 204 mg, 
1.35 mmol, 68% yield). 1H NMR (300 MHz, CDCl3) δ 8.33 – 8.24 (m, 1H), 7.73 – 7.66 (m, 1H), 7.43 
– 7.35 (m, 2H), 3.24 (q, J = 7.2 Hz, 2H), 1.22 (t, J = 7.2 Hz, 3H). All spectroscopic data were in 
agreement with the literature.38 
 
2-Pentanoylpyridine 1-oxide (92) 
 
Starting from 1-(pyridin-2-yl)pentan-1-one 161 (652 mg, 4.00 mmol) and m-chloroperbenzoic acid 
(2.416 g, 14.0 mmol) according to the general procedure to give 92 as a colorless oil (26 h, 401 mg, 
2.24 mmol, 56% yield). 1H NMR (300 MHz, CDCl3) δ 8.25 – 8.20 (m, 1H), 7.62 (dd, J = 7.2, 2.7 Hz, 
1H), 7.43 – 7.29 (m, 2H), 1.69 (p, J = 7.4 Hz, 2H), 1.38 (dq, J = 14.5, 7.3 Hz, 2H), 0.92 (t, J = 7.3 Hz, 
3H). All spectroscopic data were in agreement with the literature.38 
 
5.3.3 Synthesis of 2-acyl imidazoles 
5.3.3.1 Synthesis of weinreb amides 
All substrates were synthesized according to reported procedures with slightly modifications.17,39 
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Gernaral Procedure A: To a mixture of N,O-dimethylhydroxylamine hydrochloride (1.1 equiv) and 
pyridine (2.5 equiv) in CH2Cl2 (0.5 M for acyl chloride) were added the corresponding acyl chloride 
(1.0 equiv) at 0 oC. The reaction mixture was stirred at the room temperature for additional 2 hours. 
The reaction mixture was diluted with EtOAc. The organic layer was washed with 2 N HCl (twice), 
aqueous saturated NaHCO3 (twice) and brine. The combined organic layers were dried over anhydrous 
Na2SO4. The crude mixture was purified by flash chromatography on silica gel (EtOAc/n-hexane = 1: 
3) to give the pure Weinreb amide. 
Gernaral Procedure B: To a solution of corresponding carboxylic acid (1.0 equiv) in CH2Cl2 (0.16 M 
for carboxylic acid) were added stepwise N, O-dimethylhydroxylamine hydrochloride (1.5 equiv), 
1-(3- dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (1.5 equiv) and 4-dimethylamino- 
pyridine (1.5 equiv). The reaction mixture was stirred over night at room temperature. After that, the 
reaction mixture was quenched by water, and then was extracted with CH2Cl2. The combined organic 
layers were washed with 1 N HCl and brine, dried over Na2SO4 and the solvent was evaporated in 
vacuo. The crude mixtute was purified by flash chromatography on silica gel (EtOAc/n-hexane = 1: 3) 
to give the pure Weinreb amide. 
 
N-Methoxy-N-methyl-2-phenylacetamide (170) 
 
Following the Gernaral Procedure A, 2-phenylacetyl chloride (6.960 g, 45.0 mmol) was converted to 
Weinreb amide 170 (8.027 g, 44.8 mmol, >99% yield) as a colorless oil. 1H NMR (300 MHz, CDCl3) 
δ 7.46 – 7.15 (m, 5H), 3.79 (s, 2H), 3.62 (s, 3H), 3.21 (s, 3H). All spectroscopic data were in 
agreement with the literature.40 
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2-(4-Fluorophenyl)-N-methoxy-N-methylacetamide (171) 
 
Following the Gernaral Procedure B, 2-(4-fluorophenyl)acetic acid (1.232 g, 8.00 mmol) was convert 
to Weinreb amide 171 (1.520 g, 7.72 mmol, 97% yield) as a white solid. 1H NMR (300 MHz, CDCl3) 
δ 7.32 – 7.23 (m, 2H), 7.07 – 6.96 (m, 2H), 3.76 (s, 2H), 3.66 (s, 3H), 3.21 (s, 3H). 19F NMR (282 
MHz, CDCl3) δ –117.22 (s, 1F). All spectroscopic data were in agreement with the literature.41 
 
2-(4-Chlorophenyl)-N-methoxy-N-methylacetamide (172) 
 
Following the Gernaral Procedure A, 2-(4-chlorophenyl)acetyl chloride (1.087 g, 5.75 mmol) was 
converted to Weinreb amide 172 (0.990 g, 4.65 mmol, 81% yield) as a colorless oil. 1H NMR (300 
MHz, CDCl3) δ 7.30 (d, J = 8.7 Hz, 2H), 7.24 (d, J = 8.5 Hz, 2H), 3.75 (s, 2H), 3.65 (s, 3H), 3.20 (s, 
3H). All spectroscopic data were in agreement with the literature.42 
 
2-(3-Chlorophenyl)-N-methoxy-N-methylacetamide (173) 
 
Following the Gernaral Procedure B, 2-(3-chlorophenyl)acetic acid (1.706 g, 10.0 mmol) was convert 
to Weinreb amide 173 (1.490 g, 7.00mmol, 70% yield) as a colorless oil. 1H NMR (300 MHz, CDCl3) 
δ 7.32 – 7.27 (m, 1H), 7.26 – 7.13 (m, 3H), 3.74 (s, 2H), 3.64 (s, 3H), 3.20 (s, 3H). All spectroscopic 
data were in agreement with the literature.43 
 
2-(2-Chlorophenyl)-N-methoxy-N-methylacetamide (174) 
 
Following the Gernaral Procedure B, 2-(2-chlorophenyl)acetic acid (1.706 g, 10.0 mmol) was convert 
to Weinreb amide 174 (2.123 g, 9.97 mmol, >99% yield) as a colorless oil. 1H NMR (300 MHz, CDCl3) 
δ 7.42 – 7.35 (m, 1H), 7.33 – 7.28 (m, 1H), 7.26 – 7.16 (m, 2H), 3.92 (s, 2H), 3.71 (s, 3H), 3.23 (s, 
3H). All spectroscopic data were in agreement with the literature.44 
 
2-(4-Bromophenyl)-N-methoxy-N-methylacetamide (175) 
 
Following the Gernaral Procedure B, 2-(4-bromophenyl)acetic acid (1.720 g, 8.00 mmol) was convert 
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to Weinreb amide 175 (1.990 g, 7.74 mmol, 97% yield) as a white solid. 1H NMR (300 MHz, CDCl3) 
δ 7.44 (d, J = 8.4 Hz, 1H), 7.17 (d, J = 8.4 Hz, 2H), 3.72 (s, 2H), 3.63 (s, 3H), 3.19 (s, 3H). All 
spectroscopic data were in agreement with the literature.39 
 
N-Methoxy-N-methyl-2-(p-tolyl)acetamide (176) 
 
Following the Gernaral Procedure B, 2-(p-tolyl)acetic acid (1.200 g, 8.00 mmol) was convert to 
Weinreb amide 176 (1.540 g, 7.98 mmol, >99% yield) as a white solid. 1H NMR (300 MHz, CDCl3) δ 
7.18 (d, J = 8.1 Hz, 2H), 7.12 (d, J = 7.8 Hz, 2H), 3.73 (s, 2H), 3.61 (s, 3H), 3.19 (s, 3H), 2.32 (s, 3H). 
All spectroscopic data were in agreement with the literature.39 
 
N-Methoxy-2-(4-methoxyphenyl)-N-methylacetamide (177) 
 
Following the Gernaral Procedure A, 2-(4-methoxyphenyl)acetyl chloride (1.477 g, 8.00 mmol) was 
converted to Weinreb amide 177 (1.401 g, 6.70 mmol, 84% yield) as a colorless oil. 1H NMR (300 
MHz, CDCl3) δ 7.21 (d, J = 8.7 Hz, 2H), 6.85 (d, J = 8.7 Hz, 2H), 3.78 (s, 3H), 3.71 (s, 2H), 3.61 (s, 
3H), 3.18 (s, 3H). All spectroscopic data were in agreement with the literature.17 
 
N-Methoxy-N-methyl-2-(naphthalen-2-yl)acetamide (178) 
 
Following the Gernaral Procedure B, 2-(naphthalen-2-yl) acetic acid (1.488 g, 8.00 mmol) was 
converted to Weinreb amide 178 (1.778g, 7.76 mmol, 97% yield) as a colorless oil. 1H NMR (300 
MHz, CDCl3) δ 7.85 – 7.77 (m, 3H), 7.77 – 7.73 (m, 1H), 7.51 – 7.39 (m, 3H), 3.94 (s, 2H), 3.61 (s, 
3H), 3.22 (s, 3H). All spectroscopic data were in agreement with the literature.17 
 
5.3.3.2 Synthesis of 2-acyl imidazoles 
2-Acyl imidazoles 105-115 were synthesized starting from corresponding Weinreb amide following a 
published literature with slight modification44 and 116 was synthesized starting from propionic 
anhydride according to a reported procedure.45 
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General procedure: To a solution of N-isopropylimidazole, or N-phenylimidazole, or N-(o-tolyl)- 
imidazole (1.1 equiv) in anhydrous THF (0.4 M for the Weinreb amide) at –78 oC added n-BuLi (1.1 
equiv, 2.5 M in hexanes) dropwise. The reaction mixture was stirred at –78 oC for 30 min, and then 
stirred at room temperature for 30 min. The corresponding Weinreb amide 170-178 (1.0 equiv in THF) 
was added dropwise to the flask after the reaction mixture was cooled back down to –78 oC. The 
reaction mixture was allowed to warm to room temperature slowly and stirred over night. The reaction 
mixture was quenched with water, diluted with EtOAc. The organic phase was washed with aqueous 
saturated NaHCO3, brine, dried over anhydrous Na2SO4 and concentrated in vacuo. The crude product 
was subjected to a silica gel flash chromatography (EtOAc/n-hexane = 1: 5) to afford the 
corresponding 2-acyl imidazole 105-115. 
1-(1-Isopropyl-1H-imidazol-2-yl)-2-phenylethanone (105) 
 
Following the general procedure, the Weinreb amide 170 (1.432 g, 8.0 mmol) was converted to 2-acyl 
imidazole 105 (1.544 g, 6.77 mmol, 85% yield) as a colorless oil. 1H NMR (300 MHz, CDCl3) δ 7.39 
– 7.23 (m, 7H), 5.77 – 5.33 (m, 1H), 4.49 (s, 2H), 1.43 (d, J = 6.7 Hz, 6H). All spectroscopic data were 
in agreement with the literature.17 
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2-Phenyl-1-(1-phenyl-1H-imidazol-2-yl)ethanone (106) 
 
Following the general procedure, the Weinreb amide 170 (1.521g, 9.00 mmol) was converted to 2-acyl 
imidazole 106 (1.550 g, 5.92 mmol, 66% yield) as a white solid. 1H NMR (300 MHz, CDCl3) δ 
7.46–7.37 (m, 3H), 7.34–7.20 (m, 8H), 7.19 (d, J = 1.0 Hz, 1H), 4.45 (s, 2H). All spectroscopic data 
were in agreement with the literature.44 
 
2-Phenyl-1-(1-(o-tolyl)-1H-imidazol-2-yl)ethanone (107) 
 
Following the general procedure, the Weinreb amide 170 (1.790 g, 10.0 mmol) was converted to 
2-acyl imidazole 107 (2.230 g, 8.08 mmol, 81% yield) as a white solid. 1H NMR (300 MHz, CDCl3) δ 
7.40 – 7.16 (m, 9H), 7.15 – 7.01 (m, 2H), 4.50 (d, J = 15.3 Hz, 1H), 4.40 (d, J = 15.3 Hz, 1H), 1.90 (s, 
3H). 13C NMR (75 MHz, CDCl3) δ 188.3, 143.2, 137.7, 134.4, 134.3, 130.6, 129.9, 129.8, 128.9, 128.3, 
126.7, 126.7, 126.5, 126.2, 45.3, 17.0. IR (film): ν (cm1) 3105, 3030, 2914, 1685, 1592, 1494, 1452, 
1390, 1340, 1307, 1208, 1147, 1079, 1023, 991, 958, 912, 887, 840, 789, 761, 721, 696, 590, 542, 512, 
480, 454. HRMS (ESI, m/z) calcd for C18H16N2O1Na1 [M+ Na]+: 299.1155, found: 299.1156. 
 
2-(4-Fluorophenyl)-1-(1-(o-tolyl)-1H-imidazol-2-yl)ethanone (108) 
 
Following the general procedure, the Weinreb amide 171 (0.985 g, 5.0 mmol) was converted to 2-acyl 
imidazole 108 (1.104 g, 3.76 mmol, 75% yield) as a white solid. 1H NMR (300 MHz, CDCl3) δ 7.38 (d, 
J = 1.0 Hz, 1H), 7.37 – 7.32 (m, 1H), 7.32 – 7.22 (m, 5H), 7.15 – 7.07 (m, 2H), 7.03 – 6.93 (m, 2H), 
4.48 (d, J = 15.4 Hz, 1H), 4.38 (d, J = 15.4 Hz, 1H), 1.91 (s, 3H). 13C NMR (75 MHz, CDCl3) δ 
188.10, 188.09, 163.5, 160.2, 143.0, 137.7, 134.3, 131.4, 131.3, 130.7, 130.00, 129.95, 129.0, 126.8, 
126.5, 126.2, 115.3, 115.0, 44.4, 17.0. 19F NMR (282 MHz, CDCl3) δ –116.32 (s, 1F). IR (film): ν 
(cm1) 3051, 2925, 1683, 1603, 1502, 1454, 1397, 1305, 1221, 1151, 1092, 1027, 966, 912, 863, 832, 
792, 763, 715, 669, 608,516 355. HRMS (ESI, m/z) calcd for C18H15F1N2O1Na1 [M+ Na]+: 317.1061, 
found: 317.1051. 
 
2-(4-Chlorophenyl)-1-(1-(o-tolyl)-1H-imidazol-2-yl)ethanone (109) 
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Following the general procedure, the Weinreb amide 172 (0.980 g, 4.60 mmol) was converted to 
2-acyl imidazole 109 (1.027 g, 3.31 mmol, 72% yield) as a white solid. 1H NMR (300 MHz, CDCl3) δ 
7.37 (d, J = 1.0 Hz, 1H), 7.35 – 7.31 (m, 1H), 7.30 – 7.20 (m, 6H), 7.11 (d, J = 1.0 Hz, 1H), 7.08 (dd, J 
= 7.7, 1.4 Hz, 1H), 4.45 (d, J = 15.3 Hz, 1H), 4.36 (d, J = 15.4 Hz, 1H), 1.90 (s, 3H). 13C NMR (75 
MHz, CDCl3) δ 187.8, 143.0, 137.7, 134.4, 132.8, 131.2, 130.7, 123.0, 129.1, 128.5, 126.9, 126.6, 
126.2, 44.7, 17.1. IR (film): ν (cm1) 3111, 3029, 2913, 1684, 1591, 1494, 1451, 1392, 1306, 1207, 
1145, 1079, 1023, 958, 912, 841, 788, 764, 718, 591, 543, 454. HRMS (ESI, m/z) calcd for 
C18H15Cl1N2O1Na1 [M+Na]+: 333.0765, found: 333.0766. 
 
2-(3-Chlorophenyl)-1-(1-(o-tolyl)-1H-imidazol-2-yl)ethanone (110) 
 
Following the general procedure, the Weinreb amide 173 (1.065 g, 5.00 mmol) was converted to 
2-acyl imidazole 110 (0.810 g, 2.61 mmol, 52% yield) as a white solid. 1H NMR (300 MHz, CDCl3) δ 
7.41 – 7.25 (m, 5H), 7.24 – 7.16 (m, 3H), 7.15 – 7.05 (m, 2H), 4.47 (d, J = 15.5 Hz, 1H), 4.38 (d, J = 
15.4 Hz, 1H), 1.92 (s, 3H). 13C NMR (75 MHz, CDCl3) δ 187.6, 143.0, 137.7, 136.3, 134.4, 134.1, 
130.7, 130.1, 130.0, 129.6, 129.1, 128.1, 127.0, 126.6, 126.2, 44.9, 17.0. IR (film): ν (cm1) 3131, 
1682, 1600, 1574, 1498, 1478, 1459, 1431, 1409, 1392, 1344, 1311, 1216, 1168, 1146, 1081, 1043, 
1021, 960, 910, 893, 883, 865, 855, 811, 794, 759, 717, 705, 683, 593, 550, 542, 505, 453, 415. 
HRMS (ESI, m/z) calcd for C18H15Cl1N2O1Na1 [M+Na]+: 333.0765, found: 333.0767. 
 
2-(2-Chlorophenyl)-1-(1-(o-tolyl)-1H-imidazol-2-yl)ethanone (111) 
 
Following the general procedure, the Weinreb amide 174 (1.065 g, 5.00 mmol) was converted to 
2-acyl imidazole 111 (0.960 g, 3.10 mmol, 62% yield) as a white solid. 1H NMR (300 MHz, CDCl3) δ 
7.39 (d, J = 1.0 Hz, 1H), 7.37 – 7.20 (m, 5H), 7.20 – 7.14 (m, 3H), 7.13 (d, J = 1.0 Hz, 1H), 4.77 (d, J 
= 17.6 Hz, 1H), 4.57 (d, J = 17.7 Hz, 1H), 1.99 (s, 3H). 13C NMR (75 MHz, CDCl3) δ 187.0, 143.0, 
137.7, 134.7, 134.5, 132.9, 132.1, 130.7, 129.9, 129.3, 129.0, 128.4, 126.6, 126.5, 126.2, 43.6, 17.1. 
IR (film): ν (cm1) 3089, 1683, 1501, 1488, 1472, 1460, 1444, 1400, 1344, 1309, 1150, 1094, 1050, 
1032, 963, 948, 915, 811, 802, 787, 766, 751, 717, 692, 678, 598, 573, 554, 535, 504, 459, 448, 436. 
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HRMS (ESI, m/z) calcd for C18H15Cl1N2O1Na1 [M+Na]+: 333.0765, found: 333.0766. 
 
2-(4-Bromophenyl)-1-(1-(o-tolyl)-1H-imidazol-2-yl)ethanone (112) 
 
Following the general procedure, the Weinreb amide 175 (1.290 g, 5.0 mmol) was converted to 2-acyl 
imidazole 112 (1.153 g, 3.26 mmol, 65% yield) as a white solid. 1H NMR (300 MHz, CDCl3) δ 7.45 – 
7.38 (m, 2H), 7.37 (d, J = 1.0 Hz, 1H), 7.36 – 7.22 (m, 3H), 7.22 – 7.16 (m, 2H), 7.12 (d, J = 1.0 Hz, 
1H), 7.09 (dd, J = 7.7, 1.4 Hz, 1H), 4.45 (d, J = 15.3 Hz, 1H), 4.35 (d, J = 15.3 Hz, 1H), 1.91 (s, 3H). 
13C NMR (75 MHz, CDCl3) δ 187.7, 143.0, 137.7, 134.4, 133.3, 131.6, 131.5, 130.7, 130.0, 129.1, 
126.9, 126.5, 126.2, 120.8, 44.7, 17.0. IR (film): ν (cm1) 3113, 2896, 1688, 1487, 1456, 1442, 1408, 
1391, 1338, 1313, 1281, 1199, 1150, 1068, 1048, 1021, 1011, 969, 910, 861, 801, 766, 717, 708, 691, 
672, 627, 556, 538, 517, 469, 455. HRMS (ESI, m/z) calcd for C18H15Br1N2O1Na1 [M+Na]+: 377.0260, 
379.0241, found: 377.0261, 379.0241. 
 
2-(p-Tolyl)-1-(1-(o-tolyl)-1H-imidazol-2-yl)ethanone (113) 
 
Following the general procedure, the Weinreb amide 176 (0.965 g, 5.0 mmol) was converted to 2-acyl 
imidazole 113 (1.050 g, 3.62 mmol, 72% yield) as a white solid. 1H NMR (300 MHz, CDCl3) δ 7.38 (d, 
J = 1.0 Hz, 1H), 7.36 – 7.31 (m, 1H), 7.31 – 7.24 (m, 2H), 7.24 – 7.19 (m, 2H), 7.15 – 7.08 (m, 4H), 
4.47 (d, J = 15.2 Hz, 1H), 4.38 (d, J = 15.3 Hz, 1H), 2.32 (s, 3H), 1.93 (s, 3H). 13C NMR (75 MHz, 
CDCl3) δ 188.5, 143.2, 137.8, 136.2, 134.4, 131.2, 130.6, 129.8, 129.7, 129.1, 128.9, 126.6, 126.4, 
126.2, 44.9, 21.0, 17.0. IR (film): ν (cm1) 3025, 2922, 1680, 1512, 1492, 1459, 1398, 1341, 1304, 
1147, 1089, 1050, 1039, 1023, 963, 913, 761, 735, 714, 674, 610, 564, 550, 524, 499, 477, 457. 
HRMS (ESI, m/z) calcd for C19H19N2O1 [M+H]+: 291.1492, found: 291.1493. 
 
2-(4-Methoxyphenyl)-1-(1-(o-tolyl)-1H-imidazol-2-yl)ethanone (114) 
N
N
O OMe
 
Following the general procedure, the Weinreb amide 177 (1.045 g, 5.0 mmol) was converted to 2-acyl 
imidazole 114 (1.106 g, 3.61 mmol, 72% yield) as a white solid. 1H NMR (300 MHz, CDCl3) δ 7.36 (d, 
J = 1.0 Hz, 1H), 7.34 – 7.29 (m, 1H), 7.29 – 7.17 (m, 4H), 7.11 – 7.06 (m, 2H), 6.87 – 6.78 (m, 2H), 
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4.42 (d, J = 15.3 Hz, 1H), 4.32 (d, J = 15.3 Hz, 1H), 3.77 (s, 3H), 1.89 (s, 3H). 13C NMR (75 MHz, 
CDCl3) δ 188.7, 158.5, 143.3, 137.8, 134.5, 130.9, 130.7, 129.8, 129.0, 126.7, 126.5, 126.4, 126.3, 
113.9, 55.2, 44.5, 17.0. IR (film): ν (cm1) 3158, 2916, 1668, 1607, 1583, 1509, 1488, 1460, 1447, 
1421, 1394, 1302, 1261, 1239, 1179, 1146, 1114, 1087, 1057, 1037, 975, 941, 916, 830, 818, 787, 768, 
714, 671, 615, 567, 549, 530, 518, 458, 445, 419. HRMS (ESI, m/z) calcd for C19H18N2O2Na1 [M+ 
Na]+: 329.1260, found: 329.1263. 
 
2-(Naphthalen-2-yl)-1-(1-(o-tolyl)-1H-imidazol-2-yl)ethanone (115) 
 
Following the general procedure, the Weinreb amide 178 (0.641 g, 2.8 mmol) was converted to 2-acyl 
imidazole 115 (0.600 g, 1.84 mmol, 66% yield) as a white solid. 1H NMR (300 MHz, CDCl3) δ 7.83 – 
7.73 (m, 4H), 7.49 – 7.40 (m, 3H), 7.39 (d, J = 1.0 Hz, 1H), 7.37 – 7.29 (m, 1H), 7.28 – 7.19 (m, 2H), 
7.11 (d, J = 1.0 Hz, 1H), 7.08 (dd, J = 7.7, 1.5 Hz, 1H), 4.65 (d, J = 15.0 Hz, 1H), 4.56 (d, J = 15.0 Hz, 
1H), 1.89 (s, 3H). 13C NMR (75 MHz, CDCl3) δ 188.3, 143.2, 137.8, 134.4, 133.5, 132.4, 131.9, 130.7, 
129.9, 129.0, 128.6, 128.0, 128.0, 127.7, 127.6, 126.8, 126.5, 126.2, 125.9, 125.5, 45.6, 17.1. IR (film): 
ν (cm1) 3115, 2955, 1682, 1550, 1457, 1394, 1311, 1305, 1147, 1023, 964, 911, 867, 795, 760, 747, 
709, 675, 632, 621, 568, 540, 518, 480, 454, 404. HRMS (ESI, m/z) calcd for C22H18N2O1Na1 [M+ 
Na]+: 349.1311, found: 349.1312. 
 
1-(1-(o-Tolyl)-1H-imidazol-2-yl)propan-1-one (116) 
 
According to the literature7, n-BuLi (2.64 mL, 6.60 mmol, 2.5 M in hexane, 1.10 equiv) was added to 
a solution of N-(o-tolyl)-imidazole (0.948 g, 6.00 mmol, 1.0 equiv) in THF (10 mL) at –78°C. The 
solution was stirred for 30 min, transferred via cannula into propionic anhydride (0.848 g, 6.60 mmol, 
1.1 equiv) in THF (4 mL) at –78°C. After 30 min, the reaction mixture was allowed to warm to room 
temperture and quenched with sodium hydroxide solution (2.0 M, 12 mL) and stirred vigorously for 1 
hour. The aqueous phase was extracted with ethyl acetate (3 × 20 mL). The combined organic phases 
were washed with brine (20 mL), dried over sodium sulfate, and concentrated. The crude product was 
subjected to a silica gel flash chromatography (EtOAc/n-hexane = 1: 2) to afford the 2-acyl imidazole 
116 (0.773 g, 3.61 mmol, 60% yield) as a white solid. 1H NMR (300 MHz, CDCl3) δ 7.45 – 7.24 (m, 
4H), 7.13 (dd, J = 7.7, 1.3 Hz, 1H), 7.08 (d, J = 1.0 Hz, 1H), 3.36 – 2.97 (m, 2H), 1.99 (s, 3H), 1.13 (t, 
J = 7.3 Hz, 3H). All spectroscopic data were in agreement with the literature.45 
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5.3.4 Synthesis of amines 
All substrates were synthesized according to reported procedures with slightly modifications.46 
 
Methyl hydroxy(methyl)carbamate (179) 
 
To a stirred suspension of N-methylhydroxylamine hydrochloride (2.500 g, 30.1 mmol) in THF (50 
mL) and H2O (5 mL) was added NaHCO3 (5.000 g, 59.5 mmol) and methylchloroformate (2.5 mL, 
32.4 mmol). The resulting clear suspension was stirred over night at room temperature, then diluted 
with H2O (25 mL) and extracted with CH2Cl2 (3 × 25 mL). The combined organic extracts were dried 
(Na2SO4) and concentrated in vacuo to yield the disired compound 179 (2.969 g, 94% yield) as a 
colorless oil which was used without further purification. 1H NMR (300 MHz, CDCl3) δ 7.94 (s, 1H), 
3.72 (s, 3H), 3.19 (s, 3H). All spectroscopic data were in agreement with the literature.46 
 
Methyl ((2,4-dinitrophenyl)sulfonyl)oxy(methyl)carbamate (117) 
 
To a stirred solution of methyl hydroxy(methyl)carbamate 179 (1.000 g, 9.5 mmol) in CH2Cl2 (60 mL) 
at 0 °C was added NEt3 (1.7 mL, 12.4 mmol) and 2,4-dinitrobenzenesulfonyl chloride (2.666 g, 10.0 
mmol). The resulting orange solution was stirred at 0 °C for 3 h, then diluted with 0.5 M aqueous citric 
acid (30 mL) and extracted with CH2Cl2 (2 × 30 mL). The combined organic extracts were washed 
with saturated aqueous NaHCO3 (30 mL) and brine (30 mL), dried (Na2SO4) and concentrated under 
reduced pressure. The residue was purified by flash chromatography on silica gel (dichloromethane 
/n-hexane = 1: 1) to give 117 (2.410 g, 7.2 mmol, 76% yield) as a white solid. 1H NMR (300 MHz, 
CDCl3) δ 8.67 (d, J = 2.2 Hz, 1H), 8.56 (dd, J = 8.7, 2.2 Hz, 1H), 8.42 (d, J = 8.6 Hz, 1H), 3.61 (d, J = 
1.3 Hz, 3H), 3.39 (s, 3H). All spectroscopic data were in agreement with the literature.46 
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Methyl benzyloxycarbamate (180) 
 
To a stirred suspension of O-benzylhydroxylamine hydrochloride (3.800 g, 23.8 mmol) in THF (50 
mL) and H2O (5 mL) was added NaHCO3 (4.000 g, 47.6 mmol) and methylchloroformate (2.0 mL, 
26.2 mmol). The resulting clear suspension was stirred over night at room temperature, then diluted 
with H2O (20 mL) and extracted with EtOAc (3 × 20 mL). The combined organic extracts were dried 
(Na2SO4) and concentrated under reduced pressure to yield the disired compound 180 (4.288 g, > 99% 
yield) as a colorless oil which was used without further purification. 1H NMR (300 MHz, CDCl3) δ 
7.45 – 7.30 (m, 5H), 7.24 (s, 1H), 4.87 (s, 2H), 3.77 (s, 3H). All spectroscopic data were in agreement 
with the literature.46 
 
Methyl benzyloxy(butyl)carbamate (181) 
 
To a stirred solution of methyl benzyloxycarbamate 180 (1.000 g, 5.5 mmol) in DMF (30 mL) at 0 °C 
was added NaH (60% dispersion in mineral oil, 330 mg, 8.25 mmol). The reaction mixture was stirred 
for 10 min at 0 °C then 1-butylbromide (0.77 mL, 7.15 mmol) and TBAI (203 mg, 0.55 mmol) were 
added. The resulting suspension was stirred at room temperature for 4 h before being quenched by the 
addition of 0.5 M aqueous citric acid (25 mL). The mixture was poured into a separatory funnel and 
extracted with MTBE (3 × 25 mL). The combined organic extracts were washed with brine (25 mL), 
dried (Na2SO4) and concentrated under reduced pressure. The residue was purified by flash 
chromatography on silica gel (EtOAc/n-hexane = 1: 10) to provide the pure title compound 181 (1.204 
g, 92% yield) as a colorless oil. 1H NMR (300 MHz, CDCl3) δ 7.48 – 7.29 (m, 5H), 4.85 (s, 2H), 3.78 
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(s, 3H), 3.50 – 3.37 (m, 2H), 1.67 – 1.47 (m, 2H), 1.40 – 1.24 (m, 2H), 0.90 (t, J = 7.3 Hz, 3H). All 
spectroscopic data were in agreement with the literature.46 
 
Methyl butyl(((2,4-dinitrophenyl)sulfonyl)oxy)carbamate (118) 
 
To a solution of methyl benzyloxy(butyl)carbamate 181 (711 mg, 3.0 mmol) in MeOH (24 mL), was 
added Pd(OH)2/C (142 mg, 20 wt.%) under nitrogen and the resulting suspension was degassed by 
bubbling hydrogen (balloon) for 5 min. The mixture was stirred over night at room temperature under 
hydrogen atmosphere and then filtered directly through a pad of celite. The filter cake was washed 
with MeOH (10 mL) and the filtrate was concentrated in vacuo to give 185 as a colorless oil. The 
crude product 185 was dissolved in CH2Cl2 (27 mL), and cooled to 0 °C, then NEt3 (543 μL, 3.9 mmol) 
and 2,4-dinitrobenzenesulfonyl chloride (880 mg, 3.3 mmol) were added stepwise. The resulting 
solution was stirred at 0 °C for 30 min, then diluted with 0.5 M aqueous citric acid (20 mL) and 
extracted with CH2Cl2 (2 × 20 mL). The combined organic extracts were washed with saturated 
aqueous NaHCO3 (20 mL) and brine (20 mL), dried (Na2SO4) and concentrated in vacuo. The 
resultant was purified by flash chromatography on silica gel (EtOAc/n-hexane = 1: 8) to provide the 
pure disired compound 118 (964 mg, 85% yield) as a pale yellow solid. 1H NMR (300 MHz, CDCl3) δ 
8.66 (d, J = 2.2 Hz, 1H), 8.56 (dd, J = 8.6, 2.2 Hz, 1H), 8.40 (d, J = 8.6 Hz, 1H), 3.69 (t, J = 7.5 Hz, 
2H), 3.61 (s, 3H), 1.72 – 1.62 (m, 2H), 1.40 – 1.27 (m, 2H), 0.94 (t, J = 7.3 Hz, 3H). All spectroscopic 
data were in agreement with the literature.46 
 
Methyl benzyloxy(3-phenylpropyl)carbamate (182) 
 
To a stirred solution of methyl benzyloxycarbamate 180 (1.000 g, 5.5 mmol) in DMF (19 mL) at 0 °C 
was added NaH (60% dispersion in mineral oil, 330 mg, 8.25 mmol). The reaction mixture was stirred 
for 10 min at 0 °C then (3-bromopropyl)benzene (1.20 mL, 7.7 mmol) and TBAI (408 mg, 1.10 mmol) 
were added stepwise. The resulting suspension was stirred at room temperature for 3 h before being 
quenched by the addition of 0.5 M aqueous citric acid (25 mL). The mixture was poured into a 
separatory funnel and extracted with MTBE (3 × 25 mL). The combined organic extracts were washed 
with brine (25 mL), dried (Na2SO4) and concentrated under reduced pressure. The residue was purified 
by flash chromatography on silica gel (EtOAc/n-hexane = 1: 8) to provide the pure disired compound 
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182 (1.457 g, 88% yield) as a colorless oil. 1H NMR (300 MHz, CDCl3) δ 7.43 – 7.31 (m, 5H), 7.31 – 
7.23 (m, 2H), 7.23 – 7.13 (m, 3H), 4.79 (s, 2H), 3.78 (s, 3H), 3.59 – 3.40 (m, 2H), 2.71 – 2.55 (m, 2H), 
2.04 – 1.79 (m, 2H) (Contained the minor rotamer). All spectroscopic data were in agreement with the 
literature.46 
 
Methyl ((2,4-dinitrophenyl)sulfonyl)oxy(3-phenylpropyl)carbamate (119) 
 
To a solution of methyl benzyloxy(butyl)carbamate 182 (1.457 g, 4.87 mmol) in MeOH (16 mL), was 
added Pd(OH)2/C (291 mg, 20 wt.%) under nitrogen and the resulting suspension was degassed by 
bubbling hydrogen (balloon) for 5 minutes. The mixture was stirred over night at room temperature 
under hydrogen atmosphere and then filtered directly through a pad of celite. The filter cake was 
washed with MeOH (10 mL) and the filtrate was concentrated in vacuo to give 186 as a colorless oil. 
The crude product 186 was dissolved in CH2Cl2 (10 mL), cooled to 0 °C, then NEt3 (880 μL, 6.3 mmol) 
and 2,4-dinitrobenzenesulfonyl chloride (1.560 g, 5.84 mmol) were added stepwise. The resulting 
solution was stirred at 0 °C for 40 min, then diluted with 0.5 M aqueous citric acid (30 mL) and 
extracted with CH2Cl2 (2 × 30 mL). The combined organic extracts were washed with saturated 
aqueous NaHCO3 (30 mL) and brine (30 mL), dried (Na2SO4) and concentrated in vacuo. The 
resultant was purified by flash chromatography on silica gel (EtOAc/n-hexane = 1: 10 to 1: 5) to 
provide the pure disired compound 119 (1.905 g, 89% yield) as a pale yellow oil. 1H NMR (300 MHz, 
CDCl3) δ 8.60 (d, J = 2.2 Hz, 1H), 8.52 (dd, J = 8.6, 2.2 Hz, 1H), 8.36 (d, J = 8.7 Hz, 1H), 7.33 – 7.06 
(m, 5H), 3.63 (s over m, 5H), 2.64 (t, J = 7.6 Hz, 2H), 2.06 – 1.96 (m, 2H) (Contained the minor 
rotamer). All spectroscopic data were in agreement with the literature.46 
 
Methyl benzyloxy(isobutyl)carbamate (183) 
 
To a stirred solution of methyl benzyloxycarbamate 180 (1.000 g, 5.52 mmol) in DMF (19 mL) at 
0 °C was added NaH (60% dispersion in mineral oil, 330 mg, 8.25 mmol). The reaction mixture was 
stirred for 10 min at 0 °C then 1-bromo-2-methylpropane (840 μL, 7.73 mmol) and TBAI (408 mg, 
1.10 mmol) were added. The resulting suspension was stirred at 60oC over night before being 
quenched by the addition of 0.5 M aqueous citric acid (25 mL). The mixture was poured into a 
separatory funnel and extracted with MTBE (3 × 25 mL). The combined organic extracts were washed 
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with brine (25 mL), dried (Na2SO4) and concentrated under reduced pressure. The residue was purified 
by flash chromatography on silica gel (EtOAc/n-hexane = 1: 4) to provide the pure disired compound 
183 (1.010 g, 77% yield) as a colorless oil. 1H NMR (300 MHz, CDCl3) δ 7.45 – 7.28 (m, 5H), 4.86 (s, 
2H), 3.78 (s, 3H), 3.29 (d, J = 7.3 Hz, 2H), 2.11 – 1.98 (m, 1H), 0.91 (d, J = 6.7 Hz, 6H). 13C NMR 
(75 MHz, CDCl3) δ 157.8, 135.5, 129.2, 128.5, 128.4, 76.8, 56.9, 52.9, 26.6, 20.0. IR (film): ν (cm1) 
3032, 2956, 2872, 1703, 1497, 1448, 1376, 1330, 1250, 1193, 1154, 1124, 1066, 982, 911, 852, 805, 
747, 697, 622, 546, 499, 386. HRMS (ESI, m/z) calcd for C13H19N1O3Na [M+Na]+: 260.1257, found: 
260.1258. 
 
Methyl ((2,4-dinitrophenyl)sulfonyl)oxy(isobutyl)carbamate (120) 
 
To a solution of methyl benzyloxy(butyl)carbamate 183 (948 mg, 4.00 mmol) in MeOH (32 mL), was 
added Pd(OH)2/C (190 mg, 20 wt.%) under nitrogen and the resulting suspension was degassed by 
bubbling hydrogen (balloon) for 5 minutes. The mixture was stirred over night at room temperature 
under hydrogen atmosphere and then filtered directly through a pad of celite. The filter cake was 
washed with MeOH (10 mL) and the filtrate was concentrate in vacuo to give 187 as a colorless oil. 
The crude product 187 was dissolved in CH2Cl2 (8 mL), cooled to 0 °C, then NEt3 (720 μL, 5.20 mmol) 
and 2,4-dinitrobenzenesulfonyl chloride (1.280 g, 4.80 mmol) were added stepwise. The resulting 
solution was stirred at 0 °C for 40 min, then diluted with 0.5 M aqueous citric acid (20 mL) and 
extracted with CH2Cl2 (2 × 20 mL). The combined organic extracts were washed with saturated 
aqueous NaHCO3 (20 mL) and brine (20 mL), dried (Na2SO4) and concentrated in vacuo. The 
resultant yellow solid was purified by flash chromatography on silica gel (EtOAc/n-hexane = 1: 10 to 
1: 5) to provide the pure disired compound 120 (1.186 g, 79% yield) as a white solid. 1H NMR (300 
MHz, CDCl3) δ 8.66 (d, J = 2.2 Hz, 1H), 8.56 (dd, J = 8.7, 2.2 Hz, 1H), 8.40 (d, J = 8.7 Hz, 1H), 3.60 
(s, 3H), 3.56 (d, J = 7.3 Hz, 2H), 2.25 – 2.11 (m, 1H), 0.94 (d, J = 6.7 Hz, 6H). 13C NMR (75 MHz, 
CDCl3) δ 156.7, 151.0, 149.0, 134.2, 133.6, 126.2, 120.1, 60.6, 54.1, 26.1, 19.8. IR (film): ν (cm1) 
3113, 2990, 1722, 1606, 1568, 1538, 1472, 1443, 1403, 1389, 1376, 1343, 1330, 1306, 1268, 1189, 
1167, 1130, 1100, 1017, 972, 953, 918, 903, 880, 842, 831, 790, 757, 744, 732, 662, 651, 626, 612, 
591, 549, 515, 471, 456, 390. HRMS (ESI, m/z) calcd for C12H15N3O9S1Na1 [M+Na]+: 400.0421, 
found: 400.0424. 
 
Methyl (2-(1,3-dioxolan-2-yl)ethyl)(benzyloxy)carbamate (184) 
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To a stirred solution of methyl benzyloxycarbamate 180 (543 mg, 3.00 mmol) in DMF (12 mL) at 
0 °C was added NaH (60% dispersion in mineral oil, 180 mg, 4.50 mmol). The reaction mixture was 
stirred for 10 min at 0 °C then 2-(2-bromoethyl)-1,3-dioxolane (493 μL, 4.20 mmol) and TBAI (220 
mg, 0.60 mmol) were added. The resulting suspension was stirred at 60oC over night before being 
quenched by the addition of 0.5 M aqueous citric acid (15 mL). The mixture was poured into a 
separatory funnel and extracted with MTBE (3 × 15 mL). The combined organic extracts were washed 
with brine (15 mL), dried (Na2SO4) and concentrated under reduced pressure. The residue was purified 
by flash chromatography on silica gel (EtOAc/n-hexane = 1: 4) to provide the pure disired compound 
184 (694 mg, 82% yield) as a colorless oil. 1H NMR (300 MHz, CDCl3) δ 7.45 – 7.29 (m, 5H), 4.91 (t, 
J = 4.6 Hz, 1H), 4.86 (s, 2H), 3.98 – 3.89 (m, 2H), 3.88 – 3.79 (m, 2H), 3.78 (s, 3H), 3.64 – 3.55 (m, 
2H), 2.03 – 1.92 (m, 2H). 13C NMR (75 MHz, CDCl3) δ 157.8, 135.4, 129.2, 128.5, 128.4, 102.6, 77.1, 
64.9, 53.1, 45.2, 31.2. IR (film): ν (cm1) 2954, 2881, 1705, 1497, 1450, 1364, 1286, 1260, 1206, 1137, 
1112, 1047, 943, 894, 853, 749, 698, 620, 499, 385. HRMS (ESI, m/z) calcd for C14H19N1O5Na1 [M+ 
Na]+: 304.1155, found: 304.1157. 
 
Methyl (2-(1,3-dioxolan-2-yl)ethyl)(((2,4-dinitrophenyl)sulfonyl)oxy)carbamate (121) 
 
To a solution of methyl benzyloxy(butyl)carbamate 184 (650 mg, 2.31 mmol) in MeOH (18 mL), was 
added Pd(OH)2/C (130 mg, 20 wt.%) under nitrogen and the resulting suspension was degassed by 
bubbling hydrogen (balloon) for 5 minutes. The mixture was stirred over night at room temperature 
under hydrogen atmosphere and then filtered directly through a pad of celite. The filter cake was 
washed with MeOH (10 mL) and the filtrate was concentrate in vacuo to give 188 as a colorless oil. 
The crude product 188 was dissolved in CH2Cl2 (21 mL), cooled to 0 °C, then NEt3 (420 μL, 3.00 
mmol) and 2,4-dinitrobenzenesulfonyl chloride (648 mg, 2.43 mmol) were added stepwise. The 
resulting solution was stirred at 0 °C for 60 min, then diluted with 0.5 M aqueous citric acid (20 mL) 
and extracted with CH2Cl2 (2 × 20 mL). The combined organic extracts were washed with saturated 
aqueous NaHCO3 (20 mL) and brine (20 mL), dried (Na2SO4) and concentrated in vacuo. The 
resultant yellow solid was purified by flash chromatography on silica gel (EtOAc/n-hexane = 1: 3) to 
provide the pure disired compound 121 (920 mg, 95% yield) as a pale yellow solid. 1H NMR (300 
MHz, CDCl3) δ 8.65 (d, J = 2.2 Hz, 1H), 8.55 (dd, J = 8.6, 2.2 Hz, 1H), 8.40 (d, J = 8.7 Hz, 1H), 4.93 
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(t, J = 4.3 Hz, 1H), 3.99 – 3.91 (m, 2H), 3.90 – 3.76 (m, 4H), 3.61 (s, 3H), 2.06 (td, J = 7.3, 4.3 Hz, 
2H). 13C NMR (75 MHz, CDCl3) δ 156.5, 151.0, 149.0, 134.4, 133.2, 126.2, 120.1, 101.9, 65.0, 54.3, 
49.0, 29.9. IR (film): ν (cm1) 3114, 2966, 2872, 1736, 1604, 1559, 1541, 1475, 1446, 1428, 1401, 
1389, 1337, 1305, 1288, 1244, 1225, 1194, 1130, 1106, 1060, 1016, 1000, 973, 946, 906, 892, 840, 
833, 804, 770, 752, 736, 707, 684, 658, 633, 609, 576, 564, 535, 469, 440, 423, 395, 381. HRMS (ESI, 
m/z) calcd for C13H15N3O11S1Na1 [M+ Na]+: 444.0320, found: 444.0323. 
 
5.4 Application for Asymmetric Lewis Acids Catalysis 
5.4.1 Asymmetric conjugate additions by chiral Lewis acids 
5.4.1.1 Asymmetric Friedel-Crafts alkylations 
(S)-3-(1H-Indol-3-yl)-1-(1-methyl-1H-imidazol-2-yl)butan-1-one (36) 
 
To a solution of catalyst Λ-IrS (1.9 mg, 0.002 mmol, 1 mol%) in distilled, anhydrous THF (0.2 mL) in 
a glass vial was added 2-acyl imidazole 31 (30.2 mg, 0.20 mmol). After being stirred at room 
temperature for 20 min, 1H-indole (58.6 mg, 0.50 mmol) was added at room temperature. The reaction 
mixture was stirred for the indicated time (monitored by TLC) under argon atmosphere. Afterwards, 
the mixture was concentrated under reduced pressure. The residue was purified by flash 
chromatography on silica gel (EtOAc/n-hexane = 1: 2 to 1: 1) to give (S)-36 as a white solid (25 C, 
40 h, 50.2 mg, 94% yield, 99% ee). Enantiomeric excess was established by HPLC analysis using a 
Chiralpak AD-H column (HPLC: AD-H, 254 nm, n-hexane/isopropanol = 90: 10, flow rate 0.80 
mL/min, 40 C, tr (major) = 49.0 min, tr (minor) = 38.5 min). []D25 = –11.3 (c 0.8, CH2Cl2) (Lit.14 
[]D20 = 14.5 (c 2.7, CH2Cl2) for 96% ee of product with S-configuration). 1H NMR (300 MHz, 
CDCl3) δ 8.81 (br s, 1H), 7.67 (d, J = 7.7 Hz, 1H), 7.30 (d, J = 7.6 Hz, 1H), 7.22 – 7.18 (m, 1H), 7.17 
– 7.05 (m, 2H), 6.99 (s, 1H), 6.98 – 6.95 (m, 1H), 3.93 (s, 3H), 3.91 – 3.79 (m, 1H), 3.58 (dd, J = 16.0, 
6.2 Hz, 1H), 3.50 (dd, J = 16.0, 8.4 Hz, 1H), 1.42 (d, J = 6.9 Hz, 3H). All spectroscopic data are in 
agreement with the literature.14  
 
(S)-3-(4-(Dimethylamino)-2-methoxyphenyl)-1-(1-methyl-1H-imidazol-2-yl)butan-1-one (37) 
 
To a solution of catalyst Λ-IrO (3.7 mg, 0.004 mmol, 2 mol%) or Λ-IrS (3.8 mg, 0.004 mmol, 2 
mol%) in distilled, anhydrous THF (0.1 – 0.2 mL) was added the 2-acyl imidazole 31 (30.0 mg, 0.20 
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mmol) in a Schlenk tube. After being stirred at room temperature for 20 min, 
3-methoxy-N,N-dimethylaniline (90.6 mg, 88.0 L, 0.6 mmol) was added at room temperature. The 
reaction mixture was stirred for the indicated time (monitored by TLC) under nitrogen atmosphere. 
Afterwards, the mixture was concentrated under reduced pressure. The residue was purified by flash 
chromatography on silica gel (EtOAc/n-hexane = 1: 2 to 1: 1) to afford the product (S)-37 as a 
colorless oil (catalyzed by Λ-IrO: 1.0 M for 31, 25 C, 20 h, 59.0 mg, 98% yield, 94% ee; catalyzed 
by Λ-IrS: 2.0 M for 31, 25 C, 66 h, 58.0 mg, 97% yield, >99% ee). Enantiomeric excess established 
by HPLC analysis using a Chiralpak AD-H column (HPLC: AD-H, 254 nm, n-hexane/isopropanol = 
90:10, flow rate 0.8 mL/min, 25 C, tr (major) = 15.6 min, tr (minor) = 13.5 min). []D25 = 3.0 (c 0.5, 
CH2Cl2). 1H NMR (300 MHz, CDCl3) δ 7.13 – 7.07 (m, 2H), 6.97 (s, 1H), 6.32 – 6.23 (m, 2H), 3.93 (s, 
3H), 3.80 (s, 3H), 3.78 – 3.68 (m, 1H), 3.50 – 3.30 (m, 2H), 2.91 (s, 6H), 1.25 (d, J = 6.9 Hz, 3H). 13C 
NMR (75 MHz, CDCl3) δ 192.6, 157.7, 150.4, 143.6, 128.8, 127.5, 126.7, 123.2, 105.0, 96.8, 55.3, 
45.9, 40.9 (2C), 36.1, 28.6, 21.1. IR (film): ν (cm1) 2956, 2837, 2800, 1671, 1612, 1567, 1513, 1459, 
1404, 1351, 1288, 1234, 1188, 1125, 1092, 1032, 980, 911, 867, 813, 773, 694, 641, 606, 553, 512, 
471. HRMS (ESI, m/z) calcd for C17H24N3O2 [M+H]+: 302.1863, found: 302.1863. 
 
(S)-3-(5-Methoxyfuran-2-yl)-1-(1-methyl-1H-imidazol-2-yl)butan-1-one (38) 
 
To a solution of catalyst Λ-IrO (2.8 mg, 0.003 mmol, 1 mol%) or Λ-IrS (2.9 mg, 0.003 mmol, 1 
mol%) in distilled, anhydrous THF (0.3 mL) was added 2-acyl imidazole 31 (45.0 mg, 0.30 mmol) in a 
Schlenk tube. After being stirred at room temperature for 20 min, 2-methoxyfuran (88.3 mg, 82.9 L, 
0.9 mmol) was added at room temperature. The reaction mixture was stirred for the indicated time 
(monitored by TLC) under nitrogen atmosphere. Afterwards, the mixture was concentrated under 
reduced pressure. The residue was purified by flash chromatography on silica gel (EtOAc/n-hexane = 
1: 2 to 1: 1) to afford the product (S)-38 as a colorless oil (catalyzed by Λ-IrO: 25 C, 20 h, 67.8 mg, 
91% yield, 94% ee; catalyzed by Λ-IrS: 25 C, 36 h, 66.4 mg, 89% yield, 94% ee). Enantiomeric 
excess established by HPLC analysis using a Chiralpak IC column (HPLC: IC, 254 nm, 
n-hexane/isopropanol = 85:15, flow rate 0.5 mL/min, 40 C, tr (major) = 26.8 min, tr (minor) = 24.6 
min). []D25 = 3.3 (c 1.1, CH2Cl2) for 94% ee (Lit.18 []D25 = +4.1 (c 1.7, CH2Cl2) for 98% ee of 
product with S-configuration). 1H NMR (300 MHz, CDCl3) δ 7.17 (d, J = 1.0 Hz, 1H), 7.05 (d, J = 0.9 
Hz, 1H), 6.04 – 5.95 (m, 1H), 5.88 (dd, J = 11.5, 0.7 Hz, 1H), 4.00 (s, 3H), 3.71 (s, 3H), 3.66 – 3.52 
(m, 1H), 3.31 (dd, J = 5.2, 4.2 Hz, 1H), 2.17 – 2.06 (m, 1H), 1.29 (d, J = 6.4 Hz, 3H). All 
spectroscopic data are in agreement with the literature.18  
 
(S)-1-(1-Methyl-1H-imidazol-2-yl)-3-(1H-pyrrol-2-yl)butan-1-one (39) 
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To a solution of catalyst Λ-IrO (3.7 mg, 0.004 mmol, 2 mol%) or Λ-IrS (3.8 mg, 0.004 mmol, 2 
mol%) in distilled, anhydrous THF (0.2 mL) was added 2-acyl imidazole 31 (30.0 mg, 0.20 mmol) in a 
Schlenk tube. After being stirred at room temperature for 20 min, 1H-pyrrole (201.0 mg, 208.1 L, 3.0 
mmol) was added at room temperature. The reaction mixture was stirred for the indicated time 
(monitored by TLC) under nitrogen atmosphere. Afterwards, the mixture was concentrated under 
reduced pressure. The residue was purified by flash chromatography on silica gel (EtOAc/n-hexane = 
1: 2 to 1: 1) to afford the product (S)-39 as a white solid (catalyzed by Λ-IrO: 25 C, 20 h, 35.1 mg, 
81% yield, 95% ee; catalyzed by Λ-IrS: 25 C, 22 h, 38.6 mg, 89% yield, 94% ee). Enantiomeric 
excess established by HPLC analysis using a Chiralpak OD-H column (HPLC: OD-H, 254 nm, 
n-hexane/isopropanol = 97:3, flow rate 0.8 mL/min, 25 C, tr (major) = 27.5 min, tr (minor) = 26.0 
min). []D25 = +77.5 (c 0.4, CH2Cl2) for 94% ee (Lit.47 []D25 = 66.8 (c 1.2, CH2Cl2) for 87% ee of 
product with R-configuration). 1H NMR (300 MHz, CDCl3) δ 8.86 (brs, 1H), 7.13 (d, J = 0.7 Hz, 1H), 
7.01 (s, 1H), 6.66 (dd, J = 4.1, 2.6 Hz, 1H), 6.09 (dd, J = 5.9, 2.8 Hz, 1H), 5.95 (m, 1H), 3.99 (s, 3H), 
3.58 – 3.45 (m, 2H), 3.33 (m, 1H), 1.38 (d, J = 6.8 Hz, 3H). All spectroscopic data are in agreement 
with the literature.47  
 
(R)-3-(4-(Dimethylamino)-2-methoxyphenyl)-1-(1-methyl-1H-imidazol-2-yl)-3-phenylpropan-1-o
ne (40) 
 
To a solution of catalyst Λ-IrS (3.8 mg, 0.004 mmol, 2 mol%) in distilled, anhydrous THF (0.1 mL) 
was added the 2-acyl imidazole 32 (42.4 mg, 0.20 mmol) in a Schlenk tube. After being stirred at room 
temperature for 20 min, 3-methoxy-N,N-dimethylaniline (90.6 mg, 88.0 L, 0.6 mmol) was added at 
room temperature. The reaction mixture was stirred 40 C for 18 h under nitrogen atmosphere. 
Afterwards, the mixture was concentrated under reduced pressure. The residue was purified by flash 
chromatography on silica gel (EtOAc/n-hexane = 1: 2 to 1: 1) to afford the product (R)-40 as a 
colorless oil (72.5 mg, 99% yield, 99% ee). Enantiomeric excess established by HPLC analysis using a 
Chiralpak AD-H column (HPLC: AD-H, 254 nm, n-hexane/isopropanol = 90: 10, flow rate 1.0 
mL/min, 25 C, tr (major) = 18.6 min, tr (minor) = 23.4 min). []D25 = +15.4 (c 0.9, CH2Cl2). 1H NMR 
(300 MHz, CDCl3) δ 7.37 – 7.29 (m, 2H), 7.24 – 7.18 (m, 2H), 7.15 – 7.03 (m, 3H), 6.94 (d, J = 0.9 
Hz, 1H), 6.32 – 6.19 (m, 2H), 5.07 (t, J = 7.8 Hz, 1H), 3.96 (dd, J = 17.2, 8.3 Hz, 1H), 3.88 (s, 3H), 
3.79 (dd, J = 17.2, 8.3 Hz, 1H), 3.77 (s, 3H), 2.90 (s, 6H). 13C NMR (75 MHz, CDCl3) δ 191.5, 157.8, 
150.5, 144.9, 143.5, 128.9 (2C), 128.5, 128.1 (3C), 126.7, 125.7, 121.5, 104.9, 96.9, 55.5, 44.0, 40.9 
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(2C), 38.7, 36.1. IR (film): ν (cm1) 2993, 2904, 1672, 1611, 1561, 1514, 1491, 1469, 1452, 1441, 
1406, 1356, 1290, 1240, 1206, 1195, 1184, 1172, 1154, 1116, 1075, 1052, 1032, 986, 955, 915, 868, 
860, 844, 814, 799, 779, 739, 697, 687, 642, 561, 537, 510, 497, 465, 383. HRMS (ESI, m/z) calcd for 
C22H26N3O2 [M+H]+: 364.2020, found: 364.2021. 
 
(S)-Ethyl 
2-(4-(dimethylamino)-2-methoxyphenyl)-4-(1-methyl-1H-imidazol-2-yl)-4-oxobutanoate (41) 
 
To a solution of catalyst Λ-IrS (3.8 mg, 0.004 mmol, 2 mol%) in distilled, anhydrous THF (0.1 mL) 
was added the 2-acyl imidazole 33 (41.6 mg, 0.20 mmol) in a Schlenk tube. After being stirred at room 
temperature for 20 min, 3-methoxy-N,N-dimethylaniline (90.6 mg, 88.0 L, 0.6 mmol) was added at 
room temperature. The reaction mixture was stirred 40 C for 24 h under nitrogen atmosphere. 
Afterwards, the mixture was concentrated under reduced pressure. The residue was purified by flash 
chromatography on silica gel (EtOAc/n-hexane = 1: 2) to afford the product (S)-41 as a colorless oil 
(68.1 mg, 95% yield, 99% ee). Enantiomeric excess established by HPLC analysis using a Chiralpak 
AD-H column (HPLC: AD-H, 254 nm, hexane/isopropanol = 90:10, flow rate 1.0 mL/min, 25 C, tr 
(major) = 18.1 min, tr (minor) = 13.0 min). []D25 = +108.9 (c 0.7, CH2Cl2). 1H NMR (300 MHz, 
CDCl3) δ 7.09 (d, J = 1.0 Hz, 1H), 7.05 (d, J = 8.3 Hz, 1H), 6.98 (d, J = 0.9 Hz, 1H), 6.33 – 6.18 (m, 
2H), 4.49 (dd, J = 9.9, 4.4 Hz, 1H), 4.13 (q, J = 7.1 Hz, 2H), 4.07 – 3.97 (m, 1H), 3.96 (s, 3H), 3.79 (s, 
3H), 3.30 (dd, J = 18.2, 4.4 Hz, 1H), 2.93 (s, 6H), 1.18 (t, J = 7.1 Hz, 3H). 13C NMR (75 MHz, CDCl3) 
δ 191.3, 174.3, 157.8, 151.2, 143.1, 129.2, 129.1, 126.7, 115.8, 105.0, 96.6, 60.7, 55.5, 42.2, 40.9 (2C), 
39.9, 36.1, 14.3. IR (film): ν (cm1) 2938, 2804, 1726, 1674, 1612, 1568, 1516, 1462, 1407, 1353, 
1288, 1236, 1157, 1107, 1030, 981, 913, 848, 811, 773, 687, 641, 530, 496, 469. HRMS (ESI, m/z) 
calcd for C19H26N3O4 [M+H]+: 360.1918, found: 360.1929. 
 
(S)-3-(4-(Dimethylamino)-2-methoxyphenyl)-1-(1-methyl-1H-imidazol-2-yl)heptan-1-one (42) 
O nBu
N
N
OMe
NMe2  
To a solution of catalyst Λ-IrS (3.8 mg, 0.004 mmol, 2 mol%) in distilled, anhydrous THF (0.1 mL) 
was added the 2-acyl imidazole 34 (38.4 mg, 0.20 mmol) in a Schlenk tube. After being stirred at room 
temperature for 20 min, 3-methoxy-N,N-dimethylaniline (90.6 mg, 88.0 L, 0.6 mmol) was added at 
room temperature. The reaction mixture was stirred at 40 C for 48 h under nitrogen atmosphere. 
Afterwards, the mixture was concentrated under reduced pressure. The residue was purified by flash 
chromatography on silica gel (EtOAc/n-hexane = 1: 2) to afford the product (S)-42 as a colorless oil 
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(55.8 mg, 81% yield, 96% ee). Enantiomeric excess established by HPLC analysis using a Chiralpak 
IC column (HPLC: IC, 254 nm, hexane/isopropanol = 70:30, flow rate 1.0 mL/min, 25 C, tr (major) = 
8.3 min, tr (minor) = 12.4 min). []D25 = +3.2 (c 0.7, CH2Cl2). 1H NMR (300 MHz, CDCl3) δ 7.09 (d, 
J = 0.9 Hz, 1H), 7.03 (d, J = 8.2 Hz, 1H), 6.94 (d, J = 0.9 Hz, 1H), 6.33 – 6.18 (m, 2H), 3.89 (s, 3H), 
3.78 (s, 3H), 3.68 – 3.55 (m, 1H), 3.52 – 3.29 (m, 2H), 2.90 (s, 6H), 1.80 – 1.48 (m, 2H), 1.32 – 1.13 
(m, 4H), 0.80 (t, J = 6.9 Hz, 3H). 13C NMR (75 MHz, CDCl3) δ 192.8, 158.4, 150.2, 143.7, 128.8, 
128.6, 126.5, 121.8, 105.1, 97.0, 55.5, 44.9, 40.9 (2C), 36.1, 35.4, 34.2, 29.8, 22.9, 14.1. IR (film): ν 
(cm1) 2952, 2926, 2855, 2798, 1671, 1612, 1567, 1513, 1461, 1439, 1403, 1349, 1287, 1235, 1203, 
1180, 1152, 1124, 1108, 1078, 1059, 1034, 978, 914, 812, 779, 733, 693, 642, 505, 470. HRMS (ESI, 
m/z) calcd for C20H30N3O2 [M+H]+: 344.2333, found: 344.2340. 
 
5.4.1.2 Asymmetric Michael additions 
(S)-2-(4-(1-Methyl-1H-imidazol-2-yl)-4-oxobutan-2-yl)malononitrile (43) 
 
To a solution of catalyst Λ-IrO (1.8 mg, 0.002 mmol, 1 mol%) or Λ-IrS (1.9 mg, 0.002 mmol, 1 
mol%) in distilled, anhydrous THF (0.4 mL) was added 2-acyl imidazole 31 (30.2 mg, 0.20 mmol) in a 
Schlenk tube. After being stirred at room temperature for 20 min, malononitrile (15.8 mg, 0.24 mmol) 
was added at room temperature. The reaction mixture was stirred at 25 C for the indicated time 
(monitored by TLC) under nitrogen atmosphere. Afterwards, the mixture was concentrated under 
reduced pressure. The residue was purified by flash chromatography on silica gel (EtOAc/n-hexane = 
1: 2 to 1: 1) to afford the product (S)-43 as a colorless oil (catalyzed by Λ-IrO: 16 h, 41.5 mg, 96% 
yield, 88% ee; catalyzed by Λ-IrS: 24 h, 40.9 mg, 95% yield, 90% ee). Enantiomeric excess 
established by HPLC analysis using a Chiralpak AD-H column (254 nm, hexane/isopropanol = 90:10, 
flow rate 1.0 mL/min, 25 C, tr (major) = 23.0 min, tr (minor) = 21.8 min). []D25 = +30.0 (c 0.4, 
CH2Cl2) for 90% ee of the product (Lit.15 []D20 = 33.2, c 0.4, CH2Cl2) for 92% ee of product with 
R-configuration). It is worth noting that 97% ee of (S)-22 (albeit reduced yield of just 43% yield) can 
be obtained when malononitrile reacts instead with 2 equivalents of 2-acyl imidazole 11 catalyzed by 
Λ-IrO under otherwise identical conditions. 1H NMR (300 MHz, CDCl3) δ 7.15 (s, 1H), 7.08 (s, 1H), 
4.37 (d, J = 4.9 Hz, 1H), 3.99 (s, 3H), 3.47 (dd, J = 18.0, 5.3 Hz, 1H), 3.28 (dd, J = 18.0, 8.2 Hz, 1H), 
2.89-2.71 (m, 1H), 1.36 (d, J= 6.9 Hz, 3H). All spectroscopic data were in agreement with the 
literature.15 
 
(S)-2,2-Dimethyl-5-(4-(1-methyl-1H-imidazol-2-yl)-4-oxobutan-2-yl)-1,3-dioxane-4,6-dione (44) 
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To a solution of catalyst Λ-IrO (3.7 mg, 0.004 mmol, 2 mol%) or Λ-IrS (3.8 mg, 0.004 mmol, 2 
mol%) in distilled, anhydrous THF (0.2 mL) was added 2-acyl imidazole 31 (30.2 mg, 0.20 mmol) in a 
Schlenk tube. After being stirred at room temperature for 20 min, 2,2-dimethyl- 1,3-dioxane-4,6-dione 
(86.5 mg, 0.6 mmol) was added at room temperature. The reaction mixture was stirred at 25 C for 6 h 
under nitrogen atmosphere. Afterwards, the mixture was concentrated under reduced pressure. The 
residue was purified by flash chromatography on silica gel (EtOAc/n-hexane = 1: 2 to 1: 1) to afford 
the product (S)-44 as a white solid (catalyzed by Λ-IrO: 54.5 mg, 93% yield, 81% ee; catalyzed by 
Λ-IrS: 55.3 mg, 94% yield, 91% ee). Enantiomeric excess established by HPLC analysis using a 
Chiralpak AD-H column (254 nm, hexane/isopropanol = 90:10, flow rate 0.8 mL/min, 40 C, tr (major) 
= 28.1 min, tr (minor) = 26.4 min). []D25 = +2.1 (c 0.8, CH2Cl2) for 91% ee of the product (Lit.15 
[]D20 = –3.3 (c 0.8, CH2Cl2) for 95% ee of product with R-configuration). 1H NMR (300 MHz, 
CDCl3) δ 7.13 (d, J = 0.9 Hz, 1H), 7.03 (s, 1H), 3.98 (s, 3H), 3.56 (dd, J = 7.2, 5.0 Hz, 2H), 3.24 – 
3.10 (m, 1H), 1.77 (d, J = 5.8 Hz, 6H), 1.21 (d, J = 7.0 Hz, 3H). All spectroscopic data were in 
agreement with the literature.15  
 
(S)-tert-Butyl 
1-((S)-4-(1-methyl-1H-imidazol-2-yl)-4-oxobutan-2-yl)-2-oxocyclopentanecarboxylate (46) 
 
To a solution of catalyst Λ-IrO (3.7 mg, 0.004 mmol, 2 mol%) or Λ-IrS (3.8 mg, 0.004 mmol, 2 
mol%) in distilled, anhydrous THF (0.4 mL) was added 2-acyl imidazole 31 (30.2 mg, 0.20 mmol) in a 
Schlenk tube. After being stirred at 40 °C for 20 min, tert-butyl 2-oxocyclopentanecarboxylate (73.7 
mg, 0.40 mmol) was added at room temperature. The reaction mixture was stirred at 40 C for the 
indicated time (monitored by TLC) under nitrogen atmosphere. Afterwards, the mixture was 
concentrated under reduced pressure. The residue was purified by flash chromatography on silica gel 
(EtOAc/n-hexane = 1: 2 to 1: 1) to afford the product (S,S)-46 as a colorless oil (catalyzed by Λ-IrO: 
25 h, 35.1 mg, 53% yield, 90% ee, dr = 1.8:1; catalyzed by Λ-IrS: 25 h, 56.7 mg, 85% yield, 96% ee, 
dr = 1.5:1). Enantiomeric excess established by HPLC analysis using a Chiralpak AD-H column (254 
nm, hexane/isopropanol = 95:5, flow rate 0.5 mL/min, 40 C, tr (major) = 26.9 min, tr (minor) = 29.5 
min). []D20 = –11.5 (c 0.4, CH2Cl2) for 96% ee of the product. (Lit.15 []D20 = +13.1 (c 1.4, CH2Cl2) 
for 99% ee of the product with R,R-configuration). 1H NMR (300 MHz, CDCl3) δ 7.08 (d, J = 0.8 Hz, 
1H), 6.99 (s, 1H), 3.96 (s, 3H), 3.22 (dd, J = 16.6, 10.3 Hz, 1H), 3.08 – 2.97 (m, 1H), 2.74 (dd, J = 
16.6, 2.6 Hz, 1H), 2.50 – 2.30 (m, 2H), 2.21 – 2.06 (m, 1H), 2.01 – 1.85 (m, 3H), 1.42 (s, 9H), 0.94 (d, 
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J = 6.7 Hz, 3H). All spectroscopic data are in agreement with the literature.15 
 
(S)-tert-Butyl 2-((S)-4-(1-methyl-1H-imidazol-2-yl)-4-oxobutan-2-yl)-1-oxo-2,3-dihydro-1H- 
indene-2-carboxylate (47) 
 
To a solution of catalyst Λ-IrO (1.8 mg, 0.002 mmol, 1 mol%) or Λ-IrS (1.9 mg, 0.002 mmol, 1 
mol%) in distilled, anhydrous THF (0.2 mL) was added 2-acyl imidazole 31 (30.2 mg, 0.20 mmol) in a 
Schlenk tube. After being stirred at 40 °C for 20 min, tert-butyl 
1-oxo-2,3-dihydro-1H-indene-2-carboxylate (92.8 mg, 0.4 mmol) was added at room temperature. The 
reaction mixture was stirred at 25 C for the indicated time (monitored by TLC) under nitrogen 
atmosphere. Afterwards, the mixture was concentrated under reduced pressure. The residue was 
purified by flash chromatography on silica gel (EtOAc/n-hexane = 1: 2 to 1: 1) to afford the product 
(S,S)-47 as a colorless oil (catalyzed by Λ-IrO: 72 h, 68.1 mg, 89% yield, 97% ee, dr = 10:1; 
catalyzed by Λ-IrS: 70.4 mg, 93% yield, 97% ee, dr = 22:1). Enantiomeric excess established by 
HPLC analysis using a Chiralpak AD-H column (254 nm, hexane/isopropanol = 85:15, flow rate 0.8 
mL/min, 25 C, tr (major) = 17.1 min, tr (minor) = 11.2 min). []D25 = +94.1 (c 1.0, CH2Cl2) for 97% 
ee of the product. (Lit.15 []D20 = 96.9 (c 0.7, CH2Cl2) for 97% ee of the product with 
R,R-configuration). 1H NMR (300 MHz, CDCl3) δ 7.74 (d, J = 7.6 Hz, 1H), 7.65 – 7.56 (m, 1H), 7.50 
(d, J = 7.7 Hz, 1H), 7.40 – 7.32 (m, 1H), 7.13 (d, J = 0.9 Hz, 1H), 7.03 (s, 1H), 4.01 (s, 3H), 3.69 (d, J 
= 17.5 Hz, 1H), 3.51 – 3.39 (m, 1H), 3.32 – 3.18 (m, 2H), 3.09 (dd, J = 16.3, 2.8 Hz, 1H), 1.36 (s, 9H), 
0.76 (d, J = 6.7 Hz, 3H). All spectroscopic data were in agreement with the literature.15  
 
(S)-tert-Butyl 6-((S)-4-(1-methyl-1H-imidazol-2-yl)-4-oxobutan-2-yl)-5-oxo-6,7-dihydro-5H- 
indeno[5,6-d][1,3]dioxole-6-carboxylate (48) 
 
Starting from 31 (30.0 mg, 0.2 mmol) and tert-butyl 5-oxo-6,7-dihydro-5H-indeno[5,6-d] 
[1,3]dioxole-6-carboxylate (110.4 mg, 0.4 mmol) according to the general procedure for 47 to give 
(S,S)-48 as a colorless oil (catalyzed by 1 mol % Λ-IrS: 61 mg, 72% yield, 97% ee, dr = 13:1). 
Enantiomeric excess established by HPLC analysis using a Chiralpak AD-H column (HPLC: AD-H, 
254 nm, hexane/isopropanol = 85:15, flow rate 0.8 mL/min, 25 C, tr (major) = 33.8 min, tr (minor) = 
19.5 min); []D25 = +103.0 (c 0.60, CH2Cl2) for 97% ee of the product. 1H NMR (300 MHz, CDCl3) δ 
7.08 (d, J = 0.9 Hz, 1H), 7.04 (s, 1H), 7.01 (d, J = 0.5 Hz, 1H), 6.83 (s, 1H), 6.03 (dd, J = 2.1, 1.1 Hz, 
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2H), 3.97 (s, 3H), 3.52 (d, J = 17.4 Hz, 1H), 3.44 – 3.29 (m, 1H), 3.26 – 3.13 (m, 1H), 3.06 – 2.95 (m, 
2H), 1.34 (s, 9H), 0.72 (d, J = 6.7 Hz, 3H). 13C NMR (75 MHz, CDCl3) δ 200.0, 191.2, 169.4, 154.8, 
151.8, 148.5, 143.4, 130.5, 129.0, 127.1, 105.5, 102.9, 102.4, 81.9, 66.5, 42.3, 36.2, 33.0, 32.8, 27.8 (3 
C), 15.1. IR (film): ν (cm1) 2973, 2928, 1731, 1696, 1674, 1608, 1502, 1470, 1405, 1367, 1310, 1249, 
1217, 1145, 1073, 1033, 984, 937, 913, 864, 844, 796, 770, 734, 697, 580, 427. HRMS (ESI, m/z) 
calcd for C23H27N2O6 [M+H]+: 427.1864, found: 427.1855. 
 
(S)-tert-Butyl 2-((S)-1-ethoxy-4-(1-methyl-1H-imidazol-2-yl)-1,4-dioxobutan-2-yl)-1-oxo-2,3- 
dihydro-1H-indene-2-carboxylate (49) 
 
Starting from 33 (30.0 mg, 0.2 mmol) and 1-oxo-2,3-dihydro-1H-indene-2-carboxylate (92.8 mg, 0.4 
mmol) according to the general procedure for 47 to give (S,S)-49 as a colorless oil (catalyzed by 
Λ-IrS: 71 mg, 81% yield, 96% ee, dr = 15:1). Enantiomeric excess established by HPLC analysis 
using a Chiralpak AD-H column (HPLC: AD-H, 254 nm, hexane/isopropanol = 70:30, flow rate 0.8 
mL/min, 25 C, tr (major) = 10.3 min, tr (minor) = 11.8 min); []D25 = +112.1 (c 1.04, CH2Cl2) for 
96% ee of the product. 1H NMR (300 MHz, CDCl3) δ 7.75 (d, J = 7.6 Hz, 1H), 7.57 (td, J = 7.6, 1.1 
Hz, 1H), 7.46 (d, J = 7.7 Hz, 1H), 7.35 (t, J = 7.4 Hz, 1H), 7.14 (d, J = 0.6 Hz, 1H), 7.03 (s, 1H), 4.31 
(dd, J = 10.1, 3.0 Hz, 1H), 3.99 (s, 3H), 3.97 – 3.87 (m, 1H), 3.86 – 3.68 (m, 3H), 3.27 (dd, J = 17.5, 
3.0 Hz, 1H), 3.24 (d, J = 17.2 Hz, 1H), 1.35 (s, 9H), 0.80 (t, J = 7.1 Hz, 3H). 13C NMR (75 MHz, 
CDCl3) δ 200.2, 189.7, 172.3, 168.0, 153.4, 135.3, 135.1, 129.1, 127.6, 127.0, 126.4, 124.7, 82.9, 63.3, 
61.1, 44.1, 38.2, 36.2, 34.6, 31.6, 30.3, 27.8 (3 C), 13.6. IR (film): ν (cm1) 2979, 2934, 1712, 1677, 
1607, 1590, 1464, 1410, 1368, 1348, 1329, 1246, 1212, 1147, 1088, 1024, 983, 914, 842, 776, 742, 
691, 515, 472, 454. HRMS (ESI, m/z) calcd for C24H28N2O6Na [M+Na]+: 463.1840, found: 463.1840. 
 
(S)-tert-Butyl 2-((S)-1-(1-methyl-1H-imidazol-2-yl)-1-oxoheptan-3-yl)-1-oxo-2,3-dihydro-1H- 
indene-2-carboxylate (50) 
 
Starting from 34 (30.0 mg, 0.2 mmol) and 1-oxo-2,3-dihydro-1H-indene-2-carboxylate (92.8 mg, 0.4 
mmol) according to the general procedure for 47 except higher temperature (40 oC) to give (S,S)-50 as 
a colorless oil (catalyzed by 2 mol% Λ-IrS: 20% yield, 85% ee, dr = 9:1). Enantiomeric excess 
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established by HPLC analysis using a Chiralpak AD-H column (HPLC: AD-H, 254 nm, 
hexane/isopropanol = 85:15, flow rate 0.8 mL/min, 25 C, tr (major) = 14.3 min, tr (minor) = 10.1 min). 
1H NMR (300 MHz, CDCl3) δ 7.73 (d, J = 7.6 Hz, 1H), 7.64 – 7.55 (m, 1H), 7.49 (d, J = 7.7 Hz, 1H), 
7.36 (t, J = 7.4 Hz, 1H), 7.12 (d, J = 0.8 Hz, 1H), 7.02 (s, 1H), 4.01 (s, 3H), 3.70 (d, J = 17.5 Hz, 1H), 
3.32 (s, 1H), 3.29 – 3.10 (m, 3H), 1.30 (s, 9H), 1.20 – 1.05 (m, 6H), 0.71 (t, J = 6.8 Hz, 3H). 13C NMR 
(75 MHz, CDCl3) δ 202.6, 191.3, 169.6, 154.0, 136.3, 135.1, 128.7, 127.6, 126.9, 126.4, 124.6, 82.0, 
66.6, 41.7, 37.8, 36.3, 34.2, 31.6, 30.2, 27.9, 27.8 (3 C), 22.9, 14.0. IR (film): ν (cm1) 2956, 2930, 
2870, 1735, 1704, 1674, 1606, 1590, 1464, 1405, 1367, 1275, 1246, 1212, 1148, 1081, 1020, 984, 914, 
845, 768, 742, 691, 612, 472, 454. HRMS (ESI, m/z) calcd for C25H32N2O4Na [M+Na]+: 447.2254, 
found: 447.2257. 
 
(S)-tert-Butyl 2-((S)-4-(1-isopropyl-1H-imidazol-2-yl)-4-oxobutan-2-yl)-1-oxo-2,3-dihydro-1H- 
indene-2-carboxylate (51) 
 
Starting from 45 (35.6 mg, 0.2 mmol) and 1-oxo-2,3-dihydro-1H-indene-2-carboxylate (92.8 mg, 0.4 
mmol) according to the general procedure for 47 to give (S,S)-51 as a white solid (catalyzed by 2 
mol % Λ-IrS: 71 mg, 87% yield, 96% ee, dr = 49:1). Enantiomeric excess established by HPLC 
analysis using a Chiralpak AD-H column (HPLC: AD-H, 254 nm, hexane/isopropanol = 85:15, flow 
rate 0.5 mL/min, 25 C, tr (major) = 21.4 min, tr (minor) = 13.1 min); []D20 = +92.3 (c 0.7, CH2Cl2) 
for 96% ee of the product. 1H NMR (300 MHz, CDCl3) 1H NMR (300 MHz, CDCl3) δ 7.75 (d, J = 7.7 
Hz, 1H), 7.66 – 7.57 (m, 1H), 7.51 (d, J = 7.7 Hz, 1H), 7.37 (t, J = 7.4 Hz, 1H), 7.28 (d, J = 1.2 Hz, 
1H), 7.17 (s, 1H), 5.67 – 5.50 (m, 1H), 3.71 (d, J = 17.5 Hz, 1H), 3.54 – 3.37 (m, 1H), 3.35 – 3.07 (m, 
3H), 1.45 (d, J = 6.7 Hz, 6H), 1.38 (s, 9H), 0.77 (d, J = 6.7 Hz, 3H). 13C NMR (75 MHz, CDCl3) δ 
202.4, 191.4, 169.4, 154.1, 142.7, 136.1, 135.2, 129.4, 127.6, 126.4, 124.6, 121.2, 82.1, 66.0, 49.4, 
43.0, 33.3, 33.1, 27.9 (3 C), 23.8 (2 C), 15.3. IR (film): ν (cm1) 2976, 2928, 2875, 1705, 1668, 1602, 
1463, 1397, 1371, 1340, 1252, 1143, 1094, 1032, 1011, 985, 916, 879, 841, 809, 773, 744, 708, 621, 
566, 523, 463. HRMS (ESI, m/z) calcd for C24H30N2O4Na [M+Na]+: 433.2098, found: 433.2093. 
 
5.4.1.3 Asymmetric cycloadditions 
((3S,4R,5S)-2-Benzyl-5-methyl-3-phenylisoxazolidin-4-yl)(1-methyl-1H-imidazol-2-yl)methanone 
(52) 
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To a solution of catalyst Λ-IrO (3.7 mg, 0.004 mmol, 2 mol%) or Λ-IrS (3.8 mg, 0.004 mmol, 2 
mol%) in distilled, anhydrous CH2Cl2 (0.2 mL) was added the 2-acyl imidazole 31 (30.0 mg, 0.20 
mmol) in a Schlenk tube containing 80 mg of 4 Å molecular sieves. After being stirred at room 
temperature for 20 min, (Z)-N-benzylidene(phenyl)methanamine oxide (49.0 mg, 0.22 mmol) was 
added. The reaction mixture was stirred for the indicated time (monitored by TLC) under nitrogen 
atmosphere. Afterwards, the mixture was concentrated under reduced pressure. The residue was 
purified by flash chromatography on silica gel (EtOAc/n-hexane = 1: 2 to 1: 1) to give 52 as a white 
solid (catalyzed by Λ-IrO: 36 h, 71.2 mg, 99% yield, 92% ee, endo/exo > 99:1; catalyzed by Λ-IrS: 72 
h, 62.1 mg, 86% yield, 98% ee, endo/exo > 99:1). Enantiomeric excess established by HPLC analysis 
using a Chiralpak AD-H column (254 nm, hexane/isopropanol = 90:10, flow rate 0.8 mL/min, 40 C, tr 
(major) = 12.6 min, tr (minor) = 17.8 min). []D25 = +9.9 (c 0.5, CH2Cl2) for 98% ee of the product. 
(Lit.48 []D25 = –7.7 (c 3.2, CH2Cl2) for 97% ee of product with (3R,4S,5R)-configuration). 1H NMR 
(300 MHz, CDCl3) δ 7.55 – 7.47 (m, 2H), 7.47 – 7.41 (m, 2H), 7.39 – 7.20 (m, 6H), 7.12 (d, J = 0.9 
Hz, 1H), 7.03 (d, J = 0.9 Hz, 1H), 4.63 – 4.52 (m, 2H), 4.48 – 4.36 (m, 1H), 4.14 (d, J = 14.3 Hz, 1H), 
4.03 (s, 3H), 3.98 (d, J = 14.3 Hz, 1H), 1.69 (d, J = 6.1 Hz, 3H). All spectroscopic data are in 
agreement with the literature.48  
 
1-Methyl-2-((3aS,4S,7aR)-4-methyl-3,3a,4,7a-tetrahydro-2H-furo[2,3-b]pyran-6-yl)-1H- 
imidazole (53) 
 
To a solution of catalyst Λ-IrO (3.7 mg, 0.004 mmol, 2 mol%) or Λ-IrS (3.8 mg, 0.004 mmol, 2 
mol%) in distilled, anhydrous CH2Cl2 (0.2 mL) was added the 2-acyl imidazole 31 (30.0 mg, 0.20 
mmol) in a Schlenk tube containing 5.0 mg of 3 Å molecular sieves powder. After being stirred at 
room temperature for 20 min, 2,3-dihydrofuran (140.0 mg, 151.0 L, 2.0 mmol) was added. The 
reaction mixture was stirred for the indicated time (monitored by TLC) under nitrogen atmosphere. 
Afterwards, the mixture was concentrated under reduced pressure. The residue was purified by flash 
chromatography on silica gel (EtOAc/n-hexane = 1: 1 to 2: 1) to afford the 53 as colorless oil 
(catalyzed by Λ-IrO: 48 h, 43.9 mg, 99% yield, 98% ee, endo:exo > 50:1; catalyzed by Λ-IrS: 68 h, 
35.0 mg, 80% yield, 95% ee, endo:exo > 30:1). Enantiomeric excess established by HPLC analysis 
using a Chiralpak IC column (HPLC: IC, 254 nm, hexane/isopropanol = 70:30, flow rate 1.0 mL/min, 
25 C, tr (major) = 19.1 min, tr (minor) = 15.8 min). []D25 = 15.5 (c 0.4, CH2Cl2) for 98% ee of the 
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product. 1H NMR (300 MHz, CDCl3) δ 6.90 (d, J = 1.2 Hz, 1H), 6.76 (d, J = 1.1 Hz, 1H), 5.54 (d, J = 
4.0 Hz, 1H), 5.33 (dd, J = 2.3, 1.3 Hz, 1H), 4.13 (td, J = 8.5, 3.3 Hz, 1H), 4.00 – 3.90 (m, 1H), 3.72 (s, 
3H), 2.96 – 2.83 (m, 1H), 2.46 – 2.34 (m, 1H), 1.94 – 1.78 (m, 2H), 1.09 (d, J = 7.3 Hz, 3H). 13C NMR 
(75 MHz, CDCl3) δ 142.7, 142.1, 127.8, 122.5, 104.6, 101.3, 68.5, 43.6, 34.9, 26.5, 23.5, 18.5. IR 
(film): ν (cm1) 3111, 2958, 2929, 2874, 1733, 1711, 1677, 1456, 1407, 1281, 1231, 1158, 1118, 1026, 
981, 916, 864, 836, 765, 693, 660, 620, 600, 557, 500, 462, 388. HRMS (ESI, m/z) calcd for 
C12H17N2O2 [M+H]+: 221.1285, found: 221.1283. 
 
1-Isopropyl-2-((3aS,4S,7aR)-4-phenyl-3,3a,4,7a-tetrahydro-2H-furo[2,3-b]pyran-6-yl)-1H-imidaz
ole (54) 
 
To a solution of catalyst Λ-IrO (3.7 mg, 0.004 mmol, 2 mol%) or Λ-IrS (3.8 mg, 0.004 mmol, 2 
mol%) in distilled, anhydrous CH2Cl2 (0.2 mL) was added the 2-acyl imidazole 35 (48.0 mg, 0.20 
mmol) in a Schlenk tube containing 5.0 mg of 3 Å molecular sieves powder. After being stirred at 
room temperature for 20 min, 2,3-dihydrofuran (140.0 mg, 151.0 L, 2.0 mmol) was added. The 
reaction mixture was stirred for the indicated time (monitored by TLC) under nitrogen atmosphere. 
Afterwards, the mixture was concentrated under reduced pressure. The residue was purified by flash 
chromatography on silica gel (EtOAc/n-hexane = 1: 1 to 2: 1) to afford 54 as a colorless oil (catalyzed 
by Λ-IrO: 24 h, 50.4 mg, 81% yield, 99% ee, endo:exo > 50:1; catalyzed by Λ-IrS: 60 h, 25.2 mg, 
40% yield, 99% ee, endo:exo > 20:1). Enantiomeric excess established by HPLC analysis using a 
Chiralpak IC column (254 nm, hexane/isopropanol = 70:30, flow rate 1.0 mL/min, 25 C, tr (major) = 
19.1 min, tr (minor) = 10.3 min). []D25 = 8.0 (c 0.6, CH2Cl2) for 98% ee of the product. 1H NMR 
(300 MHz, CDCl3) δ 7.28 (d, J = 4.4 Hz, 4H), 7.25 – 7.17 (m, 1H), 6.99 (d, J = 1.1 Hz, 1H), 6.98 (d, J 
= 1.2 Hz, 1H), 5.67 (d, J = 3.7 Hz, 1H), 5.62 (dd, J = 2.4, 1.3 Hz, 1H), 4.92 (hept, J = 6.6 Hz, 1H), 
4.18 (dd, J = 6.4, 2.4 Hz, 1H), 4.14 – 4.03 (m, 1H), 3.91 – 3.75 (m, 1H), 2.75 – 2.54 (m, 1H), 1.84 (tt, 
J = 12.3, 9.7 Hz, 1H), 1.41 (dd, J = 9.1, 6.7 Hz, 6H), 1.37 – 1.33 (m, 1H). 13C NMR (75 MHz, CDCl3) 
δ 144.1, 142.1, 142.0, 128.6 (2C), 128.3, 127.7 (2C), 126.8, 116.6, 102.4, 101.1, 68.5, 48.5, 44.3, 37.9, 
24.6, 23.8 (2C). IR (film): ν (cm1) 2973, 1719, 1666, 1393, 1256, 1202, 1117, 1059, 1020, 983, 768, 
701, 620, 554, 499, 461, 403. HRMS (ESI, m/z) calcd for C19H23N2O2 [M+H]+: 311.1754, found: 
311.1753. 
 
((1R,6R)-4,6-Dimethylcyclohex-3-en-1-yl)(1-methyl-1H-imidazol-2-yl)methanone (55) 
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To a solution of catalyst Λ-IrO (3.7 mg, 0.004 mmol, 2 mol%) or Λ-IrS (3.8 mg, 0.004 mmol, 2 
mol%) in distilled, anhydrous CH2Cl2 (0.2 mL) was added 2-acyl imidazole 31 (30.0 mg, 0.20 mmol) 
in a Schlenk tube containing 10.0 mg of 4 Å molecular sieves powder. After being stirred at room 
temperature for 20 min, isoprene (136.2 mg, 200.0 L, 2.0 mmol) was added. The reaction mixture 
was stirred for the indicated time (monitored by TLC) under nitrogen atmosphere. Afterwards, the 
mixture was concentrated under reduced pressure. The residue was purified by flash chromatography 
on silica gel (EtOAc/n-hexane = 1: 4) to afford 55 as a colorless oil (catalyzed by Λ-IrO: 48 h, 32.8 
mg, 76% yield, 98% ee, dr > 99:1; catalyzed by Λ-IrS: 48 h, 24.0 mg, 56% yield, 99% ee, dr > 99:1). 
Enantiomeric excess established by HPLC analysis using a Chiralpak IC column (254 nm, 
hexane/isopropanol = 97:3, flow rate 1.0 mL/min, 25 C, tr (major) = 9.9 min, tr (minor) = 14.2 min). 
[α]D20= 46.6o (c 0.3, CH2Cl2) for 99% ee of the product. 1H NMR (300 MHz, CDCl3) δ 7.10 (d, J = 
0.84 Hz, 1H), 7.01(s, 1H), 5.36 (s, 1H), 3.98 (s, 3H), 3.75 – 3.66 (m, 1H), 2.20 – 1.96 (m, 4H), 1.82 – 
1.72 (m. 1H), 1.61 (s, 3H), 0.88(d, J = 6.36 Hz, 3H). 13C NMR (300 MHz, CDCl3) δ 197.3, 143.6, 
133.4, 129.0, 127.2, 119.3, 48.1, 38.6, 36.3, 31.2, 29.8, 23.3, 19.8. IR (film): ν (cm-1) 2956, 2919, 1665, 
1453, 1403, 1284, 1236, 1152, 1089, 1005, 907, 861, 829, 769, 697, 662, 623, 514, 426. HRMS (ESI, 
m/z) calcd for C13H19N2O [M+H] +: 219.1435, found: 219.1493. 
 
5.4.1.4 Scope of acceptor-substituted alkenes 
 
(S)-3-(4-(Dimethylamino)-2-methoxyphenyl)-1-(1-methyl-1H-benzo[d]imidazol-2-yl)butan-1-one 
(68) 
 
To a solution of catalyst Λ-IrS (9.5 mg, 0.01 mmol, 5 mol%) in distilled, anhydrous THF (0.1 mL) 
was added the benzimidazole 57 (40.0 mg, 0.20 mmol) in a Schlenk tube. After being stirred at room 
temperature for 3 min, 3-methoxy-N,N-dimethylaniline (90.6 mg, 88.0 L, 0.6 mmol) was added at 
room temperature. The reaction mixture was stirred at 60 C for 24 h under nitrogen atmosphere. 
Afterwards, the mixture was purified by flash chromatography on silica gel (EtOAc/n-hexane = 1: 4) 
to afford (S)-68 as a colorless oil (60.1 mg, 86% yield, 96% ee). Enantiomeric excess established by 
HPLC analysis using a Chiralpak AD-H column (HPLC: AD-H, 254 nm, hexane/isopropanol = 90:10, 
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flow rate 1.0 mL/min, 25 C, tr (major) = 12.2 min, tr (minor) = 11.1 min). []D25 = 14.3 (c 0.7, 
CH2Cl2). 1H NMR (300 MHz, CDCl3) δ 7.90 (dt, J = 7.9, 1.1 Hz, 1H), 7.45 – 7.30 (m, 3H), 7.12 (d, J 
= 8.3 Hz, 1H), 6.29 (dd, J = 8.3, 2.5 Hz, 1H), 6.25 (d, J = 2.5 Hz, 1H), 4.05 (s, 3H), 3.89 – 3.78 (m, 
1H), 3.79 (s, 3H), 3.62 (dd, J = 7.2, 1.4 Hz, 2H), 2.91 (s, 6H), 1.33 (d, J = 6.9 Hz, 3H). 13C NMR (75 
MHz, CDCl3) δ 195.5, 157.8, 150.5, 146.8, 141.8, 137.0, 128.3, 127.7, 125.6, 123.6, 122.0, 110.5, 
105.1, 96.9, 55.4, 47.1, 41.0 (2C), 32.3, 28.9, 21.1. IR (film): ν (cm1) 2955, 2833, 1683, 1612, 1567, 
1513, 1479, 1456, 1394, 1349, 1335, 1289, 1235, 1179, 1153, 1120, 1096, 1059, 1032, 997, 978, 895, 
812, 794, 767, 741, 640, 505, 481, 433. HRMS (ESI, m/z) calcd for C21H26N3O2 [M+H] +: 352.2020, 
found: 352.2030. 
 
(S)-3-(4-(Dimethylamino)-2-methoxyphenyl)-1-(thiazol-2-yl)butan-1-one (69) 
O
N
S
OMe
NMe2  
To a solution of catalyst Λ-IrS (3.8 mg, 0.004 mmol, 2 mol%) in distilled, anhydrous THF (0.1 mL) 
was added the 2-thiazole 58 (30.6 mg, 0.20 mmol) in a Schlenk tube. After being stirred at room 
temperature for 3 min, 3-methoxy-N,N-dimethylaniline (90.6 mg, 88.0 L, 0.6 mmol) was added at 
room temperature. The reaction mixture was stirred at 40 C for 18 h under nitrogen atmosphere. 
Afterwards, the mixture was purified by flash chromatography on silica gel (EtOAc/n-hexane = 1: 5) 
to afford (S)-69 (purified by flash chromatography on silica gel, EtOAc/n-hexane = 1: 5) as a colorless 
oil (60.6 mg, 99% yield, 98% ee). Enantiomeric excess established by HPLC analysis using a 
Chiralpak OD-H column (HPLC: OD-H, 254 nm, hexane/isopropanol = 95:5, flow rate 1.0 mL/min, 
25 C, tr (major) = 10.5 min, tr (minor) = 11.1 min). []D25 = + 20.8 (c 0.7, CH2Cl2). 1H NMR (300 
MHz, CDCl3) δ 7.98 (dd, J = 3.0, 1.2 Hz, 1H), 7.62 (dd, J = 3.0, 1.2 Hz, 1H), 7.10 (dd, J = 8.4, 1.1 Hz, 
1H), 6.47 – 5.91 (m, 2H), 3.86 – 3.70 (m, 1H), 3.78 (d, J = 1.2 Hz, 3H), 3.50 – 3.33 (m, 2H), 2.92 (d, J 
= 1.2 Hz, 6H), 1.30 (dd, J = 6.9, 1.2 Hz, 3H). 13C NMR (75 MHz, CDCl3) δ 193.5, 168.0, 157.8, 150.6, 
144.7, 127.6, 125.9, 122.8 105.1, 96.9, 55.3, 45.9, 41.0 (2C), 29.0, 20.8. IR (film): ν (cm1) 2957, 2930, 
2872, 2833, 1680, 1612, 1567, 1514, 1479, 1453, 1439, 1423, 1388, 1348, 1281, 1236, 1192, 1181, 
1122, 1094, 1060, 1035, 978, 879, 812, 792, 640, 630, 510. HRMS (ESI, m/z) calcd for C16H21N2O2S 
[M+H] +: 305.1318, found: 305.1335. 
 
(S)-3-(4-(Dimethylamino)-2-methoxyphenyl)-1-(pyridin-2-yl)butan-1-one (70) 
 
To a solution of catalyst Λ-IrS (9.5 mg, 0.01 mmol, 5 mol%) in distilled, anhydrous MeCN (0.1 mL) 
was added the pyridine 59 (88.2 mg, 0.60 mmol) in a Schlenk tube. After being stirred at room 
temperature for 3 min, 3-methoxy-N,N-dimethylaniline (30.2 mg, 29.3 L, 0.2 mmol) was added at 
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room temperature. The reaction mixture was stirred at 60 C for 24 h under nitrogen atmosphere. 
Afterwards, the mixture was purified by flash chromatography on silica gel (EtOAc/n-hexane = 1: 4) 
to afford (S)-70 as a colorless oil (52.0 mg, 87% yield, 97% ee). Enantiomeric excess established by 
HPLC analysis using a Chiralpak IC column (HPLC: IC, 254 nm, hexane/isopropanol = 95:5, flow 
rate 1.0 mL/min, 25 C, tr (major) = 17.8 min, tr (minor) = 20.3 min). []D20 = 1.2 (c 0.6, CH2Cl2). 
1H NMR (300 MHz, CDCl3) δ 8.67 (ddd, J = 4.8, 1.7, 0.9 Hz, 1H), 7.99 (dt, J = 7.9, 1.1 Hz, 1H), 7.79 
(td, J = 7.7, 1.8 Hz, 1H), 7.43 (ddd, J = 7.5, 4.7, 1.3 Hz, 1H), 7.11 (d, J = 8.3 Hz, 1H), 6.31 (dd, J = 
8.3, 2.5 Hz, 1H), 6.27 (d, J = 2.4 Hz, 1H), 3.86 – 3.71 (m, 1H), 3.78 (s, 3H), 3.58 – 3.39 (m, 2H), 2.92 
(s, 6H), 1.28 (d, J = 6.9 Hz, 3H). 13C NMR (75 MHz, CDCl3) δ 201.5, 157.9, 154.2, 150.4, 148.9, 
136.8, 127.6, 126.8, 123.7, 121.9, 105.2, 97.1, 55.4, 45.0, 41.1 (2C), 28.6, 21.0. IR (film): ν (cm1) 
2958, 2931, 2872, 2833, 1693, 1613, 1582, 1567, 1513, 1481, 1461, 1436, 1348, 1309, 1284, 1235, 
1191, 1122, 1091, 1060, 1033, 993, 978, 812, 792, 769, 742, 662, 640, 617, 508, 406. HRMS (ESI, 
m/z) calcd for C18H23N2O2 [M+H] +: 299.1754, found: 299.1762.  
 
3-(3-(4-(Dimethylamino)-2-methoxyphenyl)butanoyl)oxazolidin-2-one (71) 
 
To a solution of catalyst Λ-IrS (9.5 mg, 0.01 mmol, 5 mol%) in distilled, anhydrous THF or CHCl3 or 
Toluene (0.1 mL) was added the 2-oxazolidinone 60 (31.0 mg, 0.20 mmol) in a Schlenk tube. After 
being stirred at room temperature for 3 min, 3-methoxy-N,N-dimethylaniline (90.6 mg, 88.0 L, 0.6 
mmol) was added at room temperature. The reaction mixture was stirred at 40 C or 60 C for 24 h 
under nitrogen atmosphere. No product (71) was observed. 
 
(S)-3-(4-(Dimethylamino)-2-methoxyphenyl)-1-(2-thioxothiazolidin-3-yl)butan-1-one (72) 
 
To a solution of catalyst Λ-IrS (5.7 mg, 0.006 mmol, 2 mol%) in distilled, anhydrous THF (0.15 mL) 
was added the 2-thiazolidinethione 61 (55.8 mg, 0.30 mmol) in a Schlenk tube. After being stirred at 
room temperature for 3 min, 3-methoxy-N,N-dimethylaniline (135.9 mg, 131.2 L, 0.9 mmol) was 
added at room temperature. The reaction mixture was stirred at 40 C for 22 h under nitrogen 
atmosphere. Afterwards, the mixture was purified by flash chromatography on silica gel 
(EtOAc/n-hexane = 1: 2) to afford (S)-72 as a colorless oil (47.1 mg, 47% yield, 68% ee). 
Enantiomeric excess established by HPLC analysis using a Chiralpak OD-H column (HPLC: OD-H, 
254 nm, hexane/isopropanol = 70:30, flow rate 1.0 mL/min, 25 C, tr (major) = 11.1 min, tr (minor) = 
14.0 min). []D20 = +11.4 (c 0.5, CH2Cl2). 1H NMR (300 MHz, CDCl3) δ 7.03 (d, J = 8.2 Hz, 1H), 
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6.34 – 6.24 (m, 2H), 4.40 (td, J = 7.5, 1.5 Hz, 2H), 3.83 (s, 3H), 3.70 – 3.53 (m, 3H), 3.22 – 3.10 (m, 
2H), 2.93 (s, 6H), 1.26 (d, J = 6.6 Hz, 3H). 13C NMR (75 MHz, CDCl3) δ 201.4, 174.5, 158.0, 150.5, 
128.1, 122.3, 105.1, 97.0, 56.3, 55.5, 45.0, 41.1 (2C), 30.5, 28.5, 20.9. IR (film): ν (cm1) 2931, 2832, 
2799, 1697, 1612, 1566, 1513, 1461, 1439, 1352, 1277, 1234, 1144, 1122, 1048, 1031, 999, 977, 908, 
878, 812, 793, 728, 674, 642, 568, 506, 474, 453. HRMS (ESI, m/z) calcd for C16H22N2O2S2Na: 
[M+Na] +: 361.1015, found: 361.1025. 
 
(S)-3-(4-(Dimethylamino)-2-methoxyphenyl)-1-(1H-pyrazol-1-yl)butan-1-one (73) 
 
To a solution of catalyst Λ-IrS (5.7 mg, 0.006 mmol, 2 mol%) in distilled, anhydrous THF (0.15 mL) 
was added the pyrazole 62 (40.8 mg, 0.30 mmol) in a Schlenk tube. After being stirred at room 
temperature for 3 min, 3-methoxy-N,N-dimethylaniline (135.9 mg, 131.2 L, 0.9 mmol) was added at 
room temperature. The reaction mixture was stirred at 40 C for 26 h under nitrogen atmosphere. 
Afterwards, the mixture was purified by flash chromatography on silica gel (EtOAc/n-hexane = 1: 10) 
to afford (S)-73 as a colorless oil (74.2 mg, 86% yield, 98% ee). Enantiomeric excess established by 
HPLC analysis using a Chiralpak OD-H column (HPLC: OD-H, 254 nm, hexane/isopropanol = 95:5, 
flow rate 1.0 mL/min, 25 C, tr (major) = 8.2 min, tr (minor) = 7.7 min). []D25 = 3.2 (c 0.7, CH2Cl2). 
1H NMR (300 MHz, CDCl3) δ 8.24 (dd, J = 2.8, 0.7 Hz, 1H), 7.70 (dd, J = 1.5, 0.7 Hz, 1H), 7.10 (d, J 
= 8.3 Hz, 1H), 6.41 (dd, J = 2.9, 1.5 Hz, 1H), 6.31 (dd, J = 8.3, 2.5 Hz, 1H), 6.27 (d, J = 2.5 Hz, 1H), 
3.80 (s, 3H), 3.83 – 3.72 (m, 1H), 3.42 (d, J = 7.3 Hz, 2H), 2.94 (s, 6H), 1.34 (d, J = 7.0 Hz, 3H). 13C 
NMR (75 MHz, CDCl3) δ 171.5, 157.9, 150.6, 143.6, 128.2, 127.6, 122.3, 109.3, 105.0, 96.8, 55.3, 
41.1, 40.9 (2C), 29.4, 20.6. IR (film): ν (cm1) 2958, 2932, 2874, 2834, 1729, 1613, 1567, 1514, 1482, 
1453, 1439, 1411, 1380, 1342, 1323, 1261, 1236, 1197, 1125, 1087, 1036, 978, 925, 912, 813, 768, 
736, 644, 609, 507, 478. HRMS (ESI, m/z) calcd for C16H22N3O2 [M+H] +: 288.1707 found: 288.1712. 
 
(S)-1-(3,5-Dimethyl-1H-pyrazol-1-yl)-3-(4-(dimethylamino)-2-methoxyphenyl)butan-1-one (74) 
 
To a solution of catalyst Λ-IrS (9.5 mg, 0.01 mmol, 5 mol%) in distilled, anhydrous THF (0.1 mL) 
was added the pyrazole 63 (98.4 mg, 0.60 mmol) in a Schlenk tube. After being stirred at room 
temperature for 3 min, 3-methoxy-N,N-dimethylaniline (30.2 mg, 29.3 L, 0.2 mmol) was added at 
room temperature. The reaction mixture was stirred at 60 C for 24 h under nitrogen atmosphere. 
Afterwards, the mixture was purified by flash chromatography on silica gel (EtOAc/n-hexane = 1: 10) 
to afford (S)-74 as a colorless oil (24 h, 62.5 mg, 99% yield, 95% ee). Enantiomeric excess established 
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by HPLC analysis using a Chiralpak AD-H column (HPLC: AD-H, 254 nm, hexane/isopropanol = 
98:2, flow rate 1.0 mL/min, 25 C, tr (major) = 8.2 min, tr (minor) = 9.0 min). []D25 = 27.0 (c 0.7, 
CH2Cl2). 1H NMR (300 MHz, CDCl3) δ 7.11 (d, J = 8.2 Hz, 1H), 6.35 – 6.25 (m, 2H), 5.93 (d, J = 1.1 
Hz, 1H), 3.82 (s, 3H), 3.74 (dt, J = 8.1, 6.7 Hz, 1H), 3.46 – 3.30 (m, 2H), 2.94 (s, 6H), 2.52 (d, J = 1.0 
Hz, 3H), 2.24 (s, 3H), 1.32 (d, J = 6.9 Hz, 3H).  13C NMR (75 MHz, CDCl3) δ 173.4, 157.9, 151.4, 
150.5, 143.9, 127.5, 122.9, 110.8, 105.0, 96.9, 55.4, 42.3, 41.0 (2C), 28.9, 20.6, 14.6, 13.9. IR (film): ν 
(cm1) 2958, 2928, 2873, 2833, 2797, 1722, 1613, 1568, 1514, 1454, 1439, 1410, 1375, 1342, 1324, 
1236, 1196, 1177, 1124, 1095, 1061, 1036, 978, 961, 923, 896, 810, 764, 735, 679, 641, 586, 557, 508, 
478, 413. HRMS (ESI, m/z) calcd for C18H26N3O2 [M+H] +: 316.2020, found: 316.2026. 
 
(S)-Methyl 3-(4-(dimethylamino)-2-methoxyphenyl)butanoate (75’) 
 
To a solution of catalyst Λ-IrS (9.5 mg, 0.01 mmol, 5 mol%) in distilled, anhydrous THF (0.1 mL) 
was added the phosphonate 64 (35.6 mg, 0.20 mmol) in a Schlenk tube. After being stirred at room 
temperature for 3 min, 3-methoxy-N,N-dimethylaniline (90.6 mg, 88.0 L, 0.6 mmol) was added at 
room temperature. The reaction mixture was stirred at 60 C for 24 h under nitrogen atmosphere. 
Methanol (0.50 mL), followed by DBU (0.10 mL), were added directly to the reaction mixture at room 
temperature. The reaction mixture was stirred for 30 min. After removing the solvent, the residue was 
purified by flash chromatography on silica gel (EtOAc/n-hexane = 1: 5) directly to give (S)-75’ as a 
colorless oil (24.8 mg, 49% yield, 82% ee). Enantiomeric excess established by HPLC analysis using a 
Chiralpak OD-H column (HPLC: OD-H, 254 nm, hexane/isopropanol = 98:2, flow rate 1.0 mL/min, 
25 C, tr (major) = 12.1 min, tr (minor) = 10.9 min). []D20 = +20.1 (c 0.2, CH2Cl2). 1H NMR (300 
MHz, CDCl3) δ 7.02 (d, J = 8.1 Hz, 1H), 6.41 – 6.20 (m, 2H), 3.83 (s, 3H), 3.64 (s, 3H), 3.61 – 3.44 
(m, 1H), 2.94 (s, 6H), 2.67 (dd, J = 14.9, 5.8 Hz, 1H), 2.47 (dd, J = 14.9, 9.1 Hz, 1H), 1.25 (d, J = 7.0 
Hz, 3H). All spectroscopic data are in agreement with the literature.25  
 
(R)-Ethyl 4-(4-(dimethylamino)-2-methoxyphenyl)-2-oxo-4-phenylbutanoate (76) 
 
To a solution of catalyst Λ-IrS (3.8 mg, 0.004 mmol, 2 mol%) in distilled, anhydrous THF (0.1 mL) 
was added the α-ketoester 65 (40.8 mg, 0.20 mmol) in a Schlenk tube. After being stirred at room 
temperature for 3 min, 3-methoxy-N,N-dimethylaniline (90.6 mg, 88.0 L, 0.6 mmol) was added at 
room temperature. The reaction mixture was stirred at 25 C for 24 h under nitrogen atmosphere. 
Afterwards, the mixture was purified by flash chromatography on silica gel (EtOAc/n-hexane = 1: 8) 
Chapter 5. Experimental Part 
-163- 
to afford (R)-76 as a colorless oil (70.8 mg, 99% yield, 95% ee). Enantiomeric excess established by 
HPLC analysis using a Chiralpak AD-H column (HPLC: AD-H, 254 nm, hexane/isopropanol = 90:10, 
flow rate 1.0 mL/min, 25 C, tr (major) = 11.2 min, tr (minor) = 9.8 min). []D20 = +33.3 (c 0.8, 
CH2Cl2). 1H NMR (300 MHz, CDCl3) δ 7.32 – 7.27 (m, 4H), 7.24 – 7.15 (m, 1H), 6.95 (d, J = 8.3 Hz, 
1H), 6.33 – 6.22 (m, 2H), 4.95 (t, J = 7.6 Hz, 1H), 4.29 (q, J = 7.1 Hz, 2H), 3.80 (s, 3H), 3.63 (dd, J = 
16.5, 7.7 Hz, 1H), 3.49 (dd, J = 16.5, 7.6 Hz, 1H), 2.94 (s, 6H), 1.35 (t, J = 7.1 Hz, 3H). 13C NMR (75 
MHz, CDCl3) δ 193.3, 161.2, 157.6, 150.9, 143.8, 128.7, 128.3 (2C), 128.0 (2C), 126.2, 120.0, 104.9, 
96.6, 62.3, 55.3, 44.8, 40.8 (2C), 38.9, 14.1. IR (film): ν (cm1) 2935, 2836, 2801, 1722, 1613, 1567, 
1514, 1492, 1451, 1440, 1408, 1354, 1274, 1235, 1180, 1154, 1111, 1063, 1031. 979, 950, 855, 812, 
759, 728, 698, 641, 543, 510, 464. HRMS (ESI, m/z) calcd for C21H25N1O4Na1 [M+Na] +: 378.1687 
found: 378.1704. 
 
3-(4-(Dimethylamino)-2-methoxyphenyl)-N-methoxy-N-methylbutanamide (77) 
N
O OMe
NMe2
O
 
To a solution of catalyst Λ-IrS (9.5 mg, 0.01 mmol, 5 mol%) in distilled, anhydrous THF (0.1 mL) 
was added the Weinreb amide 66 (25.8 mg, 0.20 mmol) in a Schlenk tube. After being stirred at room 
temperature for 3 min, 3-methoxy-N,N-dimethylaniline (90.6 mg, 88.0 L, 0.6 mmol) was added at 
room temperature. The reaction mixture was stirred at 60 C for 24 h under nitrogen atmosphere. No 
product (77) was observed. 
 
Methyl 3-(4-(dimethylamino)-2-methoxyphenyl)butanoate (78) 
 
To a solution of catalyst Λ-IrS (9.5 mg, 0.01 mmol, 5 mol%) in distilled, anhydrous THF (0.1 mL) 
was added the carboxylic ester 67 (20.0 mg, 0.20 mmol) in a Schlenk tube. After being stirred at room 
temperature for 3 min, 3-methoxy-N,N-dimethylaniline (90.6 mg, 88.0 L, 0.6 mmol) was added at 
room temperature. The reaction mixture was stirred at 60 C for 24 h under nitrogen atmosphere. No 
product (78) was observed. 
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5.4.1.5 Assignment of the absolute and relative configuration of the Diels-Alder product 
 
(1R,6R)-Benzyl 4,6-dimethylcyclohex-3-enecarboxylate (56) 
 
The mixture of 55 (60.5 mg, 0.28 mmol) and 4Å molecular sieves (140 mg) in acetonitrile (2.8 mL) 
was stirred vigorously for 2 hours. Then methyl trifluoromethanesulfonate (86.9 mg, 0.53 mmol, 60 
μL, 1.90 equiv.) was added. After 40 minutes benzyl alcohol (302.0 mg, 2.8 mmol, 290 μL, 10.0 equiv) 
and diazabicyclo[5.4.0]undec-7-ene (127.7 mg, 0.84 mmol, 125 μL, 3.00 equiv) were added stepwise. 
After one hour stirring at room temperature the solvent was removed in vacuo. Purification by flash 
chromatography (EtOAc/n-hexane = 1: 20) afforded the disired compound 56 (68.1 mg, 99%) as a 
colorless oil. 1H NMR (300 MHz, CDCl3) δ 7.81 – 6.71 (m, 5H), 5.35 (br s, 1H), 5.15 (d, J = 0.9 Hz, 
2H), 2.41 – 2.12 (m, 3H), 2.11 – 1.85 (m, 2H), 1.70 (d, J = 10.0 Hz, 1H), 1.65 (s, 3H), 0.95 (d, J = 6.3 
Hz, 3H). 13C NMR (75 MHz, CDCl3) δ 176.0, 136.3, 133.3, 128.5, 128.2, 128.1, 118.7, 66.0, 47.0, 
38.1, 31.1, 28.9, 23.3, 19.7. All spectroscopic data were in agreement with the literature.49  
Optical rotation of (1R, 6R)-56: 
[]D20 = 131.6° (c 0.7, CH2Cl2, 98% ee). 
Lit.49 : []D20 = +54 (c 0.055, CH2Cl2), (1S,6S)-56. 
Lit.50 : []D = +171 (c 1.0, CH2Cl2, 99% ee), (1S,6S)-56. 
Chiral HPLC with (1R, 6R)-31: 
tr (major) = 9.6 min, tr (minor) = 11.0 min (as shown in Figure 55). 
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 Peak 
# 
RetTime 
[min] 
Type Width
[min]
Area 
[mAU*s] 
Height 
[mAU] 
Area 
% 
1 9.721 FM 0.3845 665.48962 28.84762 49.9924 
2 11.449 MM 0.4618 665.69080 24.02469 50.0076 
 Peak 
# 
RetTime 
[min] 
Type Width
[min]
Area 
[mAU*s] 
Height 
[mAU] 
Area 
% 
1 9.630 MF 0.5238 7106.03076 226.12300 99.0268 
2 11.015 FM 0.3810 69.83804 3.05505 0.9732 
Figure 55 HPLC traces of compound 56 
HPLC: Daicel Chiralpak OB-H column, 220 nm, heptane/isopropanol = 99.5/0.5, flow rate 1.0 mL/min, 25 C. 
rac-56 
(1R, 6R)-56 
98% ee, catalyzed by Λ-IrO 
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5.4.1.6 Kinetic experiments 
 
Procedure: To a solution of catalyst rac-IrS (2 mol%) in distilled, anhydrous THF was added the 
2-acyl imidazole 31 in a Schlenk tube. After being stirred at room temperature for 20 min, 
3-methoxy-N,N-dimethylaniline was added at room temperature (detail information was shown in 
Table 10). 2 hours later, the solvent was removed and the crude sample was tested by 1H NMR at 
once. Every experiment was done three times (the results were shown in Table 11).  
Table 10 Detail Information for Kinetic Experiments 
Entry 1 2 3 4 5 6 7 8 9 
31/aniline 1/3 1/2.5 1/2 1/1.5 1/1 1.5/1 2/1 2.5/1 3/1 
31 (μL;mmol) 27;0.2 27;0.2 27;0.2 27;0.2 27;0.2 41;0.3 54;0.4 68;0.5 81;0.6 
Aniline (μL;mmol) 90;0.6 75;0.5 60;0.4 45;0.3 30;0.2 30;0.2 30;0.2 30;0.2 30;0.2 
THF (μL) 83 98 113 128 143 129 116 102 89 
Vtotal (μL) 200 200 200 200 200 200 200 200 200 
Conditions: 2 mol% catalyst loading; 2 hours; at room temperature. 
 
Table 11 Conversions vs Substrate Concentrations 
[31] (M) Conv.1 (%) Conv.2 (%) Conv.3 (%) Mean (%) Standard Diviation Standard Error
1 9.0  11.2  11.2 10.5 1.27  0.73  
1.5 13.6  14.3  14.9 14.3 0.65  0.38  
2 16.6  17.8  16.3 16.9 0.79  0.46  
2.5 20.5  20.6  18.7 19.9 1.07  0.62  
3 25.2  24.0  22.7 24.0 1.25  0.72  
[aniline] (M)       
1 9.0  11.2  11.2 10.5 1.27  0.73  
1.5 9.8  11.1  10.5 10.5 0.65  0.38  
2 10.0  10.0  10.5 10.2 0.29  0.17  
2.5 9.2  10.5  10.6 10.1 0.78  0.45  
3 8.9  10.1  11.2 10.1 1.15  0.66  
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5.4.2 Generation of asymmetric quaternary stereocenters with the Henry reaction 
 
General Procedure: To an oven-dried 10 mL Schlenk tube equipped with a magnetic stir bar was 
added Λ-IrO (4 mol%), 2-acyl-pyridine N-oxides 81-92 (0.2 mmol, 1.0 equiv), toluene (0.4 mL, 
contain 20 mol% iPr2NEt), and MeNO2 (0.1 mL). The reaction mixture was stirred at room 
temperature for a certain time. And then, the reaction mixture was concentrated in vacuo. The resulting 
crude oil was purified by flash chromatography on silica gel (short column, EtOAc/n-hexane = 1: 1 to 
2: 1) to provide the target compound 93-104. 
 
(R)-2-(2-Hydroxy-1-nitropropan-2-yl)pyridine 1-oxide (93) 
 
Starting from 2-acyl-pyridine N-oxides 81 (27.7 mg, 0.20 mmol) according to the general procedure to 
give 93 as a white solid (8 hours, 23.3 mg, 0.118 mmol, 56% yield). Enantiomeric excess established 
by HPLC analysis using a Chiralpak AD-H column, ee = 94% (HPLC: AD-H, 254 nm, 
hexane/isopropanol = 70: 30, flow rate 2.0 mL/min, 25 oC), tr (minor) = 3.5 min, tr (major) = 7.5 min).  
1H NMR (300 MHz, CDCl3) δ 8.25 (dt, J = 6.2, 1.0 Hz, 1H), 7.79 (s, 1H), 7.46 – 7.40 (m, 2H), 7.38 – 
7.30 (m, 1H), 5.34 (d, J = 11.2 Hz, 1H), 4.82 (d, J = 11.1 Hz, 1H), 1.79 (s, 3H). All spectroscopic data 
were in agreement with the literature.38 
 
(R)-2-(2-Hydroxy-1-nitropropan-2-yl)-3-methylpyridine 1-oxide (94) 
 
No product 94 was formed according to the general procedure. 
 
(R)-2-(2-Hydroxy-1-nitropropan-2-yl)-4-methylpyridine 1-oxide (95) 
 
Starting from 2-acyl-pyridine N-oxides 83 (30.2 mg, 0.20 mmol) according to the general procedure to 
give 95 as a pale yellow solid (23 hours, 26.1 mg, 0.123 mmol, 62% yield). Enantiomeric excess 
established by HPLC analysis using a Chiralpak AD-H column, ee = 93% (HPLC: AD-H, 254 nm, 
hexane/isopropanol = 80:20, flow rate 2.0 mL/min, 25 oC), tr (minor) = 4.7 min, tr (major) = 16.0 min).  
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1H NMR (300 MHz, CDCl3) δ 8.21 (s, 1H), 8.14 (d, J = 6.5 Hz, 1H), 7.19 (s, 1H), 7.16 (d, J = 6.8 Hz, 
1H), 5.44 (d, J = 11.0 Hz, 1H), 4.74 (d, J = 11.0 Hz, 1H), 2.40 (s, 3H), 1.80 (s, 3H). All spectroscopic 
data were in agreement with the literature.38 
 
(R)-2-(2-Hydroxy-1-nitropropan-2-yl)-5-methylpyridine 1-oxide (96) 
 
Starting from 2-acyl-pyridine N-oxides 84 (30.2 mg, 0.20 mmol) according to the general procedure to 
give 96 as a white solid (5 hours, 31.4 mg, 0.148 mmol, 74% yield). Enantiomeric excess established 
by HPLC analysis using a Chiralpak AD-H column, ee = 98% (HPLC: AD-H, 254 nm, 
hexane/isopropanol = 70:30, flow rate 2.0 mL/min, 25 oC), tr (minor) = 4.9 min, tr (major) = 7.0 min). 
1H NMR (300 MHz, CDCl3) δ 8.12 (d, J = 0.6 Hz, 1H ), 8.01 (s, 1H), 7.29 (d, J = 8.1 Hz, 1H), 7.24 
(dd, J = 8.1 Hz, 0.6 Hz, 1H), 5.42 (d, J = 10.8 Hz, 1H), 4.72 (d, J = 11.1 Hz, 1H), 2.36 (s, 3H), 1.80 (s, 
3H). All spectroscopic data were in agreement with the literature.38 
 
(R)-2-(2-Hydroxy-1-nitropropan-2-yl)-6-methylpyridine 1-oxide (97) 
 
Starting from 2-acyl-pyridine N-oxides 85 (30.2 mg, 0.20 mmol) according to the general procedure to 
give 97 as a colorless oil (7 hours, 25.9 mg, 0.122 mmol, 61% yield). Enantiomeric excess established 
by HPLC analysis using a Chiralpak AD-H column, ee = 91% (HPLC: AD-H, 254 nm, 
hexane/isopropanol = 80:20, flow rate 1.0 mL/min, 25 oC), tr (minor) = 8.5 min, tr (major) = 12.2 min).  
1H NMR (300 MHz, CDCl3) δ 8.20 (brs, 1H), 7.31 (td, J = 7.3, 3.6 Hz, 3H), 5.40 (d, J = 10.9 Hz, 1H), 
4.74 (d, J = 10.9 Hz, 1H), 2.55 (s, 3H), 1.80 (s, 3H). All spectroscopic data were in agreement with the 
literature.38 
 
(R)-2-(2-Hydroxy-1-nitropropan-2-yl)-4-methoxypyridine 1-oxide (98) 
 
Starting from 2-acyl-pyridine N-oxides 86 33.4 mg, 0.20 mmol) according to the general procedure to 
give 98 as a whote solid (18 hours, 37.6 mg, 0.165 mmol, 82% yield). Enantiomeric excess established 
by HPLC analysis using a Chiralpak AD-H column, ee = 84% (HPLC: AD-H, 254 nm, 
hexane/isopropanol = 80:20, flow rate 1.0 mL/min, 25 oC), tr (minor) = 4.2 min, tr (major) = 18.6 min). 
1H NMR (300 MHz, CDCl3) δ 8.18 (d, J = 7.2 Hz, 1H), 6.94 (d, J = 3.4 Hz, 1H), 6.88 (dd, J = 7.2, 3.4 
Hz, 1H), 5.42 (d, J = 11.1 Hz, 1H), 4.80 (d, J = 11.1 Hz, 1H), 3.89 (s, 3H), 1.79 (s, 3H). All 
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spectroscopic data were in agreement with the literature.38 
 
(R)-4-Ethyl-2-(2-hydroxy-1-nitropropan-2-yl)pyridine 1-oxide (99) 
 
Starting from 2-acyl-pyridine N-oxides 87 (33.0 mg, 0.20 mmol) according to the general procedure to 
give 99 as a pale yellow solid (5 hours, 33.6 mg, 0.149 mmol, 75% yield). Enantiomeric excess 
established by HPLC analysis using a Chiralpak AD-H column, ee = 92% (HPLC: AD-H, 254 nm, 
hexane/isopropanol = 80:20, flow rate 2.0 mL/min, 25 oC), tr (minor) = 4.3 min, tr (major) = 10.9 min).  
1H NMR (300 MHz, CDCl3) δ 8.16 (d, J = 6.5 Hz, 1H), 7.21 (d, J = 2.4 Hz, 1H), 7.18 (dd, J = 6.6, 2.4 
Hz, 1H), 5.43 (d, J = 11.0 Hz, 1H), 4.75 (d, J = 11.0 Hz, 1H), 2.69 (q, J = 7.6 Hz, 3H), 1.80 (s, 3H), 
1.26 (t, J = 7.6 Hz, 3H). 13C NMR (75 MHz, CDCl3) δ 148.7, 146.1, 139.9, 125.0, 124.2, 80.6, 72.5, 
27.8, 23.2, 14.1. IR (film): ν (cm1) 3038, 2976, 1542, 1475, 1422, 1378, 1364, 1269, 1209, 1159, 
1131, 1089, 1077, 1059, 949, 896, 865, 852, 838, 794, 757, 730, 710, 634, 587, 532, 488, 450, 406, 
389. HRMS (ESI, m/z) calcd for C10H14N2O4Na1 [M+Na]+: 249.0846, found: 249.0847. 
 
(R)-2-(2-Hydroxy-1-nitropropan-2-yl)-4-propylpyridine 1-oxide (100) 
 
Starting from 2-acyl-pyridine N-oxides 88 (33.0 mg, 0.20 mmol) according to the general procedure to 
give 100 as a pale yellow solid (4 hours, 41.3 mg, 0.172 mmol, 86% yield). Enantiomeric excess 
established by HPLC analysis using a Chiralpak AD-H column, ee = 91% (HPLC: AD-H, 254 nm, 
hexane/isopropanol = 80:20, flow rate 2.0 mL/min, 25 oC), tr (minor) = 4.2 min, tr (major) = 7.7 min). 
1H NMR (300 MHz, CDCl3) δ 8.16 (d, J = 6.5 Hz, 1H), 7.24 – 7.04 (m, 2H), 5.43 (d, J = 11.0 Hz, 1H), 
4.75 (d, J = 11.1 Hz, 1H), 2.62 (t, J = 7.6 Hz, 2H), 1.66 (h, J = 7.4 Hz, 2H), 0.96 (t, J = 7.3 Hz, 3H). 
13C NMR (75 MHz, CDCl3) δ 148.5, 144.7, 139.7, 125.5, 124.7, 80.5, 72.5, 36.7, 23.4, 23.2, 13.4. IR 
(film): ν (cm1) 3050, 2960, 2926, 1541, 1475, 1460, 1447, 1416, 1379, 1340, 1313, 1266, 1237, 1208, 
1156, 1137, 1105, 1078, 988, 953, 900, 874, 863, 841, 809, 781, 750, 732, 705, 649, 635, 587, 528, 
495, 417, 396. HRMS (ESI, m/z) calcd for C11H16N2O4Na1 [M+Na]+: 263.1002, found: 263.1003. 
 
(R)-2-(2-Hydroxy-1-nitropropan-2-yl)-4-phenylpyridine 1-oxide (101) 
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Starting from 2-acyl-pyridine N-oxides 89 (42.6 mg, 0.20 mmol) according to the general procedure to 
give 101 as a white solid (11 hours, 40.0 mg, 0.145 mmol, 73% yield). Enantiomeric excess 
established by HPLC analysis using a Chiralpak AD-H column, ee = 93% (HPLC: AD-H, 254 nm, 
hexane/isopropanol = 80:20, flow rate 2.0 mL/min, 25 oC), tr (minor) = 7.0 min, tr (major) = 8.0 min). 
1H NMR (300 MHz, CDCl3) δ 8.30 (d, J = 6.7 Hz, 1H), 7.67 – 7.43 (m, 7H), 5.47 (d, J = 11.2 Hz, 1H), 
4.83 (d, J = 11.2 Hz, 1H), 1.88 (s, 3H). All spectroscopic data were in agreement with the literature.38 
 
(R)-4-(tert-Butyl)-2-(2-hydroxy-1-nitropropan-2-yl)pyridine 1-oxide (102) 
 
Starting from 2-acyl-pyridine N-oxides 90 (38.6 mg, 0.20 mmol) according to the general procedure to 
give 102 as a pale yellow oil (8 hours, 33.0 mg, 0.130 mmol, 65% yield). Enantiomeric excess 
established by HPLC analysis using a Chiralpak AD-H column, ee = 52% (HPLC: AD-H, 254 nm, 
hexane/isopropanol = 80:20, flow rate 2.0 mL/min, 25 oC), tr (minor) = 4.2 min, tr (major) = 4.8 min). 
1H NMR (300 MHz, CDCl3) δ 8.17 (dd, J = 6.6, 0.7 Hz, 1H), 7.38 – 7.28 (m, 2H), 5.41 (d, J = 11.1 Hz, 
1H), 4.78 (d, J = 11.1 Hz, 1H), 1.82 (s, 3H), 1.32 (s, 9H). 13C NMR (75 MHz, CDCl3) δ 153.3, 148.3, 
139.6, 122.8, 121.7, 80.6, 72.6, 34.9, 30.4, 23.2. IR (film): ν (cm1) 2966, 2872, 1550, 1479, 1466, 
1416, 1377, 1368, 1308, 1270, 1224, 1190, 1160, 1126, 1077, 950, 907, 872, 827, 748, 733, 684, 633, 
596, 530, 513, 397. HRMS (ESI, m/z) calcd for C12H18N2O4Na1 [M+Na]+: 277.1159, found: 277.1160. 
 
(R)-2-(2-Hydroxy-1-nitrobutan-2-yl)pyridine 1-oxide (103) 
 
Starting from 2-acyl-pyridine N-oxides 91 (30.2 mg, 0.20 mmol) according to the general procedure to 
give 103 as a colorless oil (8 hours, 18.6 mg, 0.088 mmol, 44% yield). Enantiomeric excess 
established by HPLC analysis using a Chiralpak AD-H column, ee = 95% (HPLC: AD-H, 254 nm, 
hexane/isopropanol = 70:30, flow rate 2.0 mL/min, 25 oC), tr (minor) = 3.8 min, tr (major) = 8.0 min). 
1H NMR (300 MHz, CDCl3) δ 8.27 (dt, J = 6.3, 1.1 Hz, 1H), 7.68 (s, 1H), 7.43 (dd, J = 5.1, 1.1 Hz, 
1H), 7.35 (m, 1H), 5.29 (d, J = 11.4 Hz, 1H), 4.97 (d, J = 11.4 Hz, 1H), 2.25 (m, 1H), 2.08 (m, 1H), 
1.07 (t, J = 7.4 Hz, 3H). All spectroscopic data were in agreement with the literature.38 
 
(R)-2-(2-Hydroxy-1-nitrohexan-2-yl)pyridine 1-oxide (104) 
 
Starting from 2-acyl-pyridine N-oxides 92 (35.8 mg, 0.20 mmol) according to the general procedure to 
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give 104 as a pale yellow oil (10 hours, 18.3 mg, 0.076 mmol, 38% yield). Enantiomeric excess 
established by HPLC analysis using a Chiralpak AD-H column, ee = 92% (HPLC: AD-H, 254 nm, 
hexane/isopropanol = 80:20, flow rate 1.0 mL/min, 25 oC), tr (minor) = 7.7 min, tr (major) = 9.5 min). 
1H NMR (300 MHz, CDCl3) δ 8.27 (dt, J = 6.3, 1.0 Hz, 1H), 7.48 – 7.37 (m, 2H), 7.39 – 7.30 (m, 1H), 
5.29 (d, J = 11.4 Hz, 1H), 4.97 (d, J = 11.4 Hz, 1H), 2.28 – 1.93 (m, 2H), 1.66 – 1.30 (m, 4H), 0.93 (t, 
J = 7.1 Hz, 3H). All spectroscopic data were in agreement with the literature.38 
 
5.5 Application for Asymmetric Photoredox Catalysis 
5.5.1 Visible-Light-Induced enantioselective C-N bond formation 
 
General Procedure: To an oven-dried 10 mL Schlenk tube equipped with a magnetic stir bar was 
added Δ-RhO (2 mol%), 2-acyl imidazoles 105-116 (0.4 mmol, 2.0 equiv), and the amine reagent 
117-121 (0.20 mmol, 1.0 equiv). The Schlenk tube was then degassed by alternative evacuation and 
back filling with nitrogen. DMSO (0.25 mL), CH3CN (0.75 mL), and 2, 6-lutidine (36.4 mg, 40 µL, 
0.34 mmol, 1.7 equiv) were then added to the Schlenk tube via syringe addition. The resulting clear 
solution was degassed for 5 min by bubbling nitrogen through the reaction medium. The reaction 
mixture was stirred at room temperature and positioned approximately 10 cm from 24 W Blue LEDs. 
Upon completion, the reaction mixture was concentrated in vacuo. The resulting crude oil was purified 
by flash chromatography on silica gel (EtOAc/n-hexane = 1: 4 to 1: 2) to provide the target 
compounds 122-137. 
 
(S)-Methyl (2-(1-isopropyl-1H-imidazol-2-yl)-2-oxo-1-phenylethyl)(methyl)carbamate (122) 
   
Starting from 2-acyl imidazole 105 (91.2 mg, 0.40 mmol) and the amine reagent 117 (67.0 mg, 0.20 
mmol) according to the general procedure to give 122 as a colorless oil (14 h, 32.3 mg, 0.103 mmol, 
52% yield). Enantiomeric excess established by HPLC analysis using a Chiralpak OD-H column, ee = 
80% (HPLC: OD-H, 254 nm, hexane/isopropanol = 85:15, flow rate 1.0 mL/min, 25 oC), tr (minor) = 
18.1 min, tr (major) = 13.1 min). []D20 = +107.0 (c 0.8, CH2Cl2). 1H NMR (300 MHz, CDCl3) δ 7.36 
– 7.22 (m, 6H), 7.11 – 7.06 (m, 2H), 5.59 – 5.50 (m, 1H), 3.72 (s, 3H), 2.83 (s, 3H), 1.46 (dd, appear t, 
J = 6.6 Hz, 6H). 13C NMR (75 MHz, CDCl3) δ 189.7, 157.5 (156.8, the rotamer), 141.1, 135.2, 130.1, 
129.4, 128.7, 128.1, 121.2, 65.2 (64.5, the rotamer), 52.9, 49.2, 32.3, 23.7, 23.4. IR (film): ν (cm1) 
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2956, 1677, 1453, 1393, 1372, 1305, 1254, 1190, 1146, 1086, 1031, 1000, 991, 955, 915, 860, 817, 
769, 734, 701, 670, 646, 617, 586, 555, 516, 492, 390. HRMS (ESI, m/z) calcd for C17H22N3O3 
[M+H]+: 316.1656, found: 316.1657. 
 
(S)-Methyl methyl(2-oxo-1-phenyl-2-(1-phenyl-1H-imidazol-2-yl)ethyl)carbamate (123) 
 
Starting from 2-acyl imidazole 106 (104.8 mg, 0.40 mmol) and the amine reagent 117 (67.0 mg, 0.20 
mmol) according to the general procedure to give 123 as a pale yellow solid (2 hours, 64.4 mg, 0.185 
mmol, 93% yield). Enantiomeric excess established by HPLC analysis using a Chiralpak OD-H 
column, ee = 89% (HPLC: OD-H, 254 nm, hexane/isopropanol = 85:15, flow rate 1.0 mL/min, 25 oC), 
tr (minor) = 11.1 min, tr (major) = 14.7 min). []D20 = +251.1 (c 0.8, CH2Cl2). 1H NMR (300 MHz, 
CDCl3) δ 7.55 – 7.42 (m, 3H), 7.40 – 7.27 (m, 7H), 7.21 (d, J = 1.1 Hz, 1H), 7.13 – 7.06 (m, 2H), 3.71 
(s, 3H), 2.74 (s, 3H). 13C NMR (75 MHz, CDCl3) δ 188.1, 157.4 (156.5, the rotamer), 141.7, 138.1, 
134.7, 130.1, 129.6, 129.0, 128.8, 128.7, 128.2, 126.9, 125.8, 64.9 (64.2, the rotamer), 52.8, 32.2. IR 
(film): ν (cm1) 2954, 1683, 1596, 1491, 1446, 1401, 1375, 1344, 1306, 1243, 1209, 1188, 1146, 1074, 
1036, 1022, 1001, 983, 974, 951, 913, 859, 817, 760, 734, 693, 587, 547, 523, 387. HRMS (ESI, m/z) 
calcd for C20H20N3O3 [M+H]+: 350.1499, found: 350.1500. 
 
(S)-Methyl methyl(2-oxo-1-phenyl-2-(1-(o-tolyl)-1H-imidazol-2-yl)ethyl)carbamate (124) 
 
Starting from 2-acyl imidazole 107 (104.8 mg, 0.40 mmol) and the amine reagent 117 (67.0 mg, 0.20 
mmol) according to the general procedure to give 124 as a pale yellow solid (2 hours, 69.4 mg, 0.191 
mmol, 96% yield). Enantiomeric excess established by HPLC analysis using a Chiralpak OD-H 
column, ee = 97% (HPLC: OD-H, 254 nm, hexane/isopropanol = 85:15, flow rate 1.0 mL/min, 25 oC), 
tr (minor) = 7.9 min, tr (major) = 12.3 min). []D20 = +328.6 (c 0.8, CH2Cl2). 1H NMR (300 MHz, 
CDCl3) δ 7.46 – 7.17 (m, 10H), 7.17 – 6.97 (m, 2H), 3.70 (s, 3H), 2.73 and 2.69 (s and s, 3H, 
contained the rotamer), 2.04 and 1.97 (s and s, 3H, contained the rotamer). 13C NMR (126 MHz, 
CDCl3) δ 188.4, 188.2, 188.0, 187.8, 157.3, 156.5, 142.0, 142.0, 137.5, 137.4, 135.1, 134.7, 134.4, 
134.0, 130.7, 130.6, 130.5, 130.3, 129.64, 129.61, 129.5, 129.3, 129.2, 129.1, 128.7, 128.6, 128.2, 
128.2, 126.8, 126.7, 126.5, 126.4, 126.2, 126.0, 64.4, 64.0, 52.7, 32.1, 31.8, 31.7, 17.2, 17.0 
(Contained the rotamer). IR (film): ν (cm1) 2954, 1685, 1490, 1453, 1403, 1374, 1344, 1303, 1241, 
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1214, 1188, 1146, 1088, 1046, 1029, 973, 951, 914, 859, 818, 799, 762, 735, 718, 701, 676, 588, 560, 
458, 390. HRMS (ESI, m/z) calcd for C21H21N3O3Na1 [M+Na]+: 386.1475, found: 386.1475. 
 
(S)-Methyl (1-(4-fluorophenyl)-2-oxo-2-(1-(o-tolyl)-1H-imidazol-2-yl)ethyl)(methyl)carbamate 
(125) 
 
Starting from 2-acyl imidazole 108 (117.6 mg, 0.40 mmol) and the amine reagent 117 (67.0 mg, 0.20 
mmol) according to the general procedure to give 125 as a white solid (1.5 hours, 76.2 mg, 0.200 
mmol, >99% yield). Enantiomeric excess established by HPLC analysis using a Chiralpak OD-H 
column, ee = 97% (HPLC: OD-H, 254 nm, hexane/isopropanol = 90:10, flow rate 1.0 mL/min, 25 oC), 
tr (minor) = 9.0 min, tr (major) = 12.4 min). []D20 = +273.4 (c 0.9, CH2Cl2). 1H NMR (300 MHz, 
CDCl3) δ 7.43 – 7.19 (m, 7H), 7.16 – 6.98 (m, 4H), 3.71 (s, 3H), 2.74 and 2.70 (s and s, 3H, contained 
the rotamer), 2.04 and 1.97 (s and s, 3H, contained the rotamer). 19F NMR (282 MHz, CDCl3) δ – 
114.13 and – 113.86 (s and s, 1F, contained the rotamer). 13C NMR (126 MHz, CDCl3) δ 188.1, 187.8, 
163.5, 161.5, 157.3, 156.5, 141.9, 137.5, 137.4, 135.1, 134.9, 134.0, 131.4, 131.2, 130.8, 130.6, 130.4, 
130.4, 129.3, 129.2, 126.8, 126.7, 126.6, 126.5, 126.0, 115.9, 115.8, 115.72, 115.65, 63.8, 63.2, 52.9, 
32.1, 32.0, 31.8, 17.2, 17.1, 17.0 (Contained the rotamer). IR (film): ν (cm1) 2956, 1684, 1604, 1508, 
1490, 1452, 1402, 1376, 1345, 1304, 1223, 1189, 1147, 1099, 1047, 1028, 974, 953, 915, 865, 846, 
816, 797, 762, 717, 674, 646, 588, 560, 454, 520, 500, 458. HRMS (ESI, m/z) calcd for 
C21H20F1N3O3Na1 [M+Na]+: 404.1381, found: 404.1381. 
 
(S)-Methyl (1-(4-chlorophenyl)-2-oxo-2-(1-(o-tolyl)-1H-imidazol-2-yl)ethyl)(methyl)carbamate 
(126) 
 
Starting from 2-acyl imidazole 109 (124.0 mg, 0.40 mmol) and the amine reagent 117 (67.0 mg, 0.20 
mmol) according to the general procedure to give 126 as a pale yellow solid (2 hours, 77.8 mg, 0.196 
mmol, 98% yield). Enantiomeric excess established by HPLC analysis using a Chiralpak OD-H 
column, ee = 98% (HPLC: OD-H, 254 nm, hexane/isopropanol = 95:5, flow rate 1.0 mL/min, 25 oC), 
tr (minor) = 9.6 min, tr (major) = 15.0 min). []D20 = +311.3 (c 1.0, CH2Cl2). 1H NMR (300 MHz, 
CDCl3) δ 7.49 – 7.17 (m, 8H), 7.16 – 6.98 (m, 3H), 3.72 (s, 3H), 2.75 and 2.71 (s and s, 3H, contained 
the rotamer), 2.04 and 1.98 (s and s, 3H, contained the rotamer). 13C NMR (75 MHz, CDCl3) δ 187.8, 
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187.5, 157.3, 156.5, 141.9, 137.4, 135.1, 134.3, 134.0, 133.4, 131.0, 130.8, 130.6, 130.5, 129.3, 129.0, 
129.0, 126.8, 126.7, 126.5, 126.0, 63.8, 63.4, 52.9, 32.1, 17.1 (Contained the rotamer). IR (film): ν 
(cm1) 2954, 1686, 1592, 1490, 1455, 1400, 1375, 1345, 1304, 1242, 1190, 1149, 1090, 1046, 1029, 
1015, 984, 952, 915, 863, 806, 764, 731, 717, 693, 675, 587, 560, 506, 458, 434, 389. HRMS (ESI, 
m/z) calcd for C21H21Cl1N3O3 [M+H]+: 398.1266, found:398.1267. 
 
(S)-Methyl (1-(3-chlorophenyl)-2-oxo-2-(1-(o-tolyl)-1H-imidazol-2-yl)ethyl)(methyl)carbamate 
(127) 
 
Starting from 2-acyl imidazole 110 (124.0 mg, 0.40 mmol) and the amine reagent 117 (67.0 mg, 0.20 
mmol) according to the general procedure to give 127 as a pale yellow solid (2 hours, 70.6 mg, 0.178 
mmol, 89% yield). Enantiomeric excess established by HPLC analysis using a Chiralpak OD-H 
column, ee = 92% (HPLC: OD-H, 254 nm, hexane/isopropanol = 90:10, flow rate 1.0 mL/min, 25 oC), 
tr (minor) = 8.7 min, tr (major) = 11.0 min). []D20 = +253.3 (c 0.8, CH2Cl2). 1H NMR (300 MHz, 
CDCl3) δ 7.48 – 7.30 (m, 4H), 7.30 – 7.22 (m, 4H), 7.14 – 7.02 (m, 3H), 3.73 (s, 3H), 2.76 and 2.72 (s 
and s, 3H, contained the rotamer), 2.05 and 2.00 (s and s, 3H, contained the rotamer). 13C NMR (126 
MHz, CDCl3) δ 187.7, 187.5, 157.3, 156.4, 142.0, 141.9, 137.5, 137.3, 137.0, 136.8, 136.6, 135.1, 
134.8, 134.6, 134.5, 134.1, 130.8, 130.7, 130.5, 130.0, 129.6, 129.6, 129.4, 129.2, 128.5, 127.8, 127.8, 
127.6, 127.5, 127.0, 126.8, 126.7, 126.6, 126.5, 126.1, 63.9, 63.4, 52.9, 32.3, 32.2, 32.1, 31.9, 17.2, 
17.0 (Contained the rotamer). IR (film): ν (cm1) 2954, 1685, 1595, 1573, 1489, 1476, 1454, 1400, 
1375, 1346, 1303, 1241, 1214, 1188, 1147, 1081, 1046, 1028, 999, 958, 915, 888, 857, 820, 762, 714, 
692, 678, 657, 589, 566, 547, 527, 459, 441, 422, 389. HRMS (ESI, m/z) calcd for C21H20Cl1N3O3Na1 
[M+Na]+: 420.1085, found:420.1088. 
 
(S)-Methyl (1-(2-chlorophenyl)-2-oxo-2-(1-(o-tolyl)-1H-imidazol-2-yl)ethyl)(methyl)carbamate 
(128) 
 
Starting from 2-acyl imidazole 111 (124.0 mg, 0.40 mmol) and the amine reagent 117 (67.0 mg, 0.20 
mmol) according to the general procedure to give 128 as a pale yellow solid (2 hours, 78.8 mg, 0.198 
mmol, 99% yield). Enantiomeric excess established by HPLC analysis using a Chiralpak OD-H 
column, ee = 97% (HPLC: OD-H, 254 nm, hexane/isopropanol = 90:10, flow rate 1.0 mL/min, 25 oC), 
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tr (minor) = 10.6 min, tr (major) = 20.1 min). []D20 = +307.9 (c 0.9, CH2Cl2). 1H NMR (300 MHz, 
CDCl3) δ 7.46 – 7.28 (m, 4H), 7.25 – 6.98 (m, 7H), 3.70 (s, 3H), 2.76 and 2.69 (s and s, 3H, contained 
the rotamer), 2.03 and 2.01 (s and s, 3H, contained the rotamer). 13C NMR (126 MHz, CDCl3) δ 187.5, 
187.4, 187.0, 186.7, 157.0, 156.6, 141.9, 141.8, 137.54, 137.49, 137.4, 137.3, 135.3, 135.2, 135.1, 
134.9, 134.8, 134.4, 134.3, 134.1, 133.23, 133.15, 132.9, 132.1, 130.8, 130.7, 130.64, 130.57, 130.52, 
130.46, 130.39, 130.36, 130.24, 130.20, 130.0, 129.9, 129.7, 129.54, 129.51, 129.3, 129.2, 129.13, 
129.07, 128.9, 128.4, 126.9, 126.8, 126.62, 126.59, 126.56, 126.50, 126.46, 126.4, 126.3, 126.1, 126.0, 
63.1, 63.0, 62.5, 62.2, 53.1, 53.0, 52.9, 52.8, 32.5, 32.3, 32.1, 32.0, 17.22, 17.17, 17.13, 17.05, 17.0 
(Contained the rotamer). IR (film): ν (cm1) 2956, 1685, 1446, 1401, 1376, 1301, 1246, 1188, 1147, 
1028, 973, 955, 915, 865, 854, 819, 759, 717, 697, 675, 589, 560, 530, 506, 458, 428. HRMS (ESI, 
m/z) calcd for C21H20Cl1N3O3Na1 [M+Na]+: 420.1085, found:420.1089. 
 
(S)-Methyl (1-(4-bromophenyl)-2-oxo-2-(1-(o-tolyl)-1H-imidazol-2-yl)ethyl)(methyl)carbamate 
(129) 
 
Starting from 2-acyl imidazole 112 (141.6 mg, 0.40 mmol) and the amine reagent 117 (67.0 mg, 0.20 
mmol) according to the general procedure to give 129 as a pale yellow solid (2 hours, 85.2 mg, 0.193 
mmol, 97% yield). Enantiomeric excess established by HPLC analysis using a Chiralpak OD-H 
column, ee = 97% (HPLC: OD-H, 254 nm, hexane/isopropanol = 90:10, flow rate 1.0 mL/min, 25 oC), 
tr (minor) = 10.0 min, tr (major) = 15.9 min). []D20 = +275.6 (c 1.1, CH2Cl2). 1H NMR (300 MHz, 
CDCl3) δ 7.50 – 7.43 (m, 2H), 7.43 – 7.09 (m, 7H), 7.09 – 6.98 (m, 2H), 3.69 (s, 3H), 2.73 and 2.69 (s 
and s, 3H, contained the rotamer), 2.02 and 1.96 (s and s, 3H, contained the rotamer). 13C NMR (126 
MHz, CDCl3) δ 187.8, 187.5, 157.3, 156.4, 141.9, 137.5, 137.3, 135.1, 134.8, 134.0, 133.6, 131.94, 
131.87, 131.3, 131.2, 131.0, 130.8, 130.6, 130.47, 130.46, 129.3, 129.2, 126.8, 126.6, 126.5, 126.0, 
122.5, 63.9, 63.4, 52.9, 32.1, 32.0, 31.9, 17.2, 17.1, 17.0 (Contained the rotamer). IR (film): ν (cm1) 
2954, 1686, 1587, 1501, 1486, 1405, 1370, 1344, 1323, 1311, 1301, 1287, 1257, 1211, 1192, 1179, 
1146, 1108, 1086, 1072, 1058, 1027, 1009, 981, 953, 915, 868, 836, 808, 763, 727, 717, 686, 677, 663, 
588, 559, 527, 501, 457, 397. HRMS (ESI, m/z) calcd for C21H20Br1N3O3Na1 [M+Na]+: 464.0580, 
486.0562, found: 464.0584, 486.0564. 
 
(S)-Methyl methyl(2-oxo-1-(p-tolyl)-2-(1-(o-tolyl)-1H-imidazol-2-yl)ethyl)carbamate (130) 
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Starting from 2-acyl imidazole 113 (116.0 mg, 0.40 mmol) and the amine reagent 117 (67.0 mg, 0.20 
mmol) according to the general procedure to give 130 as a pale yellow solid (6 h, 61.4 mg, 0.163 
mmol, 81% yield). Enantiomeric excess established by HPLC analysis using a Chiralpak OD-H 
column, ee = 97% (HPLC: OD-H, 254 nm, hexane/isopropanol = 90:10, flow rate 1.0 mL/min, 25 oC), 
tr (minor) = 7.5 min, tr (major) = 11.2 min). []D20 = +347.5 (c 0.8, CH2Cl2). 1H NMR (300 MHz, 
CDCl3) δ 7.46 – 7.21 (m, 5H), 7.21 – 7.03 (m, 6H), 3.70 (s, 3H), 2.72 and 2.68 (s and s, 3H, contained 
the rotamer), 2.33 (s, 3H), 2.05 and 1.97 (s and s, 3H, contained the rotamer). 13C NMR (126 MHz, 
CDCl3) δ 188.7, 188.5, 188.3, 188.1, 157.4, 156.6, 142.1, 142.1, 138.2, 138.1, 137.7, 137.5, 135.2, 
134.9, 134.1, 131.6, 131.2, 130.8, 130.70, 130.5, 130.4, 129.7, 129.5, 129.5, 129.3, 129.1, 126.9, 
126.8, 126.6, 126.4, 126.3, 126.1, 126.0, 64.3, 63.8, 52.7, 32.1, 31.8, 31.7, 21.1, 17.3, 17.12, 17.05 
(Contained the rotamer). IR (film): ν (cm1) 2953, 1685, 1500, 1489, 1451, 1402, 1373, 1309, 1242, 
1190, 1146, 1046, 1023, 974, 952, 914, 863, 826, 804, 786, 762, 738, 717, 675, 645, 634, 588, 560, 
515, 493, 458, 395. HRMS (ESI, m/z) calcd for C22H23N3O3Na1 [M+Na]+: 400.1632, found: 420.1635. 
 
(S)-Methyl (1-(4-methoxyphenyl)-2-oxo-2-(1-(o-tolyl)-1H-imidazol-2-yl)ethyl)(methyl)carbamate 
(131) 
 
Starting from 2-acyl imidazole 114 (122.4mg, 0.40 mmol) and the amine reagent 117 (67.0 mg, 0.20 
mmol) according to the general procedure to give 131 as a pale yellow solid (6 h, 41.0 mg, 0.104 
mmol, 52% yield). Enantiomeric excess established by HPLC analysis using a Chiralpak OD-H 
column, ee = 97% (HPLC: OD-H, 254 nm, hexane/isopropanol = 90:10, flow rate 1.0 mL/min, 25 oC), 
tr (minor) = 12.4 min, tr (major) = 20.5 min). []D20 = +313.3 (c 0.5, CH2Cl2). 1H NMR (300 MHz, 
CDCl3) δ 7.47 – 7.30 (m, 4H), 7.31 – 7.14 (m, 2H), 7.14 – 6.98 (m, 3H), 6.88 (d, J = 8.6 Hz, 2H), 3.80 
(s, 3H), 3.70 (s, 3H), 2.72 and 2.68 (s and s, 3H, contained the rotamer), 2.05 and 1.96 (s and s, 3H, 
contained the rotamer). 13C NMR (75 MHz, CDCl3) δ 189.8, 188.4, 159.5, 158.3, 142.1, 137.7, 134.1, 
131.1, 130.8, 130.6, 130.4, 130.2, 129.9, 129.2, 128.7, 126.9, 126.6, 126.5, 126.4, 126.3, 126.0, 125.8, 
125.7, 114.23, 114.17, 113.61, 113.58, 63.9, 63.5, 55.2, 55.0, 52.8, 32.0, 31.8, 17.3, 17.1 (Contained 
the rotamer). IR (film): ν (cm1) 2955, 1684, 1608, 1510, 1491, 1458, 1401, 1376, 1302, 1248, 1176, 
1146, 1028, 981, 952, 914, 863, 808, 787, 762, 717, 675, 588, 559, 526, 458. HRMS (ESI, m/z) calcd 
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for C22H24N3O4 [M+H]+: 394.1761, found: 394.1762. 
 
(S)-Methyl methyl(1-(naphthalen-2-yl)-2-oxo-2-(1-(o-tolyl)-1H-imidazol-2-yl)ethyl)carbamate 
(132) 
 
Starting from 2-acyl imidazole 115 (130.4 mg, 0.40 mmol) and the amine reagent 117 (67.0 mg, 0.20 
mmol) according to the general procedure to give 132 as a pale yellow solid (2 h, 67.0 mg, 0.162 
mmol, 81% yield). Enantiomeric excess established by HPLC analysis using a Chiralpak OD-H 
column, ee = 96% (HPLC: OD-H, 254 nm, hexane/isopropanol = 90:10, flow rate 1.0 mL/min, 25 oC), 
tr (minor) = 12.1 min, tr (major) = 17.5 min). []D20 = +341.9 (c 0.9, CH2Cl2). 1H NMR (300 MHz, 
CDCl3) δ 7.93 – 7.74 (m, 3H), 7.69 (s, 1H), 7.59 – 7.29 (m, 7H), 7.25 (d, J = 4.1 Hz, 1H), 7.15 (d, J = 
7.6 Hz, 1H), 7.05 (s, 1H), 3.77 (s, 3H), 2.78 and 2.74 (s and s, 3H, contained the rotamer), 2.10 and 
2.03 (s and s, 3H, contained the rotamer). 13C NMR (75 MHz, CDCl3) δ 188.5, 188.3, 157.5, 156.6, 
142.2, 142.1, 137.6, 135.3, 134.0, 133.07, 133.05, 132.9, 132.3, 131.9, 130.9, 130.7, 130.4, 129.2, 
128.9, 128.8, 128.0, 127.9, 127.6, 127.3, 127.0, 126.7, 126.5, 126.3, 126.1, 64.5, 64.1, 52.9, 32.2, 32.0, 
17.3, 17.1; (Contained the rotamer). IR (film): ν (cm1) 2954, 1684, 1501, 1490, 1454, 1403, 1376, 
1344, 1302, 1236, 1191, 1148, 1125, 1047, 1028, 968, 944, 915, 905, 894, 866, 817, 792, 761, 732, 
717, 692, 676, 646, 559, 478, 459. HRMS (ESI, m/z) calcd for C25H23N3O3Na1 [M+Na]+: 436.1634, 
found: 436.1634. 
 
(S)-Methyl butyl(2-oxo-1-phenyl-2-(1-(o-tolyl)-1H-imidazol-2-yl)ethyl)carbamate (133) 
 
Starting from 2-acyl imidazole 107 (110.4 mg, 0.40 mmol) and the amine reagent 118 (75.4 mg, 0.20 
mmol) according to the general procedure to give 133 as a pale yellow oil (2 h, 66.6 mg, 0.164 mmol, 
82% yield). Enantiomeric excess established by HPLC analysis using a Chiralpak OD-H column, ee = 
97% (HPLC: OD-H, 254 nm, hexane/isopropanol = 95:5, flow rate 1.0 mL/min, 25 oC), tr (minor) = 
11.6 min, tr (major) = 17.3 min). []D20 = +251.1 (c 0.8, CH2Cl2). 1H NMR (300 MHz, CDCl3) δ 7.43 
– 7.27 (m, 7H), 7.23 (d, J = 4.5 Hz, 2H), 7.06 – 6.97 (m, 3H), 3.67 (s, 3H), 3.41 – 3.16 (m, 1H), 3.15 – 
2.86 (m, 1H), 2.04 and 1.91 (s and s, 3H, contained the rotamer), 1.33 – 1.23 (m, 1H), 1.06 – 0.66 (m, 
3H), 0.63 and 0.58 (d and d, J = 7.4 Hz and 7.5 Hz, 3H, contained the rotamer). 13C NMR (75 MHz, 
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CDCl3) δ 187.9, 187.6, 157.4, 156.4, 142.2, 137.6, 135.1, 134.7, 134.5, 134.2, 130.8, 130.6, 130.20, 
130.17, 129.1, 128.7, 128.6, 128.4, 128.3, 126.9, 126.6, 126.4, 126.3, 126.2, 126.1, 65.0, 52.6, 52.6, 
45.3, 31.1, 19.7, 17.2, 17.1, 13.43, 13.41; (Contained the rotamer). IR (film): ν (cm1) 2955, 2929, 
1686, 1493, 1453, 1393, 1290, 1258, 1200, 1145, 1085, 1047, 1029, 961, 930, 913, 860, 823, 798, 761, 
736, 717, 701, 676, 616, 557, 458, 444, 405, 393. HRMS (ESI, m/z) calcd for C24H27N3O3Na1 
[M+Na]+: 428.1945, found: 428.1950. 
 
(S)-Methyl (2-oxo-1-phenyl-2-(1-(o-tolyl)-1H-imidazol-2-yl)ethyl)(3-phenylpropyl)carbamate 
(134) 
 
Starting from 2-acyl imidazole 107 (110.4 mg, 0.40 mmol) and the amine reagent 119 (87.8 mg, 0.20 
mmol) according to the general procedure to give 134 as a pale yellow oil (2 h, 80.1 mg, 0.177 mmol, 
89% yield). Enantiomeric excess established by HPLC analysis using a Chiralpak AD-H column, ee = 
97% (HPLC: AD-H, 254 nm, hexane/isopropanol = 70:30, flow rate 1.0 mL/min, 25 oC), tr (minor) = 
6.4 min, tr (major) = 16.2 min). []D20 = +173.8 (c 0.7, CH2Cl2). 1H NMR (300 MHz, CDCl3) δ 7.46 – 
7.19 (m, 9H), 7.21 – 7.11 (m, 3H), 7.14 – 6.96 (m, 3H), 6.89 (t, J = 6.6 Hz, 2H), 3.68 (s, 3H), 3.46 – 
3.24 (m, 1H), 3.19 – 2.90 (m, 1H), 2.38 – 2.13 (m, 2H), 2.04 and 1.92 (s and s, 3H, contained the 
rotamer), 1.74 – 1.50 (m, 1H), 1.37 – 1.01 (m, 1H). 13C NMR (126 MHz, CDCl3) δ 187.9, 187.6, 157.3, 
156.3, 142.1, 141.5, 137.7, 135.2, 134.6, 134.1, 130.8, 130.6, 130.3, 130.2, 130.1, 129.1, 128.8, 128.7, 
128.5, 128.5, 128.4, 128.3, 128.3, 128.2, 128.1, 128.0, 126.9, 126.6, 126.4, 126.3, 126.2, 126.1, 125.5, 
65.1, 64.8, 52.73, 52.69, 45.2, 45.00, 33.0, 30.7, 30.2, 17.3, 17.1; (Contained the rotamer). IR (film): ν 
(cm1) 2953, 2925, 1686, 1602, 1584, 1495, 1452, 1392, 1295, 1248, 1188, 1167, 1151, 1113, 1079, 
1047, 1028, 1003, 954, 913, 865, 847, 830, 819, 799, 762, 749, 737, 717, 698, 677, 619, 559, 493, 458, 
389. HRMS (ESI, m/z) calcd for C29H29N3O3Na1 [M+Na]+: 490.2101, found: 490.2106. 
 
(S)-Methyl isobutyl(2-oxo-1-phenyl-2-(1-(o-tolyl)-1H-imidazol-2-yl)ethyl)carbamate (135) 
 
Starting from 2-acyl imidazole 107 (110.4 mg, 0.40 mmol) and the amine reagent 120 (75.4 mg, 0.20 
mmol) according to the general procedure to give 135 as a pale yellow solid (2 h, 78.5 mg, 0.194 
Chapter 5. Experimental Part 
-179- 
mmol, 97% yield). Enantiomeric excess established by HPLC analysis using a Chiralpak OD-H 
column, ee = 97% (HPLC: OD-H, 254 nm, hexane/isopropanol = 95:5, flow rate 1.0 mL/min, 25 oC), 
tr (minor) = 10.1 min, tr (major) = 14.0 min). []D20 = +216.7 (c 0.5, CH2Cl2). 1H NMR (300 MHz, 
CDCl3) δ 7.43 – 7.25 (m, 7H), 7.23 (d, J = 3.8 Hz, 2H), 7.09 – 6.78 (m, 3H), 3.65 (s, 3H), 3.38 – 3.13 
(m, 1H), 3.06 – 2.80 (m, 1H), 2.04 and 1.87 (s and s, 3H, contained the rotamer), 1.36 – 1.12 (m, 1H), 
0.67 (d and d, appear t, J = 6.5 Hz, 3H, contained the rotamer), 0.46 and 0.42 (d and d, J = 6.6 Hz and 
6.7 Hz, 3H, contained the rotamer). 13C NMR (126 MHz, CDCl3) δ 187.8, 187.5, 157.9, 142.2, 137.6, 
134.5, 134.3, 130.8, 130.6, 130.4, 130.1, 130.0, 129.1, 128.6, 128.54, 128.46, 128.4, 126.9, 126.5, 
126.4, 126.1, 65.8, 65.4, 52.9, 52.6, 27.8, 27.8, 19.9, 19.8, 19.7, 17.3, 17.0; (Contained the rotamer). 
IR (film): ν (cm1) 2955, 1685, 1493, 1454, 1435, 1394, 1335, 1302, 1260, 1209, 1190, 1148, 1086, 
1047, 1028, 985, 962, 913, 858, 825, 800, 761, 736, 717, 703, 677, 663, 617, 559, 457. HRMS (ESI, 
m/z) calcd for C24H27N3O3Na1 [M+Na]+: 428.1945, found: 428.1947. 
 
(S)-Methyl (2-(1,3-dioxolan-2-yl)ethyl)(2-oxo-1-phenyl-2-(1-(o-tolyl)-1H-imidazol-2-yl)ethyl) 
carbamate (136) 
 
Starting from 2-acyl imidazole 107 (110.4 mg, 0.40 mmol) and the amine reagent 121 (84.2 mg, 0.20 
mmol) according to the general procedure to give 136 as a pale yellow oil (3 h, 56.6 mg, 0.126 mmol, 
63% yield). Enantiomeric excess established by HPLC analysis using a Chiralpak OD-H column, ee = 
97% (HPLC: OD-H, 254 nm, hexane/isopropanol = 90:10, flow rate 1.0 mL/min, 25 oC), tr (minor) = 
22.2 min, tr (major) = 25.4 min). []D20 = +196.4 (c 0.58, CH2Cl2). 1H NMR (300 MHz, CDCl3) δ 
7.49 – 7.26 (m, 8H), 7.22 (d, J = 4.4 Hz, 2H), 7.05 (d, J = 7.0 Hz, 1H), 7.00 (s, 1H), 4.52 (s, 1H), 3.87 
– 3.53 (m, 7H), 3.53 – 3.32 (m, 1H), 3.30 – 3.02 (m, 1H), 1.97 (d, J = 37.5 Hz, 3H), 1.70 (tt, J = 10.6, 
5.4 Hz, 1H), 1.38 – 1.09 (m, 1H); (Contained the rotamer). 13C NMR (126 MHz, CDCl3) δ 187.7, 
187.4, 157.2, 142.0, 137.6, 135.2, 134.5, 134.1, 130.8, 130.5, 130.23, 130.20, 130.1, 129.1, 128.83, 
128.76, 128.4, 126.9, 126.6, 126.4, 126.3, 126.2, 126.1, 102.6, 65.1, 64.6, 64.5, 64.4, 52.80, 52.77, 
40.7, 40.5, 33.4, 33.0, 17.3, 17.1; (Contained the rotamer). IR (film): ν (cm1)2956, 2883, 1686, 1492, 
1455, 1442, 1393, 1299, 1264, 1215, 1195, 1144, 1121, 1048, 1026, 986, 955, 913, 902, 858, 826, 798, 
763, 717, 701, 676, 665, 616, 559, 517, 487, 458, 395. HRMS (ESI, m/z) calcd for C25H27N3O5Na1 
[M+Na]+: 472.1843, found: 472.1847. 
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(S)-Methyl methyl(1-oxo-1-(1-(o-tolyl)-1H-imidazol-2-yl)propan-2-yl)carbamate (137) 
 
Starting from 2-acyl imidazole 116 (85.6 mg, 0.40 mmol) and the amine reagent 117 (67.0 mg, 0.20 
mmol) according to the general procedure, no product (137) was observed after 38 hours. 
 
5.5.2 Mechanistic study 
5.5.2.1 The UV/vis absorbance spectra of rac-RhO, rac-IrO, RhO-enolate and IrO-enolate 
 
Figure 56 The UV/vis absorbance spectra of rac-RhO, rac-IrO, RhO-enolate and IrO-enolate.
 
5.5.2.2 Catalytic behavior of RhO-enolate complex 
 
Procedure: To an oven-dried 10 mL Schlenk tube equipped with a magnetic stir bar was added 
RhO-enolate (2 mol%), 2-acyl imidazole 106 (0.2 mmol, 2.0 equiv), and the amine reagent 117 (0.10 
mmol, 1.0 equiv). The Schlenk tube was then degassed by alternative evacuation and back filling with 
nitrogen. DMSO (0.25 mL), CH3CN (0.75 mL), and 2, 6-lutidine (20 µL, 0.17 mmol, 1.7 equiv) were 
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then added to the Schlenk tube via syringe addition. The resulting clear solution was degassed for 5 
min by bubbling nitrogen through the reaction medium. The reaction mixture was stirred at room 
temperature and positioned approximately 10 cm from 24 W Blue LEDs. 2 hours later, the reaction 
mixture was concentrated in vacuo. The resulting crude oil was purified by flash chromatography on 
silica gel (EtOAc/n-hexane = 1: 4 to 1: 2) to provide the target compound 123 as a pale yellow solid 
(91% yield). 
 
5.5.2.3 Trapping experiments by N-methylindole 
 
Procedure: To an oven-dried 10 mL Schlenk tube equipped with a magnetic stir bar was added 
rac-IrO, rac-IrS or rac-RhO (each 2 mol%), 2-acyl imidazoles 106 (5.2 mg, 0.02 mmol, 0.2 equiv), 
and the amine reagent 117 (33.5 mg, 0.10 mmol, 1.0 equiv). The Schlenk tube was then degassed by 
alternative evacuation and back filling with nitrogen. DMSO (0.125 mL), CH3CN (0.375 mL), 
2,6-lutidine (20 µL, 0.17 mmol, 1.7 equiv) and N-methylindole (26.2 mg, 0.2 mmol, 2.0 equiv) were 
then added to the Schlenk tube via syringe addition. The resulting clear solution was degassed for 5 
min by bubbling nitrogen through the reaction medium. The reaction mixture was stirred at room 
temperature and positioned approximately 10 cm from 24 W blue LEDs. 2 hours later, the reaction 
mixture was concentrated in vacuo. The yield is determined by crude 1HNMR and based on 
trimethyl(phenyl)silane as an internal standard. After that, the reaction mixture was concentrated in 
vacuo. The resulting crude oil was purified by flash chromatography on silica gel (EtOAc/n-hexane = 
1: 10 to 1: 5) to provide the target compound 141 as a colorless oil.  
Methyl methyl(1-methyl-1H-indol-2-yl)carbamate (141) 
 
1H NMR (300 MHz, CDCl3) δ 7.60 (ddd, J = 7.9, 1.2, 0.8 Hz, 1H), 7.32 (ddt, J = 8.3, 1.5, 0.8 Hz, 1H), 
7.30 – 7.23 (m, 1H), 7.14 (ddd, J = 8.0, 6.8, 1.4 Hz, 1H), 6.34 (d, J = 0.8 Hz, 1H), 3.73 (s, 3H), 3.58 (s, 
3H), 3.33 (s, 3H). 13C NMR (75 MHz, CDCl3) δ 156.5, 137.9, 134.8, 126.4, 121.9, 120.8, 119.8, 109.4, 
95.9, 53.3, 38.7, 28.6. IR (film): ν (cm1) 3075, 2952, 2847, 1710, 1579, 1558, 1447, 1434, 1392, 1367, 
1339, 1309, 1255, 1228, 1191, 1156, 1092, 1000, 934, 893, 818, 772, 749, 734, 680, 525, 446, 404. 
HRMS (ESI, m/z) calcd for C12H14N2O2Na1 [M+Na]+:241.0947, found: 241.0954. 
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5.5.2.4 Trapping experiment by TEMPO 
 
Procedure: To an oven-dried 10 mL Schlenk tube equipped with a magnetic stir bar was added 
rac-RhO (2 mol%), 2-acyl imidazoles 107 (0.40 mmol, 2.0 equiv), the amine reagent 117 (0.20 mmol, 
1.0 equiv) and TEMPO (1.00 mmol, 5.0 equiv). The Schlenk tube was then degassed by alternative 
evacuation and back filling with nitrogen. DMSO (0.25 mL), CH3CN (0.75 mL), and 2, 6-lutidine (40 
µL, 0.34 mmol, 1.7 equiv) were then added to the Schlenk tube via syringe addition. The resulting 
clear solution was degassed for 5 min by bubbling nitrogen through the reaction medium. The reaction 
mixture was stirred at room temperature and positioned approximately 10 cm from 24 W Blue LEDs. 
18 hours later, the reaction mixture was concentrated in vacuo. The resulting crude oil was purified by 
flash chromatography on silica gel (EtOAc/n-hexane = 1: 20 to 1: 2) to provide the target compound 
140 as a white solid (53% yield) and 124 as a colorless oil (8% yield). 
2-Phenyl-2-((2,2,6,6-tetramethylpiperidin-1-yl)oxy)-1-(1-(o-tolyl)-1H-imidazol-2-yl)ethanone 
(140) 
 
1H NMR (300 MHz, CDCl3) δ 7.51 (t, J = 6.9 Hz, 2H), 7.40 – 7.04 (m, 8H), 7.03 (d, J = 0.8 Hz, 1H), 
6.62 (dd, J = 22.7, 8.9 Hz, 1H), 2.04 (s, 1H), 1.46 (q, J = 10.2, 6.8 Hz, 5H), 1.34 – 1.24 (m, 1H), 1.22 
(s, 2H), 1.18 (s, 3H), 1.06 (s, 6H), 0.75 (d, J = 6.2 Hz, 3H); (Contained the rotamer). 13C NMR (75 
MHz, CDCl3) δ 188.9, 188.7, 142.8, 142.7, 138.1, 138.0, 137.4, 137.3, 134.5, 134.2, 130.5, 129.9, 
128.9, 128.8, 128.1, 128.0, 127.3, 126.4, 126.2, 126.1, 89.6, 89.4, 59.8, 59.4, 40.0, 33.7, 33.1, 20.0, 
17.1, 17.1, 15.7; (Contained the rotamer). IR (film): ν (cm1) 2962, 2926, 2846, 1682, 1490, 1454, 
1392, 1378, 1360, 1340, 1301, 1277, 1241, 1208, 1183, 1146, 1131, 1083, 1053, 1044, 1030, 1008, 
954, 923, 908, 881, 870, 828, 790, 775, 759, 734, 717, 696, 680, 664, 646, 623, 564, 553, 520, 496, 
458. HRMS (ESI, m/z) calcd for C27H34N3O2 [M+H]+: 432.2646, found: 432.2646. 
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5.5.2.5 “Dark and Light” experiments 
Procedure: To an oven-dried 10 mL Schlenk tube equipped with a magnetic stir bar was added 
rac-RhO (2 mol%), 2-acyl imidazole 106 (0.20 mmol, 2.0 equiv), the amine reagent 117 (0.10 mmol, 
1.0 equiv) and 9.2 μL tetradecane. The Schlenk tube was then degassed by alternative evacuation and 
back filling with nitrogen. DMSO (0.25 mL), CH3CN (0.75 mL), and 2, 6-lutidine (20 µL, 0.17 mmol, 
1.7 equiv) were then added to the Schlenk tube via syringe addition. The resulting clear solution was 
degassed for 5 min by bubbling nitrogen through the reaction medium. The reaction mixture was 
stirred at room temperature and positioned approximately 10 cm from 24 W Blue LEDs for specified 
time intervals (Table 12). After irradiation for 5 min, turn off the light, and 5 μL samples were taken 
by a microsyringe and diluted with 200 μL DCM. The yield of the product was detected by GC (FID 
detector, tetradecane as reference standard). After 60 min in the dark, 5 μL samples were taken for 
testing by the same method. Repeat this “dark and light” experiment three times. (Figure 57) 
Table 12 The Data for “Dark and Light” Experiments 
Time / min Yield / % (by GC) Remarks 
0 0 / 
5 1.8 Light (5min) 
65 4.2 Dark (60min) 
70 12.0 Light (5min) 
130 16.4 Dark (60min) 
135 23.3 Light (5min) 
195 24.3 Dark (60min) 
200 29.2 Light (5min) 
0 10 20 30 40 50 60 70 80 90 100 110 120 130 140 150 160 170 180 190 200
0
5
10
15
20
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30 DarkDark
LightLightLight
 Yield
Yie
ld 
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)
t (min)
Light
Dark
 
Figure 57 “Dark and Light” experiments. 
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5.5.2.6 Quantum yield measurement 
The quantum yield was measured by standard ferrioxalate actinometry.51 A 150 W Xenon lamp (50% 
of light intensity, 420±5 nm bandpass filter high transmittance) was used as the light source. The 
measured method was designed according to published procedures with modifications. 52,53  
The solutions were prepared under the red light (1.1 W red LED) and stored in the dark: 
Potassium ferrioxalate solution (0.15 M): 736.9 mg of potassium ferrioxalate hydrate was dissolved in 
10 mL of 0.05 M H2SO4. 
Buffered solution of phenanthroline: 50 mg of 1,10-phenanthroline and 11.25 g of sodium acetate were 
dissolved in 50 mL of 0.5 M H2SO4. 
1) Measurement of light intensity at 420 nm. 
1 mL of the ferrioxalate solution was added to a quartz cuvette (l = 10 mm). The actinometry solution 
was irradiated with 150 W Xenon lamp (50% of light intensity, 420 nm ± 5 nm bandpass filter high 
transmittance) for specified time intervals (30s, 60s, 90s, 120s). After irradiation, 175 μL of the 
phenanthroline solution was added to the cuvette. The solution was kept in dark for 30 min to make 
sure the complete coordination. The absorbance of the actinometry solution was monitored at 510 nm. 
The absorbance of a non-irradiated (in dark) sample was also measured at 510 nm. (Table 13) 
Table 13 The Absorbance of the Actinometry Solution at 510 nm 
t/s 30 60 90 120 
ΔA/a.u. 0.350 0.738 1.108 1.399 
The moles of Fe2+ formed were determined using Beer’s Law (eq 1): 
 (1) 
 V is the final volume (0.01175 L) after complexation with phenanthroline;  
 ΔA (510 nm) is the optical difference in absorbance between the irradiated and non-irradiated 
solutions;  
 l is the path length (1 cm);  
 ε(510 nm) is the molar absorptivity of Fe(phen)32+(11100 L·mol-1·cm-1). 
The photon flux (it is defined as the number of photons per second per unit area) can be calculated 
using eq 2:  
 (2) 
 Φ is the quantum yield for the ferrioxalate actinometer (1.05 for a 0.15 solution at 412 nm; 1.04 
for a 0.15 solution at 422 nm; 1.03 for a 0.15 solution at 433 nm)51; 
  (3) 
 f is the fraction of light absorbed which was calculated using eq 3; where A is the absorbance of 
Chapter 5. Experimental Part 
-185- 
above ferrioxalate solution at 420 nm (as shown in Figure 58, A > 3, indicating f is > 0.999 ≈ 1). 
 
Figure 58 Absorbance of the ferrioxalate actinometer solution (0.15 M). 
 
Figure 59 The bandpass filter (420±5 nm). 
According to Table 13 and equation (1), the moles of Fe2+ are plotted as a function of time (t) in Figure 
60 (the slope in Figure 60 is d(mol Fe2+)/dt). Combine the equation (2), equation (3) with the slope, the 
photon flux can be calculated as follows: 
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Figure 60 The moles of Fe2+ are plotted as a function of time (t).  
2) Determination of the response factor (GC, FID detector, tetradecane as reference standard) 
Before a yield can be calculated, the gas chromatograph (GC) needs to be calibrated to determine the 
response factors for each individual component (reference standard and amination product 123). The 
response factor is effectively the calibration factor for each individual component and it can be 
measured by using the following formula: 
 
Tetradecane is chosen as reference standard. According to equation (4), Rf(tetradecane)/Rf(product) 
can be calculated as follows: 
 
The tetradecane and product 123 (the mass ratio is specified) are mixed in DCM and determined by 
GC. The ratio of integrated areas (tetradecane/ product) is shown in Table 14. Accoring to Table 14, fit 
linear of the integrated areas ratio (tetradecane /product) to the mass ratio (tetradecane /product) to 
give a slope of 1.645 (see Figure 61). Combined with equation (5), Rf(tetradecane)/Rf(product) is 
equal to 1.645. 
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Table 14 Determination of the Response Factor 
 
entry 1 2 3 4 
Mass of tetradecane/product (mg)  0.17/1.7 0.34/1.7 0.51/1.7 0.68/1.7 
Mass ratio of tetradecane/product 0.1 0.2 0.3 0.4 
Ratio of integrated areas 
tetradecane/product (GC) 
0.185 0.335 0.504 0.642 
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Adj. R-Square 0.99867
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B Intercept 0 --Slope 1.64533 0.02684
 
Figure 61 Fit linear of the integrated areas ratio (tetradecane /product) to the mass ratio (tetradecane /product). 
3) Measurement of quantum yield 
 
To an dried 1.0 mL cuvette (with rubber cap) equipped with a magnetic stir bar was added rac-RhO (2 
mol%), 2-phenyl-1-(1-phenyl-1H-imidazol-2-yl)ethanone 106 (209.6 mg, 0.80 mmol, 2.0 equiv), and 
the amine reagent methyl ((2,4-dinitrophenyl)sulfonyl)oxy(methyl)carbamate 117 (134.0 mg, 0.40 
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mmol, 1.0 equiv). The cuvette was then degassed by alternative evacuation and back filling with 
nitrogen. The mixture solvents of DMSO/CH3CN (v/v = 1/3), 2, 6-lutidine (80 µL, 0.68 mmol, 1.7 
equiv), and tetredacane (14.0 mg) were then added to the cuvette (the total volume is 1.0 mL) via 
syringe addition. The resulting clear solution was degassed for 5 min by bubbling nitrogen through the 
reaction medium. The reaction mixture was stirred at room temperature and irradiated with 150 W 
Xenon lamp (50% of light intensity, 420 nm ± 5 nm bandpass filter high transmittance) for specified 
time intervals (3 minutes, 6 minutes, 9 minutes, 12 minutes). The yield of product was detected by GC 
(FID detector, tetradecane as reference standard). 
According to the ratio of integrated areas tetradecane/product in GC and the response factor 
(Rf(tetradecane)/Rf(product) = 1.645), we calculate the yield of product, which is shown in Table 15. 
Table 15 The Yield of Product at Different Time 
t/min 0 3 6 9 12 
Yield% 0 0.68 1.76 2.31 2.75 
0 2 4 6 8 10 12
0.0
0.5
1.0
1.5
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Yie
ld 
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)
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Equation y = a + b*x
Adj. R-Square 0.98982
Value Standard Error
Yield Intercept 0 --
Yield Slope 0.24589 0.01114
 
Figure 62 Fit linear of yield. 
According to the Figure 62, the quantum yield is, 
Φ = mol product/ mol photons = 0.4×10-3×0.246%/(1.206×10-9×60) = 13.6 
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5.5.3 Photo reaction in flow 
 
Procedure: To a dried 50 mL centrifugal tube was added Δ-RhO (33.2 mg, 2 mol%), 2-acyl 
imidazoles 107 (4.0 mmol, 2.0 equiv), and the amine reagent 117 (2.0 mmol, 1.0 equiv). Dry DMSO 
(5.0 mL), dry CH3CN (15.0 mL), and 2,6-lutidine (400 µL, 3.4 mmol, 1.7 equiv) were then added to 
the centrifugal tube via syringe addition. The resulting clear solution was degassed for 5 min by 
bubbling nitrogen through the reaction medium. The reaction mixture is then pumped through the 
photo reactor at a flow rate (0.15 mL/min). After 180 min, the collected mixture was concentrated in 
vacuo, and then diluted with EtOAc and wahed by water. The organic phase was dried over anhydrous 
Na2SO4 and concentrated in vacuo. The resulting crude product was purified by flash chromatography 
on silica gel (EtOAc/n-hexane = 1:4 to 1:2) to provide the target compound 124 as a pale yellow solid 
(653 mg, 1.80 mmol, 90% yield and 97% ee). 
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5.6 Single Crystal X-ray Diffraction 
Crystal data and the detailed information are listed in the Appendix 8. 
rac-18 
N
O tBu
Ir
Cl
Cl
O2N
N
O
tBu
NO2
N
OtBu
Ir
NO2
N
O
tBu
O2N
 
Crystals of rac-18 suitable for single-crystal X-ray diffraction were obtained by slow diffusion from a 
solution of rac-18 (10 mg) in CH2Cl2 (1.5 mL) layered with n-hexane (0.5 mL) at room temperature 
for several days in a NMR tube. 
 
rac-IrO(NO2) 
 
Crystals of rac-IrO(NO2) suitable for single-crystal X-ray diffraction were obtained by slow diffusion 
from a solution of rac-IrO(NO2) (20 mg) in CH2Cl2 (0.5 mL) layered with n-hexane (1.5 mL) at room 
temperature for several days in a NMR tube. 
 
rac-IrO(nap) 
 
Crystals of rac-IrO(nap) suitable for single-crystal X-ray diffraction were obtained by slow diffusion 
from a solution of rac-IrO(nap) (20 mg) in CH2Cl2 (0.5 mL) layered with n-hexane (1.5 mL) at room 
temperature for several days in a NMR tube. 
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-IrS 
 
Crystals of Λ-IrS suitable for single-crystal X-ray diffraction were obtained by slow diffusion from a 
solution of Λ-IrS (30 mg) in CH2Cl2 (0.5 mL) layered with n-hexane (1.5 mL) at room temperature for 
several days in a NMR tube. 
 
rac-IrO(ada) 
 
Crystals of rac-IrO(ada) suitable for single-crystal X-ray diffraction were obtained by slow diffusion 
from a solution of rac-IrO(ada) (30 mg) in CH2Cl2 (0.5 mL) layered with n-hexane (1.5 mL) at room 
temperature for several days in a NMR tube. 
 
(S,S)-51 
 
Crystals of (S,S)-51 suitable for single-crystal X-ray diffraction were obtained by slow diffusion from 
a solution of (S,S)-51 (71 mg) in CH2Cl2 (0.5 mL) layered with n-hexane (1.5 mL) at room 
temperature for several days in a NMR tube. 
 
Iridium-coordinated substrate (79) 
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To a solution of rac-IrO (50.0 mg, 0.054 mmol) in distilled, anhydrous CH2Cl2 (0.55 mL) at room 
temperature was added 35 (13.2 mg, 0.055 mmol) under N2 in a Schlenk tube. The reaction mixture 
was stirred at room temperature over night. Then, distilled anhydrous n-hexane (2 mL) was added 
slowly. Dark brown crystals were obtained after one day by slow diffusion.  
 
Iridium-coordinated product (80) 
 
To a solution of rac-IrO (40.0 mg, 0.043 mmol) in distilled, anhydrous CH2Cl2 (0.42 mL) at room 
temperature was added 35 (10.4 mg, 0.043 mmol) under N2 in a Schlenk tube. The reaction mixture 
was stirred at room temperature over night. 2,3-Dihydrofuran (9.1 mg, 0.13 mmol) was added and 
stirred for two hours. Then distilled anhydrous n-hexane (2 mL) was added slowly. Yellow crystals 
were obtained after one day by slow diffusion. 
 
Rhodium-coordinated product (138)  
 
To a solution of Δ-RhO (21.8 mg, 0.026mmol) in CH2Cl2 (5 mL) at room temperature was added 
(R)-124 (catalyzed by Λ-RhO; 13.8 mg, 0.0380 mmol) in a bottom flask. And then the solvent was 
removed under reduced pressure. The residue was dissolved in 0.5 mL of CH2Cl2. Single crystals of 
138 suitable for X-ray diffraction were obtained by slow diffusion from a solution of residue in 
CH2Cl2 (0.5 mL) layered with n-hexane (2 mL) at room temperature for one day in a NMR tube. 
 
Rhodium-coordinated substrate (139) 
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To a mixture of rac-RhO (83.1 mg, 0.1 mmol), imidazole substrate 117 (33.1mg, 0.12 mmol) and 
NaOMe (8.1 mg, 0.15 mmol) was added MeOH (0.4 mL) and DCM (1.6 mL). The mixture was stirred 
under N2 over night. The solvents were removed in vacuo. Then 10 mL of CH2Cl2 was added. After 
centrifugation, the clear solution was reserved and concentrated. Single crystals of complex 139 
suitable for X-ray diffraction were obtained by slow diffusion from a solution of residue in CH2Cl2 
(1.0 mL) layered with n-hexane (4 mL) at room temperature for two days in a glass tube.  
 
rac-IrO(pyrene) 
 
Crystals of rac-IrO(pyrene) suitable for single-crystal X-ray diffraction were obtained by slow 
diffusion from a solution of rac-IrO(pyrene) (10 mg) in CH2Cl2 (0.5 mL) layered with n-hexane (0.5 
mL) at room temperature for several days in a NMR tube. 
 
rac-IrN(pyrene) 
N
N tBu
Ir
nBu
N
N tBu
nBu
N
N PF6
 
Crystals of rac-IrN(pyrene) suitable for single-crystal X-ray diffraction were obtained by slow 
diffusion from a solution of rac-IrN(pyrene) (20 mg) in CH2Cl2 (0.5 mL) layered with n-hexane (1.5 
mL) at room temperature for several days in a NMR tube. (The quality of this crystal is not good 
enough.) 
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Appendix 1. List of Abbreviations 
 
1H NMR proton nuclear magnetic resonance spectroscopy 
13C NMR carbon nuclear magnetic resonance spectroscopy 
9F NMR fluorine nuclear magnetic resonance spectroscopy 
δ chemical shift 
J coupling constant 
br broad 
s singlet 
d doublet 
t triplet 
q quartet 
m multiplet 
ppm parts per million 
AcOH acetic acid 
ada adamantane 
aq aqueous 
Ar argon 
bpy 2,2´-bipyridine 
Calcd calculated 
CBSA p-Cl-benzenesulfonic acid 
CD circular dichroism 
CH2Cl2/ DCM dichloromethane 
CD2Cl2 dideuteromethylenechloride 
CHCl3 chloroform 
CDCl3 deuterochloroform 
CH3CN/ MeCN acetonitrile 
conc concentrated 
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DBU 1,8-diazabicycloundec-7-ene 
DIPEA N,N-diisopropylethylamine 
DMAc dimethylacetamide 
DMAP 4-dimethylaminopyridine 
DMF dimethylformamide 
DMSO dimethyl sulfoxide 
dr diastereomeric ratio 
EDA electron donor-acceptor 
EDC 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride 
ee enantiomeric excesses 
e.g. exempli gratia (lat.: for example) 
en ethylenediamine 
er enantiomeric ratio 
EROCM enantioselective ring opening/cross-metathesis 
et al. et alii (lat.: and others) 
ESI electrospray ionization 
EtOH ethanol 
Et2O diethyl ether 
Et2NH diethyl amine 
Et3N triethyl amine 
EtOAc ethyl acetate 
h hour(s) 
HPLC high performance liquid chromatography 
HRMS high resolution mass spectrometry 
Hz Hertz 
IR spectra infrared spectra 
Ir iridium 
L liter(s) 
M mol/liter 
min minute(s) 
mL milliliter(s) 
MLCT metal-to-ligand charge transfer 
mmol millimole 
MS mass spectroscopy 
N2 nitrogen 
NBS N-bromosuccinimide 
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NCRs nitrogen-centered radicals 
Nu nucleophile 
ODN 2,4-dinitrophenylsulfonyloxy 
PCET proton-coupled electron transfer 
Ph phenyl 
PPh3 triphenylphosphine 
ppm parts per million 
ppy 2-phenylpyridine 
rac racemate 
RCM ring closing metathesis 
Rh rhodium 
r.t. room temperature 
sec secondary 
SET single-electron transfer 
TEMPO 2,2,6,6-tetramethyl-1-piperidinyloxy 
4-MeO-TEMPO 4-methoxy-2,2,6,6-tetramethyl-1-piperidinyloxy 
TFA trifluoroacetic acid 
THF tetrahydrofuran 
TLC thin layer chromatography 
UV ultraviolet 
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-(S)-26 -(S)-26 79 80 
    
  
138 139 -(S)-145 -(S)-145 
 
Appendix 5.2 List of organic compounds 
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N
O tBu
O2N
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9 10 (S)-25 (S)-29 
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NMe2
34 35 (S)-36 (S)-37 
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Appendix 6. Spectra of Enantiopure Iridium Complexes 
Appendix 6.1 NMR spectra of enantiopure iridium complexes 
 
 
Figure 63 1H NMR and 13C NMR spectrum of iridium auxiliary complex -(S)-26. 
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Figure 64 1H NMR and 13C NMR spectrum of iridium auxiliary complex -(S)-26. 
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Figure 65 1H NMR and 13C NMR spectrum of -IrS 
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Figure 66 1H NMR and 13C NMR spectrum of iridium auxiliary complex -(S)-145. 
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Figure 67 1H NMR and 13C NMR spectrum of iridium auxiliary complex Δ-(S)-145. 
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Figure 68 1H NMR and 13C NMR spectrum of iridium auxiliary complex -IrO(ada). 
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Appendix 6.2 CD spectra of enantiopure iridium complexes 
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 Figure 69 CD spectra of complexes Λ-(S)-26 and Δ-(S)-26.  
Recorded in CH3OH (0.2 mM). 
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Figure 70 CD spectra of complexes Λ-IrS and -IrS. 
Recorded in CH3OH (0.2 mM). 
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Figure 71 CD spectra of complexes Λ-(S)-145 and Δ-(S)-145. 
Recorded in DCM/CH3OH (v/v = 1/4, 0.2 mM). 
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Figure 72 CD spectra of complexes Λ-IrO(ada) and -IrO(ada). 
Recorded in CH3OH (0.2 mM). 
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Appendix 7. HPLC Traces on Chiral Stationary Phase 
 
 
 
Figure 73 Enantiomeric purities of the catalysts -IrS and -IrS. 
HPLC conditions: Daicel Chiralpak IB (250 × 4.6 mm); mobile phase: A = 0.1% TFA, B = MeCN; gradient: 
38% to 46% B in 60 min; flow rate: 1.0 mL/min; 254 nm; 20 oC. 
-IrS 
>100:1 e.r.
-IrS 
>100:1 e.r.
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Peak 
# 
RetTime 
[min] 
Type Width 
[min] 
Area 
[mAU*s] 
Height 
[mAU] 
Area 
% 
1 38.630 MM 0.8421 5687.81396 112.56605 50.0425 
2 49.450 BB 0.9830 5678.14893 89.18725 49.9575 
 
 
Peak 
# 
RetTime 
[min] 
Type Width 
[min] 
Area 
[mAU*s] 
Height 
[mAU] 
Area 
% 
1 38.509 MF 0.8772 73.19995 1.39082 0.5423 
2 49.016 BB 1.1190 1.34259e4 189.22839 99.4577 
 
Figure 74 HPLC traces of compound 36. 
rac-36 
N
N
O CH3
NH
99% ee, catalyzed by Λ-IrS 
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 Peak 
# 
RetTime 
[min] 
Type Width
[min]
Area 
[mAU*s] 
Height 
[mAU] 
Area 
% 
1 13.674 MF 0.3360 7863.81982 390.08548 50.2211 
2 15.796 BB 0.3482 7794.58643 346.69852 49.7789 
 Peak 
# 
RetTime 
[min] 
Type Width
[min]
Area 
[mAU*s] 
Height 
[mAU] 
Area 
% 
1 13.775 MF 0.3488 577.21741 27.57767 3.0786 
2 15.887 MF 0.3924 1.81718e4 771.81403 96.9214 
 Peak 
# 
RetTime 
[min] 
Type Width
[min]
Area 
[mAU*s] 
Height 
[mAU] 
Area 
% 
1 13.488 MM 0.3583 111.13294 5.16895 0.3115 
2 15.608 MF 0.4145 3.55614e4 1430.05347 99.6885 
Figure 75 HPLC traces of compound 37.
rac-37 
94% ee, catalyzed by Λ-IrO 
>99% ee, catalyzed by Λ-IrS 
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 Peak 
# 
RetTime 
[min] 
Type Width
[min]
Area 
[mAU*s] 
Height 
[mAU] 
Area 
% 
1 25.400 BB 0.6097 9759.82031 257.47388 50.1778 
2 27.614 BB 0.6390 9690.65625 242.01826 49.8222 
 Peak 
# 
RetTime 
[min] 
Type Width
[min]
Area 
[mAU*s] 
Height 
[mAU] 
Area 
% 
1 22.216 MM 0.6064 178.79048 4.91376 2.9155 
2 24.197 VB 0.5866 5953.63574 160.16139 97.0845 
 Peak 
# 
RetTime 
[min] 
Type Width
[min]
Area 
[mAU*s] 
Height 
[mAU] 
Area 
% 
1 24.611 MM 0.4763 119.39693 4.17802 2.9294 
2 26.754 BB 0.5114 3956.39990 120.44363 97.0706 
Figure 76 HPLC traces of compound 38.
rac-38 
94% ee, catalyzed by Λ-IrO
94% ee, catalyzed by Λ-IrS 
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 Peak 
# 
RetTime 
[min] 
Type Width
[min]
Area 
[mAU*s] 
Height 
[mAU] 
Area 
% 
1 26.802 BB 0.5849 1563.96350 40.99169 50.0679 
2 28.756 BB 0.6188 1559.71899 38.33744 49.9321 
 Peak 
# 
RetTime 
[min] 
Type Width
[min]
Area 
[mAU*s] 
Height 
[mAU] 
Area 
% 
1 25.117 BV 0.4952 246.83122 7.08670 2.6586 
2 26.321 VB 0.6289 9037.34082 215.55846 97.3414 
 Peak 
# 
RetTime 
[min] 
Type Width
[min]
Area 
[mAU*s] 
Height 
[mAU] 
Area 
% 
1 26.034 MF 0.5450 56.58051 1.73042 3.1815 
2 26.505 VB 0.6000 1721.82935 44.06918 96.8185 
Figure 77 HPLC traces of compound 39.
rac-39 
95% ee, catalyzed by Λ-IrO 
94% ee, catalyzed by Λ-IrS 
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Peak 
# 
RetTime 
[min] 
Type Width 
[min] 
Area 
[mAU*s] 
Height 
[mAU] 
Area 
% 
1 17.016 VB 0.4572 3975.10522 134.95076 49.7398 
2 20.724 BB 0.5652 4016.68677 109.03468 50.2602 
 
 
Peak 
# 
RetTime 
[min] 
Type Width 
[min] 
Area 
[mAU*s] 
Height 
[mAU] 
Area 
% 
1 18.622 MM 0.5737 1.09003e4 316.65167 99.6617 
2 23.427 MM 0.7214 37.00091 8.54818e-1 0.3383 
 
Figure 78 HPLC traces of compound 40.
rac-40 
99% ee, catalyzed by Λ-IrS 
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Peak 
# 
RetTime 
[min] 
Type Width 
[min] 
Area 
[mAU*s] 
Height 
[mAU] 
Area 
% 
1 12.983 MM 0.4494 5765.20459 213.81839 50.0461 
2 17.969 MM 0.6655 5754.58984 144.10692 49.9539 
 
 
Peak 
# 
RetTime 
[min] 
Type Width 
[min] 
Area 
[mAU*s] 
Height 
[mAU] 
Area 
% 
1 13.091 MM 0.4011 54.10061 2.24792 0.4526 
2 18.125 MM 0.6854 1.18990e4 289.35458 99.5474 
 
Figure 79 HPLC traces of compound 41. 
rac-41 
99% ee, catalyzed by Λ-IrS
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Peak 
# 
RetTime 
[min] 
Type Width 
[min] 
Area 
[mAU*s] 
Height 
[mAU] 
Area 
% 
1 7.983 VB 0.1929 1040.57227 82.96185 50.1166 
2 11.465 VB 0.3009 1035.72949 53.32177 49.8834 
 
 
Peak 
# 
RetTime 
[min] 
Type Width 
[min] 
Area 
[mAU*s] 
Height 
[mAU] 
Area 
% 
1 8.316 MM 0.2223 1.01627e4 762.09894 98.1677 
2 12.416 MM 0.3664 189.69049 8.62937 1.8323 
 
Figure 80 HPLC traces of compound 42. 
rac-42 
96% ee, catalyzed by Λ-IrS 
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Peak 
# 
RetTime 
[min] 
Type Width
[min]
Area 
[mAU*s] 
Height 
[mAU] 
Area 
% 
1 22.784 BB 0.4613 1178.59717 39.71305 50.2401 
2 24.168 BB 0.4840 1167.33130 37.64820 49.7599 
 Peak 
# 
RetTime 
[min] 
Type Width
[min]
Area 
[mAU*s] 
Height 
[mAU] 
Area 
% 
1 22.072 MM 0.4410 137.42838 5.19432 5.7575 
2 23.275 MM 0.5102 2249.52100 73.47902 94.2425 
 Peak 
# 
RetTime 
[min] 
Type Width
[min]
Area 
[mAU*s] 
Height 
[mAU] 
Area 
% 
1 21.830 BV 0.3479 55.00225 1.92494 4.8563 
2 23.012 VB 0.4751 1077.59302 35.48796 95.1437 
Figure 81 HPLC traces of compound 43.
rac-43 
88% ee, catalyzed by Λ-IrO 
90% ee, catalyzed by Λ-IrS 
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Peak 
# 
RetTime 
[min] 
Type Width
[min]
Area 
[mAU*s] 
Height 
[mAU] 
Area 
% 
1 25.261 BB 0.5682 3008.80444 79.23686 50.8097 
2 27.367 BB 0.6604 2912.91357 65.08873 49.1903 
 Peak 
# 
RetTime 
[min] 
Type Width
[min]
Area 
[mAU*s] 
Height 
[mAU] 
Area 
% 
1 24.908 BB 0.5208 457.89447 13.40493 9.3503 
2 26.737 BB 0.5855 4439.24023 115.80431 90.6497 
 Peak 
# 
RetTime 
[min] 
Type Width
[min]
Area 
[mAU*s] 
Height 
[mAU] 
Area 
% 
1 26.439 BB 0.4459 183.35036 6.24568 4.4242 
2 28.080 BB 0.5988 3960.94531 98.18440 95.5758 
Figure 82 HPLC traces of compound 44.
rac-44 
81% ee, catalyzed by Λ-IrO 
91% ee, catalyzed by Λ-IrS
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Peak 
# 
RetTime 
[min] 
Type Width
[min]
Area 
[mAU*s] 
Height 
[mAU] 
Area 
% 
1 26.431 BB 0.4790 1483.64502 47.93988 49.5918 
2 29.464 BB 0.5640 1508.06726 41.61650 50.4082 
 Peak 
# 
RetTime 
[min] 
Type Width
[min]
Area 
[mAU*s] 
Height 
[mAU] 
Area 
% 
1 26.669 VB 0.5623 8525.45313 229.84721 94.9877 
2 30.296 FM 0.7476 449.86661 10.02874 5.0123 
 Peak 
# 
RetTime 
[min] 
Type Width
[min]
Area 
[mAU*s] 
Height 
[mAU] 
Area 
% 
1 26.859 VB 0.5915 4339.95752 111.01386 97.9289 
2 29.508 MF 0.6054 91.78365 2.52667 2.0711 
Figure 83 HPLC traces of compound 46. 
rac-46 
N
N O (S)
H3C
(S)
O
OtBu
O
90% ee, catalyzed by Λ-IrO
96% ee, catalyzed by Λ-IrS 
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 Peak 
# 
RetTime 
[min] 
Type Width
[min]
Area 
[mAU*s] 
Height 
[mAU] 
Area 
% 
1 11.193 VV 0.4671 8330.63672 291.71237 46.1087 
2 12.073 VV 0.5207 712.80756 21.91737 3.9453 
3 13.342 VB 0.5064 682.27936 21.88411 3.7763 
4 17.099 VB 0.5085 8341.64453 261.88049 46.1697 
 Peak 
# 
RetTime 
[min] 
Type Width
[min]
Area 
[mAU*s] 
Height 
[mAU] 
Area 
% 
1 11.233 MM 0.3064 565.18250 30.74432 1.7059 
2 16.684 BB 0.4232 3.25658e4 1193.21106 98.2941 
 Peak 
# 
RetTime 
[min] 
Type Width
[min]
Area 
[mAU*s] 
Height 
[mAU] 
Area 
% 
1 11.221 MM 0,4674 101.47427 3.61864 1.4540 
2 17.126 BB 0.5091 6877.49023 215.57463 98.5460 
Figure 84 HPLC traces of compound 47. 
rac-47 
97% ee, catalyzed by Λ-IrO
97% ee, catalyzed by Λ-IrS 
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Peak 
# 
RetTime 
[min] 
Type Width 
[min] 
Area 
[mAU*s] 
Height 
[mAU] 
Area 
% 
1 19.430 VB 0.5101 8026.8709 246.11972 49.6639 
2 34.066 BV 0.8309 8135.50146 152.41451 50.3361 
 
Peak 
# 
RetTime 
[min] 
Type Width 
[min] 
Area 
[mAU*s] 
Height 
[mAU] 
Area 
% 
1 19.473 FM 0.6665 536.16663 13.40802 1.69810 
2 33.828 VV 0.8502 3.10390e4 566.59875 98.3019 
 
Figure 85 HPLC traces of compound 48. 
 
 
rac-48 
97% ee, catalyzed by Λ-IrS 
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Peak 
# 
RetTime 
[min] 
Type Width 
[min] 
Area 
[mAU*s] 
Height 
[mAU] 
Area 
% 
1 10.190 VV 0.4041 8150.41943 325.62277 49.8340 
2 11.595 FM 0.4314 8204.71973 316.99832 50.1660 
 
Peak 
# 
RetTime 
[min] 
Type Width 
[min] 
Area 
[mAU*s] 
Height 
[mAU] 
Area 
% 
1 10.287 VV 0.3653 2.59844e4 1132.11560 97.8910 
2 11.756 FM 0.4167 559.81915 22.38926 2.1090 
 
Figure 86 HPLC traces of compound 49. 
rac-49 
N
N
O
(S)
EtOOC
(S)
O
OtBu
O
96% ee, catalyzed by Λ-IrS 
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Peak 
# 
RetTime 
[min] 
Type Width 
[min] 
Area 
[mAU*s] 
Height 
[mAU] 
Area 
% 
1 8.851 VV 0.2866 286.91385 15.87020 4.9980 
2 9.897 VV 0.2985 2582.69116 136.14723 44.9900 
3 10.805 VB 0.3157 290.28879 14.37609 5.0568 
4 13.964 VB 0.3660 2580.69116 109.78651 44.9552 
 
Peak 
# 
RetTime 
[min] 
Type Width 
[min] 
Area 
[mAU*s] 
Height 
[mAU] 
Area 
% 
1 9.755 VV 0.3243 1030.00867 49.50636 7.4077 
2 13.789 FM 0.4058 1.28745e4 528.78027 92.5923 
 
Figure 87 HPLC traces of compound 50. 
rac-50 
85% ee, catalyzed by Λ-IrS
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Peak 
# 
RetTime 
[min] 
Type Width 
[min] 
Area 
[mAU*s] 
Height 
[mAU] 
Area 
% 
1 13.105 VB 0.4058 8485.14160 331.04080 48.0494 
2 21.424 VB 0.5277 9174.05078 264.03427 51.9506 
 
Peak 
# 
RetTime 
[min] 
Type Width 
[min] 
Area 
[mAU*s] 
Height 
[mAU] 
Area 
% 
1 13.125 VV 0.3646 343.55960 14.84536 2.2266 
2 21.410 VB 0.4881 1.50860e4 481.12292 97.7734 
 
Figure 88 HPLC traces of compound 51. 
 
rac-51 
96% ee, catalyzed by Λ-IrS
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Peak 
# 
RetTime 
[min] 
Type Width
[min]
Area 
[mAU*s] 
Height 
[mAU] 
Area 
% 
1 12.343 MM 0.3123 3620.26392 193.18588 49.6842 
2 17.089 VB 0.3722 3666.28467 154.11316 50.3158 
 
Peak 
# 
RetTime 
[min] 
Type Width
[min]
Area 
[mAU*s] 
Height 
[mAU] 
Area 
% 
1 12.498 VB 0.2926 7870.44824 417.71896 95.9399 
2 17.132 FM 0.3924 333.06882 14.14507 4.0601 
 Peak 
# 
RetTime 
[min] 
Type Width
[min]
Area 
[mAU*s] 
Height 
[mAU] 
Area 
% 
1 12.625 VB 0.3052 1.70790e4 873.86877 99.1053 
2 17.808 MM 0.3924 154.19363 6.54996 0.8947 
Figure 89 HPLC traces of compound 52.
rac-52 
92% ee, catalyzed by Λ-IrO 
98% ee, catalyzed by Λ-IrS
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 Peak 
# 
RetTime 
[min] 
Type Width
[min]
Area 
[mAU*s] 
Height 
[mAU] 
Area 
% 
1 16.658 VB 0.4226 1153.26770 42.15503 50.3013 
2 19.585 BB 0.4880 1139.45386 36.20518 49.6987 
 Peak 
# 
RetTime 
[min] 
Type Width
[min]
Area 
[mAU*s] 
Height 
[mAU] 
Area 
% 
1 15.830 MM 0.3723 56.21323 2.51632 1.0767 
2 19.061 BB 0.4769 5164.78027 166.51796 98.9233 
 Peak 
# 
RetTime 
[min] 
Type Width
[min]
Area 
[mAU*s] 
Height 
[mAU] 
Area 
% 
1 16.061 MM 0.4147 253.92087 10.20619 2.7101 
2 19.261 BB 0.4695 9115.51074 300.00720 97.2899 
Figure 90 HPLC traces of compound 53.
rac-53 
98% ee, catalyzed by Λ-IrO 
95% ee, catalyzed by Λ-IrS 
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 Peak 
# 
RetTime 
[min] 
Type Width
[min]
Area 
[mAU*s] 
Height 
[mAU] 
Area 
% 
1 10.229 BB 0.2539 1105.66504 66.93617 49.7197 
2 18.855 BB 0.5238 1118.12988 33.09314 50.2803 
 Peak 
# 
RetTime 
[min] 
Type Width
[min]
Area 
[mAU*s] 
Height 
[mAU] 
Area 
% 
1 10.718 MM 0.4274 5.17129 2.01642e-1 0.0366 
2 19.127 VB 0.5547 1.41132e4 394.08594 99.9634 
 Peak 
# 
RetTime 
[min] 
Type Width
[min]
Area 
[mAU*s] 
Height 
[mAU] 
Area 
% 
1 10.326 MM 0.2932 1.70789 9.70847e-2 0.0615 
2 19..127 BB 0.5278 2775.66211 82.21273 99.9385 
Figure 91 HPLC traces of compound 54. 
rac-54 
>99% ee, catalyzed by Λ-IrO 
>99% ee, catalyzed by Λ-IrS 
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 Peak 
# 
RetTime 
[min] 
Type Width
[min]
Area 
[mAU*s] 
Height 
[mAU] 
Area 
% 
1 9.941 BB 0.0992 2960.62988 464.21027 49.7363 
2 14.235 VB 0.2385 2992.02271 193.68895 50.2637 
 Peak 
# 
RetTime 
[min] 
Type Width
[min]
Area 
[mAU*s] 
Height 
[mAU] 
Area 
% 
1 9.919 VV 0.1210 1344.09253 176.27159 99.0984 
2 14.239 MM 0.2339 12.22889 8.71269e-1 0.9016 
 Peak 
# 
RetTime 
[min] 
Type Width
[min]
Area 
[mAU*s] 
Height 
[mAU] 
Area 
% 
1 9.791 BB 0.0692 582.01080 131.38844 99.7640 
2 14.408 MM 0.1505 1.37656 1.52444e-1 0.2360 
Figure 92 HPLC traces of compound 55.
rac-55 
98% ee, catalyzed by Λ-IrO
>99% ee, catalyzed by Λ-IrS
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Peak 
# 
RetTime 
[min] 
Type Width 
[min] 
Area 
[mAU*s] 
Height 
[mAU] 
Area 
% 
1 11.383 MM 0.3160 1634.16748 86.20078 49.6062 
2 12.282 MM 0.3508 1660.11389 78.87221 50.3938 
 
 
Peak 
# 
RetTime 
[min] 
Type Width 
[min] 
Area 
[mAU*s] 
Height 
[mAU] 
Area 
% 
1 11.147 MM 0.2941 66.36278 3.76076 1.9673 
2 12.176 MM 0.3618 3306.93433 152.34769 98.0327 
 
Figure 93 HPLC traces of compound 68. 
rac-68 
96 % ee, catalyzed by Λ-IrS 
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Peak 
# 
RetTime 
[min] 
Type Width 
[min] 
Area 
[mAU*s] 
Height 
[mAU] 
Area 
% 
1 10.680 MM 0.2728 1177.10059 71.91488 49.9213 
2 11.510 MM 0.2893 1180.81213 68.03181 50.0787 
 
 
Peak 
# 
RetTime 
[min] 
Type Width 
[min] 
Area 
[mAU*s] 
Height 
[mAU] 
Area 
% 
1 10.454 MM 0.2418 5096.07324 351.22644 99.0529 
2 11.124 MM 0.2265 48.72881 3.58587 0.9471 
 
Figure 94 HPLC traces of compound 69. 
 
rac-69 
98 % ee, catalyzed by Λ-IrS 
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Peak 
# 
RetTime 
[min] 
Type Width 
[min] 
Area 
[mAU*s] 
Height 
[mAU] 
Area 
% 
1 20.206 BB 0.5101 3451.11646 100.05773 49.8820 
2 23.231 BB 0.5442 3467.44946 95.88226 50.1180 
 
 
Peak 
# 
RetTime 
[min] 
Type Width 
[min] 
Area 
[mAU*s] 
Height 
[mAU] 
Area 
% 
1 17.832 MM 0.4420 1.19825e4 451.84720 98.5112 
2 20.268 MM 0.5743 181.09050 5.25510 1.4888 
 
Figure 95 HPLC traces of compound 70. 
rac-70 
O OMe
NMe2
N
97 % ee, catalyzed by Λ-IrS 
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Peak 
# 
RetTime 
[min] 
Type Width 
[min] 
Area 
[mAU*s] 
Height 
[mAU] 
Area 
% 
1 11.447 MM 0.3581 5818.03760 270.80154 49.9990 
2 14.526 MM 0.4823 5818.27344 201.05034 50.0010 
 
 
Peak 
# 
RetTime 
[min] 
Type Width 
[min] 
Area 
[mAU*s] 
Height 
[mAU] 
Area 
% 
1 11.141 MM 0.3510 1.77438e4 842.64496 84.1908 
2 13.991 MM 0.4508 3331.89551 123.17903 15.8092 
 
Figure 96 HPLC traces of compound 72. 
rac-72 
68% ee, catalyzed by Λ-IrS 
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Peak 
# 
RetTime 
[min] 
Type Width 
[min] 
Area 
[mAU*s] 
Height 
[mAU] 
Area 
% 
1 7.470 MM 0.1591 3195.52515 334.82138 49.9456 
2 7.926 MM 0.1693 3202.48779 315.31531 50.0544 
 
 
Peak 
# 
RetTime 
[min] 
Type Width 
[min] 
Area 
[mAU*s] 
Height 
[mAU] 
Area 
% 
1 7.738 MM 0.1440 85.30462 9.87063 1.2399 
2 8.152 MM 0.1767 6794.42139 640.84668 98.7601 
 
Figure 97 HPLC traces of compound 73. 
rac-73 
98% ee, catalyzed by Λ-IrS 
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Peak 
# 
RetTime 
[min] 
Type Width 
[min] 
Area 
[mAU*s] 
Height 
[mAU] 
Area 
% 
1 8.113 MM 0.2348 3866.28516 274.44803 49.7455 
2 8.869 MM 0.2546 3905.83838 255.70940 50.2545 
 
 
Peak 
# 
RetTime 
[min] 
Type Width 
[min] 
Area 
[mAU*s] 
Height 
[mAU] 
Area 
% 
1 8.241 MM 0.2278 1.26452e4 925.19641 97.6054 
2 9.017 MM 0.2138 310.23495 24.18731 2.3946 
 
Figure 98 HPLC traces of compound 74. 
rac-74
95% ee, catalyzed by Λ-IrS 
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Peak 
# 
RetTime 
[min] 
Type Width 
[min] 
Area 
[mAU*s] 
Height 
[mAU] 
Area 
% 
1 10.875 VV 0.2265 2348.59058 158.69167 50.0467 
2 12.038 BV 0.2456 2344.21094 147.09657 49.9533 
 
 
Peak 
# 
RetTime 
[min] 
Type Width 
[min] 
Area 
[mAU*s] 
Height 
[mAU] 
Area 
% 
1 10.862 MM 0.2258 154.81367 11.42458 9.0550 
2 12.146 MM 0.2815 1554.89880 92.06667 90.9450 
 
Figure 99 HPLC traces of compound 75’. 
rac-75’ 
82% ee, catalyzed by Λ-IrS 
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Peak 
# 
RetTime 
[min] 
Type Width 
[min] 
Area 
[mAU*s] 
Height 
[mAU] 
Area 
% 
1 9.788 MM 0.2870 1567.36194 91.00428 50.3164 
2 11.129 MM 0.3279 1547.64978 78.67178 49.6836 
 
 
Peak 
# 
RetTime 
[min] 
Type Width 
[min] 
Area 
[mAU*s] 
Height 
[mAU] 
Area 
% 
1 9.790 MM 0.2735 313.18546 19.08332 2.5121 
2 11.191 VV 0.3040 1.21538e4 590.927998 97.4879 
 
Figure 100 HPLC traces of compound 76.
rac-76 
O Ph OMe
NMe2
EtO
O
95% ee, catalyzed by Λ-IrS
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Peak 
# 
RetTime 
[min] 
Type Width 
[min] 
Area 
[mAU*s] 
Height 
[mAU] 
Area 
% 
1 3.530 BV R 0.1181 294.79529 36.76015 50.0183 
2 7.810 MM 0.3256 294.57977 15.07985 49.9817 
 
 
Peak 
# 
RetTime 
[min] 
Type Width 
[min] 
Area 
[mAU*s] 
Height 
[mAU] 
Area 
% 
1 3.516 MM 0.1367 235.32608 28.69759 3.0954 
2 7.520 VV 0.2981 7367.01807 367.17926 96.9046 
 
Figure 101 HPLC traces of compound 93. 
rac-93 
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Peak 
# 
RetTime 
[min] 
Type Width 
[min] 
Area 
[mAU*s] 
Height 
[mAU] 
Area 
% 
1 4.533 MM 0.1811 991.54883 91.25725 50.2787 
2 16.462 MM 0.7036 980.55707 23.22625 49.7212 
 
 
Peak 
# 
RetTime 
[min] 
Type Width 
[min] 
Area 
[mAU*s] 
Height 
[mAU] 
Area 
% 
1 4.668 MM 0.1729 32.62260 3.14398 3.6087 
2 16.029 MM 0.6833 871.38306 21.25500 96.3913 
 
Figure 102 HPLC traces of compound 95. 
rac-95 
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Peak 
# 
RetTime 
[min] 
Type Width 
[min] 
Area 
[mAU*s] 
Height 
[mAU] 
Area 
% 
1 4.849 MM 0.2026 701.48132 57.71691 50.0611 
2 6.935 VB 0.2667 699.76807 39.17224 49.9389 
 
 
Peak 
# 
RetTime 
[min] 
Type Width 
[min] 
Area 
[mAU*s] 
Height 
[mAU] 
Area 
% 
1 4.919 MM 0.1873 73.59045 6.54898 1.2285 
2 6.982 MM 0.3033 5916.45020 325.07684 98.7715 
 
Figure 103 HPLC traces of compound 96. 
rac-96 
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Peak 
# 
RetTime 
[min] 
Type Width 
[min] 
Area 
[mAU*s] 
Height 
[mAU] 
Area 
% 
1 8.465 BV 0.2508 3781.31006 220.72137 50.0392 
2 12.269 VV 0.3523 3775.39282 157.58440 49.9608 
 
 
Peak 
# 
RetTime 
[min] 
Type Width 
[min] 
Area 
[mAU*s] 
Height 
[mAU] 
Area 
% 
1 8.4679 MM 0.2825 134.71611 7.94660 4.5178 
2 12.161 MM 0.4007 2847.20312 118.43519 95.4822 
 
Figure 104 HPLC traces of compound 97. 
rac-97 
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Peak 
# 
RetTime 
[min] 
Type Width 
[min] 
Area 
[mAU*s] 
Height 
[mAU] 
Area 
% 
1 12.939 MM 0.4565 4422.56006 161.47766 50.3072 
2 32.287 MM 0.9702 4368.54346 75.04665 49.6928 
 
 
Peak 
# 
RetTime 
[min] 
Type Width 
[min] 
Area 
[mAU*s] 
Height 
[mAU] 
Area 
% 
1 12.137 MM 0.4627 116.31055 4.18928 7.8948 
2 32.555 MM 1.2179 1356.94080 18.57006 92.1052 
 
Figure 105 HPLC traces of compound 98. 
rac-98 
Chapter 6. Appendices 
-254- 
 
 
Peak 
# 
RetTime 
[min] 
Type Width 
[min] 
Area 
[mAU*s] 
Height 
[mAU] 
Area 
% 
1 4.470 MM 0.1750 426.42999 40.61774 50.0731 
2 10.527 MM 0.4465 425.18411 15.87054 49.9269 
 
 
Peak 
# 
RetTime 
[min] 
Type Width 
[min] 
Area 
[mAU*s] 
Height 
[mAU] 
Area 
% 
1 4.309 MM 0.1753 264.70172 25.15998 3.9842 
2 10.909 MM 0.4805 6379.04590 221.24951 96.0158 
 
Figure 106 HPLC traces of compound 99. 
rac-99 
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Peak 
# 
RetTime 
[min] 
Type Width 
[min] 
Area 
[mAU*s] 
Height 
[mAU] 
Area 
% 
1 4.298 MM 0.1713 787.32776 76.60849 50.0684 
2 7.609 MM 0.3232 785.17664 40.48538 49.9316 
 
 
Peak 
# 
RetTime 
[min] 
Type Width 
[min] 
Area 
[mAU*s] 
Height 
[mAU] 
Area 
% 
1 4.247 MM 0.1602 71.24998 7.41123 4.6982 
2 7.729 VB 0.2978 1445.28589 73.04000 95.3018 
 
Figure 107 HPLC traces of compound 100.
rac-100 
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Peak 
# 
RetTime 
[min] 
Type Width 
[min] 
Area 
[mAU*s] 
Height 
[mAU] 
Area 
% 
1 7.139 MM 0.2888 443.76120 25.60535 49.9337 
2 8.111 MM 0.3393 444.94006 21.85354 50.0663 
 
 
Peak 
# 
RetTime 
[min] 
Type Width 
[min] 
Area 
[mAU*s] 
Height 
[mAU] 
Area 
% 
1 7.038 MM 0.2034 36.23938 2.23299 3.4649 
2 8.018 MM 0.3441 1009.65521 48.90327 96.5351 
 
Figure 108 HPLC traces of compound 101.
rac-101 
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Peak 
# 
RetTime 
[min] 
Type Width 
[min] 
Area 
[mAU*s] 
Height 
[mAU] 
Area 
% 
1 4.004 VV 0.1432 284.57932 29.85935 50.0020 
2 4.690 VV 0.1722 284.55698 2498279 49.9980 
 
 
Peak 
# 
RetTime 
[min] 
Type Width 
[min] 
Area 
[mAU*s] 
Height 
[mAU] 
Area 
% 
1 4.162 MM 0.1603 349.24155 36.31213 23.9526 
2 4.796 MM 0.1897 1108.81396 97.44277 76.0474 
 
Figure 109 HPLC traces of compound 102. 
rac-102 
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Peak 
# 
RetTime 
[min] 
Type Width 
[min] 
Area 
[mAU*s] 
Height 
[mAU] 
Area 
% 
1 3.817 MM 0.1613 186.85374 19.31141 49.8880 
2 7.950 MM 0.3537 187.69276 8.84525 50.1120 
 
 
Peak 
# 
RetTime 
[min] 
Type Width 
[min] 
Area 
[mAU*s] 
Height 
[mAU] 
Area 
% 
1 3.808 MM 0.1571 38.64534 4.09947 2.7445 
2 8.027 MM 0.3626 1369.46814 62.95115 97.2555 
 
Figure 110 HPLC traces of compound 103. 
rac-103 
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Peak 
# 
RetTime 
[min] 
Type Width 
[min] 
Area 
[mAU*s] 
Height 
[mAU] 
Area 
% 
1 7.795 MM 0.2759 5258.63623 317.66507 49.9954 
2 9.641 MM 0.3376 5259.60400 259.68253 50.0046 
 
 
Peak 
# 
RetTime 
[min] 
Type Width 
[min] 
Area 
[mAU*s] 
Height 
[mAU] 
Area 
% 
1 7.715 MM 0.2669 204.38618 12.76480 3.9037 
2 9.498 MM 0.3478 5031.38428 241.11876 96.0963 
 
Figure 111 HPLC traces of compound 104. 
rac-104 
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Peak 
# 
RetTime 
[min] 
Type Width 
[min] 
Area 
[mAU*s] 
Height 
[mAU] 
Area 
% 
1 13.109 BV R 0.4142 821.12305 23.21243 50.0445 
2 18.099 BB 0.4880 819.66125 19.69779 49.9555 
 
 
Peak 
# 
RetTime 
[min] 
Type Width 
[min] 
Area 
[mAU*s] 
Height 
[mAU] 
Area 
% 
1 13.087 BB 0.4753 1738.34131 47.63286 89.7577 
2 18.065 MM 0.6401 198.36226 5.16501 10.2423 
 
Figure 112 HPLC traces of compound 122.
N
N
O
N COOMeMe
Chapter 6. Appendices 
-261- 

 
Peak 
# 
RetTime 
[min] 
Type Width 
[min] 
Area 
[mAU*s] 
Height 
[mAU] 
Area 
% 
1 11.297 MM 0.6378 2409.72803 62.97132 50.3106 
2 15.200 MM 0.6850 2379.97900 57.91004 49.6894 
 
 
Peak 
# 
RetTime 
[min] 
Type Width 
[min] 
Area 
[mAU*s] 
Height 
[mAU] 
Area 
% 
1 11.120 BB 0.4949 247.98788 7.44438 5.3775 
2 14.739 BB 0.5731 4363.60791 112.21796 94.6225 
 
Figure 113 HPLC traces of compound 123.
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Peak 
# 
RetTime 
[min] 
Type Width
[min]
Area 
[mAU*s] 
Height 
[mAU] 
Area 
% 
1 7.740 MM 0.2872 2911.27686 168.97226 50.1791 
2 12.493 BB 0.4829 2890.49365 81.96684 49.8209 
 Peak 
# 
RetTime 
[min] 
Type Width
[min]
Area 
[mAU*s] 
Height 
[mAU] 
Area 
% 
1 7.905 BB 0.1890 89.01913 5.62905 1.3691 
2 12.309 BB 0.4909 6412.76904 182.73834 98.6309 
 Peak 
# 
RetTime 
[min] 
Type Width
[min]
Area 
[mAU*s] 
Height 
[mAU] 
Area 
% 
1 7.894 MM 0.2456 1.95808e4 1328.85364 99.7608 
2 12.964 MM 0.3345 46.95055 2.33945 0.2392 
Figure 114 HPLC traces of compound 124.
>99.5% ee, catalyzed by Λ-RhS 
97% ee, catalyzed by Δ-RhO 
Chapter 6. Appendices 
-263- 
 
 
Peak 
# 
RetTime 
[min] 
Type Width 
[min] 
Area 
[mAU*s] 
Height 
[mAU] 
Area 
% 
1 8.568 MM 0.2672 5177.27148 322.91907 49.9924 
2 11.945 VV 0.4517 5178.84424 172.03442 50.0076 
 
 
Peak 
# 
RetTime 
[min] 
Type Width 
[min] 
Area 
[mAU*s] 
Height 
[mAU] 
Area 
% 
1 9.024 MF 0.2723 115.26480 7.05543 1.4605 
2 12.403 MM 0.5537 7776.73096 234.10115 98.5395 
 
Figure 115 HPLC traces of compound 125.
N
N
O
N COOMeMe
F
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Peak 
# 
RetTime 
[min] 
Type Width 
[min] 
Area 
[mAU*s] 
Height 
[mAU] 
Area 
% 
1 9.561 MM 0.3368 1733.38196 85.78720 50.2826 
2 15.343 BB 0.6626 1713.89758 34.17424 49.7174 
 
 
Peak 
# 
RetTime 
[min] 
Type Width 
[min] 
Area 
[mAU*s] 
Height 
[mAU] 
Area 
% 
1 9.638 MF 0.3454 47.08741 2.27230 1.2125 
2 14.985 BB 0.6719 3836.37622 73.68959 98.7875 
 
Figure 116 HPLC traces of compound 126.
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 Peak 
# 
RetTime 
[min] 
Type Width 
[min] 
Area 
[mAU*s] 
Height 
[mAU] 
Area 
% 
1 8.440 MM 0.2334 2035.65076 145.33856 50.4010 
2 10.664 MM 0.4118 2003.26196 81.07648 49.5990 
 
 
Peak 
# 
RetTime 
[min] 
Type Width 
[min] 
Area 
[mAU*s] 
Height 
[mAU] 
Area 
% 
1 8.688 MM 0.2400 132.01024 9.16889 4.1488 
2 11.013 MM 0.4774 3049.85327 106.48520 95.8512 
 
Figure 117 HPLC traces of compound 127.
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 Peak 
# 
RetTime 
[min] 
Type Width 
[min] 
Area 
[mAU*s] 
Height 
[mAU] 
Area 
% 
1 9.502 VV 0.2657 1220.65088 70.62157 49.8974 
2 16.823 VV 0.5142 1225.67053 32.18125 50.1026 
 
 
Peak 
# 
RetTime 
[min] 
Type Width 
[min] 
Area 
[mAU*s] 
Height 
[mAU] 
Area 
% 
1 10.644 MM 0.3418 62.67695 3.05606 1.6247 
2 20.065 MM 0.9098 3794.96924 69.51762 98.3753 
 
Figure 118 HPLC traces of compound 128.
N
N
O
N COOMeMe
Cl
Chapter 6. Appendices 
-267- 
 
 Peak 
# 
RetTime 
[min] 
Type Width 
[min] 
Area 
[mAU*s] 
Height 
[mAU] 
Area 
% 
1 10.054 MM 0.3659 7733.37109 352.21219 50.2251 
2 15.967 BB 0.7926 7664.04883 126.98806 49.7749 
 
 
Peak 
# 
RetTime 
[min] 
Type Width 
[min] 
Area 
[mAU*s] 
Height 
[mAU] 
Area 
% 
1 9.998 MF 0.3604 76.11834 3.52035 1.6423 
2 15.896 BB 0.6787 4558.87988 79.06895 98.3577 
 
Figure 119 HPLC traces of compound 129.
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Peak 
# 
RetTime 
[min] 
Type Width 
[min] 
Area 
[mAU*s] 
Height 
[mAU] 
Area 
% 
1 7.652 MF 0.2143 3460.02051 269.07526 50.0899 
2 11.747 MM 0.4511 3447.60010 127.36810 49.9101 
 
 
Peak 
# 
RetTime 
[min] 
Type Width 
[min] 
Area 
[mAU*s] 
Height 
[mAU] 
Area 
% 
1 7.467 MM 0.1982 57.02394 4.79609 1.6190 
2 11.243 MM 0.4173 3465.10693 138.39458 98.3810 
 
Figure 120 HPLC traces of compound 130.
N
N
O
N COOMeMe
Me
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Peak 
# 
RetTime 
[min] 
Type Width 
[min] 
Area 
[mAU*s] 
Height 
[mAU] 
Area 
% 
1 12.138 MF 0.4564 3733.34546 136.32205 50.6425 
2 20.871 MM 1.1160 3638.61792 54.34027 49.3575 
 
 
Peak 
# 
RetTime 
[min] 
Type Width 
[min] 
Area 
[mAU*s] 
Height 
[mAU] 
Area 
% 
1 12.420 MF 0.4588 139.99443 5.08594 1.3459 
2 20.535 MM 1.2725 1.02614e4 134.39609 98.6541 
 
Figure 121 HPLC traces of compound 131
N
N
O
N COOMeMe
OMe
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Peak 
# 
RetTime 
[min] 
Type Width 
[min] 
Area 
[mAU*s] 
Height 
[mAU] 
Area 
% 
1 11.944 MM 0.4452 5167.86523 193.47052 50.6815 
2 17.925 MM 1.0633 5028.87402 78.82182 49.3185 
 
 
Peak 
# 
RetTime 
[min] 
Type Width 
[min] 
Area 
[mAU*s] 
Height 
[mAU] 
Area 
% 
1 12.066 MM 0.4317 238.39705 9.20375 2.2103 
2 17.477 MM 1.1328 1.05474e4 155.18494 97.7897 
 
Figure 122 HPLC traces of compound 132.
N
N
O
N COOMeMe
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 Peak 
# 
RetTime 
[min] 
Type Width 
[min] 
Area 
[mAU*s] 
Height 
[mAU] 
Area 
% 
1 11.385 MM 0.4284 672.46295 26.15908 50.0985 
2 17.768 MM 0.9150 669.81940 12.20044 49.9015 
 
 Peak 
# 
RetTime 
[min] 
Type Width 
[min] 
Area 
[mAU*s] 
Height 
[mAU] 
Area 
% 
1 11.597 VV 0.3083 78.69935 3.14173 1.4027 
2 17.327 VB 0.8753 5531.80273 87.74110 98.5973 
 
Figure 123 HPLC traces of compound 133.
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Peak 
# 
RetTime 
[min] 
Type Width 
[min] 
Area 
[mAU*s] 
Height 
[mAU] 
Area 
% 
1 6.503 MM 0.2759 2417.96924 146.05011 50.0833 
2 16.906 MM 0.8724 2409.93018 46.04045 49.9167 
 
 
Peak 
# 
RetTime 
[min] 
Type Width 
[min] 
Area 
[mAU*s] 
Height 
[mAU] 
Area 
% 
1 6.416 MM 0.2304 263.02747 19.02546 1.7131 
2 16.193 MM 0.8279 1.50911e4 303.78659 98.2869 
 
Figure 124 HPLC traces of compound 134.
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Peak 
# 
RetTime 
[min] 
Type Width 
[min] 
Area 
[mAU*s] 
Height 
[mAU] 
Area 
% 
1 9.956 BB 0.3295 3339.85767 147.61003 49.9769 
2 14.035 MM 0.8466 3342.94507 65.80769 50.0231 
 
 
Peak 
# 
RetTime 
[min] 
Type Width 
[min] 
Area 
[mAU*s] 
Height 
[mAU] 
Area 
% 
1 10.110 VB R 0.2542 38.96045 1.79869 1.0375 
2 14.025 BV R 0.6250 3716.41553 72.38879 98.9625 
 
Figure 125 HPLC traces of compound 135.
N
N
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Peak 
# 
RetTime 
[min] 
Type Width 
[min] 
Area 
[mAU*s] 
Height 
[mAU] 
Area 
% 
1 22.575 MF 1.2512 7127.22266 94.93864 50.0634 
2 26.463 FM 1.7672 7109.17676 67.04777 49.9366 
 
 
Peak 
# 
RetTime 
[min] 
Type Width 
[min] 
Area 
[mAU*s] 
Height 
[mAU] 
Area 
% 
1 22.223 MM 1.3158 149.72749 1.89653 1.5360 
2 25.434 MM 1.7561 9598.08105 91.09293 98.4640 
 
Figure 126 HPLC traces of compound 136. 
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Appendix 8. List of Crystal Structure Data 
 
rac-18 
 
Table 16 Crystal Data and Structure Refinement for rac-18 (N,N-cis-configuration) 
 
Crystal data:  
 
Identification code  s691_0m_sq 
Habitus, colour  plate, red 
Crystal size 0.33 × 0.23 × 0.09 mm3 
Crystal system  Monoclinic 
Space group  P 21/c Z = 4 
Unit cell dimensions a = 18.3305(7) Å α= 90° 
 b = 14.4543(6) Å β = 94.3573(13)° 
 c = 29.0787(12) Å γ = 90° 
Volume 7682.3(5) Å3 
Cell determination  9974 peaks with Theta 2.3 to 27.5°. 
Empirical formula  C75 H76 Cl4 Ir2 N8 O12 
Formula weight  1807.63 
Density (calculated) 1.563 Mg/m3 
Absorption coefficient 3.664 mm-1 
F(000) 3600 
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Data collection:  
 
Diffractometer type  Bruker D8 QUEST area detector 
Wavelength  0.71073 Å 
Temperature  100(2) K 
Theta range for data collection 2.228 to 25.500°. 
Index ranges -22<=h<=22, -16<=k<=17, -35<=l<=32 
Data collection software  BRUKER APEX2 
Cell refinement software  SAINT V8.34A (Bruker AXS Inc., 2013) 
Data reduction software  SAINT V8.34A (Bruker AXS Inc., 2013) 
 
Solution and refinement: 
 
Reflections collected 40619 
Independent reflections 14192 [R(int) = 0.0311] 
Completeness to theta = 25.242° 99.1 %  
Observed reflections  11853[II > 2(I)]  
Reflections used for refinement  14192 
Absorption correction Numerical 
Max. and min. transmission 0.73 and 0.44 
Largest diff. peak and hole 1.609 and -1.393 e.Å-3 
Solution  Direct methods 
Refinement  Full-matrix least-squares on F2 
Treatment of hydrogen atoms  Calculated positions, constraint refinement 
Programs used  SHELXS-97 (Sheldrick, 2008) 
 SHELXL-2013 (Sheldrick, 2013) 
 DIAMOND (Crystal Impact) 
Data / restraints / parameters 14192 / 106 / 982 
Goodness-of-fit on F2 1.037 
R index (all data) wR2 = 0.0689 
R index conventional [I>2sigma(I)] R1 = 0.0304 
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rac-IrO(NO2) 
 
Table 17 Crystal Data and Structure Refinement for rac-IrO(NO2) 
 
Crystal data:  
 
Identification code  s745_0m 
Habitus, colour  block, orange 
Crystal size 0.360 × 0.080 × 0.080 mm3 
Crystal system  Monoclinic 
Space group  C 2/c Z = 4 
Unit cell dimensions a = 26.4047(8) Å α = 90° 
 b = 10.9883(3) Å β = 112.9949(11)° 
 c = 15.5720(6) Å γ = 90° 
Volume 4159.1(2) Å3 
Cell determination  214 peaks with Theta 5.7 to 26.8°. 
Empirical formula  C39 H38.40 Cl2 F6 Ir N6 O6.20 P 
Formula weight  1098.42 
Density (calculated) 1.754 Mg/m3 
Absorption coefficient 3.459 mm-1 
F(000) 2176 
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Data collection:  
 
Diffractometer type  Bruker D8 QUEST area detector 
Wavelength  0.71073 Å 
Temperature  100(2) K 
Theta range for data collection 2.662 to 27.555°. 
Index ranges -34<=h<=33, -14<=k<=14, -20<=l<=20 
Data collection software  BRUKER APEX2 
Cell refinement software  APEX2 v2014.1-1 (Bruker AXS) 
Data reduction software  SAINT V8.34A (Bruker AXS Inc., 2013) 
 
Solution and refinement: 
 
Reflections collected 38682 
Independent reflections 4795 [R(int) = 0.0413] 
Completeness to theta = 25.242° 99.9 %  
Observed reflections  4547[II > 2(I)]  
Reflections used for refinement  4795 
Absorption correction Numerical 
Max. and min. transmission 0.77 and 0.36 
Largest diff. peak and hole 0.628 and -0.333 e.Å-3 
Solution  Direct methods 
Refinement  Full-matrix least-squares on F2 
Treatment of hydrogen atoms  calculated positions, constr ref. 
Programs used  SHELXS-97 (Sheldrick, 2008) 
 SHELXL-2013 (Sheldrick, 2013) 
 DIAMOND (Crystal Impact) 
Data / restraints / parameters 4795 / 10 / 332 
Goodness-of-fit on F2 1.083 
R index (all data) wR2 = 0.0390 
R index conventional [I>2sigma(I)] R1 = 0.0165 
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rac-IrO(nap) 
 
Table 18 Crystal Data and Structure Refinement for rac-IrO(nap) 
 
Crystal data: 
 
Identification code  s735_0m 
Habitus, colour  block, red 
Crystal size 0.39 × 0.20 × 0.11 mm3 
Crystal system  Monoclinic 
Space group  P 21/n Z = 4 
Unit cell dimensions a = 15.4823(6) Å α = 90° 
 b = 20.4836(7) Å β = 104.5380(13)° 
 c = 15.6035(5) Å γ = 90° 
Volume 4789.9(3) Å3 
Cell determination  9378 peaks with Theta 2.4 to 27.5°. 
Empirical formula  C48 H46 Cl4 F6 Ir N4 O2 P 
Formula weight  1189.86 
Density (calculated) 1.650 Mg/m3 
Absorption coefficient 3.111 mm-1 
F(000) 2368 
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Data collection:  
 
Diffractometer type  Bruker D8 QUEST area detector 
Wavelength  0.71073 Å 
Temperature  100(2) K 
Theta range for data collection 2.403 to 27.564°. 
Index ranges -20<=h<=19, -26<=k<=26, -20<=l<=20 
Data collection software  BRUKER APEX2 
Cell refinement software  SAINT V8.34A (Bruker AXS Inc., 2013) 
Data reduction software  SAINT V8.34A (Bruker AXS Inc., 2013) 
 
Solution and refinement: 
 
Reflections collected 164058 
Independent reflections 11051 [R(int) = 0.0516] 
Completeness to theta = 25.242° 99.9 %  
Observed reflections  9800[II > 2(I)]  
Reflections used for refinement  11051 
Absorption correction Numerical 
Max. and min. transmission 0.73 and 0.48 
Largest diff. peak and hole 0.665 and -0.508 e.Å-3 
Solution  Direct methods 
Refinement  Full-matrix least-squares on F2 
Treatment of hydrogen atoms  calc. positions, riding model 
Programs used  SHELXS-97 (Sheldrick, 2008) 
 SHELXL-2013 (Sheldrick, 2013) 
 DIAMOND (Crystal Impact) 
Data / restraints / parameters 11051 / 14 / 636 
Goodness-of-fit on F2 1.055 
R index (all data) wR2 = 0.0396 
R index conventional  [I>2sigma(I)] R1 = 0.0185 
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rac-IrO(ada) 
 
Table 19 Crystal Data and Structure Refinement for rac-IrO(ada) 
 
Crystal data:  
 
Identification code  s751_0m 
Habitus, colour  prism, yellow 
Crystal size 0.400 × 0.280 × 0.150 mm3 
Crystal system  Triclinic 
Space group  P -1 Z = 2 
Unit cell dimensions a = 12.0272(8) Å α = 97.856(2)° 
 b = 20.2463(13) Å β = 102.209(2)° 
 c = 21.3725(15) Å γ = 101.316(2)° 
Volume 4900.8(6) Å3 
Cell determination  9526 peaks with Theta 2.6 to 27.5°. 
Empirical formula  C103 H106 Cl6 F12 Ir2 N8 O4 P2 
Formula weight  2406.99 
Density (calculated) 1.631 Mg/m3 
Absorption coefficient 2.989 mm-1 
F(000) 2412 
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Data collection:  
 
Diffractometer type  Bruker D8 QUEST area detector 
Wavelength  0.71073 Å 
Temperature  100(2) K 
Theta range for data collection 1.975 to 27.550°. 
Index ranges -14<=h<=15, -26<=k<=26, -27<=l<=27 
Data collection software  BRUKER APEX2 
Cell refinement software  SAINT V8.34A (Bruker AXS Inc., 2013) 
Data reduction software  SAINT V8.34A (Bruker AXS Inc., 2013) 
 
Solution and refinement: 
 
Reflections collected 98229 
Independent reflections 22587 [R(int) = 0.0437] 
Completeness to theta = 25.242° 99.9 %  
Observed reflections  18214[II > 2(I)]  
Reflections used for refinement  22587 
Absorption correction Numerical 
Max. and min. transmission 0.66 and 0.38 
Largest diff. peak and hole 1.751 and -1.401 e.Å-3 
Solution  Direct methods 
Refinement  Full-matrix least-squares on F2 
Treatment of hydrogen atoms  Calc. positions, constr. Ref. 
Programs used  SHELXS-97 (Sheldrick, 2008) 
 SHELXL-2013 (Sheldrick, 2013) 
 DIAMOND (Crystal Impact) 
Data / restraints / parameters 22587 / 348 / 1423 
Goodness-of-fit on F2 1.042 
R index (all data) wR2 = 0.0632 
R index conventional [I>2sigma(I)] R1 = 0.0276 
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rac-IrO(pyrene) 
 
Table 20 Crystal Data and Structure Refinement for rac-IrO(pyrene) 
 
Crystal data  
 
Identification code  s1412_0m 
Habitus, colour block, orange 
Crystal size 0.34 × 0.20 × 0.17 mm3 
Crystal system  Monoclinic 
Space group  C2/c Z = 4 
Unit cell dimensions a = 18.6985(10) Å = 90°. 
 b = 22.2223(11) Å = 114.850(2)°. 
 c = 13.3462(7) Å  = 90°. 
Volume 5032.2(5) Å3 
Cell determination  9913 peaks with Theta 2.5 to 26.4°. 
Empirical formula  C59 H48 Cl2 F6Ir N4 O2 P 
Moiety formula  C58 H46Ir N4 O2, F6 P, C H2 Cl2 
Formula weight  1253.08 
Density (calculated) 1.654 Mg/m3 
Absorption coefficient 2.864 mm-1 
F(000) 2504 
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Data collection:  
 
Diffractometer type  Bruker D8 QUEST area detector 
Wavelength  0.71073 Å 
Temperature  110(2) K 
Theta range for data collection 2.488 to 26.436°. 
Index ranges -23<=h<=23, -27<=k<=27, -15<=l<=16 
Data collection software  BRUKER APEX2 2014.9-0 
Cell refinement software  BRUKER SAINT 
Data reduction software  SAINT V8.34A (Bruker AXS Inc., 2013)  
 
Solution and refinement: 
 
Reflections collected 45331 
Independent reflections 5184 [R(int) = 0.0271] 
Completeness to theta = 25.242° 99.8 %  
Observed reflections  5020[I>2sigma(I) ]  
Reflections used for refinement  5184 
Absorption correction Numerical 
Max. and min. transmission 0.64 and 0.42 
Largest diff. peak and hole 0.964 and -1.160 e.Å-3 
Solution  Direct methods 
Refinement  Full-matrix least-squares on F2 
Treatment of hydrogen atoms  Calculated positions, constr. ref. 
Programs used  XT V2014/1 (Bruker AXS Inc., 2014)  
 SHELXL-2014/7 (Sheldrick, 2014)  
 DIAMOND (Crystal Impact)  
Data / restraints / parameters 5184 / 63 / 375 
Goodness-of-fit onF2 1.091 
R index (all data) wR2 = 0.0461 
R index conventional [I>2sigma(I)] R1 = 0.0184 
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-IrS 
 
Table 21 Crystal Data and Structure Refinement for -IrS 
 
Crystal data: 
 
Identification code  s829_0m 
Habitus, colour  block, yellow 
Crystal size 0.22 × 0.16 × 0.08 mm3 
Crystal system  Triclinic 
Space group  P 1 Z = 2 
Unit cell dimensions a = 12.4534(7) Å α = 102.428(3)° 
 b = 13.3039(7) Å β = 103.411(2)° 
 c = 14.0333(7) Å γ = 91.556(3)° 
Volume 2201.3(2) Å3 
Cell determination  9714 peaks with Theta 2.4 to 25.3°. 
Empirical formula  C40 H42 Cl4 F6 Ir N4 P S2 
Moiety formula  C38 H38 Ir N4 S2, F6 P, 2(C H2 Cl2) 
Formula weight  1121.86 
Density (calculated) 1.693 Mg/m3 
Absorption coefficient 3.467 mm-1 
F(000) 1112 
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Data collection:  
 
Diffractometer type  Bruker D8 QUEST area detector 
Wavelength  0.71073 Å 
Temperature  115(2) K 
Theta range for data collection 1.983 to 25.322°. 
Index ranges -14<=h<=14, -16<=k<=16, -16<=l<=16 
Data collection software  BRUKER APEX2 2014.1-1 
Cell refinement software  SAINT V8.34A (Bruker AXS Inc., 2013) 
Data reduction software  SAINT V8.34A (Bruker AXS Inc., 2013) 
 
Solution and refinement: 
 
Reflections collected 73320 
Independent reflections 15699 [R(int) = 0.0283] 
Completeness to theta = 25.242° 99.9 %  
Observed reflections  15102[I> 2σ(I)]  
Reflections used for refinement  15699 
Absorption correction Numerical 
Max. and min. transmission 0.77 and 0.54 
Flack parameter (absolute struct.)   0.0136(19) 
Largest diff. peak and hole 1.223 and -0.865 e.Å-3 
Solution  direct/ difmap 
Refinement  Full-matrix least-squares on F2 
Treatment of hydrogen atoms  geom, constr 
Programs used  SHELXS-97 (Sheldrick, 2008) 
 SHELXL-2014 (Sheldrick, 2014) 
 DIAMOND (Crystal Impact) 
Data / restraints / parameters 15699 / 168 / 1061 
Goodness-of-fit on F2 1.073 
R index (all data) wR2 = 0.0520 
R index conventional  [I>2sigma(I)] R1 = 0.0204 
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51 
 
Table 22 Crystal Data and Structure Refinement for 51 
 
Crystal data  
 
Identification code  s838b_0m 
Habitus, colour  plate, colourless 
Crystal size 0.29 × 0.25 × 0.05 mm3 
Crystal system  Orthorhombic 
Space group  P 21 21 21 Z = 4 
Unit cell dimensions a = 7.1543(4) Å = 90°. 
 b = 8.3654(5) Å = 90°. 
 c = 37.755(2) Å  = 90°. 
Volume 2259.6(2) Å3 
Cell determination  6629 peaks with Theta 2.5 to 27.5°. 
Empirical formula  C24 H30 N2 O4 
Formula weight  410.50 
Density (calculated) 1.207 Mg/m3 
Absorption coefficient 0.082 mm-1 
F(000) 880 
 
Chapter 6. Appendices 
-288- 
Data collection:  
 
Diffractometer type  Bruker D8 QUEST area detector 
Wavelength  0.71073 Å 
Temperature  100(2) K 
Theta range for data collection 2.158 to 25.498°. 
Index ranges -8<=h<=8, -10<=k<=10, -45<=l<=45 
Data collection software  BRUKER APEX2 
Cell refinement software  SAINT V8.34A (Bruker AXS Inc., 2013) 
Data reduction software  SAINT V8.34A (Bruker AXS Inc., 2013) 
 
Solution and refinement: 
 
Reflections collected 17182 
Independent reflections 4200 [R(int) = 0.0359] 
Completeness to theta = 25.242° 100.0 %  
Observed reflections  3419[II > 2(I)]  
Reflections used for refinement  4200 
Absorption correction Numerical 
Max. and min. transmission 1.00 and 0.96 
Flack parameter (absolute struct.)   0.5(4) 
Largest diff. peak and hole 0.265 and -0.241 e.Å-3 
Solution  Direct methods 
Refinement  Full-matrix least-squares on F2 
Treatment of hydrogen atoms  Calculated positions, constr. ref. 
Programs used  SHELXS-97 (Sheldrick, 2008) 
 SHELXL-2013 (Sheldrick, 2013) 
 DIAMOND (Crystal Impact) 
Data / restraints / parameters 4200 / 0 / 277 
Goodness-of-fit on F2 1.046 
R index (all data) wR2 = 0.0932 
R index conventional  [I>2sigma(I)] R1 = 0.0420 
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Complex 79 
 
Table 23 Crystal Data and Structure Refinement for 79 
 
Crystal data:  
 
Identification code  s862_0m 
Habitus, colour  plate, yellow 
Crystal size 0.35 × 0.26 × 0.07 mm3 
Crystal system  Monoclinic 
Space group  P 21/c Z = 4 
Unit cell dimensions a = 15.9181(5) Å α = 90° 
 b = 24.5405(7) Å β = 107.7885(12)° 
 c = 13.2954(4) Å γ = 90° 
Volume 4945.4(3) Å3 
Cell determination  9203 peaks with Theta 2.4 to 27.5°. 
Empirical formula  C51 H50 Cl2 F3 Ir N4 O6 S 
Formula weight  1167.11 
Density (calculated) 1.568 Mg/m3 
Absorption coefficient 2.915 mm-1 
F(000) 2344 
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Data collection:  
 
Diffractometer type  Bruker D8 QUEST area detector 
Wavelength  0.71073 Å 
Temperature  100(2) K 
Theta range for data collection 2.135 to 26.000°. 
Index ranges -19<=h<=19, -30<=k<=30, -16<=l<=16 
Data collection software  BRUKER APEX2 
Cell refinement software  SAINT V8.34A (Bruker AXS Inc., 2013) 
Data reduction software  SAINT V8.34A (Bruker AXS Inc., 2013) 
 
Solution and refinement: 
 
Reflections collected 46884 
Independent reflections 9723 [R(int) = 0.0336] 
Completeness to theta = 25.242° 99.9 %  
Observed reflections  8804[II > 2(I)]  
Reflections used for refinement  9723 
Absorption correction Numerical 
Max. and min. transmission 0.81 and 0.53 
Largest diff. peak and hole 2.048 and -1.402 e.Å-3 
Solution  Direct methods 
Refinement  Full-matrix least-squares on F2 
Treatment of hydrogen atoms  Calculated positions, constr. ref. 
Programs used  SHELXS-97 (Sheldrick, 2008) 
 SHELXL-2013 (Sheldrick, 2013) 
 DIAMOND (Crystal Impact) 
Data / restraints / parameters 9723 / 0 / 640 
Goodness-of-fit on F2 1.074 
R index (all data) wR2 = 0.0574 
R index conventional [I>2sigma(I)] R1 = 0.0261 
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Complex 80 
 
Table 24 Crystal Data and Structure Refinement for 80 
 
Crystal data:  
 
Identification code  s875_0m 
Habitus, colour  nugget, yellow 
Crystal size 0.27 × 0.22 × 0.17 mm3 
Crystal system  Monoclinic 
Space group  P 21/n Z = 4 
Unit cell dimensions a = 17.6254(7) Å α = 90° 
 b = 14.9443(5) Å β = 103.4033(14)° 
 c = 22.3943(9) Å γ = 90° 
Volume 5738.0(4) Å3 
Cell determination  9737 peaks with Theta 2.7 to 25.3°. 
Empirical formula  C58 H61 Cl4 F3 Ir N5 O7 S 
Moiety formula  C55 H57 Ir N5 O4, C F3 O3 S, 2(C H2 Cl2) 
Formula weight  1363.17 
Density (calculated) 1.578 Mg/m3 
Absorption coefficient 2.616 mm-1 
F(000) 2752 
 
Chapter 6. Appendices 
-292- 
Data collection:  
 
Diffractometer type  Bruker D8 QUEST area detector 
Wavelength  0.71073 Å 
Temperature  100(2) K 
Theta range for data collection 2.395 to 25.335°. 
Index ranges -21<=h<=21, -17<=k<=17, -26<=l<=26 
Data collection software  BRUKER APEX2 2014.1-1 
Cell refinement software  SAINT V8.34A (Bruker AXS Inc., 2013) 
Data reduction software  SAINT V8.34A (Bruker AXS Inc., 2013) 
 
Solution and refinement: 
 
Reflections collected 132737 
Independent reflections 10435 [R(int) = 0.0473] 
Completeness to theta = 25.242° 99.9 %  
Observed reflections  9261[II > 2(I)]  
Reflections used for refinement  10435 
Absorption correction Numerical 
Max. and min. transmission 0.67 and 0.47 
Largest diff. peak and hole 2.055 and -1.646 e.Å-3 
Solution  Direct methods 
Refinement  Full-matrix least-squares on F2 
Treatment of hydrogen atoms  Calculated positions, constr. ref. 
Programs used  SHELXS-97 (Sheldrick, 2008) 
 SHELXL-2014 (Sheldrick, 2014) 
 DIAMOND (Crystal Impact) 
Data / restraints / parameters 10435 / 81 / 783 
Goodness-of-fit on F2 1.046 
R index (all data) wR2 = 0.1113 
R index conventional [I>2sigma(I)] R1 = 0.0403 
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Complex 138 
 
Table 25 Crystal Data and Structure Refinement for 138 
 
Crystal data:  
 
Identification code  s1789b_0m_sq 
Habitus, colour prism, green 
Crystal size 0.44 × 0.35 × 0.09 mm3 
Crystal system  Monoclinic 
Space group  P21 Z = 2 
Unit cell dimensions a = 9.5431(4) Å α = 90°. 
 b = 22.2792(10) Å β = 97.985(2)°. 
 c = 13.6884(6) Å γ = 90°. 
Volume 2882.1(2) Å3 
Cell determination  9906 peaks with Theta 2.4 to 26.4°. 
Empirical formula  C55 H53 F6 N5 O5 P Rh 
Moiety formula  C55 H53 N5 O5 Rh, F6 P 
Formula weight  1111.90 
Density (calculated) 1.281 Mg/m3 
Absorption coefficient 0.391 mm-1 
F(000) 1144 
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Data collection:  
 
Diffractometer type  Bruker D8 QUEST area detector 
Wavelength  0.71073 Å 
Temperature  110(2) K 
Theta range for data collection 2.155 to 26.436°. 
Index ranges -11<=h<=11, -27<=k<=27, -16<=l<=17 
Data collection software  APEX3 
Cell refinement software  SAINT V8.35A (Bruker AXS Inc., 2015)  
Data reduction software  SAINT V8.35A (Bruker AXS Inc., 2015) 
 
Solution and refinement: 
 
Reflections collected 47009 
Independent reflections 11797 [R(int) = 0.0371] 
Completeness to theta = 25.242° 99.9 %  
Observed reflections  11015[I>2sigma(I) ]  
Reflections used for refinement  11797 
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 0.7454 and 0.6942 
Flack parameter (absolute struct.)   -0.015(7)  
Largest diff. peak and hole 0.284 and -0.417 e.Å-3 
Solution  Direct methods 
Refinement  Full-matrix least-squares on F2 
Treatment of hydrogen atoms  Calculated positions, constr. ref. 
Programs used  XT V2014/1 (Bruker AXS Inc., 2014)  
 SHELXL-2014/7 (Sheldrick, 2014)  
 DIAMOND (Crystal Impact)  
Data / restraints / parameters 11797 / 454 / 817 
Goodness-of-fit on F2 1.039 
R index (all data) wR2 = 0.0647 
R index conventional [I>2sigma(I)] R1 = 0.0276 
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Complex 139 
 
Table 26 Crystal Data and Structure Refinement for 139 
 
Crystal data: 
 
Identification code  s1604_0m 
Habitus, colour prism, red 
Crystal size 0.28 × 0.16 × 0.13 mm3 
Crystal system  Triclinic 
Space group  P-1 Z = 2 
Unit cell dimensions a = 12.1532(5) Å α = 80.767(1)° 
 b = 12.4927(5) Å β = 86.511(1)° 
 c = 16.5165(7) Å γ = 67.404(1)° 
Volume 2285.15(16) Å3 
Cell determination  9423 peaks with Theta 2.5 to 27.5°. 
Empirical formula  C53 H49 Cl2 N4 O3 Rh 
Moiety formula  C52 H47 N4 O3 Rh, C H2 Cl2 
Formula weight  963.77 
Density (calculated) 1.401 Mg/m3 
Absorption coefficient 0.539 mm-1 
F(000) 996 
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Data collection:  
 
Diffractometer type  Bruker D8 QUEST area detector 
Wavelength  0.71073 Å 
Temperature  100(2) K 
Theta range for data collection 2.203 to 27.579°. 
Index ranges -15<=h<=15, -16<=k<=16, -21<=l<=21 
Data collection software  BRUKER APEX2 2014.9-0 
Cell refinement software  BRUKER SAINT 
Data reduction software  SAINT V8.34A (Bruker AXS Inc., 2013)  
 
Solution and refinement: 
 
Reflections collected 45256 
Independent reflections 10428 [R(int) = 0.0287] 
Completeness to theta = 25.242° 99.6 %  
Observed reflections  9372[I>2sigma(I) ]  
Reflections used for refinement  10428 
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 0.93 and 0.89 
Largest diff. peak and hole 0.451 and -0.502 e.Å-3 
Solution  Direct methods 
Refinement  Full-matrix least-squares on F2 
Treatment of hydrogen atoms  Calculated positions, constr. ref. 
Programs used  XT V2014/1 (Bruker AXS Inc., 2014)  
 SHELXL-2014/7 (Sheldrick, 2014)  
 DIAMOND (Crystal Impact)  
Data / restraints / parameters 10428 / 21 / 603 
Goodness-of-fit on F2 1.041 
R index (all data) wR2 = 0.0603 
R index conventional [I>2sigma(I)] R1 = 0.0277 
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